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Abstract 
 
Multiple Sclerosis (MS) patients are faced with complex risk-benefit profiles of 
disease-modifying drugs (DMDs). It is important that MS patients are able to understand 
the risks and benefits of DMDs in order to make an informed treatment decision. The 
goal of the present thesis was to identify the best methods of presenting treatment risks 
and benefits to improve MS patients’ understanding and reduce conflict in their treatment 
decisions. First, systematic reviews and surveys were conducted to inform the need to 
improve MS patients’ understanding of treatments. Subsequently, three experiments were 
designed to assess the effect of different presentation methods on MS patients’ 
understanding of hypothetical treatments. Experiment 1 found that treatments presented 
using non-graphical formats had an effect on patients’ understanding (p<.001), with 
numerical frequencies improving understanding the greatest. Understanding of treatments 
was also affected by presentation using graphical formats (p<.001), and was greatest for 
bar charts and line graphs. Experiment 2 found that presenting treatments using ratios 
(p<.001) and frames (p<.05) also affected patients’ understanding. Experiment 3 showed 
that the methods to communicate differences in the risks and benefits of clinical trial 
groups further had an effect on patients’ understanding of treatments (p<.001). The 
BRIMMS protocol was developed by integrating the best presentation methods from 
Experiments 1-3 and was compared with standard consultation using a randomised 
controlled trial with crossover design. The BRIMMS protocol improved understanding 
(p<.001) and reduced decisional conflict (p<.001) in comparison to standard 
consultations. In conclusion, some methods to present treatments can improve MS 
patients’ understanding of treatment risks and benefits. The BRIMMS protocol could 
potentially be implemented into current clinical practice to improve MS patients’ 
understanding and engagement in the decision-making process. 
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Chapter 1: General introduction 
1.1 Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative 
disorder of the central nervous system, affecting over 2.3 million people worldwide 
(Browne et al., 2014). In the UK alone, approximately 124,000 people were affected with 
MS at the end of 2010 (Mackenzie, Morant, Bloomfield, MacDonald, & O’Riordan, 
2014). The onset of MS typically presents in patients between 20-40 years, with twice as 
many women affected as men (Ransohoff, Hafler, & Lucchinetti, 2015).  
Patients diagnosed with MS are faced with a great deal of uncertainty about their 
condition. The pathophysiology of MS is not fully known, symptoms of MS can vary 
considerably between patients and it is not generally possible to predict the course of 
disease for individual patients with MS.  
1.1.1 Pathophysiology of MS 
MS is a multifactorial disease with poorly understood aetiology, but is generally 
thought to result from an interaction between genetic (Sawcer, Franklin, & Ban, 2014) 
and environmental factors (Belbasis, Bellou, Evangelou, Ioannidis, & Tzoulaki, 2015). 
Although complex, the major underlying pathological processes involved in the 
development and progression of MS are considered to be inflammation and 
neurodegeneration (Compston & Coles, 2008; Sand, 2015).   
Inflammation can lead to damage of the myelin sheaths which are the insulating 
and protective layer surrounding axons of nerves in order to facilitate speedy 
communication between nerve cells (Compston & Coles, 2008). This damage is termed 
as demyelination. Consequently, demyelination can disrupt and distort neuronal signals in 
regions affected by inflammation (Ciccarelli et al., 2014). Initially, this damage can be 
reversed by the process of remyelination which restores function and conduction of nerve 
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impulses (Compston & Coles, 2008). However, repeated inflammation can cause lesions 
to manifest throughout the brain and spinal cord (Ciccarelli et al., 2014; Compston & 
Coles, 2008; Frohman, Racke, & Raine, 2006).  
Continuous demyelination can lead to axon and neuronal degeneration 
(Compston & Coles, 2008). As MS progresses and new lesions develop, axon and 
neurodegeneration can accumulate and subsequently lead to permanent neurological 
disability (Tallantyre et al., 2010). Both white matter (collection of axons which facilitate 
communication between grey matter and other areas of the body) and grey matter 
(collection of nerve cells which receive and generate information to the body) in the brain 
are affected in MS, with disease progression causing more severe damage in the grey 
matter (Ciccarelli et al., 2014).  
1.1.2 MS symptoms 
Demyelination and neurodegeneration in MS patients can lead to a wide range of 
MS symptoms which can vary considerably between people affected by MS. Severity of 
symptoms can also vary between individuals: whilst some symptoms may require 
hospitalisation, other symptoms could be so trivial that they do not generally need 
medical attention (Hauser & Oksenberg, 2006). This heterogeneous symptom profile in 
MS is related to the corresponding sites that may be damaged in MS patients (Compston 
& Coles, 2008). The range of symptoms that MS patients experience can be broadly 
categorised into physical and motor symptoms, fatigue, affective disorders and cognitive 
impairments (Compston & Coles, 2008; Shahrbanian, Duquette, Kuspinar, & Mayo, 
2015; Wood et al., 2013).  
1.1.2.1 Physical and motor symptoms in MS     
MS patients can experience a range of physical and motor symptoms which 
usually occur due to neurodegeneration in corresponding sites. For instance, patients may 
experience unilateral painful loss of vision, scotoma, reduced visual acuity, colour vision 
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and relative papillary defects due to neuronal damage of the optic nerve (Compston & 
Coles, 2008). Demyelination in the cerebellum and cerebellar pathway may result in 
tremor, clumsiness and poor balance; neuronal damage in the brainstem could lead to 
diplopia, vertigo, impaired swallowing, impaired speech, and in the spinal cord can lead 
to weakness, stiffness, painful spasms and incontinence. Additional symptoms can also 
include pain and temperature sensitivity (Compston & Coles, 2008; Hauser & Oksenberg, 
2006) 
1.1.2.2 Fatigue and affective disorders in MS 
Patients can also experience fatigue and affective symptoms of depression and 
anxiety throughout the course of their disease. 
Fatigue 
Fatigue is one of the most prevalent symptoms in MS and occurs in 
approximately 53% to 80% of MS patients (Khan, Amatya, & Galea, 2014; Wood et al., 
2013). Fatigue can be defined as a lack of physical and/or mental energy, and can 
significantly impact the quality of life in MS patients (Fisk, Pontefract, Ritvo, Archibald, 
& Murray, 1994; Kos, Kerckhofs, Nagels, D’hooghe, & Ilsbroukx, 2008). Fatigue in MS 
can either be primary which can directly occur due to inflammation and 
neurodegeneration; or secondary fatigue which can occur due to other peripheral 
mechanisms in MS such as pain, reduced activity and even depression (Kos et al., 2007). 
Studies have shown no association of fatigue in MS patients with clinical or demographic 
variables, such as age, gender, disability, type of MS and disease duration (Kos et al., 
2007), which further illustrates the heterogeneous nature of symptoms in MS.  
Depression 
Depression, or a persistent low mood, is more frequent in patients with MS than 
the general population, and can affect approximately 18% to 50% of patients (Boeschoten 
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et al., 2016; Feinstein, Freeman, & Lo, 2015; Jones et al., 2012; Wood et al., 2013). 
Depression can be a debilitating symptom, substantially affecting individuals’ working 
ability, social relationships and quality of life (Azimian et al., 2014), with elevated 
suicide rates due to depression in patients with MS (Feinstein et al., 2014). The 
distinction between depression occurring as a direct result of the inflammation and 
neurodegeneration process, and depression as a result of being diagnosed with a chronic 
condition such as MS is yet to be established (Feinstein et al., 2015). There is also a great 
deal of variability in the prevalence of depression between patients of different gender, 
ages, disease duration and MS subtype (Jones et al., 2012). However, high depression 
rates seem to occur concurrently during relapses in MS (Moore et al., 2012).  
Anxiety 
Anxiety disorders are also very prevalent in MS and occur in about 22% to 45% 
of MS patients, but are frequently disregarded and undertreated (Boeschoten et al., 2016; 
Korostil & Feinstein, 2007; Wood et al., 2013). The most common anxiety disorders in 
MS include panic disorder, obsessive compulsive disorder and generalised anxiety 
disorder (Korostil & Feinstein, 2007). Similar to depression, symptoms of anxiety can 
overlap between the somatic manifestations due to degeneration in MS and anxiety about 
diagnosis of MS as a condition. Some risk factors of anxiety include gender (Korostil & 
Feinstein, 2007; Jones et al., 2012), limited social support, as well as a co-morbid 
diagnosis of depression (Korostil & Feinstein, 2007).  
1.1.2.3 Cognitive impairments in MS 
Cognitive impairments are very prevalent in MS, occurring in approximately 
40% to 70% of MS patients (Chiaravalloti & Deluca, 2008; Rao, Leo, Bernardin, & 
Unverzagt, 1991), with significantly greater impairments appearing in patients with 
disease duration longer than 5 years (Achiron et al., 2013). Damage to both grey and 
white matter can contribute to MS-related cognitive impairments (DeLuca, Yates, Beale, 
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& Morrow, 2015). Cognitive deficits can occur independent of physical disability which 
can complicate their identification and recognition during the course of the disease 
(Chiaravalloti & Deluca, 2008). Specifically, MS patients can be impaired on a range of 
cognitive abilities, including: verbal and visual-spatial memory, information-processing 
speed and executive functioning, with some degree of comorbidity between these deficits 
(Chiaravalloti & Deluca, 2008; Fischer et al., 2014; Langdon, 2011). 
Memory 
The ability to learn and recall information at a later time is defined as long-term 
memory. MS patients show impairments in remembering both verbal information and 
visuospatial information (Langdon, 2011). Impairments in memory are one of the most 
commonly occurring cognitive deficits, appearing in about 40% to 65% of MS patients 
(Rao et al., 1993). Although it was initially thought that memory could be impaired at the 
stage of retrieval of information, recent research has established that patients are typically 
affected during the initial encoding and learning of information, which can subsequently 
lead to impairments in retrieval of information at a later time (Chiaravalloti & Deluca, 
2008; Lafosse, Mitchell, Corboy, & Filley, 2013; Thornton, Raz, & Tucke, 2002).  
Information processing speed 
Another common cognitive impairment occurs in the speed with which 
individuals are able to process and manipulate information in their working memory 
(Chiaravalloti & DeLuca, 2008). MS patients’ impairments in processing speed are 
particularly apparent in their performance across a range of cognitive tasks, which show 
improvements when patients were allowed more processing time during the task 
(Bodling, Denney, & Lynch, 2008; Denney, Gallagher, & Lynch, 2011; Denney & 
Lynch, 2009; Hughes, Denney, Owens, & Lynch, 2013; Langdon, 2011). 
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Executive functions 
Executive functioning refers to complex and higher-order cognitive processes, 
such as abstract and conceptual reasoning, inhibition, planning and problem-solving, 
which can also be impaired in MS patients. However, impairments of this type are shown 
to occur less frequently in MS patients relative to deficits in memory and information 
processing speed (Chiaravalloti & Deluca, 2008; Denney, Lynch, Parmenter, & Horne, 
2004; Drew, Tippett, Starkey, & Isler, 2008).  
1.1.2.4 Comorbidity of non-physical MS symptoms 
A majority of MS patients commonly experience non-physical symptoms, such as 
fatigue, affective disorders and cognitive impairments, at the same time.  
Many MS patients show symptoms of both anxiety and depression during the 
course of their disease (Jones et al., 2012; Moore et al., 2012). Both symptoms occurring 
together has been shown to relate with heightened risk of patients experiencing thoughts 
of self-harm, somatic complaints and social dysfunction compared to MS patients 
experiencing anxiety disorders alone (Korostil & Feinstein, 2007). In addition, symptoms 
of fatigue and depression in MS patients have also been shown to occur together, with 
improvements in depression generally improving patients’ fatigue (Kos, Duportail, 
D’hooghe, Nagels, & Kerckhofs, 2007). However the strength of this relationship is not 
always clear or consistent (Feinstein, Magalhaes, Richard, Audet, & Moore, 2014; 
Hildebrandt & Eling, 2014).  
Affective disorders also commonly occur with cognitive impairments in MS 
(Chiaravalloti & Deluca, 2008; Langdon, 2011). MS patients experiencing depression 
have consistently shown to perform poorly on tasks of information processing speed 
(Arnett, Higginson, Voss, Bender, et al., 1999; Arnett, Higginson, Voss, Wright, et al., 
1999), but not for tasks assessing long-term memory (Thornton et al., 2002). In addition, 
a recent longitudinal study of 40 MS patients illustrated that an increase in depressive 
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mood was related to low performance in tests measuring working memory and executive 
function (Hildebrandt & Eling, 2014). Similarly, another study found that anxiety 
disorder, which was experienced by 36% of the clinical sample, was independently 
related to poor performance on tasks of information processing speed even when 
controlling for depression and fatigue (Goretti et al., 2014). In terms of fatigue, whilst 
there exists some evidence of deficit in information processing speed when patients also 
experience fatigue (Andreasen, Spliid, Andersen, & Jakobsen, 2010), fatigue is generally 
not associated with poor performance on cognitive tasks (Bailey, Channon, & Beaumont, 
2007; Chiaravalloti & Deluca, 2008; Hildebrandt & Eling, 2014). However, it has been 
proposed that MS patients may experience fatigue whilst conducting extensive cognitive 
assessments (Langdon, 2011), which may indirectly affect cognitive performance on 
tasks albeit to a lesser degree than affective symptoms of MS. Thus, whilst patients that 
experience either anxiety or depression show impairments in cognitive performance, the 
findings are mixed in regards to patients who experience only fatigue. 
1.1.3 MS subtypes 
Severity and frequency of MS symptoms is generally dependent on the rate of 
neurodegeneration in patients. Due to the variability in the rates at which the disease 
progresses between patients, 4 different subtypes of MS have been proposed: clinically-
isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary progressive MS 
(PPMS) and secondary progressive MS (SPMS). 
At the very first stage of the disease, approximately 80% of MS patients can 
experience an acute attack of demyelination, also known as a relapse. At this stage, an 
independently occurring relapse is categorised as a CIS subtype (Compston & Coles, 
2008). If this relapse is accompanied by abnormalities of the white matter, the possibility 
of a second episode of demyelination can increase.  
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Multiple attacks of demyelination, or relapses, can be classified into the most 
commonly occurring RRMS subtype (Fisniku et al., 2008). RRMS is typically defined as 
multiple acute relapses followed by a period of clinical stability in which full or partial 
recovery is possible (Sand, 2015). Given this process of recovery, most patients only 
experience moderate disability at this stage of the disease (Scalfari, Neuhaus, Daumer, 
Muraro, & Ebers, 2014). RRMS may also be characterised as being active or not active, 
with activity referring to new or enlarging lesions shown through MRI and/or clinical 
relapses occurring at least annually (Lublin, 2014).  
A minority of patients (<10%) may develop individual lesions in the brain and 
spinal cord independent of any relapses, categorised as the PPMS subtype (Polman et al., 
2011; Ransohoff et al., 2015; Sand, 2015). In these patients, severe disability 
accumulation can occur at the onset of the disease (Ransohoff et al., 2015).  
Overtime, patients with RRMS can also have accumulation of disability as post-
relapse recovery remains incomplete and there is a gradual progression of neuronal 
degeneration (Rovaris et al., 2006; Sand, Krieger, Farrell, & Miller, 2014). Patients at this 
stage are classified as the SPMS subtype. To date, there are no clear pathological criteria 
to determine when RRMS transitions to SPMS (Rovaris et al., 2006) and the disease 
course is largely unpredictable in individual cases (Sand et al., 2014). This 
unpredictability was shown in a recent study by Scalfari and colleagues (2014) which 
attempted to determine a clinical portfolio of untreated individuals with MS transitioning 
from RRMS to SPMS. Approximately 66% patients progressed to the SPMS stage of the 
disease between 1 to 36 years of being diagnosed with RRMS, with the probability of 
transitioning from RRMS to SPMS increasing by 9% every 5 years. Only a few variables 
were found to reliably predict the time taken for progression of disease, that is: male sex, 
older age at onset and a high number of early relapses. However, the type and number of 
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neurological systems involved at onset were not found to affect the probability of MS 
becoming progressive (Scalfari et al., 2014). 
1.1.4 Summary 
MS patients are faced with a great deal of uncertainty throughout their disease. 
MS patients can experience a wide range of symptoms which may be either physical, 
affective or cognitive. It is not always possible to determine the reason for disease onset 
or the rate at which the disease will progress for an individual. Treatments are geared 
towards slowing down the progression of disease by reducing the rate of relapses in MS 
patients.  
1.2 Disease-modifying drugs in MS 
Although there is no cure for MS at present, extensive research and rapid 
advances in the last two decades have increased treatment options that can delay the 
progression of disease in the form of disease-modifying drugs (DMDs) (English & Aloi, 
2015; Wingerchuk & Weinshenker, 2016; Winkelmann, Loebermann, Reisinger, 
Hartung, & Zettl, 2016). Current preventive DMDs for MS primarily target relapses, 
reducing their frequency and severity by modulating or suppressing immune function, 
which can subsequently delay the progression of disease and reduce disability 
(Winkelmann et al., 2016). For this reason, DMDs are not suitable in patients who do not 
experience relapses (i.e. patients with the PPMS or SPMS subtype) (Wingerchuk & 
Weinshenker, 2016). 
Currently, 14 DMDs have been approved by the Food and Drug Administration 
(FDA) for the treatment of MS in the US (Wingerchuk & Weinshenker, 2016). Of these, 
only some DMDs are offered to patients at the very first stage after RRMS diagnosis and 
are termed “first-line treatments”. These DMDs are generally less aggressive, with 
smaller risk profiles but with modest efficacy. At present, the following drugs are usually 
offered to patients as first-line treatments in Europe: interferon betas (5 drugs), glatiramer 
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acetate (2 drugs), dimethyl fumarate, and teriflunomide (Dorr, Paul, Dörr, & Paul, 2015; 
Winkelmann et al., 2016). The remaining drugs are offered to patients with highly active 
disease and who do not show improvements with first-line choices. These drugs are often 
more aggressive than first-line treatments but also offer higher efficacy. DMDs that are 
generally used at these later stages as second-line and third-line treatments in Europe 
include: fingolimod, mitoxantrone, natalizumab, alemtuzumab and daclizumab (Dorr et 
al., 2015; Scolding et al., 2015; Wingerchuk & Weinshenker, 2016). The decision to 
transition patients from first-line treatments to other DMDs is not always clear, and is 
usually dependent on the patient’s disease activity, tolerability to DMDs and the risk-
benefit profiles of treatments (Dorr et al., 2015).  
To demonstrate the complex risk-benefit profiles of DMDs in first-line, second-
line and third-line treatments, the following section provides detailed examples of some 
commonly prescribed DMDs for MS patients in the UK. 
1.2.1 Interferon betas 
Interferon betas (IFN-β) are first-line immunomodulatory drugs with complex 
mechanism of action and have been used as treatments in MS for over 20 years, not 
including the pegylated IFN-β which was licensed only recently (Carrithers, 2014; 
Winkelmann et al., 2016). IFN-β are administered by injections, with frequency of 
injections varying depending on which of the five interferon beta drugs are prescribed to 
patients (Wingerchuk & Weinshenker, 2016; Winkelmann et al., 2016).  
IFN-βs have been established as moderately successful by clinical placebo-
controlled trials. IFN-βs consistently show a reduction in annual rate of relapses by 
approximately one third compared to patients taking a placebo. IFN-βs also show 
moderation in the development of new brain lesions, as well as a reduction in disability 
(Calabresi et al., 2014; IFNB Multiple Sclerosis Group, 1993; Jacobs et al., 1995; Jacobs 
et al., 2000; Johnson et al., 1995; Panitch et al., 2002).  
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The most frequently reported side-effects for IFN-βs include injection-site 
reactions, flu-like symptoms and fatigue. Patients may also experience adverse risks when 
taking IFN-βs, such as: leukopenia and worsening of depression (Bandari, Sternaman, 
Chan, Prostko, & Sapir, 2012; Jacobs et al., 1995; Jacobs et al., 2000; Johnson et al., 
1995; Winkelmann et al., 2016). Recently, there has also been a reported case of 
progressive multifocal leukoencephalopathy (PML) in a patient treated with IFN-β 
(Lehmann, Kruger, Fink, & Schroeter, 2015). PML is a severe infection affecting the 
CNS and is associated with high rates of mortality and serious disability. However, it has 
been suggested that the patient’s other underlying disease likely caused the PML rather 
than administration of IFN-β treatment (Winkelmann et al., 2016).  
Given the long-term treatment history of IFN-βs and the low frequency of 
adverse risks, IFN-βs are commonly offered as low invasive treatments to newly 
diagnosed patients despite only being moderately effective. 
1.2.2 Dimethyl fumarate  
Dimethyl fumarate is another first-line agent with immunomodulatory effects 
which can be taken orally. This treatment was licensed for use in MS by the FDA in 2013 
(English & Aloi, 2015).  
Two recent and large clinical trials showed an approximate 50% reduction in 
annual relapse rate after taking dimethyl fumarate for 2 years (Fox et al., 2012; Gold et 
al., 2012). Disability progression and number of lesions shown in an MRI scan was also 
significantly reduced in patients taking dimethyl fumarate when compared to a placebo 
group (Gold et al., 2012). Similar rates of efficacy were also evident in another clinical 
trial for patients taking dimethyl fumarate, compared with patients taking the first-line 
treatment glatiramer acetate (Fox et al., 2012). Improvements in perceived health status 
and quality of life were also reported by patients taking dimethyl fumarate (Kappos et al., 
2014). 
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Common side-effects of dimethyl fumarate include flushing and gastrointestinal 
symptoms, such as diarrhea, nausea and upper abdominal pains. Minor infections were 
reported in about 55-68% of MS patients, generally affecting the upper respiratory tract 
or urinary tract (Fox et al., 2012; Gold et al., 2012). Infections were classified as severe in 
about 2% of MS patients in both clinical trials (Fox et al., 2012; Gold et al., 2012). 
Another concern in dimethyl fumarate is that of PML which has been reported in 4 
patients as of November 2015 (Winkelmann et al., 2016). For this reason, new monitoring 
requirements have been proposed to reduce the risk of developing PML in patients taking 
dimethyl fumarate (Winkelmann et al., 2016).  
In comparison to interferons and glatiramer acetate, dimethyl fumarate can 
provide higher rates of efficacy in MS patients but also with somewhat higher rates of 
risks.  
1.2.3 Fingolimod 
Fingolimod was the first approved oral medication for MS by FDA in 2010 
(English & Aloi, 2015). Although formally approved as a first-line treatment, fingolimod 
is usually offered to patients as a second-line treatment in Europe (Dorr et al., 2015; 
Winkelmann et al., 2016). 
In a double-blind randomised clinical trial of 1033 RRMS patients, fingolimod 
showed a reduction in annual relapse rate by up to 67% when compared to patients taking 
a placebo (Kappos et al., 2010). Moreover, the risk of disability progression was 
significantly reduced for patients taking fingolimod (Kappos et al., 2010). Another 
clinical trial was conducted with 1292 RRMS patients to compare the efficacy of 
fingolimod with one of the IFN-β treatments (Cohen et al., 2010). Patients taking 
fingolimod showed a reduction in annual relapse rate by approximately 74%. However, 
there was no significant delay in the risk of disease progression following fingolimod in 
comparison to IFN-β treatment (Cohen et al., 2010). Both trials also showed significant 
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reductions in the number and volume of lesions in the brain (Cohen et al., 2010; Kappos 
et al., 2010).  
Frequently reported side-effects for fingolimod include headaches, nausea, back 
pain, diarrhea and fatigue (Cohen et al., 2010; English & Aloi, 2015; Kappos et al., 
2010). Adverse risks associated with fingolimod include high liver enzymes, herpes 
infection and cardiac risk of bradycardia (Braune, Lang, & Bergmann, 2015; Cohen et al., 
2010; Fox et al., 2014; Kappos et al., 2010; Winkelmann et al., 2016). Patients taking 
fingolimod may therefore need to be monitored closely for the development of these 
adverse risks. For example, due to the severe risk of bradycardia, patients’ pulse and 
blood pressure must be monitored for 6 hours following administration of the first dose 
(English & Aloi, 2015) or if taking the drug after a break of two weeks (Bandari et al., 
2012). Another severe risk associated with fingolimod is that of varicella zoster virus 
(VZV), a serious viral infection present in about 11 patients out of 1000 patients taking 
the DMD, compared to 6 patients out of 1000 patients taking the placebo (Arvin et al., 
2014). Two cases of PML infection have also been reported in MS patients taking 
fingolimod (Winkelmann et al., 2016). 
In general, fingolimod offers superior efficacy for reduction in relapse rates but 
with a number of severe risks which requires regular monitoring of patients taking the 
drug. 
1.2.4 Natalizumab 
Natalizumab is another second-line MS treatment administered by intravenous 
injection to RRMS patients, and was approved by the FDA in 2004 (Carrithers, 2014; 
Wingerchuk & Weinshenker, 2016).  
The robust efficacy of natalizumab has been demonstrated in a number of clinical 
trials; MS patients taking natalizumab had 68% reduction in relapse rate after 1 year, with 
up to 83% reduction in accumulation of new or enlarging lesions when compared to 
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patients taking the placebo (Miller et al., 2009; Polman et al., 2006). Around 42% of 
RRMS patients also show reduction in disability when compared to patients taking the 
placebo. Significant improvements have also been reported on quality-of life measures 
(Rudick, 2011).  
Despite its efficacy, natalizumab is usually reserved for patients who do not show 
delays in disease progression with first-line treatments and have a highly active disease 
(Carrithers, 2014; Dorr et al., 2015). This is due to the number of adverse risks that have 
been associated with natalizumab, such as pneumonia, neurosepsis, appendicitis and viral 
infections (Polman et al., 2006; Winkelmann et al., 2016). Another severe risk that 
patients develop following natalizumab is that of PML (Keegan, 2011; Kleinschmidt-
DeMasters, & Tyler, 2005; O’Connor & Kremenchutzky, 2015). As of 2012, some 212 
patients out of 99,571 patients developed PML after taking natalizumab; 22% of patients 
died and 40% of those that survived developed a severe disability after 6 month of 
follow-up (Bloomgren et al., 2012). Due to the severity of PML, natalizumab was 
temporarily discontinued until 2006 and was brought back into the market under the 
condition that patients are closely monitored and all cases of PML are reported (Rudick, 
2011). With regular reporting and research into natalizumab-associated PML, three risk 
factors of PML have been identified: status of a JC virus, duration of natalizumab 
treatment and prior use of DMDs (Bloomgren et al., 2012). Patients taking natalizumab 
who are negative to anti-JC virus antibodies present the lowest risk of developing the 
condition, at 0.09 cases or fewer per 1000 patients. However, if patients present with all 
possible risk factors, i.e. positive to anti-JC virus antibody, extensive use of other DMDs 
and having taken natalizumab for over 24 months, the risk of PML can reach 
approximately 11.1 cases per 1000 patients (Bloomgren et al., 2012).  
Overall, natalizumab can offer very high efficacy in RRMS patients who 
continue to show disease activity with first-line treatments. However, due to its high risk 
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profile, it is essential that patients taking this DMD are regularly monitored for their risk 
of developing PML and other serious infections.  
1.2.5 Summary 
DMDs can reduce the rate of relapses and delay progression of MS especially for 
patients with the RRMS subtype. DMDs are typically offered in two stages to MS 
patients. Patients are first offered DMDs with lower associated risks, but these are only 
moderately effective. However, tolerability to DMDs may differ considerably between 
patients. For this reason, some patients are transitioned to other first-line or later-line 
treatments if the disease continues to be active. Second- and third-line treatments are 
more effective, but also have higher associated risks. The risk-benefit profiles among 
DMDs at the same stage can also vary.  
1.3 Patient understanding of treatment information 
It is important that patients are able to understand the complex risk and benefit 
information of DMDs in order to better engage in decision-making about treatments and 
have increased adherence to the treatment they initiate. 
1.3.1 Patient-centered care and shared decision-making  
A patient-centred approach has been advocated for use in healthcare systems 
around the world (World Health Organisation, 2000), and is currently implemented in the 
UK National Health Service (NHS) (National Health Service, 2005). Patient-centred 
approach refers to involving patients in all healthcare decisions and to better acknowledge 
patients’ experiences of their condition (Barry & Edgman-Levitan, 2012; Gerteis, 
Edgman-Levitan, Daley, & Delbanco, 1993). In fact, patients with MS actually prefer 
more control in their healthcare decisions (Heesen, Kasper, Segal, Köpke, & Mühlhauser, 
2004). This is in contrast to the paternalistic approach, which advocates that health 
professionals decide what is best for the patient (i.e. patients take on a more passive role 
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in treatment decisions). However, this approach is now considered outdated in the context 
of modern healthcare services (Coulter, 1999).  
According to the patient-centred approach, patients should be incorporated in 
decisions about the treatments that are most suitable for their disease course and be 
encouraged to play an active role in the deliberation process (Michie, Miles, & Weinman, 
2003). This method of making decisions between patients and health professionals is 
referred to as the shared decision-making approach (Barry & Edgman-Levitan, 2012; 
Charles, Gafni, & Whelan, 1997, 1999; Godolphin, 2009; Stiggelbout et al., 2012). This 
approach is particularly suited to conditions where the disease course is unpredictable and 
there are variety of possible treatments available, each with different risk-benefit profiles, 
but no preferable treatment option (Charles et al., 1997, 1999; Heesen, Köpke, Solari, 
Geiger, & Kasper, 2013; Wagner & Groves, 2002). Moreover, shared decisions are more 
effective when conducted over a longer term, such as in chronic conditions like MS, in 
order for healthcare professionals and patients to fully engage with the decision-making 
process (Joosten et al., 2008).  
There are several key features that are involved in the shared decision-making 
approach. One key feature is the clear and accurate sharing of information between health 
professionals and patients, often considered a prerequisite for effective shared decision-
making (Barry & Edgman-Levitan, 2012; Charles et al., 1997, 1999; Elwyn, Frosch, & 
Rollnick, 2009; Makoul & Clayman, 2006; Quill & Brody, 1996). Patients can share their 
personal preferences and values with health professionals, for instance by conveying the 
treatment risks and benefits they will be willing to accept (Charles et al., 1999; 
Godolphin, 2009; Makoul & Clayman, 2006). This is crucial, given that patients’ 
attitudes towards risks are strongly related with the treatments they choose to initiate 
(Fraenkel, Bogardus Jr., & Wittink, 2003; Prosser, Kuntz, Bar-Or, & Weinstein, 2002). It 
is also important that health professionals share clear and accurate treatment information 
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with patients. Provision of information to patients relies on some autonomy on the part of 
patients, without advocating that patients be left completely burdened by treatment 
decisions; a type of approach which is not generally recommended (Deber, Kraetschmer, 
Urowitz, & Sharpe, 2007; Levinson, Kao, Kuby, & Thisted, 2005; Parascandola, 
Hawkins, & Danis, 2002). Information shared by health professionals can consist of: 
explaining the reasons for making a treatment decision, presenting all available treatment 
options, discussing and explaining the risks and benefits of all available options, and 
sharing personal knowledge and recommendations about treatments (Makoul & Clayman, 
2006; Thomson, 2013). However, in order for this information to be used effectively by 
patients during decision-making, it is essential that patients are able to fully understand 
the information they receive (Barry & Edgman-Levitan, 2012; Charles et al., 1997, 1999; 
Elwyn et al., 2009; Godolphin, 2009).  
1.3.2 Treatment adherence and discontinuation 
Misunderstanding treatment information can impact how patients adhere to 
treatments. This is particularly problematic for a chronic condition such as MS, as 
medications need to be adhered to for long periods of time in order to effectively reduce 
disability and delay progression of disease (Winkelmann et al., 2016). Increased 
adherence to DMDs can further lead to better clinical outcomes, such as lower risks of 
being hospitalised and fewer rates of relapses (Halpern, Agarwal, Dembek, Borton, & 
Lopez-Bresnahan, 2011; Steinberg, Faris, Chang, Chan, & Tankersley, 2010; Tan, Cai, 
Agarwal, Stephenson, & Kamat, 2011).  
MS patients are likely to discontinue treatments if they cannot tolerate the side-
effects and risks associated with their treatment (Giovannoni, Southam, & Waubant, 
2012; Jernas, Wencel, Wiak, Bieniek, & Bartosik-Psujek, 2016; Patti, 2010; Vangeli et 
al., 2015; Wicks et al., 2015), if disability increases following treatment (Rio et al., 2005), 
or if patients perceive their medication be less effective than when they began the 
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treatment (Menzin, Caon, Nichols, White, & Friedman, 2013; Vangeli et al., 2015). In 
order to improve treatment adherence, it has therefore been suggested that patients are 
provided with clear and accurate information about treatment risks and benefits during 
the decision-making process (Petrie, Perry, Broadbent, & Weinman, 2012; Smrtka, Caon, 
Saunders, Becker, & Baxter, 2010; Twork et al., 2007). 
In sum, adherence to DMDs is important for patients to observe benefits in their 
condition. Given that MS patients discontinue treatments due to high risks and poor 
efficacy, it is reasonable to expect that accurately understanding the risks and benefits of 
DMDs can lead to realistic expectations of treatment effects and subsequently improve 
adherence to treatment.   
1.3.3 Criteria for providing evidence-based patient information 
Patient understanding of DMD information can be facilitated by providing 
additional information to supplement, reinforce and improve the treatment information 
provided by clinicians during consultations (Bunge, Mühlhauser, & Steckelberg, 2010). 
In order to ensure patients are able to understand the information they receive, treatment 
information should be presented in an accessible, reliable and comprehensible manner. A 
number of recommendations have been made to ensure clear and accurate treatment 
information is provided to patients. This includes: using plain and standardised written 
language (Fagerlin, Zikmund-Fisher, & Ubel, 2011), providing unbiased information 
about the risks and benefits of treatments (Edwards, Elwyn, & Mulley, 2002; Paling, 
2003), and employing visual aids alongside numerical information (Bunge et al., 2010; 
Edwards et al., 2002; Fagerlin et al., 2011; Paling, 2003).  
MS patients’ understanding of the risks and benefits of DMDs may improve by 
implementing recommendations from the scientific literature. However, in order to 
determine whether these recommendations actually improve understanding and lead to 
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informed treatment decisions in MS, these methods should be empirically tested with the 
MS population. 
1.3.4 Summary 
Shared decision-making is crucial within a patient-centred approach in healthcare 
and is often used in the context of decision-making about treatments in chronic condition 
such as MS. A prerequisite of shared decision-making requires that patients communicate 
their preferences for treatments to health professional, and health professionals provide 
clear and accurate risk and benefit information about all available treatment options. It is 
essential that patients understand the information they receive in order to make decisions 
that correspond with their personal preferences. Misunderstanding treatment information 
and initiating treatments that do not reflect patient’s preferences can subsequently affect 
patients’ adherence to treatment. Patient understanding can be facilitated by presenting 
treatment information using methods that can be effectively understood. 
1.4 Thesis summary 
MS patients are faced with a high degree of uncertainty about their disease course 
and complex risk-benefit profiles of treatments which can potentially delay the 
progression of disease. Understanding the risks and benefits of DMDs is important to 
allow patients to make informed treatment decisions in line with personal preferences and 
adhere to treatments they initiate. However, it is likely that the complexity of DMD risk-
benefit profiles can increase difficulty in understanding treatment information. Fatigue, 
affective and cognitive symptoms of MS may further make MS patients more susceptible 
to misunderstanding treatment information. Following guidelines available in the 
literature, it is likely that patient understanding can be facilitated by presenting 
information using comprehensible methods.  
The following research proposes to develop an integrated intervention known as 
the Benefit and Risk Information for Medications in Multiple Sclerosis (BRIMMS) 
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protocol to maximise understanding of DMD risks and benefits and reduce conflict their 
treatment decisions. This protocol will be developed in light of the available literature and 
empirical studies conducted with MS patients about the best methods of presenting DMD 
information. An overview of the thesis is provided below and is also presented in figure 
1.1. 
First, chapter 2 will assess the literature on MS patients’ understanding and 
preferences of DMD risks and benefits using a systematic review methodology. A second 
systematic review will also be conducted to assess efficacy of current interventions that 
have been designed to maximise MS patients’ understanding of treatment information.  
Following this, chapter 3 will employ surveys with both MS patients and MS 
healthcare professionals to determine how MS patients currently understand DMD 
information and how treatment information is provided to patients in the UK. 
Chapters 4-6 will empirically evaluate different methods of presenting treatment 
risk and benefit information to MS patients. Specifically, chapter 4 will identify the best 
numerical and graphical formats of providing information, chapter 5 will identify the best 
numerical ratios and frames to present information and chapter 6 will explore how 
differences between risks and benefits from a clinical trial can be communicated to MS 
patients in an accessible manner. 
Findings from all chapters will subsequently inform the development of the 
evidence-based BRIMMS protocol. Chapter 7 will empirically evaluate the effectiveness 
of the BRIMMS protocol to maximise MS patients’ understanding and reduce conflict in 
treatment decisions by comparing this to standard methods of providing treatment 
information in healthcare using a randomised-controlled methodology. 
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Finally, chapter 8 will discuss limitations of the current thesis, future suggestions 
and general implications of the BRIMMS protocol to improve understanding in MS 
patients about DMDs.  
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Figure 1.1 Thesis overview 
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Chapter 2: Systematic reviews 
 
2.1 Introduction 
MS patients are faced with complex risk-benefit profiles of DMDs when making 
decisions about the best course of treatment (see section 1.2 for review about DMDs). It 
is important that MS patients are able to understand these risks and benefits to ensure 
treatment decisions are informed and in line with personal preferences, which can likely 
improve adherence to treatments and engagement with the decision-making process 
(Barry & Edgman-Levitan, 2012; Rieckmann et al., 2015; Smrtka et al., 2010).  
The current chapter sought to conduct two systematic reviews in order to evaluate 
MS patients’ understanding of the risks and benefits of DMDs: first, by systematically 
reviewing current status of MS patients’ understanding and preferences of DMD risks and 
benefits, and second, by systematically reviewing interventions that have been designed 
to improve MS patients’ understanding of DMD risks and benefits. 
2.2 Systematic review 1: MS patients’ understanding and 
preferences of DMDs1 
The first systematic review was conducted to explore MS patients’ current 
understanding and preferences for risks and benefits of treatments; factors important for 
effective decision-making. The primary aim of this review was to evaluate MS patients’ 
understanding of risk and benefit information for DMDs within standard healthcare. The 
secondary aim was to identify MS patients’ preferences for treatment risks and benefits, 
and assess to what extent these preferences informed MS patients’ treatment decisions. 
                                                     
1 This systematic review has been published as: Reen, G. K., Silber, E., & Langdon, D. W. (2017). 
Multiple sclerosis patients’ understanding and preferences for risks and benefits of disease-
modifying drugs: A systematic review. Journal of the Neurological Sciences, 375, 107–122 (see 
appendix 1).  
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2.2.1 Method 
2.2.1.1 Systematic literature search 
The systematic literature search was initially carried out in February 2015 and 
was subsequently updated for publication in February 2016. The search for studies was 
conducted in PubMed, Embase and Google Scholar using specific search terms for both 
study aims (see table 2.1). After removing duplicate entries, a total of 889 records were 
identified. 
Table 2.1 Search terms for Systematic review 1: Primary aim and secondary aim 
Search terms  
(Multiple AND Sclerosis) 
AND 
(patients OR people OR persons OR patient) 
AND 
(risk OR benefit OR side effect) 
AND  
(treatment OR medication OR therapy OR medicine OR medical OR therapies OR 
therapeutics OR Pharmaceutical preparations) 
AND 
(perception OR understanding OR comprehension OR awareness OR knowledge OR 
information OR communication OR preference OR decision-making) 
 
Studies were eligible for inclusion if they were: in English, with human adults 
and of any study design. Studies with patients of any MS disease subtype were included. 
No date restriction was applied. For both aims, studies were included if they had some 
evaluation of disease-modifying drugs and when the evaluations focused on patients with 
MS.  
Studies were excluded if they discussed medications for MS symptom 
management or complementary medicines. Studies with evaluation of patients’ 
understanding of disease-modifying drugs post educational intervention was not included. 
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However, baseline measures prior to any educational intervention were eligible for 
inclusion in the present review. Studies that assessed MS patients’ understanding of other 
areas in MS, including diagnosis and prognosis, were excluded. Studies focusing only on 
patients’ adherence to DMDs were also excluded.  
Following screening of titles and abstracts, 835 records were excluded. Full texts were 
subsequently accessed. Studies that were considered relevant from screening references 
were also identified. Thus, data was extracted for a total of 58 full-texts, and studies were 
included into the final review if inclusion and exclusion criteria were met (see figure 2.1).  
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Figure 2.1 Flow diagram for studies included in systematic review 1: Primary aim and secondary 
aim 
2.2.1.2 Data extraction 
Data extraction was carried out by one reviewer (GR) using data extraction forms 
specifically designed for the current review, and was verified by another (DL). Any 
discrepancies were resolved by discussion. After extraction of full texts, a total of 22 
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studies were included into the final review across both study aims. One study had relevant 
findings for both the primary aim and secondary aim. Thus, 14 studies were included into 
the primary aim and 9 studies were included into the secondary aim. 
Baseline characteristics of MS patients were extracted from all 22 studies, which 
covered age, the type of MS and current DMD status. Since very few studies exclusively 
assessed understanding or preferences of treatment risks and benefits in MS, studies with 
any evaluation of either aim were retained.  
For the primary aim, any data available on understanding of treatment risks or 
benefits, or understanding of the treatment overall, was retained. Only understanding of 
information about real DMDs was incorporated into this aim. This information sometimes 
existed as baseline measures in intervention studies. Both self-report and objective 
measures were included for review, in addition to themes from qualitative studies.  
For the secondary aim, patients’ preferences for treatment risks only, treatment 
benefits only and a combined trade-off between treatment risks and benefits were 
considered. Preferences for treatment risks and benefits were defined as patients’ attitudes 
towards risks and benefits, the levels of risks and benefits MS patients were willing to 
accept, or MS patients’ perception of their current DMD. Preferences for risks and 
benefits of both real DMDs and hypothetical treatment scenarios were included in this 
aim, providing that hypothetical risk-benefit scenarios were relevant to MS. Similar to the 
primary aim, information from self-report and objective measures were discussed. 
Relevant data was obtained from numerical information in texts, tables, graphs, 
and relevant statistical analysis. For qualitative studies, relevant themes were extracted 
and discussed. Medication names are given as reported in each study. Due to the 
heterogeneity of the studies in the present review, a narrative synthesis was conducted.  
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2.2.1.3. Quality assessment 
All studies in this review were examined independently for quality by two 
reviewers (GR and DL) using the Effective Public Health Practice Project (EPHPP) 
quality assessment tool for quantitative studies (Thomas, Ciliska, Dobbins, & Micucci, 
2004). This particular tool was chosen because it is often used to evaluate different types 
of quantitative studies in the health care setting (Armijo-Olivo, Stiles, Hagen, Biondo, & 
Cummings, 2012), it has high inter-rater reliability (Armijo-Olivo et al., 2012) and is 
considered ideal for use in systematic reviews (Deeks et al., 2003). As per the tool, the 
final quality rating was derived from the rating of 6 measures.  
The Critical Appraisal Skills Programme (CASP) tool was used to appraise the 
quality of qualitative studies in this review. This tool was chosen as it has often been 
recommended for reviewers (Hannes, Lockwood, & Pearson, 2010) and was previously 
used in other systematic reviews (Campbell et al., 2003)  
2.2.2 Results of primary aim 
2.2.2.1 Patient and study characteristics 
A total of 14 studies were included in the primary aim. With the exception of 
three qualitative studies (Miller, Karpinski, & Jezewski, 2012; Miller & Jezewski, 2006; 
Miller, Jezewski, Miller, & Jezewski, 2001), the studies mostly consisted of surveys and 
questionnaires. Data from some studies was derived from baseline measures of 
randomised-controlled trials (Zimmer et al., 2015; Köpke et al., 2014; Mohr et al., 1996). 
Two quantitative studies were found to have the strongest quality rating (Köpke et al., 
2014; Mohr et al., 1996; see appendix 1 for table of results). 
Across the 14 studies, a total 8032 patients were included with a range of MS 
disease subtypes, which comprised: 27 (0.3%) patients with Clinically Isolated Syndrome 
(CIS), 2,532 (31.5%) Relapsing-remitting MS (RRMS) patients, 349 (4.3%) Primary 
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Progressive MS (PPMS) patients and 870 (10.8%) Secondary Progressive MS (SPMS) 
patients. Of the remaining, 251(3.1%) patients were reported as having benign MS, with 
unclear or unreported MS disease subtype for all other MS patients (49.8%). The mean 
age of patients was 42 (range: 34 – 50). The mean value excludes MS patients in studies 
that only stated the median values of age (Visser & Van Der Zande, 2011), the range of 
ages (Miller & Jezewski, 2006; Miller et al., 2001) and those studies that did not specify 
age of MS patients (Mohr et al., 1996; Vlahiotis et al., 2010). 
Of the studies which recorded the patient’s current DMD, the majority of patients 
were taking first-line treatments, including interferons in seven studies (Abolfazli et al., 
2014; de Seze, Borgel, & Brudon, 2012; Köpke et al., 2014; Miller et al., 2001; Mohr et 
al., 1996; Syed, Rog, Parkes, & Shepherd, 2014; Vlahiotis et al., 2010) and glatiramer 
acetate in four studies (de Seze et al., 2012; Köpke et al., 2014; Miller & Jezewski, 2006; 
Vlahiotis et al., 2010). MS patients taking aggressive medications were also recorded, 
including natalizumab (Miller et al., 2012), fingolimod (Zimmer et al., 2015) and 
mitoxantrone (Hofmann et al., 2012; Vlahiotis et al., 2010). Eight studies focused 
primarily on MS patients taking a single DMD (Zimmer et al., 2015; Abolfazli et al., 
2014; Hofmann et al., 2012; Miller et al., 2012; Miller & Jezewski, 2006; Miller et al., 
2001; Mohr et al., 1996; Syed et al., 2014; see section 1.2 for reviews about DMDs). 
2.2.2.2 Study outcomes 
Understanding of overall treatment information 
MS patients’ understanding of overall DMD information during their routine 
healthcare system was assessed using questionnaires and surveys by seven studies. 
Self-report measures in one study indicated that 44% of MS patients considered 
themselves extremely well-informed about their current DMD (Syed et al., 2014). Using a 
visual analogue scale in another study, just under 20% of patients reported being fully 
informed about current DMDs (Zimmer et al., 2015). Using retrospective surveys, 28% of 
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patients reported being well-informed about DMDs at time of diagnosis, with just over 
50% patients stating that they did not receive any information about DMDs at diagnosis 
(Heesen, Kolbeck, Gold, Schulz, & Schulz, 2003). On the other hand, between 75% to 
84% of MS patients reported being partly or totally informed about current DMDs (de 
Seze et al., 2012; Visser & Van Der Zande, 2011), and 85% of MS patients felt they were 
aware about other DMD treatment options based on one question from a 12-item 
questionnaire (Vlahiotis et al., 2010). Of those patients who felt informed about DMDs, 
71% of MS patients felt the information received was of a sufficient standard (Heesen et 
al., 2003). 
Objective measurements were used by two studies within the present review to 
establish MS patients’ understanding of overall treatment information. Abolfazli and 
colleagues (2014) administered a 25-item questionnaire to MS patients, nine questions of 
which assessed understanding of the first-line treatments in general, and three questions 
each focused on understanding of the five specific DMDs that fell within this category. 
Only 30% of MS patients were able to correctly answer seven of the nine questions that 
assessed understanding of the drugs generally, with the remaining two questions 
answered correctly by just over 60% of MS patients. The authors concluded that 
understanding of overall information about first-line DMDs was low for the assessed MS 
patients (Abolfazli et al., 2014). Another study also employed an objective questionnaire, 
which was presented to patients as part of a baseline measure before intervention 
(Zimmer et al., 2015). MS patients in this study answered a median of six questions 
correctly about overall understanding of their current DMD from a maximum score of 18 
(Zimmer et al., 2015). Both studies also analysed factors which were associated with 
greater understanding by MS patients for overall information about DMDs.  A common 
significant patient factor associated with better understanding across both studies was 
gender, since females displayed greater understanding of overall information about first-
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line DMDs (Abolfazli et al., 2014) and the more aggressive treatment fingolimod 
(Zimmer et al., 2015). Greater understanding of overall DMD information was also 
related to: a high level of education (Abolfazli et al., 2014), the delay between onset of 
symptoms and diagnosis of MS (Abolfazli et al., 2014), increased mobility (Abolfazli et 
al., 2014), younger age (Abolfazli et al., 2014), ability to self-inject for some first-line 
treatments (Abolfazli et al., 2014) and patients who were in a relationship as opposed to 
being single (Zimmer et al., 2015). 
In summary, the majority of studies which assessed MS patients’ understanding 
of overall DMD information relied heavily on patient self-reports. Although the findings 
varied both within and across studies, it is clear that not all patients feel sufficiently 
informed about DMDs during the routine healthcare system. This is also supported by 
objective measures, albeit in only a few studies. The factors associated with good 
understanding of overall DMD information were also inconsistent, with only females 
showing a consistent advantage across two studies.  
Understanding of treatment risks 
MS patients’ understanding of treatment risks was evaluated by four studies in 
this review.  
Perceived accurate understanding of the risks of unspecified DMDs was reported 
by 63% of MS patients in one study (Heesen et al., 2004). A qualitative study 
interviewing MS patients taking the aggressive treatment natalizumab showed mixed 
findings for understanding of the risks associated with this treatment; patients 
demonstrated both high and low perceived risk (Miller et al., 2012). 
Three studies used objective questionnaires to assess understanding of DMD 
risks, with two of these studies administering a similar adapted 19-item questionnaire 
designed for newly diagnosed patients (Heesen et al., 2004; Köpke et al., 2014). 
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Approximately 30% of MS patients showed ‘good risk knowledge’ for their DMD based 
on their scores from this questionnaire (Köpke et al., 2014). For the other study 
employing a similar questionnaire, MS patients were only able to answer 34% of the 
questions correctly on average despite perceiving their risk knowledge as good (Heesen et 
al., 2004). Significant correlations were also established between greater understanding of 
DMD risks and patients who had been recently diagnosed, had the RRMS disease 
subtype, and were of a younger age (Heesen et al., 2004). To note, questionnaires 
employed in both studies primarily measured understanding of the risks associated with 
MS in general, with only a portion of the questions explicitly focusing on risk 
understanding of DMDs. In another study employing objective methodology for the 
understanding of the aggressive DMD mitoxantrone, 55% of MS patients underestimated 
the risk of leukaemia, and up to 82% of MS patients underestimated the risk of 
cardiotoxicity; both adverse risks associated with this DMD (Hofmann et al., 2012). 
These findings were based on baseline measures of an interventional study (Hofmann et 
al., 2012). 
In summary, although MS patients show mixed perception towards their 
understanding of DMD risks, objective measures seem to indicate that DMD risks are 
generally low and underestimated by MS patients during the routine healthcare system. 
Understanding of treatment benefits 
MS patients’ understanding of the benefits associated with their treatment was 
evaluated by five studies in the present review. 
 Over 70% of MS patients taking a range of DMDs believed their current DMD 
could help their MS (Vlahiotis et al., 2010). Likewise, a large number of MS patients 
totally or partially perceived their current medication to have strong benefits: 90% of MS 
patients perceived that their DMD could reduce the frequency of MS relapses, 86% of 
MS patients believed that their current medication could delay the progression of disease 
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and just over 70% of MS patients were generally optimistic about their condition as a 
result of taking their current medication (de Seze et al., 2012). In two qualitative studies, 
MS patients taking first-line treatments described their medication as a “saviour” (Miller 
et al., 2001) and believed that taking the DMD felt as if they were “doing something 
progressive” towards their condition (Miller & Jezewski, 2006).  
Only one early study employed an objective methodology to measure 
understanding of DMD benefits. Mohr and colleagues (1996) administered a 12-item 
questionnaire prior to providing an intervention. Only 39% of MS patients accurately 
reported the benefits of taking their first-line DMD, and 57% of MS patients were found 
to optimistically and incorrectly state that MS relapses could be reduced by a half 
following uptake of their current DMD (Mohr et al., 1996). 
Acknowledging the difficulty of comparing studies with self-report and objective 
measures, and those encompassing MS patients taking a range of DMDs, the limited data 
in the current review indicates a general trend towards underestimation of treatment risks 
and overestimation of treatment benefits by MS patients during the routine healthcare 
system. 
2.2.3 Results of secondary aim 
2.2.3.1 Patient and study characteristics 
The studies in this part of the review consisted mostly of surveys and 
questionnaires. One study that has previously been reviewed in the primary aim also 
included findings relevant to the secondary aim (Abolfazli et al., 2014).  Only one study 
in this section of the review was found to have the strongest quality rating (Kasper, 
Köpke, Mühlhauser, Nübling, & Heesen, 2008; see appendix 1 for table of results). 
From the final 9 studies included into the secondary aim, a total of 7427 patients 
were included with a range of MS disease subtypes, comprising of: 45 (0.6%) CIS 
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patients, 652 (8.4%) RRMS patients, 31 (0.4%) PPMS patients and 59 (0.8%) SPMS 
patients. Majority of the studies did not clearly report or specify the MS disease subtype 
(89.8%). The mean age of MS patients was 42 (range: 34 – 52). 
Of the studies which reported the current DMDs of MS patients, the majority 
reported patients taking first-line treatments, which includes interferons in five studies 
(Abolfazli et al., 2014; Prosser et al., 2002; Tur et al., 2013; Wilson et al., 2014; Wilson 
et al., 2015) and glatiramer acetate in four studies (Prosser et al., 2002; Tur et al., 2013; 
Wilson et al., 2014; Wilson et al., 2015). Patients taking more aggressive DMDs also 
formed a part of this review, specifically patients taking natalizumab (Johnson et al., 
2009; Tur et al., 2013; Wilson et al., 2014; Wilson et al., 2015), fingolimod (Wilson et al., 
2014; Wilson et al., 2015) and rituximab (Wilson et al., 2015). Two studies focused 
primarily on a single DMD (Abolfazli et al., 2014; Johnson et al., 2009). 
2.2.3.2 Study outcomes 
Preferences for treatment risks   
Four studies, each employing objective methodologies, looked at MS patients’ 
preferences for the risks of taking a treatment.  
Tur and colleagues (2013) assessed the level of risks that MS patients were 
willing to accept for hypothetical therapeutic scenarios. The authors also assessed the 
relationship between accepted levels of hypothetical treatment risks and current DMDs 
taken by MS patients. A visual analogue scale showed that MS patients on the aggressive 
treatment natalizumab were willing to accept higher levels of hypothetical treatment risks 
in comparison to MS patients on any other DMD (Tur et al., 2013).  
Hypothetical treatment scenarios were employed by two further studies using 
objective methodologies, which compared MS patients’ preferences for different levels of 
treatment risks (Wilson et al., 2014; Wilson et al., 2015). Both studies confirmed that 
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DMDs with significant adverse risks were less preferred than DMDs with minor side-
effects. In fact, both studies revealed that medications with no possibility of death or 
disability were significantly favoured to a medication with even a very low possibility 
(0.05% to 1%) of death or disability (Wilson et al., 2014; Wilson et al., 2015). Mood 
changes were the only side-effect that would decrease the probability of taking a DMD by 
MS patients (Wilson et al., 2014; Wilson et al., 2015). 
Using a standard gamble question task, another study employed a hypothetical 
treatment scenario which presented information about a treatment that could cure MS, 
and a real treatment scenario which presented the risk profile of the aggressive DMD 
natalizumab (Fox et al., 2015). MS patients showed similar preferences for risks in both 
the hypothetical and real treatment risk scenarios, as adverse risks were accepted when in 
the range of 1 in 10,000 (Fox et al., 2015). For the hypothetical treatment scenario, MS 
patients that were significantly likely to prefer higher levels of adverse risks were those 
presenting with the following characteristics: wheelchair bound, male, not responsible for 
dependents, not currently taking a DMD, taking natalizumab and not routinely wearing a 
seatbelt for car travel (Fox et al., 2015). With the exception of MS patients who were not 
taking a DMD, the same characteristics of MS patients preferred higher levels of 
treatment risks in the real DMD scenario (Fox et al., 2015).  
Despite the comparison of hypothetical and real treatment risk profiles in this 
section of the review, MS patients showed similar low preferences for treatment risks. 
Preferences for treatment benefits  
MS patients’ preferences for treatment benefits were assessed by five studies in 
the present review. 
Two studies used subjective measures to assess the preferences of MS patients 
towards treatment benefits (Abolfazli et al., 2014; Kasper et al., 2008). The number of 
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MS patients with a positive outlook towards their current DMD ranged from 20% to 90% 
within one study (Abolfazli et al., 2014) and was approximately averaged at 60% in 
another (Kasper et al., 2008). Patient factors significantly associated with a positive 
attitude were patients with: lack of functional problem, no MS family history and 
knowledge of their current DMDs (Abolfazli et al., 2014).  
Turning to objective measures, Prosser and colleagues (2002) utilised a gamble 
health outcomes task using hypothetical treatment scenarios to assess preferences of MS 
patients for treatment benefits. During this task, patients were required to choose either a 
drug offering a particular number of relapse-free days, or a drug offering a 50% chance of 
ending the MS relapse immediately but with 50% chance of the drug not working at all. 
On average, patients chose drugs likely to lead to 14.6 MS relapse-free days from the 
possible 29, implying a preference towards treatments offering moderate but guaranteed 
benefits. However, the authors did note that approximately 30% of MS patients chose an 
extreme number of relapse-free days, i.e. either 1 or 29 (Prosser et al., 2002). 
The frequency of MS relapses was also used as an outcome measure to assess MS 
patients’ preferences for treatment benefits in the remaining two studies and was 
compared alongside other benefits that DMDs typically offer (Wilson et al., 2014; Wilson 
et al., 2015). The highest preference for MS patients in one study was for substantial 
symptom improvement in MS, followed by prevention of disease progression over 10 
years, mild symptom improvement and a five-year delay in MS relapses (Wilson et al., 
2014). Administration in the form of an IV infusion or oral pill was also significantly 
preferred by MS patients. In fact, the ability to administer the drug orally was preferred 
even over a five-year delay in relapse (Wilson et al., 2014).  Likewise, any form of 
improvement in symptoms and the ability to take the drug orally were also strongly 
preferred by MS patients in the latter study (Wilson et al., 2015). However, unlike the 
previous findings, MS patients in this study showed no significant preference for delay in 
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MS relapses or administration of drugs via IV infusion (Wilson et al., 2015). 
Additionally, the ability to prevent MRI progression over the years was used as an 
indicator only in this study and was significantly preferred by MS patients (Wilson et al., 
2015).  
Although all studies in this review assess MS patients’ preferences for treatment 
benefits, chiefly for hypothetical treatment scenarios, the results are not directly 
equivalent as the range and actual treatment benefits offered to patients differed greatly 
between studies. In general, treatments offering high symptom improvement, a delay in 
disease progression, reduction in relapses and particular administration methods were 
preferred. 
Preferences for treatment risk-benefit profiles  
Three studies objectively measured the risk-benefit trade-off by offering MS 
patients the choice of benefits and risks for hypothetical treatments, using the conjoint 
analysis method (Johnson et al., 2009; Wilson et al., 2014; Wilson et al., 2015). Whilst all 
three studies used a similar objective methodology, the studies employed different 
treatment risk and benefit scenarios. Johnson and colleagues (2009) demonstrated that for 
a five-year delay of disease progression, a 0.48% risk of death by Leukaemia was 
acceptable for MS patients; which increased to 1.08% for an eight-year delay of disease 
progression. For a similar delay of disease progression, the acceptable risk of death by 
liver failure increased by 0.53%, and acceptable risk of severe disability or death from 
PML increased by 0.36% (Johnson et al., 2009). Wilson and colleagues (2014) found that 
patients were willing to accept 0.7% risk of developing PML given a delay in the 
progression of disease. Up to 1% adverse risks were accepted by MS patients if 
substantial improvements in symptoms could be demonstrated by the treatment (Wilson 
et al., 2014). Patients were willing to accept up to 0.59% of severe adverse effects if 
drugs could be administered orally (Wilson et al., 2014). In fact, this level of risk 
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acceptance was higher than for drugs which could delay the progression of MS by four 
years (Wilson et al., 2014) or could reduce the frequency of MS relapses from four yearly 
to no relapses within the next five years (Johnson et al., 2009). Further, a risk of up to 
30% of severe adverse effects was acceptable for MS patients given 32 years of delay in 
progression of MS (Wilson et al., 2015).  
The study by Bruce and colleagues (2015) also assessed risk and benefit trade-
offs of hypothetical treatment scenarios by using a Medical Decision Making 
Questionnaire (MDMQ). Similar to previous studies, the choice of whether to uptake a 
treatment for all patients differed significantly according to the combination of treatment 
risks and benefits (Bruce et al., 2015). Additionally, patients who were adherent to their 
current unspecified treatment were willing to take medications with significantly higher 
combinations of risks and benefits than patients who were identified as non-adherent 
(Bruce et al., 2015). 
In summary, despite using similar measures to objectively assess trade-offs of 
treatment risks and benefits, the three studies employed very different combinations of 
risks and benefits, limiting any generalised conclusions that may be based on these 
findings. However, it was clear from these studies that preferred combinations of 
treatment risks and benefits play a key role in the choice of treatment.  
2.2.4 Discussion 
This systematic review was conducted to explore MS patients’ understanding of 
DMD risks and benefits acquired through standard healthcare and MS patients’ 
preferences for these risks and benefits; factors likely to impact shared decision-making. 
MS patients with different disease subtypes and those taking a range of DMDs were 
assessed by 22 studies in the present review. Understanding of DMD risks and benefits 
were mostly addressed as part of a larger project. MS patients’ preferences for risks and 
benefits were generally assessed using treatments offering hypothetical risks and benefits. 
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Studies employed both subjective and objective measures. The majority of studies had 
methodologies that precluded firm conclusions. 
For effective decision-making, clear and accurate DMD information should be 
provided to MS patients in order to facilitate understanding of treatment risks and 
benefits. Yet, it appears from the present review that MS patients do not sufficiently 
understand information about DMDs following routine consultations in their standard 
healthcare system. Despite evaluating their risk knowledge as high (Heesen et al., 2004), 
MS patients in this review showed poor objective risk understanding (Heesen et al., 2004; 
Köpke et al., 2014). There was a trend towards underestimation of treatment risks 
(Hofmann et al., 2012; Vlahiotis et al., 2010). This is problematic for long-term treatment 
adherence as some patients are likely to initiate a treatment that they perceive has lower 
risks but then discontinue treatment when the risks are higher than initially expected 
(Colombo et al., 2014; Lizan et al., 2014). MS patients in this review were generally 
optimistic about the benefits of their current DMD (Kasper et al., 2008; Miller et al., 
2012; Miller et al., 2001; Vlahiotis et al., 2010). However, many patients overestimated 
the benefits of their DMD in reducing the frequency of relapses and delaying progression 
of disease (de Seze et al., 2012; Mohr et al., 1996). Thus, patients’ optimism towards 
DMDs may not often accurately reflect the actual benefits of the drugs. This can further 
impact treatment adherence since patients who do not accurately understand the benefits 
of DMDs are more likely to discontinue treatments over time (Lizan et al., 2014), perhaps 
as optimism for medications is replaced with the realisation that the medication does not 
offer expected levels of benefits. In fact, a significant relationship between patients who 
understand information about their treatments and their adherence to treatments is 
apparent in several studies, including those in the present review (de Seze et al., 2012; 
Köpke et al., 2014; Lizan et al., 2014; Twork et al., 2007). Providing accurate and easily 
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understandable risk and benefit information to MS patients should therefore improve 
treatment adherence towards their chosen treatment.  
Effective shared decision-making also requires patients to communicate their 
preference for a particular treatment. Preferences for risks and benefits of treatments are 
likely to influence decisions about which treatment to initiate (Currie et al., 2014; 
Fraenkel, 2013; Gong et al., 2015). The secondary aim of the present review therefore 
assessed the extent to which preferences towards risks and benefits that DMDs typically 
offer can impact MS patients’ treatment decisions. As anticipated, even very low levels of 
adverse risks reduced patients’ preference to take the treatment, and extremely small 
variations in risk had a significant impact on hypothetical treatment decisions (Fox et al., 
2015; Wilson et al., 2014; Wilson et al., 2015). Preference for medications with adverse 
risks rarely exceeded 1%.  Preferences for risks also varied with certain patient factors, as 
higher risks were generally accepted by males, functionally impaired individuals, or 
people already taking aggressive treatments such as natalizumab (Fox et al., 2015; Tur et 
al., 2013). Similarly, certain benefits that DMDs typically offer were significantly 
preferred over others and had an impact on the choice of treatment. Remarkably, patients 
strongly favoured medications that could provide symptom improvement (Wilson et al., 
2014; Wilson et al., 2015), which implies limited understanding of MS treatments since 
DMDs are not able to relieve symptoms of MS. Note, however, that medications 
presented in both studies employed hypothetical treatment scenarios and therefore it is 
possible that patients perceived symptom improvement as hypothetical despite accurate 
understanding of DMD benefits (Wilson et al., 2014; Wilson et al., 2015). It is 
nevertheless interesting that patients are likely to take higher risks if DMDs can 
seemingly help improve symptoms of their condition. MS patients in this review also 
showed a greater preference for treatments offering large reductions in frequencies of 
relapses, longer delay in disease progression and drugs that could be administered orally, 
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being prepared to accept a greater likelihood of risk in return (Bruce et al., 2015; Johnson 
et al., 2009; Wilson et al., 2014; Wilson et al., 2015).  
Overall, MS patient preferences varied according to different combinations of 
treatment risks and benefits, and had a significant impact on their choice of treatment. 
Thus, it is important to elicit patient preferences for DMD risks and benefits alongside 
increasing patients’ understanding of treatments, in order to improve shared decision-
making in MS. 
2.3 Systematic review 2: Interventions to support MS patients’ 
understanding of DMDs2 
The first systematic review showed that MS patients do not have sufficient 
understanding of the complex risk-benefit profiles of DMDs. To facilitate understanding, 
patients should ideally be presented with treatment options and treatment risk-benefit 
profiles in a clear and coherent manner (Bunge et al., 2010; Thompson, 2013). 
Interventions have been designed to provide information about the risks and benefits of 
DMDs that patients may seek beyond routine healthcare. Köpke, Solari, Khan, Heesen 
and Giordono (2014) recently reviewed 10 interventions designed to aid patient 
understanding of MS related information, which includes two interventions that 
specifically provided information about the risks and benefits of DMDs. Although all 
interventions reviewed were different in many respects, understanding of the disease 
generally improved post-intervention. Despite this improvement there was no conclusive 
effect on decision-making. This review, however, was limited to randomised controlled 
trials only, which does not allow for a comprehensive evaluation of all interventions that 
provide MS information beyond routine healthcare, particularly information on the risks 
and benefits of DMDs (Köpke et al., 2014). 
                                                     
2 This systematic review has been published as: Reen, G. K., Silber, E., & Langdon, D. W. (2016). 
Interventions to support risk and benefit understanding of disease-modifying drugs in Multiple 
Sclerosis patients: A systematic review. Patient Education and Counseling. (see appendix 2). 
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Thus, a second systematic review was conducted to evaluate interventions that 
have been primarily designed to improve understanding of risks and benefits of DMDs 
for MS patients.  
2.3.1 Methods 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) recommendations were used as guidelines for the presentation of this review 
(Moher, Liberati, Tetzlaff, Altman, & Grp, 2009).  
2.3.1.1 Systematic literature search 
The systematic literature search was also conducted in April 2015 and updated 
for publication in November 2016. The search was carried out using PubMed, Embase, 
Google Scholar and PsyINFO. Uniform search terms were developed and used with all 
databases (see table 2.2). 
Table 2.2 Search terms for systematic review 2 
Search terms 
(Multiple AND Sclerosis) 
AND 
(patients OR people OR persons OR patient) 
AND 
(risk OR benefit OR side effect OR treatment OR medication OR therapy OR medicine 
OR medical OR therapies OR therapeutics OR pharmaceutical preparations) 
AND 
(format OR framing OR educating OR design OR informing OR health literacy OR 
strategy OR program OR intervention OR communicating OR information OR education 
OR learning) 
AND 
(perception OR understanding OR comprehension OR awareness OR knowledge OR 
decision-making) 
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2.3.1.2 Eligibility criteria 
The inclusion criteria for the studies in the present review were studies in 
English, with human adults and with patients of any clinical subtype of MS. No date 
restriction was applied. Studies were not limited to any particular study design. No 
restrictions were placed on the type of control group. Studies were required to have 
interventions which provided information about treatments to MS patients. These 
interventions could either include real DMD information or information about fictitious 
treatments which would eventually support the understanding of DMD information. The 
studies were excluded if they consisted of information about complementary medicines or 
medications for the management of MS symptoms. Interventions were defined as any 
additional strategy or decision-aid which provided treatment information beyond that 
given during routine healthcare. Studies with some form of evaluation of these 
interventions were retained. 
Studies were excluded if they evaluated educational interventions for 
complementary medicines or medications for the management of MS symptoms. Studies 
assessing patients’ understanding of disease diagnosis or prognosis were not eligible for 
inclusion. Studies without any form of educational intervention, with interventions based 
on other aspects of MS such as cognition or self-management, interventions aimed 
primarily at health professionals, an intervention protocol for an upcoming study with no 
existing data, or interventions not exclusive to patients with MS, were also excluded from 
the review. 
All titles and abstracts were screened. Studies that were considered relevant from 
additional reference checking were also included. At this stage, 96 studies were 
considered for eligibility and full texts were subsequently accessed (see figure 2.2). 
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Figure 2.2 PRISMA flow chart for studies included in systematic review 2 
 
2.3.1.3 Data extraction 
Data extraction forms were created to extract relevant information from the full 
texts, and assess their eligibility into the final review. Extraction was initially carried out 
by one reviewer (GR) and was verified by another (DL).  Any discrepancies were 
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resolved by discussion. Following data extraction, 81 studies were excluded from the 
final review (see figure 1). 
Baseline characteristics of participants were extracted from the 15 shortlisted 
studies, comprising (where reported) age, type of MS, disease duration, time since 
diagnosis and current DMD. Study design and methodology was recorded. Information 
about the interventions was further extracted, including the content, length, presentation 
methods and any additional details of how the interventions were conducted. 
The impact of the interventions on either understanding of treatment information 
overall or understanding of treatment risks and benefits specifically was also extracted in 
the present review and incorporates data from self-report and objective measures. 
Patients’ feedback of the interventions was also retained. Relevant data for the present 
review was obtained from numerical information in texts, tables and graphs, and 
statistical analysis. 
2.3.1.4 Quality assessment 
Quality was independently examined by two reviewers (GR and DL) using the 
Effective Public Health Practice Project (EPHPP) quality assessment tool for quantitative 
studies (Thomas et al., 2004). This particular tool was chosen as it can evaluate all types 
of quantitative studies in the health care setting (Armijo-Olivo et al., 2012), has high 
inter-rater reliability (Armijo-Olivo et al., 2012) and is often considered ideal for 
systematic reviews (Deeks et al., 2003). As per the tool, the final quality rating was 
derived from the rating of six measures: selection bias, study design, confounders, 
blinding, data collection methods, and withdrawals or drop-outs. 
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2.3.2 Results 
2.3.2.1 Study design and participant demographics 
Fifteen studies were shortlisted in the review and comprised interventions which 
were primarily designed to improve understanding of DMD risk and benefit information 
in MS patients. Four studies in this review evaluated interventions using a randomised 
controlled procedure (Kasper et al., 2008; Kasper, Heesen, Köpke, Mühlhauser, & Lenz, 
2011; Köpke et al., 2014; Rahn et al., 2016). A type of control group was present in seven 
studies (Basso et al., 2010; Feicke, Spörhase, Köhler, Busch, & Wirtz, 2014; Heesen et 
al., 2010; Kasper et al., 2008; Köpke et al., 2016; Köpke et al., 2014; Rahn et al., 2016) 
and baseline scores prior to the intervention were recorded by ten studies (Zimmer et al., 
2015; Feicke et al., 2014; Freidel, Ortler, Fuchs, Seibert, & Schuh, 2015; Hofmann et al., 
2012; Kasper et al., 2011; Kasper, Köpke, Mühlhauser, & Heesen, 2006; Kopke et al., 
2016; Köpke et al., 2014; Mohr et al., 1996; see appendix 2 for table of results). 
Five of the 15 studies were considered to be of a high quality (Kasper et al., 
2008; Kasper et al., 2011; Köpke et al., 2016; Köpke et al., 2014; Mohr et al., 1996), with 
three studies deemed weaker in quality (Colombo et al., 2016; Hofmann et al., 2012; 
Rahn et al., 2016). Four of the 15 studies had interventions that fulfilled or reported at 
least 4 of the 8 criteria for evidence-based patient information. The most commonly 
reported criteria in the interventions were the use of comprehension enhancing tools, 
involvement of patients in the development process and inclusion of numerical data. 
A total of 2552 MS patients were included across 15 studies and had a range of 
MS disease subtypes, comprising: 79(3.1%) CIS patients, 1064 (41.7%) RRMS patients, 
214 (8.4%) PPMS patients and 391 (15.3%) SPMS patients. The remaining MS patients 
had unclear or unreported MS disease subtype (31.5%). The mean age of patients was 
43.1 years (range: 37– 50). One study did not allow for calculation of mean age (Mohr et 
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al., 1996) and two studies only presented median or mode values for age (Zimmer et al., 
2015; Heesen et al., 2010). Two studies also included 105 non-MS patients with a mean 
age of 43.5 years (Basso et al., 2010; Colombo et al., 2016).  
Nine studies reported patients’ disease duration from initial MS symptoms 
(Colombo et al., 2016; Feicke et al., 2014; Heesen et al., 2010; Hofmann et al., 2012; 
Kasper et al., 2011, 2006; Köpke et al., 2014; Rahn et al., 2016; Tur et al., 2012), with an 
average of 9.2 years. Five studies reported time since MS diagnosis (Zimmer et al., 2015; 
Freidel et al., 2015; Kasper et al., 2008; Kopke et al., 2016; Köpke et al., 2014), with an 
average of 5.8 years. 
Only one included study reported patients’ objective cognitive status (Basso et 
al., 2010). Patients were assessed on the California Verbal Learning Test-II (CVLT-II), 
Wisconsin Card Sorting Test-64 (WCST) and the Digit Span subtest from Wechsler 
Adult Intelligence Scale. MS patients were considered to be cognitively impaired if they 
scored below the 5th percentile of at least one cognitive measure (Basso et al., 2010). 
A total of 1384 (54.2%) MS patients had taken disease-modifying drugs during 
the course of their disease and 188 (7.4%) MS patients had not taken a DMD. The 
remaining studies did not specify DMD status (980 MS patients, (38.4%)). Of studies 
reporting MS patients’ current DMD, 273 patients were on the first-line treatment 
interferon-beta (Freidel et al., 2015; Köpke et al., 2014; Mohr et al., 1996), and the 
remaining patients were taking second-line treatments, with 53 patients on Mitoxantrone 
(Hofmann et al., 2012), 173 patients on Natalizumab (Heesen et al., 2010; Tur et al., 
2012) and 98 patients on fingolimod (Zimmer et al., 2015). In majority of these studies, 
DMD status was known by treating physicians or researchers involved with the study 
(Zimmer et al., 2015; Feicke et al., 2014; Freidel et al., 2015; Heesen et al., 2010; 
Hofmann et al., 2012; Mohr et al., 1996; Tur et al., 2012). 
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2.3.2.2 Intervention characteristics 
Intervention type  
The majority of interventions contained a booklet or leaflet for MS patients 
(Freidel et al., 2015; Heesen et al., 2010; Hofmann et al., 2012; Kasper et al., 2008; 
Kasper et al., 2011; Köpke et al., 2014; Tur et al., 2012). These leaflets ranged from 
providing comprehensive information (120 pages, (Kasper et al., 2008); 57 pages (Köpke 
et al., 2014)) to short summaries (Heesen et al., 2010; Hofmann et al., 2012). The booklet 
length was unclear in three studies (Freidel et al., 2015; Kasper et al., 2008; Tur et al., 
2012). Three interventions which included booklets also contained an additional 
intervention component (Freidel et al., 2015; Kasper et al., 2008; Köpke et al., 2014). A 
short vignette of information was read aloud in one intervention but was not handed to 
patients in the form of a booklet or leaflet (Basso et al., 2010).  
Four studies evaluated interventions with interactive modules, defined as 
involving patients during the intervention process. This includes discussions (Zimmer et 
al., 2015; Köpke et al., 2014), exercises (Kasper et al., 2008; Köpke et al., 2014) and 
questions and answers (Freidel et al., 2015; Köpke et al., 2014). 
Multicomponent educational programmes were utilised as an intervention in four 
studies. Four of these programmes were conducted by health professionals (Zimmer et al., 
2015; Freidel et al., 2015; Kopke et al., 2016; Mohr et al., 1996) and one education 
programme was conducted by a non-medical person (Köpke et al., 2014).  
Intervention content 
All bar one intervention (Mohr et al., 1996), provided some form of treatment 
risk information to patients with MS. Interventions also included information about: 
treatment benefits (Basso et al., 2010; Kasper et al., 2008; Kasper et al., 2011; Köpke et 
al., 2014; Mohr et al., 1996), alternative DMDs available to patients (Basso et al., 2010; 
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Köpke et al., 2014), efficacy studies for DMDs (Zimmer et al., 2015; Köpke et al., 2014), 
DMD decision-making (Kasper et al., 2008; Köpke et al., 2014), administration of DMDs 
(Zimmer et al., 2015; Freidel et al., 2015) and tailored information about DMDs for 
patients’ disease subtype (Kasper et al., 2008; Tur et al., 2012). 
Intervention presentation methods 
 Many different methods to present information were employed in the 
interventions. Methods which provided numerical information was manipulated by some 
studies, for instance by presenting or giving explanations for absolute risk numbers 
(Hofmann et al., 2012; Kasper et al., 2008; Kasper et al., 2011) and relative risk numbers 
(Kasper et al., 2011). Two studies used graphical formats in the form of pictograms to 
give treatment information (Kasper et al., 2008; Kasper et al., 2011). One study focused 
on whether the information was framed in a positive or negative manner (Kasper et al., 
2008).  
Some interventions also provided treatment information using interactive 
methods, which includes: questions and answers (Freidel et al., 2015; Köpke et al., 2014), 
discussions in person (Freidel et al., 2015; Köpke et al., 2014), recognition cues (Basso et 
al., 2010), information presented in short successions (Basso et al., 2010) and interactive 
exercises presented at the end of interventions (Zimmer et al., 2015; Kasper et al., 2008; 
Köpke et al., 2014). Media and technology was used to present treatment information in 
two studies (Köpke et al., 2014; Mohr et al., 1996).  
Together, these strategies were designed to optimise understanding of the risks 
and benefits of DMDs. 
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2.3.2.3 Intervention outcomes 
Understanding of overall treatment information. 
 Two studies looked at understanding of overall treatment information with no 
particular focus on the risks or benefits of treatments. Both employed an objective 
comprehension questionnaire to assess understanding, but maximum scores ranged from 
6 to 18. 
Despite no significant difference in the understanding of treatment information 
between a non-clinical control group and MS patients without cognitive impairment, both 
groups were significantly better than cognitively impaired MS patients (Basso et al., 
2010). The control and MS cognitively unimpaired group showed greater understanding 
following information provided in short successions or when recognition cues were 
provided to aid recall of information, compared to when treatment information was 
provided in an uninterrupted block (Basso et al., 2010). A similar trend was observed in 
the cognitively impaired MS group. However, this group also showed a significant 
improvement in understanding when recognition cues were given alongside treatment 
information provided in short successive steps, in comparison to information provided in 
successive steps alone (Basso et al., 2010). In two other studies, a significant increase in 
understanding of overall treatment information was also evident following intervention 
when compared to both baseline understanding (Zimmer et al., 2015) and a control group 
receiving standard information (Rahn et al., 2016). However, there was no significant 
improvement on patients’ understanding post-intervention when the control group 
received identical content as the intervention in a non-interactive form (Feicke et al., 
2014).  
To note, studies differed in the content of the intervention, as only two of the four 
studies provided information about real DMDs (Zimmer et al., 2015; Feicke et al., 2014). 
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Further, only some items in the questionnaires used to assess patients’ understanding 
focused specifically on treatment-related information.  
In summary, although there is a trend towards an improvement in understanding 
of overall treatment information following intervention, this cannot be established with 
just two studies employing different interventions and comparison groups. 
Treatment risk understanding.  
The understanding of treatment risks in MS patients following intervention was 
assessed objectively by three studies, using real DMD information in two studies 
(Hofmann et al., 2012; Köpke et al., 2014) and a hypothetical treatment information in 
another (Kasper et al., 2011). 
Following a short leaflet about risks of taking Mitoxantrone, MS patients showed 
a significant increase in accurate risk understanding of leukaemia, an adverse risk 
associated with the medication (Hofmann et al., 2012). This risk was initially 
underestimated by 58% of MS patients (Hofmann et al., 2012). Underestimation of risk 
persisted in 18% of MS patients following intervention. Improved risk understanding was 
not dependent on demographic factors, disease duration or the available scientific 
evidence at treatment initiation. However, patients with large errors on the Medical Data 
Interpretation Test (MDIT), which assessed the ability to handle probability data, showed 
an underestimation of Leukaemia risk after reading the leaflet (Hofmann et al., 2012). 
Following an intervention with a 4-hour education programme combined with a 57-page 
leaflet, understanding of the first-line DMD risks significantly improved for patients in 
the intervention group compared to MS patients in the control group (Köpke et al., 2014). 
Similar results were seen with another multi-component intervention, consisting of a 2-
hour and 4-hour education programme, in addition to a 120-page information brochure 
(Köpke et al., 2016). In comparison to the control group receiving standard information 
brochure and a rehabilitation programme, the intervention group showed a significant 
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increase in DMD risk understanding at 2 weeks and 6 months post-intervention (Köpke et 
al., 2016). 
One study measured risk understanding using self-report questions after trialling 
a DMD informational website for interferons (Colombo et al., 2016). Over 80% of MS 
patients stated that they found the presented risk information really or extremely clear and 
easy to understand (Colombo et al., 2016).  
Using hypothetical treatment information, Kasper and colleagues (2011) showed 
that the ability to recall treatment risks from pictograms to frequencies was generally low. 
However the authors noted that risks were recalled more accurately than benefits (Kasper 
et al., 2011). Mean errors in recalling risks from pictograms which displayed figures 
consecutively were significantly lower as opposed to pictographs with random 
arrangement of figures (Kasper et al., 2011). Patients that attributed high personal risk of 
becoming wheelchair dependent within two years showed a small correlation with 
overestimation of risk following intervention (Kasper et al., 2011).  
Overall, understanding of treatment risks showed an improvement of reasonable 
accuracy post-intervention despite the variety of interventions employed across the 
reviewed studies.  
Treatment benefit understanding.  
Understanding of treatment benefits was assessed objectively by four studies 
post-intervention (Heesen et al., 2010; Kasper et al., 2011, 2006; Mohr et al., 1996) and 
with self-report measures by one study (Colombo et al., 2016). 
Following a 3-page information booklet, MS patients showed significant 
improvements in understanding of interferon benefits post-intervention when compared to 
baseline (Kasper et al., 2006). The authors did note that around 99 of 169 patients were 
still not able to understand the information after intervention (Kasper et al., 2006). 
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Following another educational intervention, there was a significant reduction in patients 
that were overly optimistic about the general benefits of their DMD, even though 
overestimation persisted in about 33% of individuals (Mohr et al., 1996). At baseline, 
approximately 34% of MS patients were unrealistically optimistic about the benefits of 
their medication on disease progression specifically. Yet post-intervention, the number of 
MS patients overestimating these specific benefits about their current medication 
increased to about 40% (Mohr et al., 1996). Likewise, in another study, MS patients 
believed that their medication will provide a greater reduction of risk for a maximum 
walking distance of 100m following the short leaflet-based intervention on natalizumab in 
comparison to physicians (Heesen et al., 2010). Even with hypothetical treatment 
information, MS patients overestimated the benefits of the fictitious treatment by more 
than 100% following intervention (Kasper et al., 2011).  
Using self-report measures, over 75% reported that the interferon benefits 
presented in a DMD informational website were really or extremely clear and that 
graphical presentations of treatment benefits were easy to understand (Colombo et al., 
2016). 
In summary, initial overestimation of treatment benefits seemingly persists 
despite interventions that provide treatment benefit information beyond routine 
healthcare, although many patients report their own understanding of treatment benefits 
following intervention as high. 
Attitude towards treatment risks.  
Beyond understanding of treatment risk, two studies also assessed personal 
perception for treatment risks following interventions that provided information about 
real DMDs (Heesen et al., 2010; Hofmann et al., 2012). 
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Following a short leaflet about natalizumab, 84% of MS patients were willing to 
accept a 1 in 100 or higher risk of PML, an adverse side-effect of the medication, 
compared to only 51% of physicians; showing a significant difference (Heesen et al., 
2010). The authors noted that PML risk acceptance was not correlated with understanding 
of DMD information (Heesen et al., 2010). Patients’ personal risk attribution of PML as 
an adverse risk of natalizumab was deemed significantly lower than the PML risk they 
attributed to natalizumab generally post-intervention (Heesen et al., 2010). However, 
since baseline measures were not recorded in the study, it is difficult to determine 
whether personal risk attribution changed as a result of the intervention or was previously 
low at baseline. In another study which did record baseline measures, MS patients 
showed a significant increase from baseline for both general and personal risk attribution 
of the adverse risks associated with mitoxantrone after reading the informational booklet 
(Hofmann et al., 2012). Yet similar to the previous study, personal risk attribution of the 
adverse risks of the DMD was significantly lower than general attributed risk of adverse 
risks by the MS patients (Hofmann et al., 2012).  
In summary, two studies show that patients attribute lower personal risks of 
taking their current DMD than general risks they attribute to the DMD, despite improved 
understanding of their DMD risks post-intervention. 
Treatment decisions  
Four studies recorded MS patients’ decision about their DMD following 
intervention (Heesen et al., 2010; Kasper et al., 2008; Köpke et al., 2014; Tur et al., 
2012).  
Using self-report Likert-scales MS patients in the intervention group were found 
to be significantly more critical about their current DMD compared to baseline and 
control group, even after four weeks following intervention (Kasper et al., 2008). 
Likewise, patients were critical towards current DMD after intervention in another study 
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although this attitude did not persist beyond two weeks (Köpke et al., 2014). In another 
study, patients reported feeling confident in their decision to choose interferons after 
receiving information about interferons beyond routine healthcare (Colombo et al., 2016). 
MS patients in the intervention group did not show significant differences to the 
control group in progress of DMD decisions during follow-up in two studies (Kasper et 
al., 2008; Köpke et al., 2014). When compared with physicians’ decisions however, a 
considerably higher number of patients opted to continue the natalizumab DMD post-
intervention (Heesen et al., 2010). Although for the same medication following another 
intervention, 60% of MS patients discontinued treatment if they had the highest risk of 
PML, compared to 24% patients with the second-highest PML risk (Tur et al., 2012). No 
patient discontinued the treatment post-intervention in the lower risk groups (Tur et al., 
2012). 
In summary, the studies in the present review show a trend towards a critical 
attitude towards their DMD post-intervention with some discontinuation due to these 
attitudes, although the impact on patients’ decisions was generally inconclusive in the 
long-term. 
Intervention feedback  
MS patients in four studies provided feedback on the interventions using self-
report measures. Relative to the control group, MS patients in the intervention group felt 
better informed and felt that important questions had been adequately answered even after 
six months following intervention (Kasper et al., 2008). Similarly, MS patients deemed 
the intervention they received as important and felt that this did not increase worries 
(Hofmann et al., 2012). In fact, 84% of MS patients stated that they would recommend 
the intervention to other patients (Hofmann et al., 2012). The majority of patients 
reported the intervention as useful, and were particularly satisfied with specific training 
they received during the intervention (Freidel et al., 2015). Likewise, there was a 
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significant increase in patients’ perception of being informed, in addition to the feeling of 
certainty and confidence of being able to handle all treatments following a DMD 
information intervention (Zimmer et al., 2015). Over 80% of MS patients trialling an 
informational website reported that the website was easy to navigate, easy to understand 
and was useful (Colombo et al., 2016). Following informational materials explaining 
confidence intervals, patients in the intervention group consistently rated the information 
as being understandable, relevant and beneficial (Rahn et al., 2016). 
Despite the diversity of the DMD interventions employed in these four studies, 
all were positively received which indicates that patients generally perceive any type of 
interventions as favourable in facilitating understanding of DMD information.  
2.3.3 Discussion 
This systematic review was conducted to evaluate interventions designed to 
improve MS patients’ ability to understand complex risk-benefit profiles of DMDs. 
Fifteen studies were reviewed and included MS patients with different clinical subtypes 
and those taking a variety of DMDs. Studies employed a range of outcome measures and 
not all studies included baseline data or control group. Some studies had methodologies 
that precluded firm conclusions. 
Interventions within this review provided treatment information using booklets, 
websites, vignettes and education programmes. Half of the interventions included some 
form of interactive component (Zimmer et al., 2015; Basso et al., 2010; Feicke et al., 
2014; Freidel et al., 2015; Kasper et al., 2008; Kopke et al., 2016; Köpke et al., 2014). 
There was no apparent advantage of interactive versus passive interventions on 
understanding. There was also no apparent benefit of longer and multicomponent 
interventions in comparison to shorter and basic interventions such as leaflets in the 
current review. From this, it can be presumed that interventions which are easier to 
administer and require fewer resources may be just as beneficial to employ as longer 
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interventions. Moreover, less than half of the interventions manipulated or explained the 
formats used to present treatment information, such as framing, numerical formats or 
graphical formats (Colombo et al., 2016; Hofmann et al., 2012; Kasper et al., 2008; 
Kasper et al., 2011, 2006; Rahn et al., 2016). This is surprising considering that 
presentation formats are a key criteria for an effective evidence-based educational 
intervention (Bunge et al., 2010) and can significantly impact understanding of treatment 
information (Berry, Knapp, & Raynor, 2006; Bodemer, Meder, & Gigerenzer, 2014; 
Hawley et al., 2008; Lipkus, 2007; Price, Cameron, & Butow, 2007). Therefore, the use 
of presentation formats should be carefully considered when designing an educational 
intervention. 
In general, it was difficult to make comparisons between these interventions since 
they were very diverse in their content and administration. In particular, it was not 
possible to draw conclusions about the most effective intervention which could improve 
understanding of DMD information in MS patients. However studies that recorded 
patients’ feedback of the interventions all received favourable reviews (Zimmer et al., 
2015; Colombo et al., 2016; Freidel et al., 2015; Hofmann et al., 2012; Kasper et al., 
2008; Rahn et al., 2016), which indicates that any form of intervention providing DMD 
information beyond routine health-care are generally well-accepted by MS patients in 
these studies. 
In terms of the impact of interventions, four interventions improved 
understanding of overall information provided during intervention, despite using very 
different interventions and study designs (Zimmer et al., 2015; Basso et al., 2010; Feicke 
et al., 2014; Rahn et al., 2016). For treatment risk knowledge specifically, MS patients 
initially showed an underestimation of treatment risks during routine healthcare, but 
showed greater understanding of both real and hypothetical treatment risks post-
intervention. This improvement in risk understanding seemed related to multicomponent 
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interventions (Kopke et al., 2016; Köpke et al., 2014), information which was easier to 
understand (Colombo et al., 2016; Hofmann et al., 2012; Kasper et al., 2011) and when 
personal risk attribution was perceived as low (Kasper et al., 2011). However, it was not 
possible to determine the extent to which these interventions were able to improve 
understanding of both adverse risks and side-effects that are less severe but commonly 
associated with DMDs. Nevertheless, interventions designed to improve understanding of 
treatment risks could be very beneficial for patients making treatment decisions, since 
even very small changes in the risks of DMDs can have a huge impact on treatment 
choice (Wilson et al., 2014; Wilson et al., 2015). In fact, some studies in the present 
review showed a trend towards patients becoming critical or discontinuing treatment 
when risks were better understood (Heesen et al., 2010; Kasper et al., 2008; Kasper et al., 
2011; Tur et al., 2012). This suggests that patients are likely to review decisions for their 
current DMD following new and enhanced understanding of treatment risks. Considering 
this, it is important that patients perceive information accurately about DMD risks when 
making initial treatment decisions, so that the true risks associated with their chosen 
treatment are in line with patients’ preferences. Although, some studies in the review 
showed that despite greater understanding of treatments risks, MS patients seemed to 
underestimate their personal chance of developing these risks (Heesen et al., 2010; 
Hofmann et al., 2012). Interventions in the future could therefore attempt to converge 
personal risk attribution with accurate understanding of treatment risks, to ensure patients 
are able to apply the knowledge they gain from the intervention and make informed 
treatment decisions based on personal preferences. 
Improvements in understanding the benefits of treatments were less pronounced. 
Objectively, many patients did not understand or tended to overestimate the benefits of 
taking their treatment, even after receiving additional information (Heesen et al., 2010; 
Kasper et al., 2011, 2006; Mohr et al., 1996). This can be problematic for selecting a 
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course of treatment, as patients are more likely to prematurely discontinue treatment if 
DMD benefits are perceived as higher than actual benefits (Lizan et al., 2014; Mohr et al., 
1996). Such poor adherence to DMDs can have both direct and indirect costs for MS 
patients (Yermakov et al., 2015). However, patients did not significantly change their 
treatment decisions following intervention, similar to the review by Kὅpke and colleagues 
(2014). It is therefore difficult to determine the effects of accurate understanding of 
treatment information on treatment adherence and shared treatment decision-making. 
This affirms that understanding of treatment information is simply a precursor to effective 
shared decision-making and other key factors such as patient autonomy, patient 
preferences or decision regret, would also need to be addressed in interventions to 
directly improve shared treatment decision-making (Barry & Edgman-Levitan, 2012; 
Charles et al., 1999; Godolphin, 2009; Makoul & Clayman, 2006).  
Additional factors which can likely influence patients’ understanding of DMD 
information were not fully explored by interventions in the present review. Patients’ 
numeracy and literacy skills have the ability to modify understanding of the risks and 
benefits of treatments, with lower skills often leading to larger number of errors (Garcia-
Retamero & Galesic, 2010a; Peters, 2008; Peters, Hart, & Fraenkel, 2011). This was only 
examined in one study within the present review, where patients unable to interpret 
numerical data demonstrated the least accuracy in understanding the treatment risk 
information even after intervention (Hofmann et al., 2012). Aspects of cognitive 
functions affected by MS itself are also likely to influence patient understanding, 
including: verbal and visual-spatial memory (Hulst et al., 2015; Langdon, 2011), 
information-processing speed (Goretti et al., 2014) and decision-making (Muhlert et al., 
2015; Radomski et al., 2015). Yet only one interventional study monitored cognitive 
impairments of MS patients in the current review (Basso et al., 2010). This study showed 
that fictitious treatment understanding in MS patients with cognitive impairments was 
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considerably lower compared to MS patients who were cognitively intact. However, 
following additional cueing during intervention, the same level of understanding and 
recall was shown in cognitively impaired MS patients compared with cognitively intact 
MS patients (Basso et al., 2010). Hence, future interventions providing treatment 
information to MS patients may benefit from ensuring that patients of all abilities, and 
those presenting cognitive impairments due to MS, are able to benefit from the additional 
information given beyond routine healthcare.  
2.4 General discussion 
This chapter presents two systematic reviews to assess MS patients’ 
understanding of the complex risk-benefit profiles of DMDs.  
The first systematic review gathered evidence about patients’ understanding of 
the risks and benefits of DMD within their standard healthcare, and their preferences for 
these risks and benefits. Despite the heterogeneous findings, it was evident that current 
ways of providing DMD risk and benefit information are not generally uniform or 
effective. MS patients tended to underestimate treatment risks and overestimate treatment 
benefits, with some patients finding comprehension especially difficult. MS patients 
preferred treatments offering extremely low levels of adverse risks, but were willing to 
accept higher risks in exchange for substantial long-term improvements. 
This systematic review also showed that the ability to understand information 
about DMDs provided during the standard healthcare system was associated with certain 
patient factors, for example: age, education and functional status (Zimmer et al., 2015; 
Abolfazli et al., 2014). It is also possible that symptoms of MS itself, for example 
depression (Feinstein et al., 2014), anxiety (Hoang, Laursen, Stenager, & Stenager, 2015), 
fatigue (Khan et al., 2014) and cognitive impairments (DeLuca et al., 2015; D. W. 
Langdon, 2011), may further confound understanding of information about DMDs (see 
section 1.1.2 for review about MS symptoms). However, these symptoms were not 
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explored within the studies in the first systematic review. Nevertheless, it is apparent that 
some MS patients require further support to comprehend treatment information to a good 
standard.  
The second systematic review was an inclusive attempt to compare different 
types of interventions which provide treatment information beyond routine healthcare, 
while evaluating their efficacy on understanding of treatment risks and benefits, and 
treatment decisions. Despite the heterogeneous findings from the second systematic 
review, it is conceivable to conclude that interventions providing treatment information 
beyond routine healthcare are preferred by MS patients and have the potential to improve 
understanding of overall treatment information, particularly treatment risks. 
Understanding of treatment benefits do not seem to be reliably improved by the reviewed 
interventions. There was no conclusive effect of interventions on MS patients’ decision-
making of DMDs. No particular intervention type emerged as reliably efficacious. 
Interventions that were longer and comprehensive performed similar to shorter 
interventions requiring fewer resources. There is a need for a standardised information-
based tool which can draw on the strengths of currently available interventions and which 
can improve understanding of both the risks and benefits of treatments 
The findings from both systematic reviews should be interpreted in line with the 
limitations. Firstly, it was difficult to draw robust conclusions or conduct a meta-analysis 
of the studies in both systematic reviews as a result of the variety of outcome measures 
employed. There were also differences in study design, methodology and patient 
characteristics between studies in both reviews which limits conclusions from such 
findings. This may indeed reflect the lack of uniformity across studies that address MS 
patients’ understanding of medications. Secondly, a narrative synthesis was considered to 
be the most appropriate format for reviewing the studies across both systematic reviews. 
However, it is important to acknowledge that such a qualitative review is subject to 
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greater analysis bias than a quantitative systematic review. Finally, the reviews in the 
current chapter do not constitute an exhaustive search of studies or research findings; for 
example, the primary authors of studies were not contacted to resolve or expand on study 
findings owing to time and resource constraints. However, it seems unlikely that 
supplementary results or additional outcome measures could produce less heterogeneous 
results.  
2.4.1 Conclusion 
Systematic reviews carried out in the present chapter highlight that MS patients 
require extra support to effectively understand the complex risk-benefit profiles of MS 
DMDs, and that patients’ preferences for treatment risks and benefits should be taken into 
account during the shared decision-making process. Interventions that have been designed 
to provide information about DMD risks and benefits beyond the standard healthcare 
system are appreciated by MS patients. Yet, interventions need to ensure that information 
is provided using effective presentation methods and that MS patients of all abilities and 
those presenting cognitive impairments can benefit from the additional support. 
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Chapter 3: Surveys of MS patients and MS Nurses in the 
UK 
3.1 Introduction 
A systematic review of the literature, which subsequently led to publication 
(Reen, Silber, & Langdon, 2017), found that MS patients do not satisfactorily understand 
the information they receive within standard healthcare (see chapter 2). The following 
chapter will explore in detail the current status of MS patients’ understanding of DMD 
risks and benefits, and the sources that MS patients use to receive DMD information in 
the UK. It is expected that the following chapter will inform the need for evidence-based 
research in an attempt to improve treatment understanding of MS patients and identify the 
most suitable source to provide additional support. 
3.1.1 Understanding of DMD risks and benefits 
Patients’ understanding of DMD risks and benefits is a prerequisite for making 
informed treatment decisions (Thompson, 2013). Accurate understanding of DMDs can 
increase engagement with the decision-making process and improve adherence to 
treatments (see section 1.3). Identifying unmet needs in clinics with regards to provision 
of DMD risks and benefits can help target support to MS patients and improve their 
understanding. 
3.1.2 Sources of DMD risk and benefit information 
Health professionals are often cited as the primary source of receiving 
information about DMD risks and benefits (Bishop, Frain, Espinosa, & Stenhoff, 2009). 
MS patients rate health professionals as an important and trustworthy source of 
information within healthcare services in Southern Australia (Matti, McCarl, Klaer, 
Keane, & Chen, 2010) and North America (Marrie, Salter, Tyry, Fox, & Cutter, 2013). 
Surveys conducted in the UK also find that MS patients prefer face-to-face provision of 
MS information (Hepworth & Harrison, 2004) and frequently meet with their health 
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professionals to receive DMD information (Somerset, Campbell, Sharp, & Peters, 2001). 
Hence, health professionals are often the leading contact and primary source of 
information provision for MS patients across healthcare services in different countries.  
Patients also seek information about MS beyond that provided by health 
professionals. A widely used and reported source of information is the internet. Surveys 
designed to assess patients information-seeking habits find that MS patients frequently 
report searching online about their condition (Bishop et al., 2009; Hay, Strathmann, 
Lieber, Wick, & Giesser, 2008; Marrie et al., 2013), and in some studies patients report 
favouring the internet as a valuable source of MS information (Matti et al., 2010). Studies 
find that DMDs are researched the most by MS patients (Bishop et al., 2009; Marrie et 
al., 2013). In particular, the internet is regularly used to search for DMDs recommended 
by health professionals, new and available DMDs, and adverse risks associated with 
DMDs (Colombo et al., 2014). In fact, all MS patients in one study reported having used 
the internet in the past and considered it a useful resource for up-to-date information 
about DMDs (Synnot et al., 2014). Despite using the internet to independently seek 
information about DMDs, some MS patients also report feeling hesitant about the 
reliability of information available on the internet (Colombo et al., 2014; Synnot et al., 
2014). This may be in part due to the range of websites available online that provide 
information about MS treatments. For instance, patients are able to access both objective 
information about DMDs through charitable websites, as well as subjective information 
about DMDs from online forums. Colombo and colleagues (2014) noted how MS patients 
distinguish between reliable and unreliable information on the internet. Questionnaires 
and focus groups with approximately 40 MS patients showed that if treatment 
information was equivalent across multiple websites or if the information available online 
was also reported by health professionals, this information was generally considered to be 
reliable. Information was also believed to be reliable if the website hosting the 
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information had existed for a long period of time (Colombo et al., 2014). This suggests 
that MS patients increasingly seek validated information about DMD risks and benefits 
on the internet. 
Yet, the internet is rarely used as an isolated source of receiving information 
about DMDs. Online treatment information is largely used to supplement information 
received during consultations with health professionals, rather than to replace it. For 
instance, patients may search for information about DMDs prior to consultations with 
their physician or in order to better understand and collate information following 
consultations (Colombo et al., 2014). Other sources of information can also be used to 
complement the information about DMDs obtained from consultations, such as booklets 
and leaflets provided during visits to clinics. In fact, findings from an earlier systematic 
review about interventions to improve MS patients’ understanding of DMDs, found that 
these interventions were designed to primarily be implemented in the form of booklets or 
via comprehensive educational programmes (Reen, Silber, & Langdon, 2017a). This 
means that interventions designed to provide additional support about DMDs have often 
implemented these using sources that are less frequently used by MS patients. The 
sources used to provide additional support to MS patients about DMDs should be 
carefully considered.  
3.1.3 Service user involvement in research 
Involving service users in research can improve the quality of patient-centred 
services and ensure that additional support for patients is targeted effectively (Crawford 
et al., 2002). A patient’s experience about their condition and healthcare services can 
provide a complementary perspective to that of health professionals and researchers (see 
section 1.3 for review about patient-centred approach). Patient feedback can also offer 
valuable information in order to tailor existing healthcare services or design novel 
interventions to support patients in healthcare (Callard, Rose, & Wykes, 2012; Crawford 
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et al., 2002). Given the benefits of involving patients in research, the current chapter aims 
to explore the unmet needs of MS patients, and use patient responses to target appropriate 
additional support to MS patients. 
Health professionals can also be involved in research to provide their experience 
of being a service provider to patients. In the context of MS, patients may interact with 
various health professionals including general practitioners, neurologists, 
physiotherapists, occupational therapists and nurses. It is therefore important to involve 
health professionals that most commonly provide information about DMDs to MS 
patients. Strickland and Baguley (2015) established that MS patients are most likely to 
network with MS nurses during the course of their disease in comparison to other health 
professionals in the UK. This may be because of the diverse role that a MS nurse plays 
within MS healthcare services. MS nurses are ordinarily responsible for providing 
psychosocial support, co-ordinating care, referring patients to other healthcare services, 
offering specialist advice and educating patients about their condition and medications 
(Forbes, While, Dyson, Grocott, & Griffiths, 2003; While, Forbes, Ullman, & Mathes, 
2009). It is therefore important to involve MS nurses as service providers to compliment 
the feedback provided by MS patients.  
3.1.4 Surveys as methods of involving MS patients and MS nurses in research 
Effective involvement of service users in research inherently relies on the 
methods used to gather appropriate responses. According to general consensus in the 
literature, suitable approaches to acquire feedback from service users include  qualitative 
interviews, focus groups and surveys (Crow, Gage, Hampson, Hart, Kimber, Storey & 
Thomas, 2002; Pope, Van Royen, & Baker, 2002; Wensing & Elwyn, 2003). Despite 
being comprehensive, focus groups and interviews can be time-consuming and research 
intensive to conduct. On the other hand, surveys have the ability to elicit similar levels of 
quality feedback without using as many resources (Cleary, 1999; Murphy, Mercer, Bruce, 
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& Eva, 2006; Pope et al., 2002). Notably, surveys can also be adapted to the research 
question of interest; surveys can either be quantitative in nature allowing for simple 
comparisons to be made between responses, or can be provided in a qualitative format 
allowing for detailed focus on patients’ experiences (Jansen, 2010). In addition, surveys 
may be provided to service users at clinics to yield higher rates of responses or be sent 
anonymously to service users away from clinics to yield responses of a higher quality 
(Gribble & Haupt, 2005). 
Overall, surveys offer ideal opportunities to obtain feedback from patients and 
health professionals. Surveys also offer several options to collect information; surveys 
can be quantitative or qualitative, and are able to elicit detailed responses if participants 
are given anonymity. For this reason, the present study employed surveys as the method 
of acquiring feedback from MS patients and MS health professionals in the UK. 
3.1.5 Research questions  
The aim of the present study was to investigate the unmet needs of MS patients in 
the context of information about DMDs, by conducting surveys with MS patients and MS 
nurses about MS healthcare services in the UK. 
Four main points were explored in the present study: 
(i) MS patients’ self-reported understanding of DMDs complemented by 
perspectives of MS nurses; 
(ii) the most common and preferred source to receive information about 
DMDs according to MS patients, complemented by perspectives of MS 
nurses; 
(iii) frequency of receiving information about DMDs in healthcare services 
according to MS patients, complemented by perspectives of MS nurses; 
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(iv) feedback from both MS patients and MS nurses on how information 
provision about DMDs can be improved. 
3.2. Methodology 
3.2.1 Participants 
MS patients were recruited from two hospitals in the UK: Queen Elizabeth 
Hospital as part of the Lewisham and Greenwich Trust, and King’s College NHS 
Foundation Trust. MS patients were also recruited from the MS Trust charity. Patients 
were eligible to take part in the survey if they reported having a diagnosis of MS and 
were currently taking a DMD. MS nurses were recruited only from the MS Trust charity. 
MS nurses had no professional relationship with the recruited MS patients in the study. 
MS nurses were eligible to take part if they reported having consulted at least one MS 
patient.  
No limit on the number of surveys distributed to both MS patients and nurses was 
applied due to the exploratory nature of the study. Patients and nurses were not 
compensated for their participation. Surveys for both MS patients and MS nurses received 
ethical approval from the Psychology Department Ethics Committee at Royal Holloway 
and the NHS Research Ethics Committee (see appendix 3 and 4).  
3.2.2 Materials and design 
The present study employed a cross-sectional survey methodology. Surveys for 
MS patients and MS nurses were author-developed for online and offline use (see 
appendix 5 and 6 for copy of offline MS patient and MS nurse survey). The online survey 
was hosted on the Qualtrics online survey platform and the offline surveys were 
distributed at hospital clinics. The survey consisted of both quantitative and qualitative 
questions with five distinct sections. The first section was designed to assess eligibility to 
take part in the study, and the remaining four sections related to the four research 
questions of interest. Questions that were not relevant for health professionals were 
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excluded from surveys distributed to MS nurses. Other than questions determining 
eligibility, patients were not required to answer all questions in the survey and therefore 
missing data was expected. 
3.2.2.1 Survey section 1: Eligibility  
The eligibility questions for MS patients assessed whether patients had been 
given a diagnosis of MS and were currently taking a DMD. Patients could only proceed 
with the survey if they responded affirmative to the MS diagnosis questions and stated 
their current medication. Patients were also encouraged to state duration of MS diagnosis 
and duration of taking the current DMD. Diagnosis information was also recorded for MS 
patients that did not report taking a DMD, but these patients were not eligible to complete 
the remaining survey. For surveys distributed to MS nurses, eligibility was determined by 
confirming whether nurses had conducted consultations with at least one MS patient in 
the past. If MS nurses responded with a yes, they were considered suitable to take part in 
the complete survey. MS nurses were also encouraged to state the duration of being a MS 
nurse. 
Since surveys provided to both MS patients and MS nurses were anonymous, no 
other identifying demographic information was recorded.  
3.2.2.2 Survey section 2: Understanding of DMD information 
Questions about understanding of DMD information were split into two groups. 
First, questions 1-3 of the survey used 5-point Likert scales to determine how well 
patients felt they understood their current DMD, which ranged from ‘slightly understood’ 
to ‘completely understood’. For MS nurses, the same question was stated in terms of how 
well they felt MS patients understood their DMDs. Three Likert scales were provided for: 
understanding of benefits, understanding of side-effects and understanding of the risks 
associated with DMDs. Both MS patients and MS nurses were provided with a qualitative 
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comment section immediately after each Likert-scale. In the second group, qualitative 
questions 9 to 13 were included at the end of MS patient surveys. These questions 
directly checked patients’ knowledge about the benefits, side-effects and risks associated 
with their current treatment. Patients were further asked to state the risks and benefits 
they had experienced while taking the DMD. No corresponding questions were included 
in the surveys for MS nurses. 
3.2.2.3 Survey section 3: Source of DMD information 
Question 4 of both surveys required MS patients and nurses to state the source of 
DMD information they or their patients currently use, respectively. A choice of seven 
most-common sources of information were presented based on previous findings and 
respondents were encouraged to select all options that applied. An option of ‘other’ was 
also provided, and if selected, patients and nurses were required to specify the source of 
information not stated in the set of options provided. Both MS patients and nurses were 
then requested to comment on the usefulness of the selected sources of DMD 
information.  
MS patients were further asked to state their preferences for all seven sources of 
DMD information in question 6 of the survey, excluding any other source of information 
that the patients reported using. Specifically, patients were asked to rate choices from 1 to 
7, where 1 referred to the most preferred source and 7 to the least preferred source. A 
qualitative comment box was also provided for this question. No corresponding question 
was included in MS nurse surveys. 
3.2.2.4 Section survey 4: frequency of DMD information provision 
Both MS patients and nurses were asked to state, on average, how often 
information about DMD benefits, side-effects and risks were provided from a choice of 5 
options: from ‘every consultation’ to ‘in less than 1 in 10 consultations’. This was 
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question 8 of the MS patient survey and question 7 of the MS nurse survey. A qualitative 
comment section was also provided for this question. 
3.2.2.5 Section survey 5: improvement of current ways of providing DMD information 
Both MS patients (question 7) and nurses (question 5) were provided with one 
question to state how they believe current ways of providing DMD risk and benefit 
information could be improved. 
3.3.3 Procedure 
For patients recruited at hospital clinics, an information sheet and consent form 
was provided with the offline surveys (see appendix 7 and 8). If consent was given, 
patients were told they could either complete the survey during their clinic visit and hand 
back to the researcher, or take the survey home and mail to the researchers using the 
address provided. Patients were also informed that they could complete the survey online 
using the website address provided on the information sheet and at the end of the offline 
survey. 
For surveys hosted online, both MS patients and nurses were provided with an 
online version of the information sheet to read prior to starting the survey (see appendix 9 
and 10). Consent was assumed if both groups continued with the survey. 
Since responses to the surveys were expected to inform all stages of the research 
and analysis, surveys were distributed to MS patients and MS nurses from September 
2014 to December 2016. 
3.2.4 Analysis 
All data from offline surveys was transcribed by the researcher and combined 
with data from online surveys.  
The quantitative data was analysed using frequencies and means as relevant. 
Missing quantitative data was excluded from analysis. Responses from the ordinal Likert 
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scales were collapsed into two categories: (i) completely understood, very well 
understood, and (ii) satisfactorily understood, moderately understood and slightly 
understood. For question 6 of MS patient surveys requesting patients to rate preference of 
source of DMD information, missing responses were rated as ‘0’.  
For all qualitative data, main themes were derived and frequencies of these 
themes from patients and nurses were documented. No specific qualitative analysis was 
conducted as this was considered beyond the scope and exploratory nature of the present 
study.  
3.3 Results 
3.3.1 MS patient and MS nurse characteristics 
A total of 106 MS patients completed the survey. Patients had been diagnosed 
with MS from within a year of taking the survey to 28 years, with average time since 
diagnosis of 8.08 years (SD: 7.34). The majority of patients were taking interferon betas 
as their current DMD (33.1%), followed by natalizumab (21.7%) and dimethyl fumarate 
(18.9%). Teriflunomide was taken by the least number of MS patients in this survey 
(1.9%). Patients had been taking their DMD medication from as recently as a few weeks 
to 19 years, with average duration of taking the DMD of 3.17 years (SD: 4.52).  
A total of 146 patients who reported a diagnosis of MS were excluded from the 
study on account of reporting not taking a DMD. These patients had on average been 
diagnosed with MS for longer (mean: 12.60 years, SD: 10.57) than patients included in 
the study. In fact, majority of excluded MS patients had been diagnosed for over 20 years 
(26.1%). These patients are likely to have had the SPMS subtype of MS which currently 
has no licensed treatment (see section 1.1.3 for review of MS subtypes). 
There are approximately 124,000 MS patients in the UK (Mackenzie et al., 2010) 
and around 80% of MS patients have reported seeing an MS specialist nurse within the 
last year according to the recent GEMSS report (2015). There are around 270 MS 
Chapter 3 
85 
specialist nurses in the UK (Mynors et al., 2012), which means that each MS specialist 
nurse sees approximately 360 MS patients per year. A total of 13 MS nurses were 
included in the current survey. Together, these nurses saw approximately 3,700 MS 
patients in the last year according to the above report. MS nurses in the survey reported 
being a specialist nurse from 2 years to 13 years, with an average experience of being a 
MS specialist nurse of 5.69 years (SD: 3.59).  
3.3.2 Understanding of DMD information 
3.3.2.1 Quantitative synthesis 
Approximately half of all MS patients reported poor overall understanding of 
DMDs according to quantitative Likert-scales (see table 3.1). MS patients reported the 
least understanding of DMD risks (54.9%). In comparison, a greater percentage of MS 
nurses reported that patients do not understand information about DMDs in general, with 
lowest understanding of treatment benefits and side-effects (84%).  
Table 3.1 MS patients’ and MS nurses’ feedback on patients’ understanding of DMDs  
  MS patient 
feedback (n=106) 
MS nurse 
feedback (n=13) 
Understanding 
of benefits 
Good understanding, n (%) 56 (52.8) 2 (15.4) 
Poor understanding, n (%) 50 (47.2) 11 (84.6) 
Understanding 
of side-effects 
Good understanding, n (%) 54 (50.9) 2 (15.4) 
Poor understanding, n (%) 52 (49.1) 11 (84.6) 
Understanding 
of risks 
Good understanding, n (%) 46 (45.1)1 3 (23.1) 
Poor understanding, n (%) 56 (54.9)1 10 (76.9) 
DMD, disease-modifying drug; 1, n=102  
 
When MS patients were clustered together in terms of DMDs they were currently 
taking, patients reported greatest understanding of alemtuzumab and lowest 
understanding of interferon betas. Specifically, MS patients reported the least 
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understanding of the benefits of interferon betas (62.9%) and dimethyl fumarate (55%), 
the least understanding of side-effects of teriflunomide (100%) and interferon betas 
(62.9%), and the least understanding of risks for alemtuzumab (100%), interferon betas 
(75%) and dimethyl fumarate (70%).  
3.3.2.2 Qualitative synthesis 
A qualitative synthesis was conducted for questions 8-10 of the MS patient 
survey which requested patients to report their understanding of benefits, side-effects and 
risks of their current DMD. The responses from patients that answered this question were 
grouped together and frequencies were recorded. 
Reduction in relapse rate was the most commonly reported benefit of DMDs. 
However, approximately 40% of patients taking interferon betas did not report that their 
current DMD could reduce the rate of relapses. From an overview of the qualitative 
responses, the majority of patients did not report how much their DMDs were able to 
reduce the rate of relapses. The route of administration was further reported as a benefit 
of taking dimethyl fumarate (11.7%), fingolimod (8.3%), glatiramer acetate (12.5%), 
teriflunomide (100%) and natalizumab (9.1%), of which some treatments are taken orally 
and some treatments are taken by intravenous infusions.  
Several side-effects of DMDs were reported by MS patients taking the survey. 
The most commonly reported side-effects for some of the DMDs were as follows: flu-like 
symptoms (46.4%) for interferon betas, flu-like symptoms (66.7%) and thyroid disorder 
(66.7%) for alemtuzumab, gastrointestinal problems (47.1%) for dimethyl fumarate, and 
injection site problems (50%) for glatiramer acetate. MS patients also reported 
understanding several risks of DMDs. The risk of PML was reported by the majority of 
patients taking natalizumab (77.3%), followed by low levels of immunity and serious 
infection for patients taking fingolimod (50%).  
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3.3.3 Source of DMD information 
3.3.3.1 Quantitative synthesis 
MS patients and nurses were asked to state all possible sources that MS patients 
used to receive information about DMDs. The majority of MS patients reported MS 
nurses (77.4%) and MS neurologists (65.1%) as their primary source of receiving 
information about DMDs (see figure 3.1). Similarly, MS nurses also stated that MS 
patients commonly speak with MS nurses (92.3%) and MS neurologists (100%) to 
receive information about DMDs (see figure 3.2). Other more common reported sources 
were booklets and charity websites according to both MS patients and MS nurses. The 
majority of MS nurses also reported patient websites as a frequently used source by 
patients, whereas only 24.5% of MS patients rated this as a source of information they 
currently use.  
 
 
Figure 3.1 DMD information resources as reported by MS patients 
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Figure 3.2 DMD information sources for patients as reported by MS nurses 
 
3.3.3.2 Qualitative synthesis respondents  
Approximately 17% of MS patients and 50% of MS nurses stated that other 
sources of DMD information provision were also used by patients. Qualitative synthesis 
of the main themes reported by MS patients and MS nurses identified 12 additional 
sources that patients use to receive DMD information (see table 3.2). These ranged from 
social media groups, online forums and scientific research papers, to personal experience 
of taking the DMD. Interestingly, 9 of the additional sources of DMD information 
reported by MS patients were not reported by MS nurses in this survey. 
Main themes were also identified from qualitative questions asking MS patients 
and MS nurses to report the usefulness of all sources of DMD information they currently 
use. Approximately 57% of MS patients stated that the current sources used to receive 
information about DMDs was very useful. However, the remaining 43% of MS patients 
stated that they would like improvements to how they receive treatment information. The 
most common themes that emerged from qualitative responses of MS nurses to this 
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question were that multiple sources of information were often more useful for MS 
patients.  
Table 3.2  MS patients’ and MS nurses’ qualitative feedback on additional sources used to 
receive DMD information 
Other source of information,      
n (%) 
MS patient feedback 
(n=19) 
MS nurse feedback 
(n=7) 
Social media group 6 (31.6) 0 
Online forum 2 (10.5) 1 (14.3) 
Friends/family 2 (10.5) 0 
Patient contact helpline 1 (5.3) 0 
Personal experience 1 (5.3) 0 
Library 1 (5.3) 0 
Other patients 2 (10.5) 3 (42.9) 
Online blog 4 (21.1) 0 
Research papers 3 (15.8) 0 
NICE guidelines 1 (5.3) 0 
Podcast 0 1 (14.3) 
MS decisions 4 (21.1) 3 (42.9) 
DMD, disease-modifying drug; NICE, The National Institute for Health and Care Excellence 
 
3.3.4 Frequency of DMD information provision during consultations 
3.3.4.1 Quantitative synthesis 
MS patients and MS nurses reported the average number of consultations that 
were dedicated to providing information about DMDs to patients. A similar proportion of 
MS patients (37.4%) and MS nurses (38.5%) reported that patients receive DMD 
information at every consultation (see figures 3.3 and 3.4). However, a large number of 
MS patients also reported receiving DMD information in less than 1 in 10 consultations 
(24.2%), whilst no MS nurses reported that such few consultations were dedicated to 
information about DMDs.  
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Figure 3.3 Frequency of consultations about DMDs as reported by MS patients; 1 n=99 
 
 
 
 
Figure 3.4: Frequency of consultations about DMDs as reported by MS nurses 
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3.3.5 Suggestions to improve DMD information provision 
3.3.5.1 Qualitative synthesis 
Main themes were derived from MS patients’ and MS nurses’ qualitative 
feedback on how DMD information provision could be improved. Of MS patients who 
answered this question, 13 different ways of improving DMD information were suggested 
(see table 3.3). The most common suggestions were providing more detailed and clear 
information about DMD risks and benefits (35.9%) and improving the consultations with 
health professionals (23.1%). The most common suggestion for improvement by MS 
nurses was that treatments should be provided such that patients are able to readily 
compare the risks and benefits (30.7%). 
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Table 3.3  MS patients’ and MS nurses’ feedback on improvement of DMD information 
provision 
Possible improvements to DMD information 
provision, n (%) 
MS patient 
feedback 
(n=39) 
MS nurse 
feedback 
(n=13) 
Patient-focused 2 (5.1) 0 
Advice from experienced patients 3 (7.7) 0 
Social media by health professionals 1 (2.6) 0 
Booklet by independent bodies 1 (7.7) 0 
Magazine articles 1 (2.6) 0 
Clear information about risks and benefits 14 (35.9) 0 
Standardised information 1 (2.6) 1 (7.7) 
Case studies 1 (2.6) 0 
Improved consultations with health professionals 9 (23.1) 1 (7.7) 
Updated information about risks and benefits 3 (7.7) 1 (7.7) 
Audiovisual presentation 1 (2.6) 0 
Scientific/clinical trial information 1 (2.6) 2 (15.4) 
Training of non-specialist health professionals 1 (2.6) 0 
Interactive website 0 2 (15.4) 
Application 0 1 (7.7) 
Information sheets 0 1 (7.7) 
Comparison of risks and benefits 0 4 (30.7) 
DMD, disease-modifying drugs 
 
3.4 Discussion 
The current study sought to obtain feedback from MS patients and MS nurses 
about their experiences of how patients’ receive information about DMDs in healthcare 
services across the UK. Surveys were used as a tool to collect both quantitative and 
qualitative data from service users in MS. Feedback was gathered to compliment a 
systematic review which found that MS patients do not satisfactorily understand the 
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DMD information they receive within their healthcare service (Reen et al., 2017). It was 
expected that exploring unmet needs of patients could ascertain how information about 
DMDs should be improved using evidence-based research. Four key research questions 
were explored: MS patients’ current understanding of DMDs, the source that patients 
access to receive information about DMDs, the frequency with which DMD information 
is received and suggestions to improve current practices. 
Approximately half of the MS patients in this study reported poor understanding 
of treatments, particularly the risks of DMDs. This finding was reinforced by MS nurses 
in the current study, as the majority of nurses reported that MS patients have poor 
understanding of DMD risks and benefits. This is consistent with studies included in the 
systematic review which recognised that many MS patients did not feel sufficiently 
informed about DMDs (Zimmer et al., 2015; de Seze et al., 2012; Heesen et al., 2003; 
Syed et al., 2014; Visser & Van Der Zande, 2011; Vlahiotis et al., 2010), and were poor 
at objectively understanding the treatment risks (Heesen et al., 2004; Hofmann et al., 
2012; Köpke et al., 2014) and benefits (Mohr et al., 1996).  
The benefits, side-effects and risks of interferon betas were the least understood 
by MS patients in the current study. This is of interest, given that interferon betas are 
typically offered to MS patients at the first stage of treatment and have well-established 
risk and benefit profiles (English & Aloi, 2015; Fogarty, Schmitz, Tubridy, Walsh, & 
Barry, 2016; Garg & Smith, 2015; Michel, Larochelle, & Prat, 2015; Wingerchuk & 
Weinshenker, 2016). It is possible that the safety profiles of interferons may be the reason 
why these treatments are not discussed in detail during consultations with health 
professionals compared to other drugs (see section 1.2 for review about risk-benefit 
profiles of interferon betas). This could be problematic for adherence to these commonly 
prescribed treatments. Evidence-based research should thus seek to facilitate 
understanding of information about all DMDs for MS patients. 
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MS patients reported accessing several sources to accumulate DMD information. 
The most commonly identified sources were consultations with MS neurologists and MS 
nurses, as well as access to charity websites. Similarly, MS nurses stated that MS health 
professionals and charity websites were commonly used by MS patients. An example of 
DMD information provided by charity websites, in the form of an online and offline 
booklet, is presented in appendix 11. Together, this data is consistent with previous 
survey findings which have identified health professionals and the internet as primary 
sources of obtaining information about DMD risks and benefits (Bishop et al., 2009; 
Colombo et al., 2014; Marrie et al., 2013; Matti et al., 2010; Synnot et al., 2014). Despite 
this, interventions that have been designed to provide additional support to MS patients 
have commonly employed booklets and comprehensive educational programmes to 
implement interventions (Reen et al., 2017a). To effectively promote MS patients’ 
understanding of DMDs, future educational interventions should therefore be 
implemented using the most frequently accessed sources for information about DMDs. 
Interestingly, questions about sources of DMD information also revealed 
discrepancies between MS patients and MS nurses. For example, despite majority of MS 
nurses stating patient websites as a commonly used method of receiving DMD 
information by MS patients, this was not reported by a large proportion of MS patients. In 
addition, there were differences in the additional sources used for receiving DMD 
information as stated by MS patients and MS nurses beyond those given in the survey. 
These disparities indicate that MS patients do not discuss their information-seeking 
behaviours with MS nurses during consultations. This, in turn, suggests that consultations 
could be improved by ensuring information is discussed between patients and health 
professionals in a clear and transparent manner. 
MS patients reported very differently with regards to the frequency of receiving 
information about DMDs during consultations. Interestingly, a large proportion of 
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patients reported receiving information about DMDs at every consultation, with a 
similarly large number of patients reporting only having received information about 
DMDs in less than 1 in 10 consultations. Likewise, MS nurses’ responses to the 
frequency of providing DMD information during consultations also varied considerably. 
One possibility for the variability amongst responses could be that information about 
DMDs are not provided to patients in a uniform or standardised manner across clinics. 
Given that all MS patients vary substantially in disease course and tolerability to DMDs, 
it is likely that patients are provided with information about DMDs based on their 
individual needs and stage of the disease. It is thus not possible to determine from the 
current study whether increasing the frequency of consultations for providing information 
about DMDs could improve patients’ understanding of this information. 
The current study identified a need for improving patient understanding about 
DMDs. By directly collecting suggestions from MS patients and MS nurses, it was 
possible to determine how provision of DMD information could be improved to meet the 
needs of patients and effectively target additional support, which is a recommended 
method by scientists advocating the involvement of service users in research (Callard et 
al., 2012; Pope et al., 2002). The most common suggestion offered by MS patients in this 
study was that detailed DMD risks and benefits should be clearly provided within 
healthcare services. Another suggestion was that the quality of consultations with health 
professionals should be improved. Moreover, MS nurses suggested that an effective 
comparison between DMD risks and benefits should be offered to patients seeking DMD 
information. It is reasonable to assume that applying these suggestions to current 
healthcare services could improve the way information is provided to MS patients about 
DMDs. 
There are a number of limitations to the present study due to which the survey 
findings should be interpreted with caution. First, there was no attempt to statistically 
Chapter 3 
96 
analyse the quantitative information obtained from the surveys, and interpretations about 
the responses were not based on statistically significant results. Moreover, evidence-
based qualitative analytical methods, such as a phenomenological analysis or a discourse 
analysis (Starks & Trinidad, 2007), were not employed in the current study, and themes 
from qualitative feedback were derived purely on the basis of frequency. Hence, 
conclusions based on both quantitative and qualitative data from the surveys are not 
statistically reliable. However, these analytical methods were deemed unsuitable and 
beyond the scope of the present study, considering that the primary purpose of the study 
was simply to determine unmet patient needs in the context of DMD information rather 
than conclusively establish how information about DMDs is provided to patients in the 
UK.  
Second, it is not possible to determine the representativeness of participants in the 
current study. For MS patients, important demographic information such as age, ethnicity, 
education status, MS subtype, and level of disability was not recorded. These questions 
were excluded from the survey so that patients may provide comprehensive feedback 
about their experiences of MS clinics without feeling that they may be identified. 
However, in the absence of patient demographic information, it is not possible to 
determine whether the results obtained from the survey are truly representative of MS 
patients across the UK.  In addition, there was an extremely low sample size of MS 
nurses in the current survey. The results from a small number of MS nurses was included 
as it was established that MS nurses in the current study would have consulted with 
approximately 3,700 MS patients in the last year and had experience of many 
consultations with MS patients (see section 3.3.1). However, it is important to 
acknowledge that the quality and style of consultations that are provided to patients may 
differ between MS nurses across the UK. Thus, the results obtained from MS nurses in 
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the current survey may be limited to the consultation styles of only a few nurses and not 
represent the types of consultations provided to most MS patients.  
Finally, a selection bias may have been introduced in the current study which 
could further limit the representativeness of the sample. The majority of MS patients had 
been recruited from an online MS charity. These patients are more likely to have used 
online sources of information and be better informed than patients who are not members 
of an online charity. It is also possible that these patients were particularly interested in 
their condition and had access to other sources to receive treatment information. Yet, 
patients in the current survey still displayed limitations in understanding the risks and 
benefits of DMDs, which indicates that even patients with access to resources beyond 
consultations need additional support to better understand DMD information 
3.4.1 Conclusion 
In sum, the responses from the surveys employed in this survey indicate that not 
all MS patients feel satisfactorily informed about the risks and benefits of their DMD. 
The most common source of DMD information is through consultations with health 
professionals and searching the internet. In accordance with the suggestions offered by 
MS patients and nurses, future evidence-based research should focus on providing clear 
and accurate information about DMD risks and benefits, ideally during consultations with 
health professionals, in order to effectively improve MS patients’ understanding of DMD 
risks and benefits. 
  
Chapter 4 
98 
Chapter 4: Verbal, numerical and graphical formats to 
present treatment information3 
 
4.1 Introduction 
Patients’ understanding of treatment information is an integral part of shared 
decision-making within a patient-centred approach (see section 1.3). Systematic reviews 
of the literature (Reen et al., 2017) and surveys with MS patients and health professionals 
in the UK (see chapter 3), have established that MS patients are unable to satisfactorily 
understand the treatment information they receive. Several recommendations have been 
proposed in order to facilitate understanding in patients, including providing clear and 
accessible information using easily comprehensible presentation formats (Bunge, 
Mühlhauser, & Steckelberg, 2010; Edwards, Elwyn, & Mulley, 2002; Paling, 2003). 
These guidelines are largely based on evidence from studies with non-clinical populations 
or patients with conditions other than MS. Yet, interventions have been designed for MS 
patients in line with these guidelines. Notably, the methods used to present DMD risks 
and benefits in these interventions have been employed without directly evaluating these 
methods with MS patients (Reen et al., 2017a).  
 The following chapter will first identify the most optimal formats to present 
treatment risks and benefits to MS patients by reviewing studies conducted with different 
population groups, before reviewing the formats that have been evaluated directly with 
MS patients. Studies conducted with healthy, non-MS and MS clinical population groups 
will be used to identify the different types of formats that are used to present treatment 
information. The most common presentation formats from this review will then be 
empirically tested with MS patients in order to identify the best presentation formats to 
                                                     
3 The data from this experiment was presented as a poster at ECTRIMS conference, London, 
September 2016. The abstract developed for this conference was published as: Reen, G., Silber, E 
& Langdon, D. (2016). The influence of information presentation formats on treatment 
understanding and decision-making in MS patients. Multiple Sclerosis Journal, 22(S3), 884-917. 
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improve understanding of DMDs and reduce conflict in treatment decisions. Following 
this, a theoretical framework will be developed to demonstrate how MS patients’ 
understanding of treatment information is likely to be affected by these formats.  
4.1.1 Verbal formats 
Medical information can be communicated verbally using a variety of commonly 
recognised terms, including anything from ‘likely’ to ‘unlikely’, or ‘common’ to ‘rare’ 
(Lipkus, 2007). European Commission (EC) guidelines recommend the use of specific 
verbal terms which are assigned to precise quantities when presenting information within 
treatment patient leaflets, and consist of: very common, common, uncommon, rare and 
very rare (EC Guidelines, 1998, 2009; see table 4.1). Verbal terms are also used to 
display DMD risk information in current clinical practises in the UK (see example in 
appendix 11). The following section will evaluate the use of verbal formats to denote 
treatment risks and benefits in studies with non-clinical and clinical populations. 
Table 4.1 Verbal terms and assigned quantities as recommended by EC guidelines (1998, 
2009) 
Verbal terms Assigned quantities 
Very common >10% 
Common 1-10% 
Uncommon 0.01 – 1% 
Rare 0.01 – 0.1% 
Very rare < 0.01% 
 
4.1.1.1 Evaluation of verbal formats in non-clinical populations 
Studies evaluating the effectiveness of verbal formats to communicate 
quantitative information in non-clinical populations have produced mixed findings. 
Wallsten, Budescu, Zwick and Kemp (1993) conducted a large survey with students to 
record preferences about the best mode of communication. An equal number of 
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participants showed preferences for information communicated numerically and verbally. 
Verbal formats were preferred due to their ease of use, and their natural and personalised 
qualities (Wallsten et al., 1993). In another study, participants were presented with two 
scenarios which comprised uncertain but equivalent outcomes (Windschitl & Wells, 
1996). Participants were randomly assigned to state the likelihood of an outcome 
occurring either using numbers or a verbal format (e.g. somewhat likely, very likely etc.). 
Findings showed that when using verbal terms, participants were more likely to state the 
correct likelihood of the outcomes occurring irrespective of the uncertainty. In subsequent 
experiments, Windschitl and Wells (1996) also found that employing verbal terms was 
better related with individual preferences for an outcome and behavioural intentions in 
comparison to employing numerical information. Windschitl and Wells (1996) concluded 
that verbal formats were more likely to encourage associative and intuitive thinking, and 
thus facilitate decisions based on uncertain outcomes. A similar conclusion was drawn by 
a review which found that individuals were more likely to make reasoned decisions when 
perceiving information in verbal formats (Moxey & Sanford, 2000).  
In contrast, some studies have reported large variability in judgments when 
quantitative information is presented verbally to non-clinical populations. In an early 
study, participants were provided with a list of varying verbal terms (e.g. small 
probability, possible, great chance etc.) either in isolation or within different contexts 
(Brun & Teigen, 1988). Participants were required to assign a quantitative number to each 
format and state how much others would agree with their assignment in both conditions. 
The results showed large differences between participants when verbal terms were 
provided in context (e.g. a medical context), rather than in isolation. Individuals also 
underestimated the level of variability for each verbal format (Brun & Teigen, 1988). 
These findings pose a problem for verbal formats that could be provided within a 
treatment context, and also suggest that participants do not define verbal formats in the 
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same way. Critically, however, this study is not directly comparable with previous studies 
which showed benefits of employing verbal formats since different verbal phrases were 
used across all these studies. 
It has been proposed that verbal phrases should be standardised and assigned to 
specific probabilities to avoid misunderstanding (Lipkus, 2007). For instance, guidelines 
by the European Commission (EC) have assigned specific quantities to verbal descriptors 
when communicating treatment risk information to patients: for instance, where ‘very 
common’ refers to over 10% patients experiencing a risk and rare referring to less than 
0.01% patients who could experience a risk (EC Guidelines, 1998, 2009; see table 4.1). 
Studies have subsequently attempted to empirically test the efficacy of the verbal terms 
proposed by EC in the context of providing treatment risk information. 
Berry, Knapp, and Raynor (2002) conducted two randomised studies with non-
clinical population groups using hypothetical treatment information. The first study 
objectively examined the quantities that individuals assign to the five verbal terms 
recommended by the EC. All participants received all five verbal terms, but were 
randomised to either report back their numerical estimates as frequencies (e.g. 50 out of 
10,000) or percentages (e.g. 5%). Participants were further randomised to receive 
information about either the minor risks of the treatment or severe risks of the treatment. 
Findings of the study showed large individual variability in interpretation of the five 
verbal terms, which could not be explained by the severity of the risk or how numerical 
estimates were made. These incongruities were particularly apparent for the terms 
‘common’ and ‘very common’, as these were significantly overestimated in comparison 
to the actual quantities assigned by EC guidelines. In a follow-up study, participants also 
perceived the risks of the hypothetical treatment as increasingly severe and showed less 
intention to comply with treatments when the risks were presented using verbal terms in 
comparison to numbers (Berry et al., 2002). These findings converge with data from other 
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studies with large groups of non-clinical population, which found that treatment risks 
were poorly understood and significantly overestimated when presented using the verbal 
terms recommended by the EC (Berry, Raynor, Knapp, & Bersellini, 2004; Berry, 
Raynor, & Knapp, 2003). 
The evidence reviewed thus far suggest that despite some mixed findings for the 
use of verbal terms to present quantitative information, numerical quantities assigned to 
verbal terms recommended by the EC guidelines are not clearly interpreted by non-
clinical populations. 
4.1.1.2 Review of verbal formats in clinical populations 
The efficacy of verbal formats proposed by EC guidelines have further been 
assessed with clinical populations. In one study, Knapp, Raynor and Berry (2004) 
presented patients recovering from cardiac surgery with minor risks and adverse risks of 
two real medications in either verbal or numerical format. Patients were required to state 
the likelihood of the risks occurring, in addition to their perceived risk severity and their 
decision of whether to take the medication. The findings showed that both minor risks 
and adverse risks of medications were overestimated when presented in the verbal 
formats proposed by EC guidelines. Further, patients were more likely to perceive the 
risks as higher and decide against the medication when the risks were presented in verbal 
formats, indicating that poor understanding could lead patients to make inappropriate 
treatment decisions (Knapp et al., 2004).  
It has been suggested that understanding of verbal formats may be improved if 
accompanied by numerical information (Lipkus, 2007). In fact, the most recent EC 
guidelines (2009) strongly recommend the use of verbal formats alongside the correct 
numerical quantity, if available (see table 4.1). Knapp and colleagues (2009) examined 
these recommendations by randomly allocating cancer patients to three possible formats 
of presenting treatment risk information: verbal formats, numerical formats, or a 
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combination of verbal and numerical formats. Data from this study showed that patients 
were not able to accurately understand treatment risks when presented verbally, in 
comparison to numerically presented information. Interestingly, patients also showed 
poor understanding when treatment risks were presented using a combination of both 
verbal and numerical formats (Knapp et al., 2009), supported by a more recent version of 
the study (Knapp, Gardner, & Woolf, 2015).  
Overall, findings from this section indicate that verbal descriptors are not clearly 
understood by both non-clinical and clinical population groups, even when accompanied 
with numerical quantities as recommended by EC guidelines. These verbal terms are used 
in current clinical practise in the UK (see appendix 11). Yet, no studies to date have 
evaluated the efficacy of presenting treatments using verbal terms to patients with MS. 
For this reason, verbal formats were incorporated into the theoretical framework of 
factors that could affect MS patients’ understanding of treatments (see figure 4.1). 
4.1.2 Numerical formats 
Treatment risks and benefits can also be conveyed to patients using numerical 
information. The most commonly used numerical formats to present information in a 
medical context are percentages (e.g. 5%) and frequencies (e.g. 20 events observed out of 
100). Both frequencies and percentages are employed in UK clinical practises to provide 
DMD risks and benefits to MS patients (see appendix 11). 
Numerical information has several positive qualities, such as precision, scientific 
credibility and the ease in which numbers can be converted from one form to another (e.g. 
frequencies to percentages) (Lipkus, 2007). In fact, people generally prefer numerical 
formats based on these qualities (Gurmankin, Baron, & Armstrong, 2004; Wallsten et al., 
1993), although numerical formats are also considered to be impersonal relative to 
information presented verbally (Ancker, Chan, & Kukafka, 2009; Wallsten et al., 1993). 
With respect to understanding the information, numerical formats are consistently shown 
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to be superior in comparison to verbal formats (Berry et al., 2004; Berry et al., 2003; 
Berry et al., 2002; Windschitl & Wells, 1996). These studies, however, also show that 
understanding between different numerical formats can vary. To examine which 
numerical format can maximise understanding of treatment risk and benefit information 
in MS patients, the following section will review findings from studies conducted with 
both non-clinical and clinical populations.  
4.1.2.1 Review of numerical formats in non-clinical populations 
A number of studies have assessed the effects of frequencies and percentages on 
understanding of a screening test problem with both physicians and the general 
population (Bramwell, West, & Salmon, 2006; Gigerenzer, 1996; Hoffrage & Gigerenzer, 
1998; Mellers & McGraw, 1999) (see table 4.2 for an example of the screening test 
problem). Based on this problem, participants were required to state the number of 
patients that could have breast cancer after a positive mammography screening result. 
Overall understanding of the screening test problem was poor across all studies, likely 
due to inferences and calculations required in order to correctly arrive at the answer. 
However, both physicians and the general population consistently showed better 
understanding when the screening test problem was presented in frequencies rather than 
percentages (Bramwell et al., 2006; Gigerenzer, 1996; Hoffrage & Gigerenzer, 1998; 
Mellers & McGraw, 1999). Whilst these findings indicate that medical information 
presented in frequencies are easier to interpret, understanding the likelihood of detecting a 
disease may be different to understanding the risks and benefits of a treatment.  
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Table 4.2 The screening test problem in frequencies and percentages, as adapted from 
Gigerenzer and Edwards (2003) 
Numerical format Screening test problem 
Percentages The probability that a woman has breast cancer is 0.8%. If she 
has breast cancer, the probability that a mammogram will 
show a positive result is 90%. If a woman does not have 
breast cancer the probability of a positive result is 7% 
Frequencies Eight out of every 1000 women have breast cancer. Of these 
eight women with breast cancer seven will have a positive 
result on mammography. Of the 992 women who do not have 
breast cancer, some 70 will still have a positive mammogram. 
 
The effect of frequencies and percentages in the context of treatment risk and 
benefit information has been evaluated by Waters, Weinstein, Colditz, and Emmons 
(2006). Participants were presented with a hypothetical risk of cancer for which a 
treatment could reduce the risk to a certain degree but with a potential risk of developing 
another type of cancer. Understanding was measured by asking participants whether their 
total cancer risk would increase, decrease or remain the same. The findings showed that 
treatment risk and benefit information presented in percentages was better understood 
than information presented in frequencies (Waters et al., 2006). Similar findings were 
obtained by Woolshin and Schwartz (2011), as they randomly presented participants with 
treatment risks and benefits in frequencies, percentages, or a combination of percentages 
and frequencies. Participants showed greater understanding of treatment risks and 
benefits when provided in percentages compared to frequencies. Understanding of 
treatment risks and benefits when presented in a combination of the two numerical 
formats was equivalent to that of percentages (Woolshin & Schwartz, 2011). 
Interestingly, two types of frequencies were presented in this study. For one frequency, 
the denominator remained constant (e.g. 4 out of 1000, 10 out of 1000), whereas for the 
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other frequency, the numerator remained constant at 1 (e.g. 1 out of 10, 1 out of 100). To 
explain why neither of these frequencies improved understanding, Woolshin and 
Schwartz (2011) proposed that small frequencies may be magnified when the 
denominator is kept constant, whereas the denominator is likely to be ignored when only 
the numerator is kept constant. 
In short, providing medical information numerically improves understanding in 
non-clinical populations in comparison to information presented verbally. However, it is 
unclear to what extent understanding can be improved when presented in specific 
numerical formats. In fact, some studies show no effects on understanding when 
treatment risks and benefits are presented in either frequencies or percentages (Cuite, 
Weinstein, Emmons, & Colditz, 2008; Gurmankin et al., 2004; Peters et al., 2011). 
Although, it is possible that understanding may differ for population groups that are more 
likely to make treatment decisions based on treatment information. Thus, findings based 
on clinical population groups need to first be reviewed prior to drawing any conclusions 
about the efficacy of different numerical formats. 
4.1.2.2 Review of numerical formats in clinical populations 
Chapman, Litton, Chamberlain and Ho (2015) used surrogate decision-makers to 
assess perceived risk of treatment presented in different numerical formats. Surrogate 
decision makers in this study were the next of kin of critically ill patients and responsible 
for making medical decisions for patients. Participants were randomised to hypothetical 
treatment scenarios, with information in one scenario presented in percentages (e.g. 20% 
risk of death) and information in the other scenario presented in frequencies (e.g. 1 in 5). 
Participants were then required to state the perceived risk of death on a visual analogue 
scale. The study found that the risks were consistently interpreted as higher when 
presented in frequencies rather than percentages, suggesting a difference in understanding 
Chapter 4 
107 
between these formats. Note, however, that objective understanding was not measured in 
this study. 
In another study, Bramwell and colleagues (2006) provided women who were 
pregnant with the potential risk of their child having Down’s syndrome following a 
screening test. Women were randomly assigned to information presented in either 
frequencies or percentages. To note, the structure of the information presented to women 
was similar to that of the screening test problem reviewed previously (see table 4.2). 
When women were assessed on the likelihood their child having a risk of the condition 
following a positive result on the test, the majority of women were not able to accurately 
answer the question. However, of women who had answered questions correctly, there 
was a trend for information to be better understood when presented in frequencies in 
comparison to percentages although this finding was nonsignificant.   
In summary, the effects of presenting treatment risk and benefit information in 
frequencies or percentages on understanding remains inconclusive based on findings with 
physicians, patients likely to make healthcare decisions and the general population. This 
is supported by reviews of the literature which did not find any format to be more reliable 
at improving understanding of treatment information (Lipkus, 2007; Zipkin et al., 2014). 
Despite these heterogeneous findings, recommendations have been made for the use of 
frequencies when presenting medical information to patients primarily based on the 
screening test problem (Akl et al., 2011; Bunge et al., 2010), which needs to be 
interpreted with caution when communicating treatment risks and benefits to patients. In 
addition, no study to date has directly tested the impact of frequencies and percentages on 
understanding of treatments with MS patients. These formats were therefore included into 
the theoretical framework of MS patients’ understanding (see figure 4.1). 
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4.1.3 Graphical formats 
Treatment risks and benefits can also be represented visually through the use of 
graphical formats, such as bar charts, line graphs, pie charts and pictographs. The positive 
qualities of graphical formats include their ability to summarise large data and reveal 
patterns that would otherwise go undetected (Lipkus, 2007). In fact, when numerical 
information is accompanied by visual formats, patients’ accuracy of risk perception can 
be facilitated more so than numbers alone (Garcia-Retamero & Galesic, 2010b; Garcia-
Retamero & Hoffrage, 2013; Tait, Vopel-Lewis, Zikmund-Fisher, & Fagerlin, 2010). 
This has been supported by a review of the literature which found that all types of visual 
presentations generally facilitate patients’ understanding of medical information (Bunge 
et al., 2010). Nonetheless, not all graphical formats have the same effects on 
understanding of treatment risks and benefits. The following section will explore the 
effects of particular graphical formats on understanding treatment information with both 
non-clinical and clinical populations, prior to discussing the limited findings with MS 
patients.  
4.1.3.1 Review of graphical formats in non-clinical populations 
A number of studies have assessed preferences of specific graphical formats with 
non-clinical populations. Using a qualitative methodology, Schapira, Nattinger and 
McHorney (2001) compared horizontal bar charts, vertical bar charts and pictographs 
displaying highlighted figures corresponding to the risk of treatment, in a non-clinical 
population. The human figures in these pictographs were either highlighted consecutively 
or randomly arranged. Schapira and colleagues (2001) found that vertical bar charts were 
unanimously favoured in comparison to horizontal bar charts. However, the most 
preferred visual format for the majority of participants was the consecutively arranged 
human-figured pictographs. In contrast, the random highlighted pictographs were 
considered too cognitively difficult to comprehend. Interestingly, participants still 
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reported randomly arranged formats as being more ‘true’ than those arranged 
consecutively (Schapira et al., 2001). Likewise, the positive comments for randomly 
arranged pictographs outnumbered the negative comments in another qualitative study 
(Ancker et al., 2009). Together, these studies indicate that people interact with treatment 
risk information differently depending on the graphical formats used to represent the 
information. Critically, however, it is not possible to determine how understanding is 
affected simply based on preferential judgments. Subsequent studies with objective 
measures have shown that medical risks are actually overestimated when presented using 
pictographs with human figures highlighted at random (Schapira, Nattinger, & 
McAuliffe, 2006), despite some preference for these formats (Ancker et al., 2009; 
Schapira et al., 2001).  
A number of studies have objectively assessed understanding of medical risk 
information when presented in different graphical formats. Brewer, Gilkey, Lillie, Hesse 
and Sheridan (2012) conducted two experiments to assess preferences and accuracy of 
understanding of bar charts and tables to present information about hypothetical medical 
test results. In the first experiment, participants were assigned to either the bar chart or 
table condition (between subjects), whereas the second experiment presented participants 
with both graphical formats (within subjects). Participants in both experiments preformed 
equally well on measures of understanding and showed no preferences for either format 
(Brewer et al., 2012). Conversely, when tables were compared to pictographs in another 
study, understanding was found to be greatest for pictographs (Tait et al., 2010). More 
recently, Hamstra and colleagues (2014) evaluated four different types of graphical 
formats against each other, consisting of line graphs, pie charts, bar charts and 
pictographs. Participants were assessed on verbatim and gist understanding of the 
hypothetical risk of developing prostate cancer. Understanding was the greatest for bar 
charts and pictographs, and poorest for line graphs and pie charts (Hamstra et al., 2014). 
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Despite these findings showing clear differences in understanding when medical 
information is presented in different graphical formats, it is possible that information 
about treatment risks and benefits may be understood differently. 
Some studies have evaluated graphical formats in a treatment context. Tait, 
Voepel-Lewis, Brennan-Martinez, McGonegal and Levine (2012) examined the effects of 
pie charts, bar charts and pictographs to present treatment risks and benefits. Participants 
did not show differences in understanding of treatment risks and benefits presented in 
different graphical formats, although pictographs and bar charts were preferred more than 
pie charts. Interestingly, this study did find that participants presented with graphical 
formats for which they previously stated a preference, showed the greatest understanding 
and satisfaction in comparison to participants who were not provided with their preferred 
graphical format (Tait et al., 2012). In another study, McCaffery and colleagues (2012) 
compared the effects of presenting treatments using both pictographs and bar charts on 
understanding in a non-clinical population. Participants showed better understanding for 
pictographs when treatment risks were low (e.g. 100 out of 1000), whereas bar charts 
were better understood for medium to large levels of risk (e.g. 500 out of 1000) 
(McCaffery et al., 2012). Bar charts were preferred the most even though this did not 
influence performance, unlike the study by Tait and colleagues (2012). Another study 
provided non-clinical populations with hypothetical treatment risks and benefits in six 
different graphical formats (Hawley et al., 2008). These formats consisted of: pie chart, 
bar chart, pictograph, modified pictograph, modified pie chart and table. Participants were 
assessed for their verbatim and gist understanding using a number of comprehension 
questions. Findings showed that tables and bar charts were more effective at increasing 
verbatim accuracy of hypothetical treatment risks and benefits, even though people had 
poor gist understanding of treatments. The table was rated as the most effective and 
scientific graphical format. Notably, pictographs performed consistently well on all 
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variables in this study; both verbatim and gist knowledge was high and the graph was also 
strongly preferred by people in the study. Hawley and colleagues (2008) thus concluded 
that pictographs are an ideal graphical format to present treatment risks and benefits to 
individuals. 
Taken together, studies with non-clinical populations indicate that individuals 
perceive medical and treatment risks and benefits differently when this information is 
represented in various graphical formats. Bar charts, tables and pictographs seem to 
greatly improve understanding in comparison to other graphical formats. However, 
reliable conclusions cannot be drawn from these findings given that the graphical formats 
compared in studies vary greatly.  
4.1.3.2 Review of graphical formats in clinical populations 
Only very few studies have examined different graphical formats on 
understanding of medical information in clinical populations. Garcia-Retamero and 
Hoffrage (2013) evaluated the efficacy of pictographs to present the screening test 
problem (see table 4.2 for example) to patients recruited from a primary health care 
service. In comparison to the screening test problem presented only in frequencies, 
patients that were also provided with pictographs showed significant improvements in 
their ability to solve the problem. Similarly, Zikmund-Fisher and colleagues (2008) 
employed pictographs to represent treatment information with the total pictograph 
referring to either 100 people or 1000 people. Real treatment risks were communicated to 
women with elevated risk of breast cancer going through consultations at health clinics. 
Understanding of treatment risks was shown to be high when information was presented 
in pictographs, regardless of the total figure size, in comparison to when information was 
only presented in frequencies (Zikmund-Fisher et al., 2008).  
In sum, very few studies have been conducted with clinical populations to 
evaluate the efficacy of graphical formats. Of these, comparisons were limited to 
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pictographs and frequencies, with pictographs improving understanding the most. Studies 
comparing different types of graphical formats in clinical populations are thus lacking. 
4.1.3.3 Review of graphical formats in MS patients 
With regards to MS, only one study has assessed the efficacy of graphical 
formats to present treatment risk and benefit information. Similar to other findings in the 
clinical literature (Garcia-Retamero & Hoffrage, 2013; Zikmund-Fisher, Ubel, et al., 
2008), the study by Kasper, Heesen, Köpke, Mühlhauser and Lenz (2011) only assessed 
the effectiveness of pictographs in communicating the risks and benefits of hypothetical 
treatments in MS. Yet unlike previous findings, Kasper and colleagues (2011) found that 
MS patients were not able to understand the treatment risks when presented with human-
figured pictographs, in addition to significantly overestimating the treatment benefits. 
Whilst the effects found in this study were only based on hypothetical treatments and may 
not necessarily correspond to risk and benefits of actual MS medications (Kasper et al., 
2011), the fact that pictographs do not have the same effect on MS patients’ 
understanding in comparison to other studies poses a problem for adopting methods from 
studies with non-clinical populations to healthcare practises.  
4.1.3.4 Additional elements in graphical formats 
The elements in graphical formats can also influence understanding of treatment 
information, as demonstrated by studies conducted predominantly with non-clinical 
populations. These elements include numerical formats added to graphical formats, 
orientation of graphical formats, pictograph arrangement and the type of figures used 
within pictographs. 
Reviews of the literature recommend that visual aids and numbers should be 
provided together to maximise understanding of medical information in patients (Bunge, 
Mühlhauser, et al., 2010; Lipkus, 2007). In fact, Hamstra and colleagues (2014) found 
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that frequencies added to pictographs significantly improved understanding in 
comparison to presenting information using graphical formats alone. These findings were 
further supported by Hawley and colleagues (2008), as understanding was shown to 
improve when graphical formats also displayed numerical frequencies. Conversely, when 
a combination of graphical formats and frequencies to present treatment information was 
compared with numerical formats alone, no differences in understanding information was 
observed in a group of non-clinical populations (Henneman et al., 2013). Thus, whether 
numbers and graphical formats presented together can improve understanding of 
treatment risks and benefits more than numerical or graphical formats presented alone 
need to be examined further. 
Vertically oriented graphical formats have also been shown to improve 
understanding compared to graphs orientated horizontally, irrespective of the graphical 
format itself, i.e. vertical pictographs and bar charts were considered more effective than 
horizontal pictographs and bar charts, respectively (McCaffery et al., 2012). Likewise, 
vertical bar charts led to fewer comprehension errors in comparison to horizontal bar 
charts presenting medical information in other studies (Feldman-Stewart, Kocovski, 
McConnell, Brundage & Mackillop, 2000). In contrast, Price, Cameron and Butow 
(2007) found that accuracy of understanding was greater for horizontal pictographs as 
opposed to pictographs orientated vertically, suggesting that the impact of graph 
orientation on understanding is uncertain.  
Treatment information displayed in pictographs can also be represented using 
different types of figures, which range from human faces and human bodies, to abstract 
symbols such as ovals and rectangles. Although results from various studies have 
favoured the use of pictographs, the figures employed in pictographs across studies tend 
to vary considerably. Zikmund-Fisher and colleagues (2014) directly compared six 
different types of figures on participants’ understanding and preferences. Understanding 
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was greatly improved for all anthropomorphic figures (i.e. outline of human bodies, 
outline of human heads and photos of humans) in comparison to abstract figures. The 
most preferred pictograph figure was the outline of human bodies (Zikmund-Fisher et al., 
2014). Yet, no difference in understanding emerged between human or abstract 
pictographs for individuals with poor numeracy skills (Zikmund-Fisher et al., 2014). 
Similarly, no differences were observed in risk perception when participants were 
presented with human figures or abstract figures in pictographs within another study 
(Schapira et al., 2006), indicating a need to further examine the effects of different figures 
in pictographs on understanding of medical information. 
Relatedly, the figures within pictographs can either be arranged consecutively or 
randomly to represent the number of people affected by a risk or benefit. Random 
arrangement in pictographs are often considered to be more realistic as they represent the 
randomness of patients who may be affected by a treatment risk or experience a treatment 
benefit (Ancker et al., 2009; Schapira et al., 2001). Despite this, participants also describe 
randomly arranged figures as too visually complex to comprehend (Schapira et al., 2001) 
and generally overestimate the risks when pictographs are presented randomly rather than 
consecutively (Schapira et al., 2006). The impact of pictograph arrangement on 
understanding treatment information has in fact been conducted with MS patients in one 
study (Kasper et al., 2011). Although consecutively arranged pictographs were strongly 
preferred by MS patients, there were only very small differences between understanding 
of treatment risks and benefits between these different arrangements (Kasper et al., 2011).  
In summary, understanding of medical information can vary depending on how 
information is presented graphically to both non-clinical and clinical populations. Studies 
conducted with clinical populations, including patients with MS, have generally only 
assessed the effectiveness of pictographs as graphical tools to present medical 
information. For this reason, it is important that research with MS patients compares 
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different graphical formats in order to determine which graphical format is able to 
maximise understanding of treatment risk and benefit information. Moreover, studies 
conducted largely with non-clinical populations have shown that different elements of 
graphical formats may further influence understanding of treatment risks and benefits. 
Aside from arrangement of pictographs, other elements of presenting graphical formats 
have not been examined in MS populations on their understanding of the risks and 
benefits of treatments. With these findings in mind, graphical formats were also 
incorporated into a theoretical framework of MS patients’ understanding (see figure 4.1). 
4.1.4 Patient understanding and patient characteristics 
The ability to accurately understand treatment risk and benefit information from 
verbal, numerical and graphical formats can also be dependent on patient characteristics. 
These characteristics are reviewed in some detail below and are also included into the 
theoretical framework of MS patients’ understanding. 
4.1.4.1 Numerical reasoning, health literacy and premorbid IQ 
Numeracy skills, health literacy and IQ are individual characteristics closely 
related with level of education (Peters, 2008). These skills are likely to influence how 
treatment information from different formats is understood.  
Participants with poor numeracy skills experience difficulty in understanding 
medical information provided in percentages compared to information presented in 
frequencies. The absence of these differences in highly numerate individuals thus 
signifies that numeracy skills can impact interpretation of information presented in certain 
numerical formats (Peters et al., 2011). It has been proposed that individuals with poor 
numeracy skills may benefit from numerical information presented alongside graphical 
formats (Lipkus, 2007; Paling, 2003). This is supported by studies showing that graphical 
formats can significantly improve understanding of information for low numerate 
individuals (Garcia-Retamero & Galesic, 2010b; Hamstra et al., 2014). Understanding 
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information presented in specific graphical formats has also shown to be dependent on 
individuals’ numeracy skills. Hawley and colleagues (2008) found that participants with 
high numeracy scored significantly higher on comprehension questions for all graphical 
formats. However, for respondents with weaker numeracy skills, information presented in 
pie charts, tables and pictographs was better understood in comparison to all other graphs. 
Likewise, during comparison of different pictograph figures, Zikmund-Fisher and 
colleagues (2014) found that participants with poor numeracy skills misunderstood risk 
information when presented with human figures, unlike patients with greater numeracy 
skills. 
Overall, studies with non-clinical populations indicate that patients’ numeracy 
skills may affect understanding of treatment risk and benefit information when presented 
using a range of numerical and graphical formats. Studies did not examine the impact of 
health literacy or IQ for treatment information presented using these formats. Regardless, 
it is conceivable that health literacy and IQ can also affect how treatment information is 
understood from different verbal, numerical and graphical formats.  
4.1.4.2 Symptoms of MS 
Understanding of treatment information presented in different verbal, numerical 
and graphical formats may be influenced by symptoms of MS. Clinical opinion holds that 
particular MS symptoms, such as fatigue, mood and cognitive impairments, are likely to 
influence understanding of treatment information (Chiaravalloti & Deluca, 2008; 
Langdon, 2011) (see section 1.1.2 for review about MS symptoms). Non-clinical 
participants have reported that complex formats, such as randomly arranged pictographs, 
tend to increase cognitive load and thus are difficult to comprehend (Schapira et al., 
2001). Therefore, it is expected MS patients experiencing cognitive impairments in 
particular may show differences in understanding treatment information when presented 
in different verbal, numerical and graphical formats.  
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4.1.5 Patient understanding and decisional conflict 
Patients’ understanding of treatments can lead to informed treatment decisions 
(see section 1.3 for review). It is therefore expected that patients may experience conflict 
in their treatment choice if treatment information is not accurately understood. Decisional 
conflict is especially likely when patients are confronted with uncertainty of outcomes, 
the risks and benefits for each outcome varies considerably, and there is a need to make 
trade-offs between acceptable levels of risks and benefits (Janis & Mann, 1977; 
O’Connor, 1995). These conditions are likely in a chronic condition such as MS, as 
patients making the decision to take a DMD are confronted with complex risk-benefit 
profiles and the impact of treatments on an individual’s disease course is often unclear 
(see section 1.2). Thus, MS patients making decisions about the most suitable DMD are 
likely to experience conflict in their decisions. 
Decisional conflict can be measured by the Decisional Conflict Scale (DCS) 
(Janis & Mann, 1977; O’Connor, 1995). The DCS is generally considered a reliable and 
validated measure which discriminates between patients who are conflicted in their 
decisions and those who are not conflicted in their treatment choice (O’Connor, 1995; 
Stacey et al., 2014). The scale assigns patients an overall decisional conflict score, which 
is a composite of the scores on the following five measures: uncertainty in choosing 
between available options, perception of feeling informed about the risks and benefits of 
each option, personal values towards benefits and risks of options, level of perceived 
support during decision-making and the likelihood of implementing the chosen option 
(O’Connor, 1995; Stacey et al., 2014). Thus, a greater score on the overall DCS and the 
DCS subscales pertains to a high level of conflict in patients’ decisions. 
Despite poor understanding of available options considered as one contributing 
factor of patients’ conflict in their decisions, studies that have assessed the relationship 
between patients’ understanding of treatment choices and patients’ decisional conflict 
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have produced inconsistent findings. A small significant inverse correlation between 
understanding and overall decisional conflict was reported in the DCS validation study, 
indicating that as understanding increases the conflict in decisions tends to reduce albeit 
by a small margin (O’Connor, 1995). However, other studies have demonstrated a higher 
significant inverse relationship between understanding of treatment information and 
decisional conflict, with both the overall DCS score (Cormiers, Legare, Simard, & 
Boulet, 2015) and scores on the DCS subscale which assesses patients’ perception of 
being informed (Sun, 2005). On the other hand, several studies have examined an indirect 
relationship between understanding and decisional conflict by independently examining 
both outcomes following interventions designed to improve patients’ healthcare 
decisions. Some interventions have demonstrated both improvements in understanding 
and reduction in overall decisional conflict (Arterburn et al., 2011; Evans et al., 2010; 
Nassar, Roberts, Raynes-Greenow, Barratt, & Peat, 2007; Wong, Thornton, Gbolade, & 
Bekker, 2006), whilst other interventions only showed improvements in understanding 
but with no apparent reduction in overall decisional conflict (Köpke et al., 2014; Leighl et 
al., 2011; Mann, Ponieman, Montori, Arciniega, & McGinn, 2010; Schapira et al., 2007). 
When interventions were pooled together into a review, both understanding was 
improved and decisional conflict was reduced in clinical populations (Stacey et al., 2014). 
Given that such interventions are often designed by integrating several different factors, it 
is not possible to assess whether there was a direct relationship between understanding 
and decisional conflict or whether a relationship was moderated by components of the 
intervention. 
In summary, accurately understanding treatment risks and benefits is likely to 
reduce decisional conflict in MS patients. Decisional conflict can generally be measured 
using the DCS measure. Although findings are inconsistent, patients’ understanding tends 
to directly and indirectly reduce conflict in treatment decisions. It therefore remains to be 
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explored whether this relationship holds for MS patients attempting to understand 
treatment information using verbal, numerical and graphical formats. 
4.1.6 Research questions and hypothesis 
The following experiment addressed five important research questions motivated 
by the review of the literature. First, can verbal formats maximise understanding of 
treatment risk and benefit information compared to numerical formats? Second, which 
numerical format (frequencies or percentages) can maximise understanding of treatment 
risk and benefit information in MS patients? Third, which graphical format can maximise 
understanding of treatment risk and benefit information in MS patients? Fourth, which 
additional elements can be added to graphical formats (orientation, pictograph figures, 
pictograph arrangement and numbers displayed on graphical formats) in order to 
maximise understanding of treatment information in MS patients? Finally, what is the 
relationship between MS patients’ understanding of treatments presented in different 
formats with patients’ conflict in treatment decisions? Additional exploratory questions 
attempted to address how patients’ numerical reasoning, health literacy and symptoms of 
MS could impact MS patients’ understanding of treatments presented in different 
formats? 
Hypotheses for the following experiment was generated from the literature and 
were as follows: 
(i) Numerical formats will maximise understanding of treatment information in 
comparison to verbal formats; 
(ii) Frequencies and percentages will have the same effect on patients’ 
understanding; 
(iii) Pictographs would maximise understanding of treatment information compared 
to other graphical formats (bar charts, line graphs and pie charts); 
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(iv)  All graphical formats with numbers displayed would maximise understanding of 
treatment information; 
(v) Orientation of graphical formats will show no difference in patients’ 
understanding; 
(vi)  Human figures on pictographs will maximise understanding compared to 
abstract shapes on pictographs; 
(vii) Consecutively arranged pictographs will maximise understanding compared to 
randomly arranged pictographs; 
(viii) Greater understanding of treatment information will be related to reduced conflict 
in treatment decisions by MS patients; 
(ix)  Numerical reasoning will be positively related with understanding of treatment 
information. 
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Figure 4.1 Theoretical framework 1: Factors affecting MS patients’ understanding of treatment 
risks and benefits 
Key: Grey arrows, no relationship; Question, Untested factors; arrows do not signify causation 
 
4.2 Experiment 1 methodology 
4.2.1 Participants 
A total of 45 patients diagnosed with the relapsing-remitting form of Multiple 
Sclerosis (RRMS) under the current diagnostic criteria (Polman et al., 2011) were 
included in this experiment. Patients were recruited from two hospitals in the UK: King’s 
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College Hospital NHS Foundation Trust and Queen Elizabeth Hospital as part of the 
Lewisham and Greenwich NHS Trust. The experiment received ethical approval from the 
Psychology Department Ethics Committee at Royal Holloway and the NHS Research 
Ethics Committee (see appendix 3 and 4). 
Patients were eligible to take part in the experiment if currently taking a DMD, 
able to provide informed consent and meet task demands of the experiment in terms of 
sensorimotor abilities. People with any significant changes in the condition or medication 
in the last 4 weeks were excluded. The exclusion criteria also extended to patients with 
significant medical or psychiatric condition other than MS. All patients were initially 
assessed on a visual acuity scale, also known as a Jaeger chart (Keeney & Duerson, 
1958), given that visual impairments are a commonly occurring symptom in MS. Patients 
were excluded if visual acuity was less than 20/70. 
4.2.2 Materials and design 
Hypothetical medical information was used throughout the experiment to ensure 
sensitive medical information was not provided to patients in the absence of healthcare 
professionals and appropriate support. 
Patients in the current experiment received information about two hypothetical 
diseases. A brief summary of the disease was initially provided followed by a list of 
symptoms (see appendix 12 for example of one disease). To mimic the progressive and 
uncertain nature of MS, patients were informed that the hypothetical diseases were 
progressive but that the rate of progression could vary between patients. It was also stated 
that individuals may not experience all symptoms of the disease. For each disease, 
patients also received information about the minor risks, adverse risks and benefits for 
two hypothetical treatments. Specifically, each hypothetical treatment presented four 
minor risks, two adverse risks and two benefits (i.e. each treatment had eight outcomes). 
The diseases and the treatments names were designed by the experimenter to increase 
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validity. All names were checked for their similarity with names of real diseases and 
treatments in a small survey with a non-clinical population group, prior to conducting the 
experiment (N=10). Each of the minor risks and adverse risks assigned to the treatments 
in this experiment were plausible and could be associated with real medications, further 
increasing validity. Prior to selecting these risks, a comprehensive list of treatment risks 
were checked by a small non-clinical population group (N=10). Risks were selected and 
assigned as either minor or adverse risks if 80% of the survey sample were in agreement 
about the level of risk. With respect to treatment benefits, these related back to the 
symptoms of the hypothetical disease; i.e. the benefit of the treatment was a delay in 
progression of a symptoms of the disease. Even though treatments were hypothetical, the 
risk-benefit profiles were drawn from real clinical trials of DMDs (e.g. Cohen et al., 
2010; IFNB Multiple Sclerosis Group, 1993; Kappos et al., 2010; Miller et al., 2009; 
O’Connor et al., 2009). That is, for each disease, one treatment represented a second-line 
treatment (i.e. high risk and high benefit) whereas the other treatment had a low risk-
benefit profile. To ensure the adverse risks of DMDs could be clearly represented, a 
denominator of 1000 patients were chosen and presented with all formats and during all 
comprehension questions (i.e. treatment outcome out of 1000 patients). Moreover, all 
minor risks, adverse risks and benefits of the treatments were provided for multiple time 
points (i.e. after 1 year, 2 years and 5 years of taking the treatment) in order to mimic the 
long-term effects of taking DMDs in MS.  
The formats to present treatment risks (minor and adverse) and benefits were 
manipulated in the present experiment. Verbal terms, based on EC guidelines, were 
employed to represent numerical information (EC Guidelines, 2009; see table 4.1 for 
example). The two numerical formats used to present treatment information consisted of 
frequencies and percentages. Several graphical formats were also employed in the present 
experiment, comprising: tables, bar charts, line graphs, pie charts and pictographs. 
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Finally, graphical format elements were also manipulated in the present experiment, 
including: pictograph figures (abstract or human), pictograph arrangement (consecutive 
or random), bar chart orientation (vertical or horizontal) and the addition of numbers with 
some graphical formats (graphical formats with numbers and without numbers). All 
formats were developed by authors. Tables, bar charts, line graphs and pie charts were 
designed in Microsoft Excel, and pictographs were designed using an available online 
template ("Icon array", n.d.) (see figure 4.2 for some examples of author-developed 
formats). 
 
 
Figure 4.2 Examples of graphical formats presented in Experiment 1 
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A within-subjects design was employed in the present experiment, so that every 
patient received information about all treatment minor risks, adverse risks and benefits 
presented in all possible formats across both diseases. In total, patients were presented 
with 16 different formats. Each format was employed twice in immediate succession. 
Thus, 16 different formats were used to present 32 treatment outcomes (see tables 4.3 and 
4.4; see appendix 13 for presentation formats presented with Treatment A only). To 
dissipate order effects, the initial order of all formats and treatment outcomes were 
randomised using a random number generator (see tables 4.3 and 4.4). In addition, the 
order in which the hypothetical diseases and treatments were presented to each patient 
was counterbalanced between patients using a Latin square design (Bradley, 1958; Winer, 
1962) (see table 4.5). 
The main outcome measures in the experiment were understanding of treatment 
information and decisional conflict for treatment choice. In addition, the following patient 
characteristics were assessed: demographics, numerical reasoning, health literacy, 
premorbid IQ and symptoms of MS (i.e. fatigue, affective and cognitive symptoms). 
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Table 4.3 Randomisation order of treatment outcomes and formats for hypothetical disease 
1 
Medical 
disease 
Treatment Treatment 
outcome 
Formats 
Disease 1 
(Septhitus) 
Treatment A 
(Difoxitin) 
Adverse risk Vertical bar chart, with numbers 
Benefit Vertical bar chart, with numbers 
Adverse risk Line graph, with numbers 
Minor risk Line graph, with numbers 
Minor risk Pie chart 
Minor risk Pie chart 
Minor risk Horizontal bar chart 
Benefit Horizontal bar chart 
Disease 1 
(Septhitus) 
Treatment B 
(Tephemerol) 
Minor risk Consecutive pictograph, abstract figures 
Adverse risk Consecutive pictograph, abstract figures 
Benefit Line graph 
Minor risk Line graph 
Minor risk Vertical bar chart 
Minor risk Vertical bar chart 
Benefit Pie chart, with numbers 
Adverse risk Pie chart, with numbers 
Names assigned to hypothetical medical disease and hypothetical treatments provided in brackets; 
all formats were presented twice in immediate succession; formats provided with treatment A are 
included in appendix 13 
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Table 4.4 Randomisation order of treatment outcomes and formats for hypothetical disease 
2 
Medical 
disease 
Treatment Treatment 
outcome 
Formats 
Disease 2 
(Pariplexia) 
Treatment C 
(Tripoxac) 
Minor risk Horizontal bar chart, with numbers 
Adverse risk Horizontal bar chart, with numbers 
Minor risk Random pictograph, abstract figures 
Benefit Random pictograph, abstract figures 
Minor risk Random pictograph, human figures 
Minor risk Random pictograph, human figures 
Benefit Percentages 
Adverse risk Percentages 
Disease 2 
(Pariplexia) 
Treatment D 
(Lapoxil) 
Adverse risk Consecutive pictograph, human figures 
Benefit Consecutive pictograph, human figures 
Minor risk Verbal format 
Minor risk Verbal format 
Adverse risk Table 
Minor risk Table 
Benefit Frequencies 
Minor risk Frequencies 
Names assigned to hypothetical medical disease and hypothetical treatments provided in brackets; 
all formats were presented twice in immediate succession 
 
Table 4.5 Latin square design for Experiment 1 
Disease Treatment Treatment Disease Treatment Treatment 
1 A B 2 C D 
1 B A 2 D C 
2 C D 1 A B 
2 D C 1 B A 
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4.2.2.1 Patient understanding 
Understanding of treatment risk and benefit information was assessed by asking 
patients three comprehension questions immediately after presenting information in a 
particular format, reflecting the three time points (i.e. 1 year/2 years/5 years). For 
instance, after presenting each treatment outcome patients were asked: ‘Out of 1000 
people, how many people would experience this minor risk/adverse risk/benefit after 1 
year/2 years/5 years?’ (see appendix 13 for example of comprehension questions). 
Questions were author-developed for the purpose of the current experiment, but were 
adapted from previous studies (Hamstra et al., 2014; Hawley et al., 2008). Answers were 
marked as correct and awarded 1 point if patients either stated the precise value or 
provided an answer within a range of + or – 10. Answers within a 1% range of the total 
denominator (i.e. + or - 10 for 1000 patients) were accepted due to the difficulty in 
reporting the most precise numbers when these were not presented with some formats. In 
fact, 100% on scores is not generally considered a sensitive nor required measure to 
measure understanding and it is practical for responses that indicate understanding to be 
scored accordingly (Tait et al., 2010). Similar cut-offs for acceptable correct answers for 
comprehension questions have also been applied in previous studies (Hamstra et al., 
2014; Hawley et al., 2008; McCaffery et al., 2012). Incorrect or missing answers were 
scored as 0. The maximum correct answers for treatment side-effect, risks or benefits was 
three points. Given that each format presented information about two treatment outcomes, 
the maximum score for each format was six points. 
4.2.2.2 Decisional conflict 
Following the presentation of two hypothetical treatments for each disease, 
patients were required to make a treatment decision or choose to take no treatment.  
Following a treatment decision, the DCS was employed to assess patients’ conflict in 
their treatment decisions (O’Connor, 1995). In the present experiment, the DCS was 
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given twice to each patient. The DCS was provided after disease 1 (for treatments A and 
B) and disease 2 (for treatments C and D).  
The DCS is a multi-dimensional scale of 16 items divided into 5 subscales: 
personal uncertainty (3 items) and its modifiable deficits of feeling uninformed (3 items), 
unclear values (3 items), inadequate support (3 item), and perception that an ineffective 
choice has been made (4 items). Participants’ ratings on these subscales correspond to the 
treatment choice they make at the start of the scale, which includes the option of being 
unsure. The scores can be standardised to range from 0 (no decisional conflict) to 100 
points (extreme decisional conflict) (O’Connor, 1995). Scores of 25 are associated with 
continuing with a decision, whereas scores that exceed 38 are associated with delay in 
decision-making. The DCS has been shown to have high reliability, with test-retest 
correlation of 0.81. Internal consistency for the total DCS score ranged from 0.78 to 0.92, 
and this ranged from 0.58 to 0.92 for the DCS subscales (O’Connor, 1995). The scale has 
also been demonstrated as a valid measure to discriminate between patients who accept or 
reject the decision, relative to patients who delay the decision (O’Connor, 1995). 
4.2.2.3 Patient characteristics 
In addition to the main outcome measures, patients in the experiment were also 
assessed on: numerical reasoning, health literacy, anxiety, depression, fatigue, premorbid 
IQ and cognitive abilities. Patient demographics were also recorded. 
Demographics 
Patient demographic information recorded as part of the experiment includes: 
age, gender, level of education, employment status, years since MS diagnosis and current 
DMD. All demographic information was collected by questioning patients at the start of 
the experiment. 
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Patients’ disability status was also recorded in the present experiment by using 
the Hauser Ambulation Index (Hauser et al., 1983). Participants were timed while 
walking 25 feet and their walking ability was graded on a 7-point Likert scale, with 0 
referring to asymptomatic patients and higher scores indicating severe disability. 
Health Literacy 
The present experiment employed the Rapid Estimate of Adult Literacy in 
Medicine - Revised task (REALM-R; Bass, Wilson, & Griffith, 2003) which is a short 8-
item word recognition task designed to rapidly assess patients for health literacy 
problems. The shortlisted words of REALM-R have been chosen from 66 words used in 
the original Rapid Estimate of Adult Literacy task (REALM), and demonstrates very high 
internal consistency. The task shows a correlation of 0.72 with the REALM test and 0.64 
with other commonly used health literacy tasks (Bass et al., 2003). 
 This task was chosen due to its quick administration length to keep the 
experiment duration short and avoid patient fatigue. The task required participants to 
verbally read aloud a list of 11 health related words, with correct pronunciation of words 
marked as a correct response. The three initial words in the list were not scored but are 
usually included to decrease test anxiety in patients. Therefore, the maximum score on 
this measure was eight, with scores of six or below indicating low health literacy.  
Numerical reasoning 
Numerical reasoning and skills were assessed using the series completion subtask 
from the Verbal and Spatial Reasoning Task (VESPAR; Langdon & Warrington, 1995). 
The series completion task consisted of 25 items, progressively increasing in difficulty 
from simple arithmetic series to more complex numerical patterns. Participants were 
required to select the subsequent number to complete a series (i.e. 2, 4, 8, ?) from a 
choice of four numbers (16, 10, 12, 20). The two “screen” items at the beginning of the 
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task had to be answered correctly before attempting the test items. Scores were classified 
as low numerical reasoning if 2 standard deviations below the control mean (Langdon & 
Warrington, 1995). 
Depression and anxiety 
Affective MS symptoms were assessed using the Hospital Anxiety and 
Depression Scale in the current experiment (HADS; Zigmond & Snaith, 1983). The 
HADS measure is often used in non-psychiatric settings, usually taking about 2-6 minutes 
to complete. The scale comprises a subscale for depression and a subscale for anxiety, 
each containing 7 items in total, with 4-point verbal rating scales for each item (i.e. a 
score of 0 to 3). The maximum points for each subscale is 21 points. Patients scoring 
above 11 points on each of the subscales are considered to have depression or anxiety. 
Scores between 8 and 10 on each subscale indicates that patients have borderline 
depression or anxiety, with scores below 8 referring to no affective symptoms in MS 
patients. 
Reviews on the HADS measure have demonstrated high internal consistency for 
both subscales, with Cronbach’s alpha ranging from 0.67 to 0.93. Reviews have also 
supported its two-factor structure, test-retest reliability, and construct validity (Bjelland, 
Dahl, Haug, & Neckelmann, 2002; Herrmann, 1997). HADS also demonstrates sensitivity 
of 90% and specificity of over 87% when conducted with MS patients (Honarmand & 
Feinstein, 2009). In fact, the HADS anxiety subscale has recently been recommended for 
use in MS patients (Litster et al., 2016), further supporting its use in the current 
experiment. 
Fatigue 
The Fatigue Severity Scale (FSS), originally developed for people with MS, was 
administered in the present experiment to identify patients with significant fatigue 
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(Krupp, Alvarez, LaRocca & Steinberg, 1989). Compared to other scales of fatigue, FSS 
was found to be highly discriminative and a reliable measure of fatigue (Flachenecker et 
al., 2002). The FSS consists of a seven-point scale for nine items and requires patients to 
rate their experience of physical or psychological fatigue in the past seven days. The test 
takes between 2-5 minutes to administer. After averaging scores on all items, patients 
scoring 5 or higher were deemed to have severe fatigue, consistent with classifications in 
previous studies that have employed this scale (Bakshi et al., 2000; Flachenecker et al., 
2002; Lerdal, Celius, Krupp, & Dahl, 2007).  
Premorbid IQ 
Measures of premorbid intellectual function (IQ) aims to quantify the cognitive 
impact of neurological injury by using assessments that are resistant to neurological 
damage, typically measuring crystallised intelligence or stored knowledge (Green et al., 
2008). The Wechsler Test of Adult Reading is one such measure (WTAR; Wechsler, 
2001), developed and normed alongside the Wechsler Adult Intelligence Scale (Wechsler, 
Laicardi, & Orsini, 1997). WTAR is shown to be a highly stable test which does not 
appear to be altered by the cognitive effects of different types of brain injury or 
impairments, such as those present in MS (Green et al., 2008). The measure itself is an 
untimed word-pronunciation task which requires respondents to read aloud 50 irregular 
English words. All words pronounced correctly were scored with 1 point. Thus, patients 
could score a maximum of 50 points on this task. To classify patients with poor IQ, raw 
scores were converted to standard scores according to the age-norms and then converted 
to scaled scores as per the testing manual (Wechsler, 2001). Scores below 85 standard 
scores (<1 SD) were classified as poor IQ. 
Cognitive impairment 
The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS; 
Langdon et al., 2012) was employed as a screening tool to identify cognitive deficits of 
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information processing speed, verbal memory and visual memory. Although cognitive 
impairments in MS are not exclusive to these domains, these abilities are the most likely 
to be affected in MS (Langdon et al., 2012). The subtests included as part of this battery 
were: the Symbol Digit Modalities Test (SDMT; Smith, 1982), the California Verbal 
Learning Test-II recall trials (CVLT-II; Delis, Kramer, Kaplan, & Ober, 2000) and the 
Brief Visuospatial Memory Test Revised, recall trials (BVMTR; Benedict, 1997) 
administered in this order as recommended by the authors. To classify whether MS 
patients were impaired on any of these measures, patients scoring 1.5 standard deviation 
below the control mean were considered as cognitively impaired according to a UK 
validation of BICAMS (Orchard, Giovannoni & Langdon, 2013). 
The SDMT task consists of abstract symbols, randomly paired with single digits 
as a key on top of the page. This is then followed by randomly arranged symbols alone on 
the rest of the page. The respondent’s task is to orally state the digit corresponding to the 
abstract symbols according to this key. Participants are required to complete 10 example 
items prior to commencing the actual task for 90 seconds. The SDMT measure is shown 
to have high sensitivity of up to 90% in detecting cognitive impairment in MS relative to 
similar tasks (Parmenter, Weinstock-guttman, Garg, Munschauer, & Benedict, 2007; 
Sepulcre et al., 2006; Strober et al., 2009; Van Schependom et al., 2014), even at one year 
follow-up (López-Góngora, Querol, & Escartín, 2015).  
The CVLT-II is a simple immediate list recall task, where participants are given 
five trials to one item list. The list consists of 16 words, with four items belonging to four 
different categories but arranged in a random order and is read aloud five times at a 
slightly slower rate than 1 second or less (Langdon et al., 2012). It has been noted that 
low scores on the CVLT-II list recall task predicts poor understanding of the informed 
consent procedure in MS (Basso et al., 2010) and is considered a sensitive measure to 
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detect cognitive impairment in MS, also demonstrating high external validity (Stegen et 
al., 2010). 
The BVMTR is a visuospatial memory task consisting of an array of six figures 
presented three times to participants for 10 seconds each. Once the array is removed, 
participants are required to draw the figures from memory, ensuring that the correct 
shapes are drawn in the correct location. Figures are scored for their correct shape and 
their correct location, and patients could score a maximum of 12 points in each trial. The 
total score is calculated by summing the scores of all three trials. The BVMTR is 
considered a reliable measure for MS patients; scores on this task are significantly 
correlated with total brain lesions in MS (Benedict et al., 2002) and also shows high 
sensitivity in detecting cognitive impairments in MS (Strober et al., 2009). 
4.2.3 Procedure 
MS patients were first assessed for eligibility by the Consultant Neurologist or 
the MS Specialist Nurse at the two hospital clinics. Interested patients were then invited 
to take part in the experiment and were presented with a NHS approved information sheet 
and consent form (see appendix 14). Following consent, an appointment was made with 
patients to take part in the experiment. The experiment was conducted either at the clinics 
or at the patient’s home, depending on patient’s preference. The experiment took 
approximately 2 hours to complete and was conducted face-to-face using offline materials 
only. 
Initially, patients were presented with the visual acuity scale to ensure they were 
eligible to view the remaining experiment (see section 4.2.1). If eligible to continue, 
patients were asked demographic questions and assessed on the disability status scale. 
Next, patient characteristics were measured in the following order: health literacy, 
numerical reasoning, depression and anxiety, fatigue and premorbid IQ. Patients were 
then provided with two hypothetical diseases, each of which were followed by two 
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hypothetical treatments presented in different formats. A 2-minute break was provided 
after the first disease but patients were encouraged to take more breaks when necessary. 
Comprehension questions to assess understanding were provided after each treatment 
outcome. Patients were also required to make their treatment decision and complete the 
DCS measure at the end of each disease (i.e. after viewing two hypothetical treatments). 
Finally, the BICAMS measure was conducted with patients. All patients were then 
debriefed and informal consent was obtained to confirm whether patients would like to be 
contacted again for additional studies in this thesis project.  
4.2.4 Sample size 
Sample size estimates were based on power calculations to detect a medium 
effect (0.5) on MS patients’ understanding scores. A previous questionnaire that assessed 
understanding in MS patients found a large effect size in detecting patients with good 
understanding and poor understanding of their condition. However, only 5 out of 19 items 
focused on patients’ understanding of MS treatments (Heesen et al., 2015; Köpke et al., 
2014). We therefore chose a conservative medium effect size for this experiment. It was 
estimated that for an alpha of 0.05 and power of 0.80, a minimum number of 45 MS 
patients were required to take part in the experiment. 
4.2.5 Statistical analysis 
All statistical analyses were carried out using SPSS 21. Means and standard 
deviations were provided for all continuous data. Maximum scores were also presented 
for all measures in the experiment. A test of normality was conducted for the 
understanding outcome measure for each format using the Shapiro-Wilks test. The 
assumption of normality was significantly violated for each format (p<.001) and therefore 
a nonparametric Friedman analysis of variance was conducted. Where the Friedman test 
was significant, pairwise comparisons were conducted by using the nonparametric 
Wilcoxon Signed Ranks test. Bonferroni corrections were applied for multiple 
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comparisons. Effect sizes are calculated for all pairwise comparisons by dividing the z 
score by the square root of total number of observations, based on Rosenthal’s formula 
(Rosenthal, 1994); where, 0.1, 0.3 and 0.5 equates to small, medium and large effect 
sizes, respectively. For the purpose of the analysis, several formats were sometimes 
collapsed into one average understanding score. 
In addition, two bivariate Pearson’s product moment correlations were conducted 
to assess the relationship between patient understanding and the standardised scores of 
the decisional conflict scale, including all subscales. This is because all patients were 
exposed to both hypothetical diseases, and thus made two treatment decisions in total (i.e. 
treatment decision for disease 1 and treatment decision for disease 2; see tables 4.3 and 
4.4). Analysis with standardised rather than raw DCS scores have been recommended by 
the authors of the DCS (O’Connor, 1995). Bivariate Pearson’s product-moment 
correlations were also computed to assess the relationship between understanding and raw 
scores on measures of numerical reasoning, health literacy, premorbid IQ and symptoms 
of MS. Due to multiple correlations, a stringent alpha of p<.01 was applied and accepted 
as significant. 
4.3 Results 
4.3.1 Patient demographics 
Analysis was conducted for all 45 patients in the current experiment. Patient 
demographic information is displayed in Table 4.6.  
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Table 4.6  Patient demographics and disease status for Experiment 1 (n=45) 
 Mean (SD) n (%) 
Age, years 42.51 (9.46)  
Gender   
Female  34 (75.6) 
Male  11 (24.4) 
Level of education   
High school  13 (28.9) 
College   7 (15.6) 
Bachelor’s degree  15 (33.3) 
Postgraduate  10 (22.2) 
Employment status   
Full-time (>16 hours)  17 (37.8) 
Part-time (<16 hours)  8 (17.8) 
Self-employed  6 (13.3) 
Unemployed  9 (20.0) 
Medical leave  5 (11.1) 
Retired  0 (0) 
Time since MS diagnosis, years 9.80 (8.10)  
HAI disability scale 1.49 (1.67)  
Current DMD   
Interferon betas  18 (40) 
Glatiramer Acetate  4 (8.9) 
Teriflunomide  0 (0) 
Fingolimod  6 (13.3) 
Alemtuzumab  0 (0) 
Dimethyl Fumarate  9 (20) 
Natalizumab  7 (15.6) 
Mitoxantrone  1 (2.2) 
DMD= disease-modifying drugs; HAI = Hauser Ambulation Index 
* Score of 1 on HAI scale = Able to walk normally but report fatigue interfering with athletic 
activities 
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4.3.2 The effect of verbal and numerical formats on patients’ understanding 
There was a statistically significant difference between verbal and numerical 
formats (verbal, percentages and frequencies), X2(2) = 74.112, p<.001. Pairwise 
comparisons were conducted to statistically compare the means for verbal terms (M=.04, 
SD=.21), percentages (M=4.69, SD=2.17) and frequencies (M=5.82, SD=.91). Pairwise 
comparisons revealed that understanding was greater for frequencies compared to verbal 
terms (z=-6.386, r=0.67, p<.001) and percentages (z=-3.308, r=0.35, p<.01). 
Understanding was also greater for percentages compared to verbal terms (z=-5.769, 
r=0.61, p<.001). 
4.3.3 The effect of graphical formats without numbers displayed on patients’ 
understanding 
There was a statistically significant difference between graphical formats that did 
not display numbers (bar charts, pictographs, line graph and pie chart) on patients’ 
understanding of treatments, X2(2) = 92.779, p<.001. Pairwise comparisons were 
conducted to statistically compare the means for bar charts (M=4.11, SD=1.24), 
pictographs (M=2.56, SD=.85), line graphs (M=3.71, SD=1.53) and pie charts (M=1.09, 
SD=.95). Understanding was greater for bar charts compared to pictographs (z=-5.407, 
r=0.57, p<.001) and pie charts (z=-5.772, r=0.61, p<.001). Understanding was also 
greater for line graphs compared to pictographs (z=-4.359, r=0.46, p<.001) and pie charts 
(z=-5.809, r=0.61, p<.001). Understanding was also greater for pictographs compared to 
pie charts (z=-5.558, r=0.59, p<.001). There was no significant difference in patients’ 
understanding for information presented in bar charts and line graphs (p=.088). 
4.3.4 The effect of graphical formats with numbers displayed on patients’ 
understanding 
There was no statistically significant difference between graphical formats that 
displayed numbers (tables, bar chart, line graph and pie chart) on patients’ understanding, 
X2(3) = 3.194, p=.363. 
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4.3.5 The effect of numbers on graphical formats on patients’ understanding 
There was a statistically significant difference between graphical formats that 
displayed numbers and the corresponding graphical formats without numbers on patients’ 
understanding of treatments, X2(1) = 45.000, p<.001. According to the mean scores, 
understanding was greater for graphical formats with numbers displayed (M=5.87, 
SD=.66) compared to graphical formats without numbers displayed (M=3.26, SD=.99). 
Further pairwise comparison revealed that pie charts showed the greatest effect when 
numbers were displayed compared to no numbers (z=-5.915, r=0.62, p<.001). The effects 
for other formats were as follows: bar chart horizontal (z=--4.763, r=0.50, p<.001), bar 
chart vertical (z=-5.424, r=0.57, p<.001) and line graph (z=-5.341, r=0.56, p<.001). 
4.3.6 The effect of bar chart orientation on patients’ understanding 
 There was a statistically significant difference between orientation of bar charts 
(horizontal bar charts, vertical bar charts) on patients’ understanding, X2(1) = 12.902, 
p=.001. According to the mean scores, understanding was greater for bar charts with 
horizontal orientation (M=5.20, SD=1.01) compared to bar charts with vertical 
orientation (M=4.77, SD=.95, z=-3.441, r=0.36). 
4.3.7 The effect of pictograph figures on patients’ understanding 
There was no statistically significant difference for the figures displayed in 
pictographs (human figures, abstract figures) on patients’ understanding, X2(1) = .231, 
p=.631. 
4.3.8 The effect of pictograph arrangement on patients’ understanding 
There was a statistically significant difference in arrangement of pictographs 
(consecutive arrangement, random arrangement) on patients’ understanding, X2(1) = 
45.000, p<.001. According to mean scores, understanding was greater for consecutive 
arrangement (M=4.26, SD=1.38) compared to random arrangement (M=.86, SD=.61, z=-
5.856, r=0.62). 
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4.3.9 Patient understanding and decisional conflict 
A bivariate Pearson product-moment correlation conducted for the understanding 
and decisional conflict score for hypothetical disease 1 revealed no significant correlation 
between patients’ understanding and the total DCS measure. There were also no 
significant correlations between understanding and the subscales of the DCS measure (see 
table 4.7). 
Similarly, a bivariate Pearson product-moment correlation conducted for the 
understanding and decisional conflict score for hypothetical disease 2 revealed no 
significant correlation between patients’ understanding and the total DCS measure. There 
were also no significant correlations between understanding and the subscales of the DCS 
measure (see table 4.8). 
Table 4.7 Correlations between patient understanding and decisional conflict scores for 
hypothetical disease 1 
 Max score Mean SD Correlation  
Total understanding 48 38.84 6.03  
DCS informed 100 14.44 14.80 -.130 
DCS values  100 19.62 17.78 -.246 
DCS support 100 21.48 17.09 -.068 
DCS uncertainty 100 42.40 24.54 .033 
DCS effective 100 46.30  61.28 -.093 
DCS total score 100 24.57  14.41 -.122 
* = indicates significance at the p<.05 level; ** at p<.01 level; *** at p<.001 level; DCS, 
Decisional Conflict Score 
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Table 4.8 Correlations between patient understanding and decisional conflict scores for 
hypothetical disease 2 
 Max score Mean SD Correlation  
Total understanding 48 28.31 5.50  
DCS informed 100 19.83 26.89 -.195 
DCS values  100 19.25 18.10 -.237 
DCS support 100 23.51 19.49 -.100 
DCS uncertainty 100 41.37 24.38 .062 
DCS effective 100 43.89  26.73 .110 
DCS total score 100 27.12  15.39 -.057 
* = indicates significance at the p<.05 level; ** at p<.01 level; *** at p<.001 level; DCS, 
Decisional Conflict Score 
 
4.3.10 Patient understanding and patient characteristics  
Patients were assessed for numerical reasoning skills, health literacy, premorbid 
IQ and MS symptoms in the current experiment. As shown in table 4.9, MS patients in 
this experiment mostly showed symptoms of anxiety, fatigue and cognitive impairments. 
A bivariate Pearson product-moment correlation coefficient revealed significant 
correlations for patients’ health literacy (r=.713, p<.01), numerical reasoning (r=.609, 
p<.01), premorbid IQ (r=.641, p<.01), information processing speed (r=.473, p<.01) and 
verbal memory (r=.477, p<.01). Means, standard deviations and correlations for all 
factors are presented in table 4.10. 
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Table 4.9 Patients impaired on assessments of numerical reasoning, health literacy, 
premorbid IQ and MS symptoms (n=45) 
Patient characteristics and MS symptoms n (%) 
Health literacy 3 (6.7) 
Numerical reasoning 4 (8.9) 
Depression 6 (13.3) 
Anxiety 14 (31.1) 
Fatigue 21 (46.7) 
Premorbid IQ  1 (2.2) 
Information processing speed 13 (28.9) 
Verbal memory 15 (33.3) 
Visual memory 25 (55.6) 
 
Table 4.10 Correlations between patient understanding and patient characteristics 
Patient characteristics Max score Mean SD Correlation  
Total understanding 96 63.16 10.89  
Numerical reasoning 25 16.20 3.61 .609** 
Health literacy 8 7.49 1.25 .713** 
Depression 21 5.02 4.23 -.194 
Anxiety 21 7.51 4.57 -.250 
Fatigue 63 42.64  13.56 -.202 
Premorbid IQ 50 37.78 6.86 .641** 
Information processing speed 110 57.07 11.09 .473** 
Verbal memory 80 48.44 14.08 .477** 
Visual memory 36 20.29  6.99 .288 
* = indicates significance at the p<.05 level; ** at p<.01 level; *** at p<.001 level, correlations in 
bold accepted as significant due to multiple correlations 
 
4.4 Discussion 
In order to make informed treatment decisions, it is important that MS patients 
are able to understand the risks and benefits of treatments (see section 1.3). Studies with 
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both non-clinical and clinical population groups have shown that the formats used to 
present treatment risk and benefit information can affect understanding. However, 
findings conducted with MS patients are very limited. The present experiment was the 
first to conduct a comprehensive assessment of several presentation formats with MS 
patients in order to examine which presentation formats could maximise understanding of 
treatment information. 
Guidelines made by EC recommend the use of standardised verbal terms to 
present treatment risks and benefits to patients (EC Guidelines, 2009). These terms are 
currently employed within the UK National Healthcare Service (NHS) to present DMD 
risks and benefits to patients with MS (see appendix 11). However, the present 
experiment found that MS patients cannot effectively understand treatment risks and 
benefits when verbal formats were presented alone in comparison to information 
presented in numerical formats. This is consistent with previous studies that have been 
conducted with both non-clinical and clinical patient groups (Berry et al., 2003; Berry et 
al., 2002; Knapp et al., 2009). It has been suggested that verbal formats should be 
provided together with numerical formats to maximise understanding (Lipkus, 2007). 
This was not explored in the present experiment. However, previous studies have shown 
no improvements in understanding when information was presented both verbally and 
numerically (Knapp et al., 2015), indicating that verbal formats are likely to interfere with 
understanding of numerical information. 
Although numerical formats can improve understanding in comparison to verbal 
formats, it is also important to identify whether different types of numerical formats 
affect MS patients’ understanding. It was predicted that there will be no differences in 
understanding when numerical information was presented in either frequencies or 
percentages, due to the inconsistent findings in the literature. However, this hypothesis 
was not supported. Significant differences in understanding of treatments was observed in 
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the current experiment when presented in frequencies and percentages, in favour of 
frequencies. Although this result supports only some previous findings (Gigerenzer, 
1996; Gigerenzer & Edwards, 2003; Hoffrage & Gigerenzer, 1998), these findings are 
based on a complex screening test problem rather than information about treatment risks 
and benefits. The current results did not support previous studies that have assessed 
numerical formats in the context of treatment information specifically (Waters et al., 
2006; Woolshin & Schwartz, 2011). However, these studies were conducted with a 
general population who are unlikely to make decisions based on treatment risk and 
benefit information.  
Moving onto graphical formats, it was hypothesised that pictographs would 
maximise understanding of treatment information in MS patients, considering that several 
studies with non-clinical and clinical populations favour the use of pictographs relative to 
other graphical formats to improve understanding (Hamstra et al., 2014; Hawley et al., 
2008; McCaffery et al., 2012; Schapira et al., 2001; Schapira et al., 2006). Nevertheless, 
this hypothesis was not supported in the present experiment. Understanding of treatment 
information was greatest when patients were presented risks and benefits using bar charts 
and line graphs. This is consistent with some previous findings which show support for 
bar charts (Brewer et al., 2012; Hamstra et al., 2014; Hawley et al., 2008). Furthermore, 
the least understood graphical format was pie charts followed by pictographs in the 
current experiment, indicating that these formats should generally be avoided when 
presenting treatment information to MS patients. Although inconsistent with findings 
from previous studies, one reason for the results of the present experiment may be due to 
the long-term treatment risks and benefits that were presented to MS patients in order to 
mimic DMD risk and benefit profiles. Bar charts and line graphs are both able to display 
long-term trends for treatment outcomes in one graph, whereas equivalent long-term risks 
and benefits for pie charts or pictographs can only be presented using multiple charts. 
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Given that decisions about DMDs are generally based on treatment risks and benefits 
over a longer period of time, the present experiment signifies that long-term DMD risk-
benefit profiles could be easier to interpret when presented using a bar chart and line 
graph format.  
Several elements of graphical formats were also manipulated in the current 
experiment. Following recommendations that understanding of treatments can be 
improved if numbers are added to graphs (Bunge et al., 2010; Lipkus, 2007), the current 
experiment added numbers to bar charts, line graphs and pie charts and also added 
numbers to tables. As hypothesised, understanding of treatment risks and benefits was 
improved when numbers, in the form of frequencies, were presented alongside graphical 
formats.  
Orientation of graphical formats was also manipulated in the present experiment. 
In contrast to previous findings, orientation did affect how MS patients’ understood the 
risks and benefit of treatments. Specifically, horizontally displayed information showed 
better understanding than verbal formats, consistent with one previous study (Price et al., 
2007). Explanations for better understanding of horizontal formats has not been 
previously discussed in the literature. One possible reason could be that horizontally 
displayed information is able to effectively present trends of treatment risks and benefits 
over time in comparison to graphs presented vertically. Note, however, that only 
orientation of bar charts was manipulated in the present experiment. It is therefore not 
possible to make any reliable conclusions about the effects of orientation for different 
graphical formats. 
The presentation styles of pictographs were further manipulated in the current 
experiment. As predicted, consecutively arranged pictographs significantly improved 
accuracy of treatment understanding when compared to pictographs that were randomly 
arranged. This is consistent with previous studies conducted with non-clinical populations 
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(Schapira et al., 2006; Schapira et al., 2001). However, the result of the present 
experiment differs to the only other study conducted with MS patients which showed no 
improvements in understanding information about treatment benefits when pictographs 
were consecutively arranged versus pictographs arranged randomly (Kasper et al., 2011). 
The findings were different despite the present experiment sharing similar features with 
the study by Kasper and colleagues (2011), such as employing only hypothetical 
treatment information and displaying the pictograph in a total of 1000 figures. To note, 
Kasper and colleagues (2011) did find that MS patients’ understanding of treatment risks 
specifically was better when presented using the consecutive arranged pictograph. Since 
the current experiment did not explore understanding individually for treatment minor 
risks, adverse risks or benefits, it was not possible to replicate these effects. With regards 
to the figures displayed within pictographs, the present experiment found no evidence of 
the impact of figures on understanding. Thus, despite human-figures being commonly 
employed in pictographs (Henneman et al., 2013), this is not an essential requirement 
when presenting treatments using pictographs as only the arrangement of figures can 
affect understanding in MS patients. 
Associations between understanding of treatment information and the conflict 
patients experience for treatment decisions was also examined in the present experiment. 
It was predicted that improving understanding could reduce MS patients’ decisional 
conflict. However, this hypothesis was not supported. This is inconsistent with the very 
few studies that have directly evaluated the relationship between understanding and 
decisional conflict (Cormiers et al., 2015; Sun, 2005). The differences between these 
findings and those of the current experiment could be because MS patients’ 
understanding was measured for a range of different presentation formats in the current 
task. Moreover, since the DCS measure tends to assess several different components that 
contribute to decisional conflict, all these factors may not be correlated with patient 
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understanding. For this reason, correlations were also conducted between understanding 
scores and the different DCS subscales in the current experiment. Yet, there were no 
correlations for understanding with any of the DCS subscales. Importantly, there was no 
correlation between understanding scores and the DCS informed subscale, which 
typically assesses understanding of alternate treatment options. The absence of this 
relationship could be because the informed DCS subscale tends to only measure 
perceived knowledge, which may not necessarily relate to subjective understanding of 
information (O’Connor, 1995; Stacey et al., 2014). Thus, according to the current 
experiment improving patients’ understanding did not reliably reduce MS patients’ 
conflict for treatment decisions. 
The relationship between understanding and patient characteristics were also 
examined in this experiment. As predicted, patients’ numerical reasoning skills were 
positively related with patients’ understanding. In other words, patients with low 
numeracy skills were more susceptible to misunderstanding treatment information when 
presented in different formats. Similar effects have been found in previous studies (e.g., 
Hamstra et al., 2014; Paling, 2003; Peters et al., 2011). Understanding was also strongly 
related with health literacy and premorbid IQ in the current experiment. Given that health 
literacy, numeracy and IQ can relate to patients’ educational background (Peters, 2008), 
the current finding indicates that patients with low educational background may be more 
susceptible to misunderstanding treatment information. The current experiment also 
assessed the relationship between MS symptoms and patient understanding. Cognitive 
impairments, particularly information processing speed and verbal memory were 
significantly correlated with patient understanding. However, anxiety, depression and 
fatigue showed no significant relationship with MS patients’ understanding. This 
indicates that patients presenting with cognitive impairments may be more susceptible to 
poor understanding of treatment risks and benefits, compared to patients displaying other 
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symptoms of MS. To note, however, it is also likely that the current experiment did not 
have enough statistical power to detect the relationship between other patient symptoms 
which may be identified in future studies with better statistical power. Yet, this does 
emphasise that all significant correlations in the current experiment had large effect sizes 
than all other nonsignificant correlations.  
The current experiment also has a number of limitations which must be addressed 
prior to drawing any conclusions. First, several other formats to present treatment risks 
and benefits were not assessed in this experiment. For instance, although frequencies 
were shown to improve understanding of treatment information relative to percentages, 
frequencies can also be presented in different ratios; either by keeping the numerator 
constant (1-in-X format) or by keeping the denominator constant (the N-in-N*X format). 
Both types of frequency ratios are used to display treatment information in current 
clinical practises within the UK (see appendix 11). Only the N-in-N*X format was 
employed in the current experiment. For this reason, the next empirical question is the 
extent to which different frequency formats are able to influence understanding, which 
will be directly tested in the subsequent experiment (see chapter 5). Another limitation of 
the current experiment is that it was not possible to conclude which specific verbal, 
numerical and graphical formats could improve understanding of patients with poor skills 
in numerical reasoning, literacy and IQ, and those with cognitive impairments. Additional 
research with MS patients should be conducted to determine the efficacy of each 
individual format with patient groups that have these specific characteristics.  
4.4.1 Conclusion 
 In summary, the current experiment was the first comprehensive evaluation of 
verbal, numerical and graphical formats on MS patients’ understanding of treatment risks 
and benefits. The results established that different presentation methods could affect how 
MS patients were able to understand treatment information. However, improving 
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understanding did not reliably reduce patients’ conflict in their treatment decisions. All 
findings were integrated into an updated theoretical framework of MS patients’ 
understanding (see figure 4.3). 
Based on the findings from the current experiment, it is possible to make some 
recommendations about the methods to improve MS patients’ understanding of treatment 
information. Treatment risks and benefits should be presented to patients numerically 
where possible and verbal terms should be avoided. Specifically, frequencies are the most 
ideal numerical choice. In addition, numbers should be added to graphical formats to 
facilitate understanding. With regards to the best graphical formats, treatment information 
should be provided to patients using horizontal bar charts or line graphs. If pictographs 
are used, human or abstract figures should be arranged consecutively. Pie charts should 
be avoided to present treatment information. Moreover, patients with low skills in 
numerical reasoning, health literacy, IQ or those presenting with cognitive impairments 
associated with MS should be provided with additional support to ensure all patients are 
able to accurately understand the risks and benefits of treatments. 
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Figure 4.3 Theoretical framework 2: Factors affecting MS patients’ understanding of treatment 
risks and benefits 
Key: Black arrows, significant effects; Grey arrows, no relationship; Question, Untested factors; 
arrows do not signify causation 
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Chapter 5: Frequency ratios and framing to present 
treatment information  
 
5.1 Introduction 
The risk and benefit profiles of a DMD can be determined by the results of a 
clinical trial, whereby one group of MS patients receives the DMD of interest and are 
then compared with a group of patients that either take the placebo or an established 
DMD (Braune et al., 2015; Chahin, Balcer, Miller, Zhang, & Galetta, 2015; Fogarty et al., 
2016; Maruszczak, Montgomery, Griffiths, Bergvall, & Adlard, 2015; McFarland, 2009; 
Miller et al., 2014). Findings from Experiment 1 showed that when MS patients were 
provided with information about the risks and benefits of a treatment based only on the 
hypothetical group of patients taking the drug, information presented in specific 
numerical and graphical formats could maximise MS patients’ understanding (see chapter 
4). For instance, frequencies were found to be an optimal method of presenting numerical 
information to improve MS patients’ understanding of treatment risks and benefits. Yet, 
frequencies can also be presented using discrete ratios (e.g., either 1 in 20 or the 
equivalent 50 in 1000), which were not evaluated in Experiment 1. In fact, both frequency 
ratios are presented to patients in current clinical practise (see appendix 11). In addition, 
the statements that are used to present treatment information to patients can also be 
framed in either a positive or negative way. Framing of risks and benefits was also not 
manipulated in Experiment 1. Both ratios and framing to present treatment information is 
therefore investigated in the current experiment. These factors are also included in the 
theoretical framework, which is designed to indicate how MS patients’ understanding of 
treatment information is likely to be affected (see figure 5.1). 
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5.1.1 Frequency ratios 
5.1.1.1 Definition of frequency ratios 
Numerical frequencies are an ideal way of presenting DMD information to MS 
patients (see chapter 4). However, frequencies can be represented using different ratios. 
The frequency ratio used to present risks and benefits to MS patients in Experiment 1 was 
the N-in-N*X format (see chapter 4). This format can be obtained by keeping the 
denominator constant and changing the numerator to reflect the magnitude of risks and 
benefits. For instance, the adverse risks of a hypothetical medication A could occur in 5 
people out 1000, which may be compared to the adverse risks of a hypothetical 
medication B which could occur in 32 people out of 1000. Another ratio to represent 
frequencies can be obtained by keeping the numerator of the frequency constant at 1 and 
simply changing the denominator to reflect differences in magnitude of risks and benefits. 
This ratio is termed as the 1-in-X format. The 1-in-X ratio can be calculated by dividing 
the denominator by the numerator from frequencies presented in N-in-N*X format, and 
usually rounding up this result. Using the examples presented above, the adverse effects 
of medication A would occur in 1 in 200 people, whereas the adverse effects of 
medication B would occur in 1 in 31 people taking the drug in question.  
Although frequencies are the most optimal method of providing treatment risk 
and benefit information to MS patients, the effect of the different frequencies on MS 
patients’ understanding is unclear. The subsequent sections will first attempt to review 
evidence that has been obtained from non-clinical and non-MS populations, prior to 
empirically evaluating the best ratio to improve understanding in MS patients. 
5.1.1.2 Review of frequency ratios is non-clinical populations 
Studies with non-clinical populations reveal mixed findings with respect to 
different frequency ratios on understanding and decision-making. An early study 
presented participants with equivalent risks for a hypothetical treatment using different 
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ratios. For example, treatment risks were stated as occurring in either 1 person in 12,000 
people or 8.3 people in 100,000 people (Halpern, Blackman, & Salzman, 1989). 
Participants did not differ in their treatment decisions irrespective of the frequency ratios 
in which the risks were presented, implying that participants are equally able to 
understand both frequency ratios. Note, however, that the outcome measure employed in 
this study was treatment choice which cannot establish patients’ objective understanding 
of risks. In addition, the authors proposed that the absence of any effect may be due to the 
small differences between the numerator of the frequencies presented (i.e. 1 versus 8.3), 
and suggested that treatment information may need to be presented using a greater range 
of frequencies to detect differences in understanding based on frequency ratios (Halpern 
et al., 1989).  
Findings from other studies have shown that frequency ratios to present risks and 
benefits in a medical context can affect how people understand the information. An early 
study assessed understanding of participants when risks were presented using different 
frequency ratios (Grimes & Snively, 1999). Participants showed better understanding of 
risks when expressed in the N-in-N*X ratio, regardless of respondent’s age, language and 
education (Grimes & Snively, 1999). Similar findings were observed by Cuite, Weinstein, 
Emmons, and Colditz (2008), who randomly assigned participants to various magnitude 
of risks and benefits of hypothetical treatments and assessed understanding by asking 
participants to perform a series of operations with the risk and benefit information, such 
as comparing differences, halving and adding the information. The authors found that 
understanding of treatment risks and benefits was greatest when information was 
presented in percentages and frequencies using N-in-N*X format compared to the 1-in-X 
frequency format (Cuite et al., 2008). Although inconsistent with findings from 
Experiment 1 which showed that frequencies are better understood than percentages by 
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MS patients (see chapter 4), these findings do suggest that frequencies can be understood 
differently depending on the ratios.  
To further demonstrate this effect, Sirota, Juanchich, Kostopoulou and Hanak 
(2014) conducted 5 replications of studies using non-clinical populations. The authors 
designed experiments using stricter criteria than existing studies comparing N-in-N*X 
ratios with 1-in-X ratios, namely by providing a large number of risks and benefits of a 
disease with a wider range of magnitudes. Participants were assessed on the probability, 
severity, worry and frequency of a risk using a 7-point Likert scale. The findings from all 
5 experiments showed a trend towards poor understanding when frequencies were 
presented using the 1-in-X ratio. Specifically, probabilities of risks and benefits were 
considered to be higher when information was presented using the 1-in-X ratio in 
comparison to when presented in N-in-N*X ratio. However, this effect was statistically 
significant in only two experiments (Sirota et al., 2014). To determine the size of this 
effect, Sirota and colleagues (2014) further combined findings from 5 experiments that 
had been conducted with clinical populations. The authors concluded that understanding 
was indeed poor when information was presented in frequencies with the 1-in-X ratio, but 
with a considerably lower effect size than suggested by previous studies (Sirota et al., 
2014).  
In summary, studies conducted with non-clinical populations generally show 
support for frequencies presented in the N-in-N*X ratios as opposed to the 1-in-X ratio. 
The following section will examine the strength of this effect in clinical populations. 
5.1.1.3 Evaluation of frequency ratios in clinical populations 
Studies with clinical populations, although limited, consistently show that risk 
and benefit information for diseases are perceived as higher when frequencies are 
presented in the 1-in-X ratio, with no clear effect on understanding of treatment risk and 
benefit information. A number of studies were conducted with pregnant women who were 
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presented with prenatal risk of their child developing Downs syndrome at birth (Pighin et 
al., 2011, 2013, 2015) or adverse effects during pregnancy (Pighin et al., 2013). 
Numerical frequencies of this risk were presented in either N-in-N*X or 1-in-X ratio. 
Patients were more likely to perceive risks as larger (Pighin et al., 2011, 2015) and as 
more worrying (Pighin et al., 2011), and were also less able to discriminate the magnitude 
of the risks (Pighin et al., 2013) when these were presented using the 1-in-X frequency 
ratio. However, there was no difference in patients’ ability to understand risk information 
when presented using different frequency ratios (Pighin et al., 2015). 
Overall, there are a limited number of studies that have analysed how individuals 
understand frequencies of risks and benefits presented using different ratios, especially 
with clinical populations likely to make decisions based on the information. In 
conjunction with studies from non-clinical populations, there is some evidence to state 
that treatment risk and benefit information is difficult to understand when presented using 
the 1-in-X ratio. For this reason, researchers have discouraged the use of 1-in-X ratios 
when communicating risks and benefits in healthcare settings (Pighin et al., 2015; Sirota 
et al., 2014; Zikmund-Fisher, 2011, 2014). Yet, these ratios are employed in current 
clinical practise with MS patients (see appendix 11), even in the absence of empirical 
evidence conducted in this population. 
5.1.2 Framing 
5.1.2.1 Definition of the framing effect 
Although numerical treatment information may clearly present treatment 
information, individuals may be still be biased about the magnitude of treatment risks and 
benefits. For instance, the outcome chosen by an individual during decision-making could 
vary depending on if the options are framed in positive terms (e.g. what a person stands to 
gain from the options) or if the options are framed in negative terms (e.g. what a person 
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stands to lose from the options). This phenomena is termed as the framing effect (Tversky 
& Kahneman, 1981; Wilson, Purdon, & Wallston, 1988).  
A common example used to demonstrate the framing effect in the literature is that 
of an Asian disease epidemic (Tversky & Kahneman, 1981). Participants are presented a 
scenario in which an unusual Asian disease is expected to kill 600 people. The 
participants are then told that two alternative programs have been proposed to combat this 
disease: if Program A is adopted, 200 people can be saved and if program B is adopted, 
there is one third possibility that all 600 people will be saved and two thirds probability 
that no one will be saved. Tversky and Kahneman (1981) presented this problem to 152 
students and asked them to state their preference for one of these two programs to combat 
the disease. Around 72% of participants stated their preference for Program A. The 
authors noted that this was a risk averse choice, as the prospect of certainly saving 200 
lives was considered more favourable than a riskier and uncertain prospect of Program B 
with an equal value (i.e. a one-in-three chance of saving 600 lives in Program B is 
statistically equivalent to saving 200 lives in Program A).  Subsequently, a new group of 
students were given the same problem but with two different programs. Participants were 
given either a choice of Program C, which if adopted would mean that 400 people will die 
and Program D, which offered a one third probability that nobody will die and two thirds 
probability that 600 people will die. Tversky and Kahneman (1981) found that 78% of 
155 participants chose to take the riskier option of Program D, since the certain death of 
400 people was considered less acceptable than two-in-three chance that 600 people will 
die, despite these options offering the same statistical outcome (i.e. a two-in-three chance 
that 600 people will die in program D is statistically equivalent to 400 people dying in 
program C). Given that the options provided for both scenarios were effectively the same, 
the decision to choose an option was dependent on how the information was framed. 
Thus, the authors concluded that people are more likely to be risk averse when 
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information is framed positively and more likely to be risk seeking when information is 
framed negatively (Tversky & Kahneman, 1981).  
This effect of framing has been shown to have its roots in the influential prospect 
theory, first proposed by Kahneman and Tversky (1979). One key aspect of the theory is 
that when comparing choices during decision-making, people are likely to be influenced 
by the gains and losses of the choice. This is evident in the Asian disease example above, 
where preference for the programs were reversed when framing of the programs changed 
from gains to losses. According to prospect theory, the values people place on gains and 
losses also vary. People are likely to consider losses as more extreme than gains, which 
can subsequently influence the decisions they make (Kahneman & Tversky, 1979). 
Hence, when comparing choices during decision-making, the difference between options 
would be perceived as much greater if framed as a disadvantage or a loss compared to 
options that are framed as an advantage. Thus, people will be likely to adopt riskier 
programs, such as treatments, when framed in negative terms than positive terms. 
In general, the framing effect explains how individuals may be biased towards an 
option based on the manner in which the options are framed, irrespective of the absolute 
risk and benefit content. Given that patients making treatment decisions are often faced 
with alternative treatment choices, it would be of interest to examine the effects of 
framing treatment information on understanding of this information. Studies have 
predominately looked at the effects of framing in medical contexts with non-clinical 
populations and with clinical populations other than MS. These studies will first be 
reviewed prior to evaluating the effects of framing on MS patients’ understanding.  
5.1.2.2 Review of framing treatment information in non-clinical populations  
One of the earlier studies that explored the effects of framing in a medical context 
was conducted by McNeil, Pauker, Sox and Tversky (1982). Lung cancer was selected as 
a premise for decisions for which two alternative treatment options were presented: 
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radiation therapy and surgery. In reality, surgery was shown to have more patients 
surviving after 5 years and have a longer life expectancy in comparison to radiation 
therapy, indicating a better treatment choice. Participants were separated into two groups: 
information about therapies framed in terms of mortality or framed in terms of survival. 
The findings showed that 43% of participants chose radiation therapy over surgery when 
both therapies were framed in terms of mortality. When therapies were framed in terms of 
survival however, only 17% of the students chose radiation therapy. Considering that 
surgery was the most rational choice, it is interesting that simply framing the information 
positively was able to encourage people to choose the better treatment. Similar trends 
were observed for physicians who participated in the study (McNeil et al., 1982). The 
authors noted that despite physicians’ considerable experience with medical data, 
physicians were also susceptible to the effects of framing (McNeil et al., 1982). This was 
further supported by another study which found that physicians made a risk-averse 
treatment choice when treatment information was framed in survival terms and a risk-
seeking treatment choice when framed in terms of mortality (Tversky, 1986).  
In further support of the framing effect as explained by the prospect theory, 
Meyerowitz and Chaiken (1987) assessed the impact of pamphlets framed in loss versus 
gains on performance of breast self-examination in non-clinical populations. Participants 
were randomly assigned to either of the following four conditions: pamphlets framed 
using gain terms (i.e. increased survival if performing breast self-examination), pamphlets 
framed using loss terms (i.e. decreased survival of not performing breast self-
examination), pamphlets with neutral language or no pamphlets about breast self-
examination. At a 4-month follow up, participants who received the pamphlet in the loss 
frame reported engaging in breast self-examination significantly more often than 
participants in the other three conditions. Likewise, participants in another study were 
assessed for their risk perception following equivalent medication information framed in 
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either a positive, negative or a combination of both frames (Peters et al., 2011). 
Participants provided with information in positive frame perceived the medication to be 
less risky in comparison to people given information framed negatively or in a 
combination frame. These studies further provide support for a framing effect in the 
context of treatment decision-making based on the prospect theory.  
Conversely, some studies with non-clinical population groups have shown effects 
of framing on an individual’s decision but in the opposite direction to that explained by 
the prospect theory. Wilson, Kaplan and Schneiderman (1987) presented non-clinical 
population groups with a hypothetical medical scenario and a choice of two alternative 
treatments. A framing effect was observed. Only 28% of the subjects reported they would 
seek surgery for the hypothetical condition if the surgery was framed in terms of 90 per 
cent dying, whereas 46% of students chose to take the surgery if framed as 10 per cent 
surviving the surgery (Wilson et al., 1987). That is, people were willing to take treatments 
if framed in terms of surviving rather than in terms of dying, contrary to the prospect 
theory. Even though the risk and benefit information for both treatments were statistically 
equivalent, it may be assumed that understanding of treatment information was 
influenced by the framing of the information which subsequently affected the decision for 
the treatment. However, objective understanding was not measured in this study. Similar 
findings were observed in the study by Marteau (1989). One of their experiment focused 
on presenting the outcomes associated with surgery in a positive frame or a negative 
frame. Probabilities for the outcomes of surgery were manipulated to either: 10 per cent 
chance of dying/90 per cent chance of surviving, 40 per cent chance of dying/60 per cent 
chance of surviving or 60 per cent chance of dying/40 per cent chance of surviving. 
Marteau (1989) found that significantly more people chose to take surgery when the risk 
of surgery was framed as 10 per cent chance of survival compared to 90 per cent chance 
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of death. Overall, more people chose the option of surgery when the information was 
framed in terms of survival than when it was presented in terms of dying.  
There are a number of explanations for these inconsistent effects of framing on 
decisions across studies. The inconsistencies may be due to the different types of options 
that could be differently framed. For instance, although the prospect theory suggests that 
people are more likely to choose riskier options when information is framed negatively, 
this may only apply when people are presented with two competing options, with one 
being a risky option and the other a riskless option (Tversky & Kahneman, 1981). 
Another explanation for the differences in decisions of participants in these could be due 
to the general aim of the options. For instance, a review by Rothman, Bartels, Wlaschin 
and Salovey (2006) found that loss-framed messages were more effective when options 
that were provided to patients were about detecting the presence of a disease. To note, an 
updated review found very minimal effects of loss-based framed messages on detecting 
the presence of disease (O’Keefe & Jensen, 2009). In contrast, when the options that were 
framed were about prevention of a disease, such as by taking a medication, gain-framed 
messages were more likely to be influential (Gallagher & Updegraff, 2012; Rothman et 
al., 2006). Although findings against and in support of the prospect theory show that 
framing of information can impact decisions for equivalent options, it was not possible to 
determine whether changes in decisions for options were due to differences in 
comprehension of information when framed in different ways.  
Only two studies have assessed understanding when information is framed 
differently. Armstrong, Schwartz, Fitzgerald, Putt and Ubel, (2002) assessed both 
understanding and preferences for a hypothetical treatment in non-clinical populations. 
Participants were presented with graphs and numerical information framed in either the 
chance of surviving after taking the treatment, the chance of mortality after taking the 
treatment, or a combination frame stating both the chance of survival and mortality, prior 
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to assessing participants’ understanding of the information. Participants who received the 
benefits of treatments in terms of surviving or in a combination of both frames, showed 
significantly greater understanding compared to treatment information provided in a 
negative frame (Armstrong et al., 2002). As expected from previous studies, the 
preference towards a treatment also varied by framing. However, inconsistent with the 
prospect theory, preventative treatment were more likely to be adopted when framed in a 
positive manner (Armstrong et al., 2002). In another study, non-clinical populations were 
presented treatment information in either positive or negative frames and patients’ 
decision to take the treatment was recorded (Carling et al., 2010). All participants were 
then given more detailed information about the treatment, which the authors presumed 
will lead to informed treatment decisions. Findings showed that participants provided 
with treatment information in a positive frame were more likely to choose treatments 
consistent with treatments chosen following information provided comprehensively. 
From this, the authors were able to conclude that understanding was greater for 
information presented in a positive frame (Carling et al., 2010).  
In sum, studies with non-clinical populations show that framing of information 
can influence decisions made about numerically equivalent options. However, the 
decision to choose an option based on a particular type of frame was inconsistent between 
studies. Only two studies have specifically assessed understanding of information when 
framed differently in non-clinical populations. Positively framed information was more 
likely to increase understanding of treatment information in comparison to negatively 
framed information. The following section will explore whether the effects of framing are 
also evident in clinical populations, given that clinical populations are directly affected by 
medical information.  
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5.1.2.3 Review of framing treatment information in clinical populations  
One study found an effect of framing on decisions to take hypothetical treatments 
in clinical populations. Consistent with findings observed in non-clinical populations, the 
study conducted by McNeil and others (1982) found that patients showed an effect of 
framing, as the option of riskier surgery was chosen when information was framed in 
terms of living compared to mortality. 
However, the framing effect for participating in a clinical trial was not observed 
for cancer patients in another study (Llewellyn-Thomas, McGreal, & Thiel, 1995). 
Rather, the decision to take part in a clinical trial was mostly effected by age, sex and 
education of patients. The authors concluded that patient characteristics may be a more 
sensitive predictor for decisions based in real clinical contexts, instead of how 
information is framed. Similarly, when breast cancer patients were given information 
about risks and benefits of treatment, the framing of treatment risks and benefits did not 
influence the choice to take the treatment (Zimmermann, Baldo, & Molino, 2000). 
Instead, the choice of taking a treatment was dependent on the risk and benefit profiles of 
treatments. These findings were further supported by a review of the literature of clinical 
populations conducted by Edwards, Elwyn, Covey, Matthews and Pill (2001). Overall, 
the review did not discover any statistically significant effect of framing treatment 
information positively or negatively, with inconsistent trends for positive and negative 
framing of information on the decision to choose a treatment. However, these studies do 
not necessarily rule out the possibility that patients’ understanding of treatment 
information could be affected by how treatment information is framed.  
More recently, a study looked at patients’ preferences for different ways of 
expressing treatment risk and benefits, including how information was framed (Raval, 
Goodyear-Smith, & Wells, 2015). Patients in the study showed a consistent preference for 
treatment risks when framed positively. The authors suggested that these preferences 
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could be based on information which was easier to understand (Raval et al., 2015). 
However, it is not possible to draw such conclusions without objectively assessing 
understanding of treatment risks and benefits in patients.  
Overall, framing has been shown to affect decisions in non-clinical populations 
and physicians, but with limited evidence in clinical populations. Only two studies 
assessed understanding of non-clinical populations when information was framed 
differently and found that people better understood information framed positively. No 
studies have looked at the effects of framing on MS patients’ understanding. 
5.1.3 Patient understanding and decisional conflict 
Patients’ understanding of treatment risks and benefits could have an impact on 
how conflicted patients feel about their treatment choice (Janis & Mann, 1977; O’Connor, 
1995) (see section 4.1.5). Some studies have shown that treatment decisions can alternate 
depending on the ratios used to present frequencies (Halpern et al., 1989). In terms of 
framing, several studies have shown that decisions between equivalent outcomes can 
depend on how information is framed (Kühberger, 1998; Peng, Jiang, Miao, Li, & Xiao, 
2013; Perneger & Agoritsas, 2011; Tversky, 1986; Zipkin et al., 2014). It is therefore 
reasonable to assume that patients’ conflict in treatment decisions can depend on the 
frequency ratios and the manner in which treatment information is framed. However, this 
relationship has not been previously explored in the context of treatment decisions. 
5.1.4 Patient understanding and patient characteristics 
The ability to accurately understand treatment information may also be 
moderated by factors other than frequency ratios and framing of the informational 
content. 
5.1.4.1 Numerical reasoning, health literacy and IQ 
Numeracy skills were shown to moderate comprehension of information provided 
in different frequency ratios within one study (Reyna & Nelson, 2010), but not in others 
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(Oudhoff & Timmermans, 2015; Sirota et al., 2014). People with poor numeracy skills 
were also found to be more susceptible to the effects of framing across studies (Garcia-
Retamero & Galesic, 2010a; Peters & Levin, 2008; Reyna & Nelson, 2010). Although 
these findings are inconsistent, it is likely that numerical reasoning will play a role in MS 
patients’ understanding of information depending on framing and frequency ratios. 
No studies have explored the relationship between health literacy and IQ on 
understanding of treatment information when presented in different frequency ratios 
frames or different frames. 
5.1.4.2 Symptoms of MS 
MS patients with cognitive and affective symptoms may be particularly 
susceptible to poor understanding when information is presented in different frequency 
ratios or frames. These symptoms include: fatigue, depression, anxiety, deficits in 
information processing-speed and impairments in working memory (see section 1.1.2 for 
overview on MS patient symptoms).  
5.1.5 Research questions and hypothesis 
The following study addressed three specific questions based on the findings 
from the review, as represented in the theoretical framework below (see figure 5.1). First, 
which ratios should be used to present frequencies of treatment risks and benefits (N-in-
N*X ratio/1-in-X ratio) to maximise MS patients’ understanding? Second, how should 
treatment risk and benefit information be framed (positive frame/negative 
frame/combined frame) to maximise MS patients’ understanding? Finally, what is the 
relationship between MS patients’ understanding of treatment information presented in 
different frequency ratios and frames, and patients’ conflict in their treatment decisions? 
Additional exploratory questions attempted to address how numerical reasoning, health 
literacy, premorbid IQ and symptoms of MS could impact MS patients’ understanding of 
information presented in different frames and frequency ratios? 
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Specific hypotheses for the current experiment was derived from studies with 
non-clinical and clinical populations and were as follows: 
(i) N-in-N*X ratio would maximise understanding compared to the 1-in-X format; 
(ii) Positively framed treatment risk and benefit information will maximise 
understanding compared to negative frames and combination frames; 
(iii) Greater understanding of treatment information will reduce decisional conflict in 
MS patients; 
(iv) Numerical reasoning will be positively related to understanding of information. 
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Figure 5.1 Theoretical framework 3: Factors affecting MS patients’ understanding of treatment 
risks and benefits 
Key: Black arrows, significant effect; Grey arrows, no relationship; Question, Untested factors; 
arrows do not signify causation 
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5.2 Experiment 2 methodology 
5.2.1 Participants 
A total of 45 relapsing-remitting MS patients took part in this study, which 
includes 33 patients that had previously taken part in experiment 1. The inclusion and 
criteria for eligibility to take part was the same as in experiment 1 (see section 4.2.1). 
5.2.2 Materials and design 
The current study employed a cross-sectional within-subject design in order to 
assess patients’ understanding of treatment risks and benefits, and their conflict for their 
treatment decisions when treatments were presented in different frequency ratios and 
frames. 
One hypothetical disease was included in this study, for which risk and benefit 
information was provided for two hypothetical treatments. The name and symptoms of 
the disease were new in the current experiment, but mimicked the progressive nature of 
MS similar to Experiment 1 (see appendix 15 for hypothetical disease). Treatment names, 
and the associated risks and benefits of the treatments were also new in the current study, 
but were checked by a small survey sample as discussed in Experiment 1 (see section 
4.2.2). However, the risk-benefit profiles of the treatments were deliberately manipulated 
to mimic risk-benefit profiles of first-line and second-line DMDs (i.e. one treatment 
offered high risks and high benefits, and one treatment offered low risks and low 
benefits).  
Each hypothetical treatment presented information for a minor risk, an adverse 
risk and two possible benefits of taking the treatment based on a clinical trial conducted 
with patients for 1 year, 2 years and 5 years. Participants were informed that the 
information they would see denotes a hypothetical clinical trial where the intervention 
group refers to the group of patients taking the treatment and the control group refers to a 
group of patients with the same disease taking a placebo drug which does not have any 
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effect on the disease (i.e. this group essentially did not take a treatment). Patients were 
further informed that presenting information about two groups in a clinical trial will help 
them to see treatment risks and benefits in the context of clinical trial data. 
Patients were presented with information framed in three different ways for both 
treatment risks (minor and adverse) and treatment benefits. Thus, there were a total of six 
treatment outcomes presented in three frames (positive, negative and combined frame). 
Patients were also presented with frequencies in either N-in-N*X ratio or 1-in-X ratio. 
Hence, in total, patients were presented with 8 different formats across two treatments 
(see appendix 16 for presentation formats presented in treatment 1).  
The order of all six framing conditions were randomised between either a 
treatment risk (minor and adverse) or benefit. The order of the ratios was subsequently 
randomised to the remaining treatment risk and benefit (see table 5.1). To further reduce 
any effects of order, the treatments were counterbalanced between patients.  
Table 5.1  Order of framing and frequency ratios presented in Experiment 2 
Treatment Outcome Method of communicating differences 
Treatment 1 Adverse risk Combined frame 
Treatment 1 Minor risk Positive frame 
Treatment 1 Benefit Positive frame 
Treatment 1 Benefit 1-in-X 
Treatment 2 Adverse risk Negative frame 
Treatment 2 Minor risk N-in-N*X frame 
Treatment 2 Benefit Combined frame 
Treatment 2 Benefit Negative frame 
Treatment 1 was named Sprantil; Treatment 2 was named Mylobryne 
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The main outcome measures employed in the current experiment were patient 
understanding and conflict in treatment decisions.  
The patient understanding measure was similar to that used in Experiment 1 but 
with the addition of new questions to reflect information provided for both intervention 
and control group of a hypothetical clinical trial. Similar to Experiment 1, the first 
question directly assessed the magnitude of minor risks, adverse risks and benefits of the 
treatments based on the intervention group of a clinical trial. This was a free-recall 
question. The second question was added for the purpose of the current experiment. This 
question required patients to calculate differences in treatment risks and benefits from 
patients in the intervention group and patients in the control group of a hypothetical 
clinical trial (see appendix 16 for example of questions presented to patients). Calculating 
differences as a method of assessing understanding the treatment information has also 
been used by Cuite and colleagues (2008). Given that poor numeracy skills may affect the 
ability to calculate differences between groups, a multiple choice format was provided for 
this question. Patients were provided a total of 4 possible answers and were told that all 
multiple choice values were an approximate number only. Patients were asked to choose 
one answer that was the closest to the true difference and were awarded 1 point for 
answers that were correct. No score was awarded if patients chose an incorrect answer or 
did not answer the question. The filler answers in the multiple choice were randomly 
modified throughout the questions to avoid patients guessing at the correct answer based 
on repetition of filler answers. With the addition of this question to the patient 
understanding question, patients were able to get two points for every treatment minor 
risk, adverse risk and benefit that was provided. Given that each treatment outcome was 
presented for 1, 2 and 5 years of taking the clinical trial, the maximum score for each 
treatment risk (minor and adverse) and benefit was 6 points. The maximum understanding 
score for each treatment was 24 points, based on information provided for one minor risk, 
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one adverse risk and two possible benefits of taking the treatment (i.e. 4 possible 
outcomes for one treatment). The total understanding score across both treatments was 
therefore 48 points.  
The decisional conflict measure was the same as that employed in experiment 1 
(see section 4.2.2.2). 
All other assessments presented to patients throughout the study were also the 
same as those provided in Experiment 1, and includes: patient demographics, numerical 
reasoning, health literacy, premorbid IQ, and cognitive and affective symptoms of MS.  
5.2.3 Procedure 
The procedure for recruiting interested patients from the two hospital clinics was 
the same as discussed in Experiment 1 (see section 4.2.3). Following consent, an 
appointment was made with patients to take part in the study. The study was conducted 
either at the clinics or at the patient’s home, depending on patients’ preference. The study 
took approximately 2 hours to complete and was conducted face-to-face using offline 
materials only. 
Initially, patients were presented with the visual acuity scale to ensure they were 
eligible to view the remaining study (see section 4.2.1). If eligible to continue, patients 
were asked demographic questions and assessed on the disability status scale. Next, 
patient characteristics were measured in the following order: health literacy, numerical 
reasoning, depression and anxiety, fatigue and premorbid IQ. All patients were then 
shown information about one hypothetical chronic medical disease followed by two 
hypothetical treatments. Comprehension questions to assess understanding were provided 
after each treatment outcome. Patients were also required to make their treatment choice 
and complete the DCS measure after viewing both treatments. Finally, the BICAMS 
measure was conducted with patients at the end of the study. Note, however, that since 
this experiment was conducted alongside Experiment 3, all measures (aside from the 
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main task) were only measured once. Both Experiment 3 and the current experiment were 
conducted in alternating order between patients. 
5.2.4 Sample size 
Sample size was calculated to detect an effect on MS patients’ understanding of 
treatment risks and benefits. The calculation was similar to that given in Experiment 1 
(see section 4.2.4) and required a minimum sample of 45 MS patients.  
5.2.5 Statistical analysis 
All statistical analyses were carried out using SPSS 21. Means and standard 
deviations were provided for all continuous data. Maximum scores were given for all 
assessments in the study. A test of normality was conducted for the understanding 
outcome measure for each format using the Shapiro-Wilks test. The assumption of 
normality was significantly violated for all ratios and framing (p<.001) and therefore a 
nonparametric Friedman analysis of variance was conducted. Where the Friedman test 
was significant, pairwise comparisons were conducted by using the nonparametric 
Wilcoxon Signed Ranks test. Bonferroni corrections were applied for multiple 
comparisons. Effect sizes are calculated for all pairwise comparisons by dividing the z 
score by the square root of total number of observations, based on Rosenthal’s formula 
(Rosenthal, 1994); where, 0.1, 0.3 and 0.5 equates to small, medium and large effect 
sizes, respectively. For the purpose of the analysis, several formats were sometimes 
collapsed into one average understanding score. 
A bivariate Pearson’s product moment correlation was conducted to assess the 
relationship between patient understanding and the standardised scores of the DCS, 
including all subscales. Bivariate Pearson’s product-moment correlations were also 
computed to assess the relationship between understanding and raw scores on measures 
of numerical reasoning, health literacy, premorbid IQ and symptoms of MS. Due to 
multiple correlations, a stringent alpha of p<.01 was applied and accepted as significant. 
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5.3 Results 
5.3.1 Patient demographics 
A total of 45 patients took part in this experiment. Demographic information for 
patients are displayed in Table 5.2. 
5.3.2 The effect of frequency ratios on patients’ understanding  
There was a statistically significant difference in understanding scores for 
frequency ratios (1-in-X ratio, N-in-N*X ratio), X2(1) = 44.000, p<.001. According to 
mean scores, understanding was greater for N-in-N*X ratio (M=5.67, SD=.64) compared 
to 1-in-X ratio (M=.67, SD=1.15, z=-5.869, r=0.61) 
5.3.3 The effect of framing on patients’ understanding 
There was a statistically significant difference in framing across risks and 
benefits of treatments (positive framing, negative framing, combined framing) on 
patients’ understanding, X2(2) = 10.227, p<.01. Pairwise comparisons were conducted to 
statistically compare the means for positive frames (M=4.83., SD=1.37), negative frames 
(M=5.25, SD=.90) and combined frames (M=4.81, SD=1.18). Understanding was greater 
for negative framing compared to positive frames (z=-2.995, r=0.31, p<.01) and 
combined frames (z=-2.519, r=0.27, p<.05). There was no significant difference between 
positive frames and combined frames (z=-.301, p=.763). 
There was no statistically significant difference when framing was manipulated 
for risks and when framing was manipulated for benefits, X2(1) = .243, p=.622. 
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Table 5.2  Patient demographics and disease status for Experiment 2 (n=45) 
 Mean (SD) n (%) 
Age, years 46.76 (10.50)  
Gender   
Female  36 (80.0) 
Male  9 (20.0) 
Level of education   
High school  15 (33.3) 
College   11 (24.4) 
Bachelor’s degree  8 (17.8) 
Postgraduate  11 (24.4) 
Employment status   
Full-time (>16 hours)  13 (28.9) 
Part-time (<16 hours)  10 (22.2) 
Self-employed  7 (15.6) 
Unemployed  11 (24.4) 
Medical leave  3 (6.7) 
Retired  1 (2.2) 
Time since MS diagnosis, years 10.89 (8.51)  
HAI disability scale 1.64 (1.77)  
Current DMD   
Interferon betas  15 (33.3) 
Glatiramer Acetate  4 (8.9) 
Teriflunomide  0 (0) 
Fingolimod  8 (17.8) 
Alemtuzumab  4 (8.9) 
Dimethyl Fumarate  5 (11.1) 
Natalizumab  8 (17.8) 
Mitoxantrone  1 (2.2) 
DMD= disease-modifying drugs; HAI = Hauser Ambulation Index 
* Score of 1 on HAI scale = Able to walk normally but report fatigue interfering with athletic 
activities 
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5.3.4 Patient understanding and decisional conflict 
A bivariate Pearson product-moment correlation showed no significant 
correlation between patients’ understanding and the total decisional conflict score. There 
were also no significant correlations between understanding of treatment information and 
any other DCS subscales (see table 5.3). 
Table 5.3  Correlations between patient understanding and decisional conflict 
 Max scores Mean SD Correlation 
Total understanding 48 36.13 6.24  
DCS informed 100 15.37 14.43 -.265 
DCS values 100 25.00 20.26 -.127 
DCS support 100 23.15 16.94 -.159 
DCS uncertainty 100 42.77 23.21 -.125 
DCS effective 100 43.89  30.07 -.218 
DCS total score 100 28.13  17.30 -.207 
* = indicates significance at p<.05 level; ** at p<.01 level; *** at p<.001 level; DCS, Decisional 
conflict scale 
 
5.3.5 Patient understanding and patient characteristics   
Patients were assessed for numerical reasoning skills, health literacy, premorbid IQ and 
MS symptoms in the current experiment. As shown in table 5.4, MS patients in this 
experiment mostly showed symptoms of fatigue and cognitive impairments. A bivariate 
Pearson product-moment correlation coefficient was computed to assess the relationship 
between treatment understanding score and symptoms of MS. Means, standard deviations 
and correlations for all assessments are presented below (see table 5.5). There were 
significant correlations between understanding of treatment information with numerical 
reasoning (r=.509, p<.001), premorbid IQ (r=.393, p<.01), information processing speed 
(r=.462, p<.01), verbal memory (r= .462, p<.01) and visual memory (r= .382, p=.01). 
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There was no significant relationship between understanding of treatment information 
with health literacy, anxiety, depression, fatigue and visual memory. 
Table 5.4  Patients impaired on assessments of numerical reasoning, health literacy, 
premorbid IQ and MS symptoms (n=45) 
Patient characteristics and MS symptoms n (%) 
Health literacy 6 (13.3) 
Numerical reasoning 3 (6.7) 
Depression 1 (2.2) 
Anxiety 5 (11.1) 
Fatigue 22 (48.9) 
Premorbid IQ 3 (6.7) 
Information processing speed 14 (31.1) 
Verbal memory 15 (33.3) 
Visual memory 23 (51.1) 
 
Table 5.5  Correlations between patient understanding and patient characteristics 
Patient characteristics Max scores Mean SD Correlation 
Total understanding 48 36.13 6.24 - 
Numerical reasoning 25 16.36 3.80 .509*** 
Health literacy 8 7.42 1.32 .175 
Anxiety 21 6.27 3.98 -.118 
Depression 21 4.11 3.69 -.059 
Fatigue 63 44.00 13.47 -.087 
Premorbid IQ 50 36.69 8.46 .393** 
Information processing speed 110 56.62 12.62 .462** 
Verbal memory 80 49.07 12.43 .466** 
Visual memory 36 21.16  6.46 .382** 
* = indicates significance at p<.05 level; ** at p<.01 level; *** at p<.001 level, 
correlations in bold accepted as significant due to multiple correlations.  
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5.4 Discussion 
Studies with both non-clinical and clinical populations have generally shown that 
frequencies presented in the 1-in-X ratio are more difficult to understand. The current 
experiment was the first to evaluate MS patients’ understanding of treatment risks and 
benefits when presented using frequencies with different ratios. Consistent with findings 
from a range of population groups, MS patients also showed poor understanding of 
frequencies presented in the 1-in-X ratios in comparison to N-in-N*X ratios. Considering 
that frequencies in the N-in-N*X ratio are also better than percentages at improving MS 
patients’ understanding as demonstrated by Experiment 1 (see chapter 4), further 
indicates that N-in-N*X ratios are the best way to present quantitative treatment risk and 
benefit information to MS patients. 
Several explanations have been proposed for the difficulty in comprehending 
frequencies presented in the 1-in-X format. Given that the 1-in-X ratio has shown to lead 
to overestimation of treatment risks and benefits in clinical populations, it has been 
suggested that this effect may be due to underestimation of frequencies presented in N-in-
N*X ratios (Pighin et al., 2011, 2015). Unlike these studies, the current experiment 
employed a within-subject design and it was therefore not possible to assess the under 
and overestimation of equivalent risks and benefits across patients. However, the current 
study was able to show that objective understanding was greater for frequencies in the N-
in-N*X format, indicating that underestimation of N-in-N*X ratios were not the reason 
for overestimation of frequencies based on the 1-in-X ratio.  
Another explanation is that the 1-in-X effect has similar underpinnings to other 
well-known ratio effects, including: numerator neglect, denominator neglect and group-
diffusion. Numerator neglect refers to individuals focusing only on different 
denominators between ratios (Yamagishi, 1997), as these are typically smaller in the case 
of 1-in-X compared to N-in-N*X. However, Pighin and colleagues (2011) found no 
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differences in patients’ understanding when the denominators were increased from 48 to 
160. Denominator neglect, on the other hand, refers to people simply focusing on the 
numerator of the ratios and neglecting the denominator (Miller, Turnbull, & McFarland, 
1989). Considering that the 1-in-X ratio always has a numerator of 1, the denominator 
neglect theory would predict that the 1-in-X frequencies would be perceived as lower 
than N-in-N*X. However, the opposite effect is evident for frequencies presented using 
the 1-in-X ratio (Pighin et al., 2011, 2015; Sirota et al., 2014). The group-diffusion effect 
is another commonly known ratio effect which suggests that the larger the denominator, 
the lower the perceived probability of developing a risk due to the illusion of being a 
member of a larger group (i.e. 5 in 60 should be perceived as lower than 1 in 12) 
(Yamagishi, 1997). However, this effect has not been replicated in frequencies presented 
with both the numerator and denominator present, such as the 1-in-X ratio (Price et al., 
2007; Sirota et al., 2014). In sum, although the 1-in-X cannot be easily comprehended, 
the theoretical reason for this effect is not clearly understood. Regardless, 
recommendations may be made for the use of N-in-N*X ratios when presenting treatment 
risk and benefit information. 
The current experiment also aimed to determine how framing of treatment 
information could affect MS patients’ understanding. The results showed that treatment 
risks and benefits framed negatively (e.g. the number of people who will have a treatment 
risk, and the number of people who will not show a delay in the disease symptoms, 
respectively) was easier to understand by MS patients than treatment risks and benefits 
framed positively or in a combination of both frames. This is contrary to a previous study 
which found that hypothetical treatment information framed positively was easier to 
understand, compared to negative or combined frames (Armstrong et al., 2002). The 
differences between this study and the current experiment may be due to two reasons. 
Firstly, both studies differed in respect to the treatment information that was manipulated 
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using different frames. Whilst Armstrong and colleagues (2002) used survival and 
mortality curves for treatments framed positively and negatively, respectively, the current 
experiment framed a wide range of treatment risks and benefits differently. Secondly, the 
study by Armstrong and colleagues (2002) employed non-clinical populations, whereas 
the current experiment assessed MS patients who are more likely to make decisions based 
on the information framed in different ways. In fact, disparities between non-clinical and 
clinical populations are also evident when looking at the effects of framing on decision-
making, as studies with non-clinical populations generally observe a framing effect 
(Abhyankar, Summers, Velikova, & Bekker, 2014; Armstrong et al., 2002; Carling et al., 
2010; Gallagher & Updegraff, 2012; Marteau, 1989; Meyerowitz & Chaiken, 1987; 
Peters et al., 2011; Wilson et al., 1987), whereas studies with clinical populations have 
not shown a consistent effect on decisions based on framing (Llewellyn-Thomas et al., 
1995; McNeil et al., 1982; Zimmermann et al., 2000). This indicates that the context in 
which information is provided may play an important role in the extent to which framing 
can affect decisions or understanding in individuals. 
Strategies have been proposed to reduce any effects of framing on understanding 
and decision-making. In a study conducted by Almashat, Ayotte, Edelstein and Margrett 
(2008), participants that listed all the risks and benefits of a treatment, regardless of the 
framing, were less susceptible to the effects of framing when compared to a group who 
did not employ this strategy. However, such a strategy would not be applicable in the 
context of providing DMD risks and benefits to MS patients given the time-consuming 
nature of the task. Another strategy was proposed by Garcia-Retamero and Galesic 
(2010), who found that the addition of graphical formats, particularly bar charts and pie 
charts, was able to eliminate the effects of framing. Consistent with this strategy, 
Experiment 1 has shown that particular graphical formats are able to improve 
understanding of patients with MS. Although, pie charts were shown to be the least 
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understood graphical format according to Experiment 1. In general, given the low effect 
size for the impact of framing on patients’ understanding in the current experiment and 
the inconsistent effects of framing in previous studies, it is likely that framing treatment 
information negatively only marginally improves understanding. However, it seems that 
any effects of framing on patients’ understanding could further be reduced by addition of 
graphical formats.  
The current experiment also explored the relationship between treatment 
understanding scores with patients’ characteristics, including symptoms of MS. As 
predicted, numerical reasoning showed a significant positive relationship with 
understanding of treatment risk and benefit information. This was supported by some 
studies for both frequency ratios and framing of information (Garcia-Retamero & 
Galesic, 2010a; Peters & Levin, 2008; Reyna & Nelson, 2010), but not others (Oudhoff & 
Timmermans, 2015; Sirota et al., 2014). Interestingly, significant relationships were also 
observed with impairments in verbal memory, visual memory and information processing 
speed indicating that MS patients with cognitive impairments may be particularly 
susceptible to information framed in different ways and presented using different 
frequency ratios. Presenting treatment information only using the N-in-N*X frequency 
ratios can likely improve understanding in these patients. 
Although the current experiment is the first to explore the effects of framing and 
frequency ratios on MS patients’ understanding and their conflict for treatment decisions, 
there a number of limitations present. First, framing and frequency ratios were not 
assessed separately in this experiment, which meant that total scores of understanding and 
decisional conflict used in correlations were a combination of both framing and frequency 
ratios. However, the experiment was designed in order to use the minimal number of 
patients and yet still investigate the impact of framing and frequency ratios. Second, 
information provided throughout the experiment was for two groups of patients in a 
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clinical trial context. However, this experiment did not assess whether the methods to 
communicate differences between groups could also affect patients’ understanding of 
treatment risks and benefits. This will be explored in a subsequent experiment. 
5.4.1 Conclusion 
 Despite the limitations, the present experiment indicates that the ratios used to 
present frequencies can have an effect on MS patients’ understanding of treatment risks 
and benefits. Understanding for treatment information could be maximised if presented 
using the N-in-N*X ratio. In addition, the frames used to present information could 
further influence treatment understanding in MS patients, with risks and benefits 
presented in negative frames more likely to improve understanding. However, the effects 
of framing on patients’ understanding is likely to be very low. MS patients with low 
numerical reasoning skills and increased cognitive impairments may be particularly 
susceptible to the effects of ratios and framing of treatment information. These findings 
were integrated into an updated theoretical framework of MS patients’ understanding (see 
figure 5.2). 
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Figure 5.2 Theoretical framework 4: Factors affecting MS patients’ understanding of treatment 
risks and benefits 
Key: Black arrows, significant effect; Grey arrows, no relationship; Question, Untested factors; 
arrows do not signify causation 
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Chapter 6: Methods to communicate treatment 
differences from groups in clinical trials 
 
6.1 Introduction 
Experiment 2 presented patients with treatment information from a hypothetical 
clinical trial based on two groups: an intervention group in which patients receive the 
treatment of interest and a placebo group in which patients do not take a treatment. Yet, 
the differences between these groups were not clearly communicated to MS patients. It is 
possible that communicating these differences could maximise MS patients’ 
understanding of the differences between groups of a clinical trial, and help determine the 
risks and benefits of a treatment. There are a number of methods which can be used to 
communicate such differences between two groups, and include: absolute terms, relative 
terms and numbers needed to treat or harm. The most effective method of communicating 
these differences to MS patients needs to be identified. 
The effectiveness of these methods on understanding risks and benefits have been 
primarily assessed with non-clinical populations and clinical populations other than MS. 
The best method to communicate differences between clinical trial groups to MS patients 
is unclear. Yet, relative terms are frequently used to display treatment benefits to patients 
with MS in current clinical practise in the UK (see appendix 11). The current chapter will 
first aim to define all these methods of communicating differences between groups. 
Second, findings from both non-clinical and clinical populations will be reviewed to 
identify the best method of communicating risk and benefits differences. Finally, a study 
will be conducted directly with MS patients to evaluate the best method of improving 
understanding in MS patients.  
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6.1.1 Definition of methods to communicate differences between groups 
Several methods can be used to communicate differences between risks and 
benefits of two groups, such as the groups within a clinical trial. These methods vary in 
the calculations to obtain these differences. To better explain these calculations, some 
example data from a faux clinical trial is presented in table 6.1 and the formulas used to 
calculate these methods are presented in table 6.2. Additionally, the following terms will 
be used to define the different methods of communicating differences: event rate (ER), 
experimental event rate (EER) and control event rate (CER): where ER refers to the risk 
or benefit of a treatment, EER refers to the ER of the intervention group of a clinical trial 
(i.e. patients taking the treatment of interest), and CER refers to ER of a control group of 
the clinical trial (i.e. patients taking the placebo or an existing treatment). The EER and 
CER may be added to the beginning of any method and this additional information is 
termed the baseline information.  
Table 6.1 Example data to calculate differences between risks and benefits of clinical trial 
groups 
 Risk increase (risks) Risk reduction (benefits) 
 
Experimental/ 
intervention 
group (E) 
Control/ 
placebo group 
(C) 
Experimental/ 
intervention 
group (E) 
Control/ 
placebo 
group (C) 
Events 3 1 150 50 
Total subjects 1000 1000 1000 1000 
Event rate (ER) 3 (0.3%) 1 (0.1%) 150 (15%) 50 (5%) 
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Table 6.2 Formulas to calculate differences between risks and benefits of clinical trial 
groups 
Methods Abbr. Formula Example data 
from table 6.1 
Absolute risk increase (risk) ARI EER – CER 100 (10%) 
Absolute risk reduction (benefit) ARR EER – CER 2 (0.2%) 
Relative risk increase (risk) RRI (EER – CER) / CER Double (200%) 
Relative risk reduction (benefit) RRR (EER – CER) / CER Double (200%) 
Numbers needed to harm (risk) NNH 1 / (EER – CER)  10 
Number needed to treat (benefit) NNT 1 / (EER – CER) 500 
Abbr., abbreviation; CER, control group rate; EER, experimental group rate 
6.1.1.1 Absolute risk increase and absolute risk reduction 
Absolute risk increase (ARI) and absolute risk reduction (ARR) refers to the 
difference between the event rate of the intervention and control group of a clinical trial 
(i.e. EER – CER). With the example data presented in table 6.1, the absolute risk increase 
between the intervention and control will be 2 (i.e. 3 -1 = 2) and the absolute risk 
reduction will be 100 (i.e. 150 – 50 = 100). The absolute risk differences can be larger or 
smaller depending on the size of the original event rate.  
To communicate the differences between the risks of the intervention group and 
the risks of the control group using the ARI method, the following statement may be 
presented to patients: “compared to the control group, 2 more people out of 1000 people 
will show an increase in the risk of developing the adverse effect when taking the 
medication”. Similarly, to communicate the differences between the benefits of the 
intervention group and the benefits of the control group using the ARR method, the 
following statement may be used: “compared to the control group, 100 more people out 
of 1000 people will show a benefit of the disease symptom when taking the medication”. 
Absolute terms can also be conveyed in the form of percentages (Covey, 2007; Raval et 
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al., 2015). Thus, the risks could be stated as: “compared to a placebo group, 0.2% more 
people will show an increase in the risk of adverse effect when taking the medication”. 
Likewise, using percentages to communicate the benefits, the following statement could 
be used: “compared to the placebo group, 10% more patients will show a benefit in terms 
of the disease symptom when taking the medication”. 
5.1.4 Relative risk increase and relative risk reduction 
Relative risk increase (RRI) and relative risk reduction (RRR) methods refer to 
differences between two groups expressed as a proportion of the event rate of the control 
group. This is calculated using the following formula: (EER – CER)/CER (see table 6.2). 
With the examples presented above (table 6.1), the RRI will be 2 ((3 -1)/1 = 2), and the 
RRR will also be 2 ((150 – 50)/50 = 2). In order to get a percentage value, the total score 
can be multiplied by 100 as demonstrated by the following formula: ((EER – 
CER)/CER)*100. Contrary to absolute risk methods, the relative risk method remains 
constant regardless of the size of the original event rate. 
In order to communicate how much the medication will increase the risk of an 
adverse effect, the following statement may be provided to patients in which the relative 
terms can be expressed in the form of frequencies, probabilities or percentages: 
“compared to the placebo group, 2 times as many patients OR double the number of 
patients OR 200% more patients will show an increase in the risk of adverse effect when 
taking the medication”. Since the example for RRR produces the same result, a similar 
statement could be used to provide RRR information about the benefits of taking the 
medication in comparison to the placebo group. Relative terms are commonly employed 
to present treatment benefits to patients with MS in current clinical practise within the 
UK (see appendix 11). 
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5.1.5 Numbers needed to harm and numbers needed to treat 
Numbers needed to harm (NNH) and numbers needed to treat (NNT) refers to the 
average number of people who must be treated in the intervention group in comparison to 
the control group, in order for one patient to develop the risk or benefit. Both NNH and 
NNT are the reciprocal of the absolute method of communicating differences (i.e. the 
number one can be divided by the absolute method to obtain NNH and NNT). Thus, both 
NNH and NNT can be calculated using the formula: 1/ (EER – CER) (see table 6.2), 
where EER and CER are the fractions of the EER and CER presented in table 6.1. With 
the example data from table 6.1, NNH will be 500 (1/(0.003-0.001) = 500), and NNT will 
be 10 (1/(0.15-0.05) = 10).  
Both the NNH and NNT are usually expressed in the form of the average patients 
that would need to be treated at any certain point in time. Thus, the following statement 
may be used to express the NNH method or the risks between groups: “compared to the 
placebo group, 500 people would need to take the treatment for 1 person to show a risk of 
the adverse effect after 1 year”. Similarly, to communicate NNT (i.e. benefits) from 
differences between the intervention group and the placebo group, patients may be 
provided with the following statement: “compared to the placebo group, 10 people would 
need to take the treatment for 1 person to perceive a benefit in the disease symptom.”  
Overall, it should be noted that the statements used to convey each of these 
methods are not standardised across studies (Covey, 2007). For this reason, the statements 
presented above do not represent the precise text, or indeed an exhaustive set of 
statements that may be used to communicate the differences between two groups. 
In summary, the differences between the intervention group and control group of 
a clinical trial can be communicated using absolute terms, relative terms and numbers 
needed to harm or treat, all of which rely on different formulas to calculate these 
differences. The following section will compare studies that have looked at the 
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effectiveness of these methods primarily in non-clinical populations and clinical 
populations other than MS, due to a limited number of studies that have examined this 
effect with MS patients. It is expected that studies from other populations will be able to 
inform the best methods to improve understanding in MS patients, which consequently 
could be used to develop a theoretical framework of MS patient understanding. 
6.1.2 Review of methods to communicate differences between groups in non-clinical 
populations 
Some studies have assessed only individual methods of communicating risk or 
benefit differences between groups in non-clinical populations. In earlier studies, 
participants perceived the risk as higher when presented with differences of risks between 
two groups using relative terms in comparison to simple frequencies (Halpern et al., 
1989; Stone, Yates, & Parker, 1994). These findings showed that relative terms could 
influence the choices made by non-clinical populations. However, given that frequencies 
on their own do not communicate differences between groups, the comparison of relative 
terms with frequencies does not imply the efficacy of relative terms as a method of 
communicating risk differences. Another study sought to evaluate the effectiveness of 
communicating differences of benefits between groups using a relative risk reduction 
method alone. Participants were randomly presented with one of six probabilities of 
experiencing a benefit after taking a hypothetical drug (Sorensen, Gyrd-Hansen, 
Kristiansen, Nexøe, & Nielsen, 2008). Participants in this study did not generally change 
their decision to take the drug depending on the magnitude of the benefit, indicating 
difficulty in discriminating between probabilities when expressed in relative terms. 
Interestingly, self-reported understanding of the relative terms was high (Sorensen et al., 
2008). Together, these studies suggest that relative terms are difficult to comprehend, but 
without directly assessing understanding of differences communicated in relative terms. 
Other studies examined only the numbers needed to treat method to communicate 
differences to non-clinical populations. Kristiansen, Gyrd-Hansen, Nexoe and Nielsen 
Chapter 6 
188 
(2002) randomly presented participants with different levels of benefits (i.e. delay in 
adverse effects) of a hypothetical drug using the numbers needed to treat method. The 
authors found that, irrespective of the probabilities of treatment benefits, 80% of 
participants consented to the hypothetical drug. From this, Kristiansen and colleagues 
(2002) concluded that people cannot comprehend benefits expressed using the numbers 
needed to treat method. One explanation for this effect was proposed by Halvorsen, 
Selmer and Kristiansen (2007), who suggested that the numbers needed to treat method 
could be misleading for medications which do not treat a disease, but rather offer a delay 
in an adverse effect. This is of particular importance for DMDs in MS, which cannot cure 
the disease but rather offers delays in disease progression and the rate of relapses (see 
section 1.2). To test this theory, Halvorsen and colleagues (2007) presented non-clinical 
populations with a hypothetical drug either in terms of numbers needed to treat, or in a 
statement which provided the length and duration of the delay in developing the adverse 
effect (e.g. “patients who take the drug therapy for 5 years will live about 2 months 
longer before they get a heart attack”). The benefits provided for both methods were 
equivalent. The study found that a greater number of participants chose to take the drug 
when the benefits were expressed in terms of numbers needed to treat, rather than in 
delay of an adverse effect. This implied that both methods were understood differently by 
participants in the study. However, only self-reported understanding was measured which 
was equally poor for both methods (Halvorsen et al., 2007). Overall, the findings imply 
that numbers needed to treat may be difficult for non-clinical populations to understand, 
but the effect of this method on objective understanding is unclear. 
Studies that have directly compared methods to communicate differences have 
observed some consistent findings on understanding of treatment risk and benefit 
differences in non-clinical populations. In one study, Hembroff, Holmes-Rovner and 
Wills (2004) presented participants with hypothetical risks and benefits of a medication in 
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absolute and relative terms, and recorded the respondent’s willingness to recommend the 
medication to a friend. The authors concluded that rational decisions based on risks and 
benefits were made when information was presented in absolute terms, signifying better 
understanding of absolute terms rather than relative terms. However, objective 
understanding was not recorded. In addition, the absolute terms in this study were 
presented using the 1-in-X ratio (e.g. 1 in 200 and 1 in 500), which as shown in 
Experiment 2, can significantly reduce understanding when compared to the N-in-N*X 
ratios (e.g. 4 in 1000 and 2 in 1000; see chapter 5). For this reason, it is not possible to 
deduce from this study whether differences in treatment choice were due to information 
presented in absolute terms or due to information presented in specific ratios (Hembroff 
et al., 2004). Therefore, the numerical formats within the methods of communicating 
differences between groups also need to be carefully considered during presentation.  
A number of studies have manipulated numerical formats in the methods used to 
communicate group differences to non-clinical populations. Two studies expressed the 
baseline information (i.e. information about EER and CER which can be presented at the 
beginning of every method) in either frequencies or percentages (Bodemer et al., 2014; 
Covey, 2011). Since the relative method relies on using a format such as a percentage, 
providing the baseline information with the relative risk meant that formats could be 
easily manipulated. Covey (2011) specifically recorded participants’ decisions for 
whether to take the medication. Although participants showed no differences in their 
treatment choice when presented with absolute and relative terms in any numerical 
format, both methods provided in frequencies induced greater rational decisions than 
those provided in percentages (Covey, 2011). In a subsequent experiment with absolute 
and relative terms presented only in frequencies, but with a wider range of probabilities of 
risks and benefits, Covey (2011) found that absolute terms increased rational decisions 
compared to relative terms. However, both these experiments did not include a rigorous 
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measure of understanding. On the other hand, Bodemer and colleagues (2014) explicitly 
measured objective understanding by asking participants to state the baseline risk of the 
treatment group (i.e. EER). Similar to findings by Covey (2011), majority of participants 
showed greater understanding of treatment risks and benefits when baseline information 
was presented in a frequency format (Bodemer et al., 2014). However, when baseline 
information was presented using percentages, absolute terms were shown to improve 
understanding compared to relative terms presented using percentages (Bodemer et al., 
2014). Hence, whilst differences presented in absolute terms generally show 
improvements in understanding, adding baseline information in the correct numerical 
format could further improve understanding of differences between groups. This was 
further supported by Berry, Knapp and Raynor (2006) who found no differences in 
objective understanding of absolute risk, relative risk and numbers need to harm when 
baseline information was included, suggesting better understanding of the presence of 
baseline information. Note, however, that without the addition of baseline information, 
absolute terms showed a greater advantage in understanding (Berry et al., 2006). These 
findings support the need for adding baseline information to all methods, and are also 
consistent with findings from Experiment 1 which found that formatting numerical 
information as frequencies can improve understanding of treatment information (see 
chapter 4).   
In sum, studies with non-clinical populations can inform the need to employ 
methods of expressing differences between two groups to improve MS patients’ 
understanding. Although objective understanding was rarely measured in the reviewed 
studies, absolute methods showed improvements in rational decisions compared to 
relative terms and numbers needed to treat or harm. Baseline information provided with 
these methods also seemed to increase understanding, provided this was presented in 
formats that could be easily understood. The next section will focus on evaluating these 
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methods in clinical populations which represent the population more likely to make 
decisions based on treatment information. 
6.1.3 Review of methods to communicate differences between groups in clinical 
populations 
Many studies with clinical populations have evaluated methods to communicate 
differences in risks and benefits by assessing patients’ choice of medications. For 
instance, two studies presented patients with equally efficacious hypothetical treatments 
in both absolute and relative terms (Forrow, Taylor, & Arnold, 1992; Malenka, Baron, 
Johansen, Wahrenberger, & Ross, 1993). The findings showed that patients were more 
likely to choose medications when presented using relative terms, insinuating differences 
in understanding risks and benefits presented in different methods. In a more recent study, 
Perneger and Agoritsas (2011) randomly presented hospitalised patients and physicians 
with hypothetical differences between drugs in either of the following conditions: 
absolute method framed positively, absolute method framed negatively, relative method 
framed negatively, or a combination of all of these methods. The authors presumed that 
the combination of all methods will provide the most information and would increase 
understanding the most, hence all other methods were compared with this condition. Both 
physicians and patients showed similar differences in the decision to take a drug 
depending on the condition. However, since the condition which combined all methods 
was not significantly different to the decisions based on information presented in absolute 
terms, the authors concluded that absolute terms were the least biased method of 
presenting treatment information (Perneger & Agoritsas, 2011). These findings and other 
similar studies with clinical populations have been grouped together in a range of 
reviews, and consistently show that information provided in relative terms is more likely 
to unreasonably persuade patients to choose a treatment (Covey, 2007; Edwards et al., 
2001; Fagerlin et al., 2011; Waldron, van der Weijden, Ludt, Gallacher, & Elwyn, 2011), 
whereas medications presented with numbers needed to treat or harm were least likely to 
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be accepted (Waldron et al., 2011). Studies have additionally found that numbers needed 
to treat were least preferred by cardiovascular patients (Goodyear-Smith et al., 2008) and 
treatment adherence was improved when presenting information using absolute terms to 
another group of cardiovascular patients (Stovring, Gyrd-Hansen, Kristiansen, Nexoe, & 
Nielsen, 2008). In general, many studies with clinical populations show clear 
discrepancies in the methods to communicate differences on patients’ decision to take a 
medication, but how well these methods are understood by patients cannot be 
conclusively established from these studies.  
A number of studies have evaluated the methods of communicating differences 
on understanding of risk and benefit information in clinical populations. In one study, a 
randomised cross-sectional survey presented patients in outpatient clinics with benefits of 
two hypothetical drugs for a hypothetical disease (Sheridan, Pignone, & Lewis, 2003). 
Baseline information was presented to all patients for these drugs. Differences in benefits 
between these drugs were communicated in either of the three methods: relative risk 
reduction, absolute risk reduction and numbers needed to treat. A combination of all three 
methods was also given to one group of patients. Understanding was assessed by asking 
patients to calculate the benefits of only one drug or compare the benefits of both drugs. 
Sheridan and colleagues (2003) found that patients were least accurate at understanding 
the benefits of drugs when treatment information was provided using numbers needed to 
treat. A combination of all methods also made it difficult for patients to calculate benefits 
of two drugs. Thus, both absolute and relative risk reduction were shown to be the most 
effective method to improve understanding of the benefits of two drugs (Sheridan et al., 
2003). In another randomised approach by O’Donoghue and colleagues (2014), patients 
who had been diagnosed with high cholesterol were provided with hypothetical 
information about drugs to target their condition using absolute or relative methods 
without baseline information. Numerical formats were also manipulated in this study, in 
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that absolute terms were presented in either frequency, percentages or a combination of 
the two, and relative terms were presented in frequency or a combination of frequency 
and percentages. Findings showed poor understanding of risks and benefits when 
presented in relative terms in frequency and the greatest understanding of absolute terms 
presented in a combination of frequency and percentages (O’Donoghue et al., 2014). The 
authors concluded that providing information using absolute terms and combining the 
numerical formats was a better method to improve understanding. 
6.1.4 Review of methods to communicate differences between groups in MS patients 
Only one study with MS patients evaluated the methods of communicating 
differences between groups. Using a pre-post design, this study examined the effects of 
providing treatment information using absolute risk methods as part of developing a 
larger educational intervention (Kasper et al., 2006). The study revealed that MS patients 
were unable to calculate differences in risks and benefits between groups when presented 
only in absolute terms. Understanding of information provided in absolute terms showed 
improvements when baseline information was present. However, these improvements 
were only apparent in a small number of patients, as the majority of MS patients were 
unable to answer the question altogether (Kasper et al., 2006). The authors concluded that 
since the MS patient sample also included PPMS patient groups (see section 1.1.3 for an 
overview of MS subtypes) who do not typically make decisions about DMDs, the 
difficulties in understanding the information could reflect a motivational bias in these 
patients rather than the method used to provide treatment information.  
In summary, whilst studies with clinical samples can provide important 
information about the best method to communicate differences between groups to 
improve understanding in MS patients, there was immense heterogeneity amongst studies 
in the methods employed and the outcome assessments. Reviews also indicate that there 
are large disparities between how one method is presented to patients across studies (Akl 
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et al., 2011; Covey, 2007; Zipkin et al., 2014). Regardless, the current evidence seems to 
show a trend towards absolute terms as the most effective method to improve 
understanding. Findings also suggest that adding baseline information to any method can 
be beneficial for understanding the information. However, the study directly conducted 
with MS patients, shows unclear findings about the best methods that can improve MS 
patients’ understanding (see figure 6.1 for theoretical framework of MS patients’ 
understanding based on this review). 
6.1.5 Patient understanding and decisional conflict 
Patients’ understanding of medication information can have an impact on how 
conflicted they feel about making a treatment decision (Janis & Mann, 1977; O’Connor, 
1995) (see section 4.1.5). It is evident from the above reviewed studies that the methods 
of communicating differences between groups can impact the decision to choose a 
treatment by non-clinical and patient populations (Covey, 2011; Fagerlin et al., 2011). 
However, the relationship between patients’ understanding of these methods and the 
conflict in their decisions is unclear. 
6.1.6 Patient understanding and patient characteristics 
The ability to understand accurately the differences between intervention and 
control group of clinical trials may also be moderated by factors other than the methods 
that can be used to communicate these differences. 
6.1.6.1 Numerical reasoning, health literacy and premorbid IQ 
Numeracy skills have shown to mediate understanding of particular methods of 
communicating differences between groups. Sheridan and colleagues (2003) found that 
correct responses to information displayed in relative terms were as little as 5.8% for low 
numerate individuals. However, individuals with better numeracy skills were able to 
respond correctly to 40% of the questions. Likewise, individuals with low levels of 
numeracy showed the least understanding of medication information presented in relative 
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terms in another study (Bodemer et al., 2014). To note, the effect of numeracy skills on 
understanding of differences between groups disappeared on provision of baseline 
information for all methods (Bodemer et al., 2014). From these findings, it is expected 
that numeracy will play a role in MS patients’ understanding of treatment information 
when differences between groups are communicated using different methods. 
No studies explored the relationship between health literacy and IQ on 
understanding of treatment differences based on different methods to communicating 
these differences. 
6.1.6.2 Symptoms of MS 
MS patients with cognitive and affective symptoms may be particularly 
susceptible to poor understanding when differences between groups in clinical trials are 
presented using complex methods. These symptoms include: fatigue, depression, anxiety, 
deficits in information processing-speed and impairments with working memory (see 
section 1.1.2 for overview of MS patient symptoms).  
6.1.7 Research questions and hypothesis 
The following study addressed two specific questions, which were represented in 
the form of a theoretical framework (see figure 6.1). First, which methods of 
communicating differences between groups (absolute risk reduction/increase, relative risk 
reduction/increase, and numbers needed to treat/harm), with or without baseline 
information, could maximise understanding of risk and benefit information in MS 
patients? Second, what is the relationship between MS patients’ understanding when 
presented in these methods and patients’ conflict in treatment decisions? Additional 
exploratory questions attempted to address how patients’ numerical reasoning, health 
literacy, premorbid IQ and symptoms of MS could impact MS patients’ understanding of 
information communicated in different methods? 
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Hypotheses for the following study was derived from previous literature and were 
as follows: 
(v) Baseline information added to all methods will maximise understanding 
compared to methods without baseline information; 
(vi) Absolute risk reduction and absolute risk increase would maximise 
understanding in comparison to other methods, without baseline information; 
(vii) Numbers needed to treat and numbers needed to harm would result in the 
least understanding in comparison to other methods, without baseline 
information; 
(viii) Greater understanding of information will reduce decisional conflict in 
MS patients; 
(ix) Numerical reasoning will be positively related with understanding of 
information. 
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Figure 6.1 Theoretical framework 5: Factors affecting MS patients’ understanding of treatment 
risks and benefits 
Key: Black arrows, significant effect; Grey arrows, no relationship; Question, Untested factors; 
arrows do not signify causation 
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6.2 Experiment 3 methodology 
6.2.1 Participants 
All participants in the current experiment were the same as participants who had 
taken part in experiment 2. The inclusion and criteria also remained the same for these 
participants (see section 4.2.1). 
6.2.2 Materials and design 
This was a cross-sectional within-subject experiment designed to assess patients’ 
understanding and decisional conflict for different methods of communicating differences 
between two groups.  
One hypothetical disease was presented in the experiment, for which risk and 
benefit information was provided for two hypothetical treatments. The name and 
symptoms of the disease were new in the current experiment, but mimicked the 
progressive nature of MS, similar to experiments 1 and 2 (see appendix 17 for the 
hypothetical medical disease). Two hypothetical treatments were provided to patients for 
this hypothetical disease. Treatment names and the associated risks and benefits of the 
treatments were also new in the current experiment, but were checked by a small survey 
sample as discussed in Experiment 1 (see section 4.2.2). The risk-benefit profiles of the 
treatments were also similar to those provided to patients in Experiments 1 and 2 (i.e. one 
treatment offered high risks and high benefits, and the other treatment offered low risks 
and low benefits).   
All three methods of communicating differences between two groups (absolute 
terms, relative terms and numbers needed to treat or harm) were presented to patients, 
either with or without baseline information; hence, there was a total of six possible 
methods to communicate differences between the intervention and control group. 
Baseline information was provided in frequencies presented in the N-in-N*X ratio, which 
are shown to be the best format for presenting quantitative information to MS patients 
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(see chapters 1 and 2). The order of all six methods to communicate differences between 
groups was initially randomised across the two hypothetical treatments (see table 6.3). To 
further reduce any effects of order, the treatments were counterbalanced between patients. 
Each method either communicated differences between the intervention group or control 
group, for either the minor risk, adverse risk or benefit of the hypothetical treatment over 
1 year, 2 years and 5 years of taking the treatment (see appendix 18 for example of 
communication methods for one treatment).  
Table 6.3  Order of methods to communicate differences between groups in Experiment 3 
Treatment Outcome Method of communicating differences 
Treatment 1 Adverse risk Absolute risk– without baseline 
Treatment 1 Minor risk Numbers needed to harm – with baseline 
Treatment 1 Benefit Numbers needed to treat – without baseline 
Treatment 2 Adverse risk Relative risk – with baseline 
Treatment 2 Minor risk Relative risk – without baseline 
Treatment 2 Benefit Absolute risk – with baseline 
Treatment 1 was named Triptyte; Treatment 2 was named Frodytin 
 
The main outcome measures in the experiment were patients’ understanding and 
patients’ conflict in their treatment decisions. These measures were collected in the same 
way as Experiment 2. However, given the fewer number of methods that were compared 
in the current experiment, treatments only included one minor risk, one adverse risk and 
one benefit. Maximum score for each treatment outcome was 6 points and therefore total 
score for each treatment was 18 points. Maximum scores for understanding across both 
treatments was therefore 36 points (see appendix 18 for example of understanding 
questions). All other materials provided to patients throughout the experiment were the 
same as those used in Experiments 1 and 2, and include measures assessing: numerical 
reasoning, health literacy, premorbid IQ and the cognitive and affective symptoms of MS.  
Chapter 6 
200 
6.2.3 Procedure 
The procedure for recruiting interested patients from the two hospital clinics was 
the same as discussed in Experiment 1 (see section 4.2.3). Following consent, an 
appointment was made with patients to take part in the study. The study was conducted 
either at the clinics or at the patient’s home, depending on patients’ preference. The study 
took approximately 2 hours to complete and was conducted face-to-face using offline 
materials only. 
Initially, patients were presented with the visual acuity scale to ensure they were 
eligible to view the remaining study (see section 4.2.1). If eligible to continue, patients 
were asked demographic questions and assessed on the disability status scale.  Next, 
patient characteristics were measured in the following order: health literacy, numerical 
reasoning, depression and anxiety, fatigue and premorbid IQ. All patients were then 
shown information about one hypothetical chronic medical disease followed by two 
hypothetical treatments. Comprehension questions to assess understanding were provided 
after each treatment outcome. Patients were also required to make their treatment choice 
and complete the DCS measure after viewing both treatments. Finally, the BICAMS 
measure was conducted with patients at the end of the study. Note, however, that since 
this experiment was conducted alongside Experiment 2, all measures (aside from the 
main task) were only measured once. Both Experiment 2 and the current experiment were 
conducted in alternating order between patients. 
6.2.4 Sample size 
Sample size was calculated to detect an effect on MS patients’ understanding of 
treatment risks and benefits. The calculation was similar to that given in Experiment 1 
(see section 4.2.4) and required a minimum sample of 45 MS patients.  
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6.2.5 Statistical analysis 
All statistical analysis were carried out using SPSS 21. Means and standard 
deviations were provided for all continuous data. Maximum scores were also given for all 
measures in the experiment. A test of normality was conducted for the understanding 
outcome measure for each format using the Shapiro-Wilks test. The assumption of 
normality was significantly violated for all numerical ratios and framing (p<.001) and 
therefore a nonparametric Friedman analysis of variance was conducted. Where the 
Friedman test was significant, pairwise comparisons were conducted by using the 
nonparametric Wilcoxon Signed Ranks test. Bonferroni corrections were applied for 
multiple comparisons. Effect sizes are calculated for all pairwise comparisons by dividing 
the z score by the square root of total number of observations, based on Rosenthal’s 
formula (Rosenthal, 1994); where, 0.1, 0.3 and 0.5 equates to small, medium and large 
effect sizes, respectively. For the purpose of the analysis, several methods were 
sometimes collapsed into one average understanding score.  
A bivariate Pearson’s product moment correlation was further computed to assess 
the relationship between patient understanding and the standardised scores of the 
decisional conflict scale, including all subscales. Bivariate Pearson’s product-moment 
correlations were also computed to assess the relationship between understanding and raw 
scores on measures of numerical reasoning, health literacy, premorbid IQ and symptoms 
of MS. Due to multiple correlations, a stringent alpha of p<.01 was applied and accepted 
as significant. 
6.3 Results 
6.3.1 Patient demographics 
Since the present experiment contains the same sample as Experiment 2, all 
patient demographics were the same as those presented in Experiment 2 (see section 
5.3.1). 
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6.3.2 The effect of methods to communicate differences between groups on patients’ 
understanding  
There was a statistically significant difference in the methods to communicate 
clinical trial data (absolute terms, relative terms, numbers needed to treat/harm) on 
patients’ understanding, X2(2) = 39.688, p<.001. Pairwise comparisons were conducted to 
statistically compare the means for absolute terms (M=3.99, SD=.93), relative terms 
(M=2.93, SD=.91) and numbers needed to treat/harm (M=2.89, SD=.88). Understanding 
was greater for absolute terms compared to relative terms (z=-4.800, r=0.51, p<.001) and 
numbers needed to treat/harm (z=-5.058, r=0.53, p<.001). There was no significant 
difference between relative terms and numbers needed to treat/harm (z=--.620, p=.535). 
There was also a statistically significant difference between baseline added to all 
methods and no baseline information on all methods, X2(1) = 45.000, p<.001. According 
to mean scores, understanding was greater for baseline information on all methods 
(M=5.04, SD=.96) compared to no baseline information on all methods (M=1.49, 
SD=.74, z=-5.856, r=0.62). 
6.3.3 Patient understanding and decisional conflict  
A bivariate Pearson product-moment correlation showed no significant 
correlation between patients’ understanding and the total decisional conflict score. There 
were also no significant correlations between understanding of treatment information and 
any other DCS subscales (see table 6.4).  
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Table 6.4  Correlations between patient understanding and decisional conflict  
 Max score Mean SD Correlation 
Total understanding 36 19.62 4.22  
DCS informed 100 30.74 21.31 .100 
DCS values 100 33.52 24.07 -.344* 
DCS support 100 30.19 20.97 -.033 
DCS uncertainty 100 57.04 26.35 -.001 
DCS effective 100 60.56  33.40 -.163 
DCS total score 100 39.44  19.70. -.131 
* = indicates significance at the p<.05 level; ** at p<.01 level; *** at p<.001 level; DCS, 
Decisional conflict scale 
 
6.3.4 Patient understanding and patient characteristics  
Patients were assessed for numerical reasoning skills, health literacy, premorbid 
IQ and MS symptoms in the current experiment. The number of patients impaired on each 
of these measures are the same as discussed in Experiment 2 (see table 5.4). A bivariate 
Pearson product-moment correlation coefficient was computed to assess the relationship 
between treatment understanding scores and patient characteristics. Means, standard 
deviations and correlations for all factors are presented below (see table 6.5). 
There was a significant correlation between understanding of treatment 
information and numerical reasoning (r=.517, p<.001), premorbid IQ (r=.434, p<.001), 
information processing speed (r=.439, p<.01) and verbal memory (r= .409, p<.01). There 
was no significant relationship between understanding of treatment information with 
health literacy, anxiety, depression, fatigue and visual memory. 
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Table 6.5  Correlations between patient understanding and patient characteristics 
Patient characteristics Max score Mean SD Correlation 
Total understanding 36 19.62 4.22  
Numerical reasoning 25 16.36 3.80 .517*** 
Health literacy 8 7.42 1.32 .257 
Anxiety 21 6.27 3.98 -.348* 
Depression 21 4.11 3.69 -.257 
Fatigue 63 44.00 13.47 -.123 
Premorbid IQ 50 36.69 8.46 .434*** 
Information processing speed 110 56.62 12.62 .439** 
Verbal memory 80 49.07 12.43 .409** 
Visual memory 36 21.16  6.46 .287 
* = indicates significance at p<.05 level, ** at p<.01 level; *** at p<.001 level; correlations in 
bold accepted as significant due to multiple correlations 
 
6.4 Discussion 
The risk and benefit profiles of DMDs can be derived from clinical trials by 
comparing the risks and benefits patients experience when taking the DMD, with patients 
taking a placebo or an existing treatment (e.g. Braune et al., 2015; Chahin et al., 2015; 
Fogarty et al., 2016; Maruszczak et al., 2015; McFarland, 2009; Miller et al., 2014). Risk 
and benefit differences between groups in clinical trials should be effectively 
communicated to MS patients in order for patients to make informed decisions about 
DMDs. There are a number of methods that can be used to communicate differences 
between two groups such as those in clinical trials, including absolute terms, relative 
terms and numbers needed to treat or harm. The current experiment confirmed that 
certain methods to communicate group differences from clinical trials can impact MS 
patients’ understanding of treatment risk and benefit information.  
In support of our hypothesis, communicating differences using absolute terms 
significantly improved understanding of treatment information compared to relative terms 
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and numbers needed to treat irrespective of the baseline information. This is consistent 
with previous studies of non-clinical and clinical populations which found that 
individuals were more likely to make rational decisions (Covey, 2011; Hembroff et al., 
2004) and have greater understanding (Berry et al., 2006; Bodemer et al., 2014) of 
treatment information presented using absolute methods. The advantage of using absolute 
terms was particularly apparent in the absence of baseline information or when baseline 
information was provided using percentages (Berry et al., 2006; Bodemer et al., 2014). 
Given that Experiment 1 shows that percentages can often lead to errors in understanding 
by MS patients (see chapter 4), these findings suggest that absolute methods can be 
beneficial when baseline information is misunderstood or missing.  
MS patients showed the least understanding of treatment information presented in 
relative terms and numbers needed to treat or harm in the current experiment. One 
explanation for why MS patients may have had difficulty in understanding relative terms 
could be because MS patients may have misinterpreted the group differences expressed in 
relative terms as absolute differences. This was shown to be the case in a recent study 
carried out by Bodemer and colleagues (2014) with non-clinical populations. These 
misinterpretations are likely to lead to large errors in comprehension, considering that 
differences expressed in relative terms are substantially larger and more impressive than 
the same differences presented using absolute methods (Barratt et al., 2005). This also 
explains why many patients choose to take a medication when the benefits of a treatment 
derived from differences between two groups are expressed using the relative risk 
reduction method (Covey, 2007; Edwards & Elwyn, 2001; Fagerlin et al., 2011; Forrow 
et al., 1992; Malenka et al., 1993; Waldron et al., 2011). This is especially problematic 
for MS patients, given that relative terms are commonly employed to display DMD 
benefits to patients in current clinical practices within the UK (see appendix 11). 
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 Moreover, although the method of numbers needed to treat or harm has been 
recommended for use in healthcare due to its reciprocal nature with the absolute method 
(Barratt et al., 2005) and due to patients making conservative decisions for treatments 
with this method compared to relative terms (Waldron et al., 2011), studies with non-
clinical populations has also shown that individuals are not able to distinguish between 
treatments when expressed as numbers needed to treat (Kristiansen et al., 2002). One 
explanation is that numbers needed to treat is not appropriate for medications that cannot 
treat a disease but rather offer a delay in progression of the disease. This is true for DMDs 
which are not able to treat MS but can offer a delay in relapses and progression of 
disability (see section 1.2 for reviews about DMD benefits). Thus, in one study, when 
equivalent numerical data was provided to non-clinical populations by stating the delay in 
adverse effect rather than simply stating the numbers needed to treat, participants’ 
decision to choose a particular treatment was affected (Halvorsen et al., 2007). However, 
since this experiment did not assess participants’ understanding, it is not possible to 
determine whether MS patients’ understanding could be improved by changing numbers 
needed to treat to numbers needed to delay. Another explanation is that numbers needed 
to treat or harm is essentially written in the form 1-in-X which in itself is difficult to 
comprehend (Bodemer et al., 2014; Sheridan et al., 2003). Poor understanding of 
information presented using 1-in-X has been demonstrated by studies with non-clinical 
and clinical population groups, and was also shown in Experiment 2 (see chapter 5), 
further providing support to this explanation.  
The effect of baseline information on MS patients’ understanding was also 
explored in the current experiment. The presentation format of the baseline information 
was deliberately chosen as frequencies using the N-in-N*X ratio in light of findings from 
Experiments 1 and 2, and that of previous findings which show an effect on 
understanding of baseline information depending on different formats (Akl et al., 2011; 
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Ancker et al., 2009; Garcia-Retamero & Hoffrage, 2013; Knapp et al., 2009; Knapp et al., 
2015). In support of our hypothesis, the addition of baseline information with the 
different methods significantly improved understanding of treatment information in MS 
patients. Adding baseline information could be especially important when absolute terms 
are used to communicate differences between groups, since absolute risk differences can 
vary depending on the size of the original event rate. Therefore, to avoid presenting 
patients with misleading information when event rates differs between clinical trials, 
baseline information should ideally be included at all times. 
When understanding of medication information was compared with patients’ 
conflict about their treatment decision, no significant relationship was observed. These 
results mimic our previous experiment (see chapters 4 and 5). Thus according to the 
present experiment, improving patients’ understanding did not reliably reduce conflict 
patients experience in their treatment decision based on different methods of 
communicating differences. The symptoms of MS and individual characteristics of 
patients were also compared with treatment understanding scores in the present 
experiment. As hypothesised, numerical reasoning showed a significant positive 
relationship with understanding of treatment risk and benefit information. This is 
supported by previous studies of clinical and non-clinical populations which show a 
consistent advantage of higher numeracy on understanding the information about 
medications (Bodemer et al., 2014; Galesic & Garcia-Retamero, 2015; Peters, 2008). 
Interestingly, significant relationships were also observed with measures of premorbid 
IQ, information processing speed, verbal memory, depression, anxiety and fatigue. This 
indicates that patients with these characteristics are more susceptible to misunderstanding 
when differences between clinical trial groups are not communicated clearly. It is likely 
that when these differences are communicated using absolute terms with baseline 
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information, according to the findings from the current experiment, the most vulnerable 
patient groups will show improvements in understanding the treatment information. 
Although the present experiment adds to the pool of findings about the impact of 
different methods to communicate differences between groups, there are some limitations 
present. First, not all methods of communicating differences were explored in this 
experiment. For instance, the method designed to present numbers needed to delay an 
adverse effect proposed by Halvorsen et al (2007) was not assessed in the present 
experiment. However, given that this method also provides a similar 1-in-X ratio as 
provided in the numbers needed to treat method, it is unlikely that this method could have 
improved understanding of treatment information in MS patients based on the findings 
from Experiment 2. Second, understanding of treatment information when all methods 
were combined was not examined in the current experiment. However, a previous study 
that did combine these methods found no significant improvements in understanding of 
treatment risks and benefits (Perneger & Agoritsas, 2011). 
6.4.1 Conclusion 
Despite the limitations, findings from the current experiment indicate that 
methods to communicate differences between groups in a clinical trial can significantly 
influence MS patients’ understanding of treatment risks and benefits. The present 
findings also suggest that there is no relationship between patients’ objective 
understanding and their decisional conflict when treatment information from clinical 
trials are communicated using different methods. Having established these effects, the 
theoretical framework based on the literature review was updated (see figure 6.2). 
With the evidence obtained from this experiment, some recommendations may be 
made on ideal communication methods when providing DMD risks and benefits from 
clinical trials to MS patients. For instance, it is recommended that baseline information 
using frequencies be provided with any form of method. In addition, the differences of 
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risks or benefits from the intervention and control group from clinical trial information 
should be communicated using absolute terms. Relative terms and numbers needed to 
treat or harm should be avoided. Patients with poor numerical skills, poor IQ and 
cognitive impairments may further benefit from additional support when information is 
provided about clinical trial data.  
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Figure 6.2 Theoretical framework 6: Factors affecting MS patients’ understanding of treatment 
risks and benefits 
Key: Black arrows, significant effect; Grey arrows, no relationship; Question, Untested factors; 
arrows do not signify causation 
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Chapter 7: A crossover randomised controlled trial to 
evaluate the BRIMMS protocol  
 
7.1 Introduction 
Within patient-centred healthcare, it is recommended that treatment decisions 
between health professionals and patients be based on shared decision-making (see 
section 1.3 for review of shared decision-making). A prerequisite for effective shared 
decision-making is that patients are fully informed about all available treatment options 
and clearly understand the minor risks, adverse risks and benefits associated with the 
treatments (Barry & Edgman-Levitan, 2012; Charles et al., 1997, 1999; Godolphin, 
2009). However, there is evidence that MS patients do not satisfactorily understand the 
complex risk and benefit profiles of disease-modifying drugs (DMDs) they receive during 
standard healthcare; DMD risks are generally underestimated and DMD benefits are 
generally overestimated by MS patients (Reen et al., 2017). MS patients in the UK also 
report poor understanding of DMD risks and benefits (see chapter 3 for surveys with MS 
patients). Patients with poor numerical reasoning, low premorbid IQ and those displaying 
symptoms of cognitive impairments in MS are particularly susceptible to 
misunderstanding treatment risks and benefits (see Experiments 1, 2 and 3, and updated 
theoretical framework presented in figure 6.2). Misunderstanding treatment information 
can likely affect treatment decisions and lead to treatment discontinuation, as risks and 
benefits of the chosen DMD may not reflect preferred levels of risks and benefits patients 
are willing to take (Menzin et al., 2013; Vangeli et al., 2015). This may consequently 
affect adherence to treatments in MS, given that DMDs need to be administered for long 
durations to show reduction in progression of disease (see section 1.2 for review about 
DMDs). Thus, it is crucial that MS patients have greater understanding about the risks 
and benefits of DMDs when making treatment decisions during standard healthcare. 
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Interventions have been designed to improve MS patients’ understanding of 
DMD risks and benefits, and show moderate success (Reen et al., 2017a). However, the 
design and implementation of these interventions vary considerably between studies. In 
particular, the methods used to present treatment risk and benefit information differs 
between these interventions, and these are rarely incorporated with direct evidence from 
MS patients (Reen et al., 2017a). Given that the methods used to present treatment risks 
and benefits can significantly affect understanding in MS patients (see Experiments 1, 2 
and 3), interventions designed for MS patients should only present treatment information 
using methods that best support understanding in MS patients.  
7.1.1 Methods to improve MS patients’ understanding and reduce conflict in 
treatment decisions  
Experiments 1, 2 and 3 of the current thesis were designed to evaluate the best 
methods of presenting treatment risk and benefit information to MS patients in order to 
improve understanding. Experiment 1 showed that MS patients presented with treatment 
information in frequencies were better able to understand the information in comparison 
to information presented in percentages or verbal terms. Experiment 1 also demonstrated 
that presenting treatment information in bar charts or line graphs was able to improve MS 
patients’ understanding in comparison to pictographs or pie charts. In particular, 
information in horizontal bar charts was better understood compared with vertical bar 
charts. Findings from Experiment 2 showed that frequencies were better understood by 
MS patients when information was presented in the N-in-N*X ratio (e.g. 20 in 1000), 
instead of the 1-in-X ratio (e.g. 1 in 50). Experiment 3 found that MS patients were better 
able to understand the differences between two groups (i.e. differences between 
intervention and control group of a clinical trial) when communicated using absolute 
terms, in comparison to relative terms or numbers needed to treat or harm. These findings 
are shown in an integrated theoretical framework (see figure 6.2). 
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In short, these experiments were designed to find the best methods to present 
treatment risks and benefits to MS patients. It was expected that integrating the most 
effective methods of presenting treatment risk and benefit information into an 
intervention could maximise MS patients’ understanding of DMD risks and benefits. 
These experiments, however, did not show any relationship between patients’ 
understanding of treatment information presented in different formats and conflict in their 
treatment decisions. Despite this, several studies find that interventions providing 
treatment information to non-MS patients are able to both improve understanding and 
reduce decisional conflict (e.g. Arterburn et al., 2011; Evans et al., 2010; Nassar, Roberts, 
Raynes-Greenow, Barratt, & Peat, 2007; Wong, Thornton, Gbolade, & Bekker, 2006). 
Thus, it is conceivable that an intervention combining all effective presentation methods 
could also reduce MS patients’ conflict in treatment decisions. 
The current experiment was designed to evaluate an intervention to provide 
treatment risks and benefits to MS patients. Considering that MS patients primarily 
receive treatment information from neurologists and nurses (Bishop, Frain, Espinosa, & 
Stenhoff, 2009; Hepworth & Harrison, 2004; Marrie, Salter, Tyry, Fox, & Cutter, 2013; 
Matti, McCarl, Klaer, Keane, & Chen, 2010; Somerset, Campbell, Sharp, & Peters, 2001; 
see also MS patient surveys in chapter 3), the intervention was primarily designed for use 
in consultations by health professionals. For this reason, the current experiment sought to 
compare this intervention with standard consultations that MS patients currently receive 
using a randomised controlled trial with a crossover design. 
7.1.2 Randomised controlled trial with a crossover design 
A crossover design was employed in the current randomised controlled trial 
(RCT). A crossover design refers to a trial where every participant receives all possible 
conditions such that each participant serves as his/her own control (Wellek & Blettner, 
2012). For instance, after a participant receives the first condition (in period 1) and all 
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relevant outcome measures have been recorded, they are ‘crossed-over’ to the next 
condition (in period 2) until they have received all possible conditions (Wellek & 
Blettner, 2012). The randomisation then occurs for the order or sequence in which the 
conditions are given to each participant (Wang, Wang, & Gong, 2009; Wellek & Blettner, 
2012). For example, in a crossover study with an intervention condition and a control 
condition, all patients in the study would experience both the intervention and control 
conditions. However, the randomisation would occur for the sequence in which the 
interventions and control will be given: patients could be randomised to a sequence where 
the intervention is given first (period 1) followed by the control (period 2), or patients 
may be randomised to the sequence where the control is given first (period 1) followed by 
the intervention (period 2). This design can be referred to as a 2-condition 2-period design 
and is demonstrated by figure 7.1 below. To note, crossover designs can also consist of 
more than 2 conditions over more than 2 periods. 
 
Figure 7.1: Example of randomisation in 2-condition 2 -period crossover design 
 
 Crossover designs should only be applied in medical diseases where the first 
condition cannot completely change the disease course (for example, by curing the 
disease) prior to subsequent conditions. Thus, crossover designs are better suited to 
chronic medical diseases such as MS. In addition, any interaction between period and 
conditions, termed as the carry-over effect, must be minimised during the design of the 
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study or at least accounted for in the analysis to effectively use the crossover design 
(Senn, 2002). One way to prevent any carry-over effects is to ensure the gap between 
subsequent conditions is sufficient, such that one condition given to participants does not 
affect any subsequent conditions given to participants (Senn, 2002). Alternatively, all 
conditions should be kept as different as possible to all other conditions in the RCT 
(Senn, 2002). 
There are many reasons why a crossover trial is preferable to the most commonly 
used parallel group design RCT, in which participants are separated into independent 
groups and each group only receives one condition (Senn, 2002). First, confounding 
variables that occur between participants in a parallel group design are eliminated in a 
crossover design, as each participant receives all conditions (Senn, 2002; Wellek & 
Blettner, 2012). Because the error between participants is reduced, fewer number of 
observations are needed in a crossover design in order to achieve the same precision and 
statistical power as a parallel group design (Senn, 2002). For this reason, a fewer number 
of participants are needed in a crossover trial in order to obtain the same number of 
observations as a parallel group design (Senn, 2002; Wellek & Blettner, 2012).  
Given that the current experiment met the basic criteria of a crossover trial (i.e. 
chronic disease and minimal carry-over effects as different treatment information was 
used in each condition), and due to a limited number of MS patients available for 
recruitment, a crossover RCT was considered the most suitable design to compare the 
intervention with standard consultations.  
7.1.3 Research question and hypothesis 
A protocol for providing benefit and risk information for medication in Multiple 
Sclerosis (BRIMMS) was developed for the present experiment, to provide treatment 
risks and benefits using the best presentation methods based on findings from 
Experiments 1, 2 and 3. All presentation methods had been previously tested in a written 
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form, and thus a written BRIMMS protocol was developed. The BRIMMS protocol was 
then compared with medication information as presented in a standard consultation in the 
UK. Since standard consultations are usually conducted aurally with patients, the 
BRIMMS protocol was also designed for aural presentation to allow for direct 
comparisons between the aural standard consultation with the BRIMMS protocol. 
Further, in order to examine the efficacy of the BRIMMS protocol developed in a written 
format, a direct comparison was also made with a written version of a standard 
consultation.  
The current experiment addressed two main questions. First, could the BRIMMS 
protocol (either written or aural) improve patients’ understanding compared to standard 
consultations (either written or aural)? Second, could the BRIMMS protocol (either 
written or aural) reduce patients’ conflict in their treatment decisions compared to 
standard consultations (either written or aural)? Additional exploratory questions 
attempted to address how understanding was associated with patients’ numerical 
reasoning, health literacy, premorbid IQ and MS symptoms?  
The hypothesis from this study was derived from Experiments 1, 2 and 3 and the 
previously reviewed literature in this thesis, and were as follows: 
(i) The BRIMMS protocol (written and aural) would improve patients’ 
understanding of treatment risks and benefits compared to standard consultation (written 
and aural); 
(ii) The BRIMMS protocol (written and aural) would reduce patients’ conflict in 
treatment decisions compared to standard consultation (written and aural); 
(iii) The BRIMMS protocol (written and aural) would be positively rated 
compared to standard consultation (written and aural). 
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7.2 Experiment 4 methodology 
7.2.1 Participants 
A total of 24 RRMS patients were recruited in this experiment. All patients had 
not previously taken part in previous experiments of this thesis. The recruitment location, 
and inclusion and exclusion criteria for eligible patients were the same as those discussed 
elsewhere (see section 4.2.1).  
7.2.2 Materials and design 
The present experiment was a single-blinded crossover randomised controlled 
trial (RCT).  In total, four conditions were evaluated in the present experiment, defined by 
the four possible combinations of the factors ‘type of consultation’ (standard or 
BRIMMS) and ‘method of consultation’ (written or aural). Therefore, this was a 4-
condition 4-period design. This means that MS patients were assigned to all four 
conditions over four subsequent periods of time (see figure 7.1 for example of 
randomisation for 2-condition 2-period design). The sequences that determined the order 
in which MS patients received all four conditions were balanced by using Latin squares 
containing 4 sequences in each ‘square’. Latin squares are balanced in that every 
condition is represented in every period with the same frequency throughout the square, 
as each condition within a square is represented once in each column of the square and 
once in each row of the square (Senn, 2002). To balance the sequences even further in the 
present experiment, the Latin squares used for the crossover design had the property that 
every condition followed every other condition once in each square. Latin squares with 
these properties are also termed as Williams squares (Senn, 2002). In total, 6 William 
squares were used in the present experiment with 4 sequences in each set; i.e. all 24 
possible sequences were included in the present experiment (see appendix 19). 
All patients were allocated randomly to each of the 24 sequences in the 
experiment using a random sequence generator. Random allocation was conducted 
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independently by the supervisor (DL) who had no role in data collection. The random 
order was given to the data collector (GR) using sealed envelopes. The experiment was a 
single-blind study as patients were blind to both the condition they received and the order 
in which they received the conditions. 
Patients were presented with information about one hypothetical disease 
throughout the experiment. Similar to previous studies (see section 4.2.2), the disease was 
described as progressive and a list of symptoms were presented. A name was also 
provided for the hypothetical disease (see appendix 20 for disease information given to 
patients). Throughout the experiment, patients were presented with hypothetical 
treatments for the disease. Specifically, two minor risks, one adverse risk and one benefit 
was provided to patients for each hypothetical treatment. All hypothetical treatment risks 
(minor and adverse) and benefits mimicked DMD risk-benefit profiles as closely as 
possible, as previously done in Experiments 1, 2 and 3 (see section 4.2.2). To increase the 
validity of the experiment, all risks were feasible and could be associated with 
medications. The disease and treatment names were assigned by the experimenter, and 
the level of treatment risks were checked by a small survey sample prior to beginning the 
experiment, as discussed in Experiment 1 (see section 4.2.2). The treatment benefits were 
stated as the delay in progression of the hypothetical disease, which is similar to the 
benefits offered by all DMDs in MS. Levels of risks and benefits approximated those 
observed in MS DMDs. 
For the purpose of this experiment, a ‘set’ of two hypothetical treatments were 
always presented together. There were four sets in total, each with two different 
treatments. In order to decide the set of treatments that would be presented in each 
consultation (i.e. BRIMMS written, BRIMMS aural, standard written and standard aural), 
the order of sets was randomised for all 24 sequences prior to beginning the experiment. 
That is, treatments in one set could be given to patients for either of the BRIMMS 
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protocol or either of the standard consultations. The order that each treatment will be 
presented within the set was further randomised. What remained common between sets 
was that one medication always presented patients with high risks and high benefits, 
whereas the other treatment yielded low risks but in return for lower benefits. These 
different risk-benefit profiles were chosen to mimic the choices that may be faced by 
some MS patients during treatment decision-making: choosing between a first-line DMD 
(low risk and low benefit), or second-line DMD (high risk and high benefit) (see section 
1.2 for review about DMDs). After presentation of each set, patients were asked to make 
a treatment decision (i.e. either choose one of the two hypothetical treatments, choose 
neither option, or state that they were unsure). Since all patients were presented with all 
four sets of treatments, patients were required to make four different treatment decisions.  
7.2.2.1 BRIMMS protocol 
The intervention given to MS patients in the current RCT was the BRIMMS 
protocol. This protocol was developed by combining the best methods of presenting 
treatment information based on findings from Experiments 1 to 3, as presented in a 
theoretical framework (see figure 6.2). 
The content of the intervention mimicked real DMD information as closely as 
possible. MS patients were presented with risks and benefit information for two 
hypothetical treatments, based on the set that was assigned to the BRIMMS consultation. 
Treatments were always presented in the order of benefits of taking the drug, minor risks 
of taking the drug and adverse risks of taking the drug. To further mimic real DMD 
information, all risks and benefits were provided for both short-term (1 year and 2 year) 
and long-term (5 years) outcomes. A hypothetical clinical trial scenario was provided to 
patients to communicate the treatment benefits, and patients were provided with 
differences between the intervention group (taking a treatment) and a placebo group 
(taking no treatment) from this clinical trial. This was done to mimic the manner in which 
Chapter 7 
220 
DMD benefit information is provided to patients during standard healthcare. Although 
real DMD clinical trials also increasingly compare the intervention group taking the 
treatment with patients taking other active DMDs as the control condition, only the 
placebo group was used as a control group in the BRIMMS protocol for simplicity. Both 
minor risks and adverse risks were derived from only the intervention group of the 
clinical trial, which is how risks are commonly provided to patients during standard 
healthcare. 
The following methods were used to present risks and benefits of treatments to 
MS patients in the BRIMMS protocol, based on earlier findings. All quantitative 
information was presented using frequencies only (see Experiment 1). The frequencies 
were presented in the form of N-in-N*X ratio, by keeping the denominator constant and 
only changing the numerator as necessary to represent the benefits or risks (e.g. 20 out of 
1000 get benefits, 50 out of 1000 get risks etc.) (see Experiment 2).  All quantitative 
information was further represented using horizontal bar charts, with numbers added to 
all charts (see Experiment 1). To provide treatment benefits, absolute terms were used to 
communicate differences between the intervention group and control group from a 
hypothetical clinical trial (see Experiment 3). Baseline information was further added to 
the absolute method of communicating differences between groups (see Experiment 3).  
The BRIMMS protocol was provided to patients both aurally (all information was 
read aloud and only graphs were shown to patients in the written form) and written (all 
information was given to patients in writing as well as being read aloud) (see appendix 21 
for example of the BRIMMS protocol for one hypothetical treatment). 
7.2.2.2 Standard consultation 
The control group in the present experiment received treatment risks and benefits 
in a standard consultation style. An approximation to a standard consultation was 
developed by speaking to MS Nurses at Lewisham and Greenwich NHS Trust and King’s 
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College NHS Trust about how DMD risk and benefit information is presented to patients 
during consultations. With this information, a preliminary standard consultation was 
developed and reviewed by another MS nurse. With agreement from the MS nurse, a final 
standard consultation format was developed.  
Only the method of presenting treatment information differed in this consultation 
compared to the BRIMMS protocol. The minor and adverse risks of treatments were 
presented using a combination of verbal terms and 1-in-X frequencies, which are 
recommended for use by EC guidelines (EC Guidelines, 2009). The differences between 
the intervention and placebo groups of clinical trials were communicated using relative 
terms, presented in percentages. No graphical formats were provided with the quantitative 
information. 
Similar to the BRIMMS protocol, the standard consultation was presented to 
patients both aurally (all information was read aloud to patients) and the written form (all 
information was given to patients in writing as well as being read aloud) (see appendix 22 
for example of the standard consultation for one hypothetical treatment). 
7.2.2.3 Outcome measures and assessments to measure patient characteristics 
The main outcome measures in the current experiment were patients’ 
understanding of the treatment risks (minor and adverse) and benefits, and patients’ 
conflict in their treatment decisions. Patients’ feedback on all consultations was also 
recorded in the experiment. Patient characteristics were also recorded in the present RCT.  
Patient understanding 
Understanding of treatment risk and benefit information was assessed by asking 
comprehension questions directly after presenting benefits or risks of medications. 
Questions for treatment risks were similar to the questions employed in Experiment 1. All 
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questions for treatment benefits also included the additional questions, as discussed in 
Experiments 2 and 3 (see section 5.2.2). 
In total, patients could score a maximum of 15 points for each treatment, as 15 
comprehension questions were provided for each treatment (i.e. 6 questions for treatment 
benefits after 1 year, 2 years and 5 years, 3 questions each for the two treatment minor 
risks after 1 year, 2 years and 5 years, and 3 questions for adverse risks of the treatment 
after 1 years, 2 years and 5 years).  The maximum score for each set of treatments was 
therefore 30 points. 
Decisional conflict 
Following presentation of one set of treatments (i.e. two hypothetical treatments), 
patients were required to either choose between the two treatments, choose neither of the 
treatments or state that they were unsure. Patients’ conflict in their decision was measured 
using the Decisional Conflict Scale (DCS) as described in previous experiments (see 
section 4.2.2.2).  
Patient feedback 
In addition to the main outcome measures, patients’ feedback for the BRIMMS 
protocol and standard consultation was recorded by collecting a Likert scale rating 
(ranging from 0 to 10) on three measures: perceived understanding, perceived satisfaction 
and perceived preference for each consultation. A score of 0 on the scale meant a 
negative rating and a score of 10 meant a positive rating. 
Patient characteristics 
The current experiment also recorded MS patients’ characteristics, specifically: 
patient demographics, numerical reasoning, health literacy, premorbid IQ and symptoms 
of MS (fatigue, anxiety, depression, verbal memory, visual memory and information-
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processing speed). All assessments to record these characteristics have been previously 
discussed elsewhere (see section 4.2.2.3). 
7.2.3 Procedure 
The procedure to recruit eligible MS patients for the experiment was the same as 
those described previously (see section 4.2.3). However, new information sheets and 
consent forms were provided for this experiment (see appendix 23). Prior to obtaining 
consent, patients were informed that the experiment was designed to assess which ways 
of providing treatment information is the most effective at improving understanding of 
treatment information. Following consent, all patients were tested either at patients’ home 
or clinics. The experiment took approximately 2 hours and 30 minutes to conduct. Each 
consultation took approximately 20 minutes to administer to patients, but could take up to 
30 minutes for some individuals. 
Initially, patients were presented with the visual acuity scale to ensure they were 
eligible to view the remaining experiment. If eligible to continue, patients were asked 
demographic questions and assessed on the disability status scale at the start of the 
experiment. Patients were then presented with the hypothetical disease that had four 
major symptoms (see appendix 20 for hypothetical disease given to patients). The 
medical disease was read aloud to patients at the beginning of the experiment and was 
also provided in a written form for patients to refer back to throughout the experiment. 
Following this, the researcher referred to the sealed envelope to determine the order in 
which the BRIMMS protocol and the standard consultation would be presented to the 
patient. The order of the sets and treatments within the set were also specified in the 
sealed envelope. At the beginning of either the intervention or control conditions, patients 
were asked to imagine being at the stage of their disease where only two treatments were 
available for them to take. MS patients were then told that the purpose of the session was 
for them to make a decision about whether they would choose to take any of the 
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treatments for the hypothetical disease. Patients did not receive any specific information 
about the parameters of formats being evaluated, or which condition was the standard 
consultation and which was a new presentation style. Patients were also blinded to the 
order in which they received the conditions.  
Patients were administered comprehension questions immediately after 
presentation of each treatment minor risk, adverse risk and benefit. After presentation of 
both treatments within the RCT condition, patients were asked to make a treatment 
decision and conflict in their decision was assessed using the DCS. Following 
administration of the DCS, patients were presented with the three feedback questions. To 
ensure that no carry-over effects were introduced, patients were given the next RCT 
condition after a break of 10 minutes. During this break, patients were given tasks to 
assess patient characteristics, namely: numerical reasoning, health literacy, premorbid IQ, 
fatigue, mood and cognitive impairments. To ensure that no tasks systematically affected 
subsequent conditions, the same tasks were presented immediately after each condition 
(see table 7.1 for the order of tasks presented after each condition). For example, 
immediately after the BRIMMS protocol aural, patients were given the SDMT task 
(which assesses information processing speed) and WTAR task (which assesses 
premorbid IQ), in that order. Therefore, if one task was able to improve understanding of 
subsequent conditions, the use of a balanced William’s square design would mean that all 
conditions would benefit from such an advantage. 
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Table 7.1 Order of tasks to assess patient characteristics after each condition 
RCT condition Tasks Patient characteristics assessed 
BRIMMS protocol aural 
SDMT Information processing speed 
WTAR Premorbid IQ 
BRIMMS protocol written 
CVLT Verbal memory 
BVMTR Visual memory 
Standard consultation aural VESPAR Numerical reasoning 
Standard consultation written 
REALM-R Health literacy 
FSS Fatigue 
HADS Anxiety and depression 
BVMTR, Brief visuospatial memory test revised; CVLT, California verbal earning test-II recall 
trials; FSS, Fatigue severity scale, HADS, Hospital anxiety and depression scale; RCT, 
randomised controlled trial; REALM-R, Rapid estimate of adult literacy in medicine – revised; 
SDMT; Symbol digit modalities test; VESPAR, Verbal and spatial reasoning task; WTAR, 
Wechsler test of adult reading  
 
7.2.4 Sample Size 
Sample size estimates were based on power calculations for detecting a 0.7 effect 
size on the DCS outcome measure following the intervention, based on previous RCT 
studies for interventions designed to improve patients’ decisions of treatments 
(Montgomery, Fahey, & Peters, 2003; Murray et al., 2001; Protheroe, Bower, Chew-
Graham, Peters, & Fahey, 2007). It was estimated that for an alpha of 0.05 and power of 
0.80 (roughly equivalent to the ‘fair’ precision level as stated by Senn (2002)), at least 22 
MS patients were required in the current experiment. Since patients had to be balanced 
across all possible sequences of the Williams square (see appendix 19), a sample of 24 
MS patients were needed for the present crossover RCT. 
7.2.5 Statistical analysis 
All statistical analyses were carried out using SPSS 21. Means and standard 
deviations were provided for all continuous data. Maximum scores were also presented 
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for all measures in the experiment. Assumptions of parametric analysis were first tested 
for all outcome measures. A test of normality was conducted for the outcome measure of 
patients’ understanding using the Schapiro-Wilks test. The assumption of normality was 
significantly violated (p<.001) and therefore a nonparametric Friedman two-way analysis 
of variance was conducted. Where the Friedman test was significant, pairwise 
comparisons were conducted by using the nonparametric Wilcoxon Signed Ranks test. 
Bonferroni corrections were applied for multiple comparisons. Effect sizes are calculated 
for all pairwise comparisons by dividing the z score by the square root of total number of 
observations, based on Rosenthal’s formula (Rosenthal, 1994); where, 0.1, 0.3 and 0.5 
equates to small, medium and large effect sizes, respectively. 
A second test of normality was conducted for the outcome measure of patients’ 
decisional conflict, as measured by the DCS measure, using the Schapiro-Wilks test. The 
assumption of normality was not violated (p>.05). The assumption of sphericity was 
tested using the Mauchly’s Test of Sphericity and was also not violated (p>.05). It was 
therefore deemed appropriate to conduct a one-way repeated measures ANOVA to 
analyse the effects of consultations on patients’ decisional conflict. Pairwise comparisons 
were conducted and Bonferroni corrections were applied for multiple comparisons. 
Standardised DCS scores were used for the purpose of this analysis, as recommended by 
the authors of the assessment (O’connor, 1995).  
A third test of normality was conducted for the outcome measure of patients’ 
feedback scores using the Shapiro-Wilks test. The assumption of normality was not 
violated (p>.05). The assumption of sphericity was tested using the Mauchly’s Test of 
Sphericity and was violated (p<.05). Therefore, a Greenhouse-Geisser correction was 
applied when interpreting the analysis. A one-way repeated measures ANOVA was 
conducted. Pairwise comparisons were conducted and Bonferroni correction was applied 
to correct for multiple comparisons. Patients’ feedback scores were obtained by averaging 
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patient ratings on the measures of perceived understanding, perceived satisfaction and 
perceived preference. 
Bivariate Pearson’s product-moment correlations were also computed to assess 
the relationship between understanding of each of the conditions with raw scores on 
measures of numerical reasoning, health literacy, premorbid IQ and symptoms of MS. 
Correlations were conducted with all conditions to assess whether patients’ numerical 
reasoning, health literacy, premorbid IQ and MS symptoms could predict how well 
patients understood the treatment information across the four different conditions. It was 
expected that a ‘good’ condition would increase understanding of treatment information 
irrespective of numerical reasoning, health literacy, premorbid IQ and MS symptoms, and 
a ‘bad’ condition will increase understanding in only some patients. Due to multiple 
correlations, a stringent alpha of p<.01 was applied and accepted as significant. 
7.3 Results 
7.3.1 Patient demographics 
A total of 24 patients were analysed in the RCT, with no dropouts or missing 
data. Patient demographics is displayed in Table 7.2. 
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Table 7.2 Patient demographics and disease status for RCT (n=24) 
 Mean (SD) n (%) 
Age, years 42.59 (8.63)  
Gender   
Female  21 (87.5) 
Male  3 (12.5) 
Level of education   
High school  7 (29.2) 
College   5 (20.8) 
Bachelor’s degree  7 (29.2) 
Postgraduate  5 (20.8) 
Employment status   
Full-time (>16 hours)  11 (45.8) 
Part-time (<16 hours)  7 (29.2) 
Self-employed  0 (0) 
Unemployed  2 (8.3) 
Medical leave  4 (16.7) 
             Retired  0 (0) 
Time since MS diagnosis, years 7.88 (4.63)  
HAI disability scale 1.17 (1.34)  
Current DMD   
Interferon betas  8 (33.3) 
Glatiramer Acetate  1 (4.2) 
Teriflunomide  0 (0) 
Fingolimod  7 (29.2) 
Alemtuzumab  1 (4.2) 
Dimethyl Fumarate  3 (12.5) 
Natalizumab  4 (16.7) 
Mitoxantrone  0 (0) 
DMD= disease-modifying drugs; HAI = Hauser Ambulation Index (65) 
* Score of 1 on HAI scale = Able to walk normally but report fatigue interfering with athletic 
activities 
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7.3.2 The effect of BRIMMS protocol and standard consultation on patients’ 
understanding 
There was a significant effect of consultations (BRIMMS written, BRIMMS aural, 
standard written, standard aural) on patients’ understanding, X2(3) = 63.436, p<.001. 
Pairwise comparisons revealed that understanding was greatest for BRIMMS written, 
compared to BRIMMS aural (p<.001, r=0.56), standard written (p<.001, r=0.62) and 
standard aural (p<.001, r=0.62). Understanding was also greater for BRIMMS aural when 
compared to standard written (p<.001, r=0.62) and standard aural (p<.001, r=0.62). There 
was no difference between understanding for standard consultation aural and standard 
consultation written (p=0.985). Mean scores for patients’ understanding on all conditions 
are presented below (see table 7.3). Higher mean scores indicate greater understanding of 
treatment information. 
Table 7.3  Mean scores for patient understanding across all conditions 
Conditions Max 
score 
Mean (SD) Confidence interval (95%) 
BRIMMS protocol written 30 27.79 (2.41) 26.77 – 28.81 
BRIMMS protocol aural 30 24.88 (2.94) 23.63 – 26.12 
Standard consultation written 30 3.71 (2.29) 2.74 – 4.68 
Standard consultation aural 30 3.71 (2.96) 2.46 – 4.96 
BRIMMS, Benefit and risk information for medication in Multiple Sclerosis 
 
7.3.3 The effect of BRIMMS protocol and standard consultation on decisional 
conflict 
There was a significant effect of conditions (BRIMMS aural, BRIMMS written, 
standard aural, standard written) on patients’ decisional conflict, F(3,69) = 75.109, 
p<0.001, partial η2=.87. Pairwise comparisons revealed that conflict in decisions were 
reduced the most for the BRIMMS written protocol, compared to standard written 
(p<.001) and standard aural (p<.001). Decisional conflict was also reduced the most for 
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BRIMMS aural compared to standard written (p<.001) and standard aural (p<.001). There 
was no difference in decisional conflict for standard written compared to standard aural 
(p=.216). There was no difference between decisional conflict for patients presented 
either the BRIMMS written or BRIMMS aural protocol (p=1.00). Mean scores for 
patients’ decisional conflict for all conditions are presented below (see table 7.4). Lower 
mean scores indicate reduced decisional conflict. 
Table 7.4  Mean scores for decisional conflict across all conditions 
Conditions Max 
score 
Mean (SD) Confidence interval 
(95%) 
BRIMMS protocol written 100 26.17 (8.06) 22.77 – 29.58 
BRIMMS protocol aural 100 25.78 (7.98) 22.41 – 29.15 
Standard consultation written 100 47.61 (11.97) 42.60 – 52.71 
Standard consultation aural 100 52.80 (10.43) 48.40 – 57.20 
BRIMMS, Benefit and risk information for medication in Multiple Sclerosis; DCS, Decisional 
conflict scale 
 
7.3.4 Patients’ feedback on BRIMMS protocol and standard consultation 
A one-way repeated measures ANOVA found a significant main effect of 
condition on patients’ feedback scores, F(1.27, 29.24) = 111.835, p<0.001. Pairwise 
comparisons revealed that BRIMMS written was rated more positively by patients 
compared to BRIMMS aural (p<.001), standard written (p<.001) and standard aural 
(p<.001). More positive ratings were also given for BRIMMS aural when compared to 
standard written (p<.001) and standard aural (p<.001). There was no difference between 
patients’ feedback for standard written and standard aural (p<.01). Mean scores for 
patient feedback on all conditions are presented below (see table 7.5). 
 
 
Chapter 7 
231 
Table 7.5  Mean scores for patient feedback across all conditions 
Conditions Max 
score 
Mean (SD) Confidence interval 
(95%) 
BRIMMS protocol written 10 8.63 (.89) 8.25 – 9.00 
BRIMMS protocol aural 10 7.92 (.97) 7.51 – 8.33 
Standard consultation written 10 3.78 (2.06) 2.91 – 4.65 
Standard consultation aural 10 3.26 (1.91) 2.46 – 4.07 
BRIMMS, Benefit and risk information for medication in Multiple Sclerosis 
 
7.3.5 Patient understanding and patient characteristics  
Patients were assessed for numerical reasoning skills, health literacy, premorbid 
IQ and MS symptoms in the current experiment. As shown in table 7.6, MS patients in 
the current experiment mostly showed symptoms of anxiety, fatigue and cognitive 
impairments. Mean scores for all measures assessing patient characteristics are presented 
in table 7.7. Mean scores show that patients on average had high literacy and scored high 
on fatigue, whereas other patient characteristics showed greater variability between 
patients.  
Table 7.6  Patients impaired on assessments of numerical reasoning, health literacy, 
premorbid IQ and MS symptoms (n=24) 
Patient characteristics and MS symptoms n (%) 
Health literacy 2 (8.3) 
Numerical reasoning 1 (4.2) 
Depression 4 (16.7) 
Anxiety 5 (33.3) 
Fatigue 13 (54.2) 
Premorbid IQ 1 (4.2) 
Information processing speed 0 (0) 
Verbal memory 7 (29.2) 
Visual memory 10 (41.7) 
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Table 7.7  Maximum and mean scores for assessments measuring patient characteristics 
Patient characteristics and MS symptoms Max score Mean SD 
Numerical reasoning 25 16.63 3.00 
Literacy 8 7.79 .59 
Anxiety 21 6.88 4.20 
Depression 21 5.38 4.45 
Fatigue 63 44.71 12.84 
Premorbid IQ 50 35.83 8.02 
Information processing speed 110 63.79 6.72 
Verbal memory 80 49.58 9.82 
Visual memory 36 22.04 6.08 
 
Bivariate product Pearson correlations were computed for all conditions to assess 
whether patients’ numerical reasoning, health literacy, premorbid IQ and MS symptoms 
could predict how well patients understood the treatment information across the four 
different conditions. It was expected that the BRIMMS protocol written and aural (the 
conditions with the best understanding) would increase understanding of treatment 
information irrespective of numerical reasoning, health literacy, premorbid IQ and MS 
symptoms. 
Only two patient characteristics were correlated with understanding scores in 
BRIMMS protocol written: health literacy (r=.519, p<.01) and depression (r=-.539, 
p<.01) (see table 7.8). Three patient characteristics were correlated with understanding 
scores in the BRIMMS protocol aural: anxiety (r=.596, p<.01), depression (r=.674, 
p<.01) and verbal memory (r=.549, p<.01). In addition, correlation for treatment 
understanding score on standard consultation written and patient characteristics revealed 
significant correlations for numerical reasoning (r=.564, p<.01), premorbid IQ (r=.543, 
p<.01), information processing-speed (r=.558, p<.01) and verbal memory (r=.585, p<.01). 
Similarly, correlations for treatment understanding score on standard consultation aural 
Chapter 7 
233 
revealed significant correlations for numerical reasoning (r=.550, p<.01), premorbid IQ 
(r=.504, p<.01), information processing-speed (r=.590, p<.01) and verbal memory 
(r=.647, p<.01). 
Table 7.8  Correlations between patient understanding and patient characteristics across all 
conditions 
 Understanding scores 
Assessment scores BRIMMS 
written 
BRIMMS 
aural 
Standard 
written 
Standard 
aural 
Numerical reasoning .391 .359 .564** .550** 
Health literacy .519** .362 .469* .414* 
Anxiety -.328 -.596** -.450* -.300 
Depression -.539** -.674** -.453* -.299 
Fatigue -.117 -.493* -.338 .007 
Premorbid IQ .385 .422* .543** .504** 
Info processing speed .335 .432* .558** .590** 
Verbal memory .302 .549** .585** .647** 
Visual memory .116 .363 .216 .378 
* = indicates significance at p<.05 level; ** at p<.01 level; correlations in bold accepted as 
significant due to multiple correlations; BRIMMS, Benefit and risk information for medication in 
Multiple Sclerosis; Info, information 
 
7.4 Discussion 
Patients should accurately understand the risks and benefits of treatments in order 
to make informed treatment decisions in a shared decision-making context (Colligan, 
Metzler, & Tiryaki, 2016; Godolphin, 2009). However, MS patients do not satisfactorily 
understand the risks and benefits of DMDs presented during standard healthcare (Reen et 
al., 2017). Previous experiments in this thesis have shown that MS patients’ 
understanding can be affected by methods used to present treatment information (see 
chapters 4-6). A BRIMMS protocol was designed in the current experiment to combine 
the best methods of presenting medication risk and benefit information based on findings 
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from Experiments 1 to 3. This protocol was developed in both a written form and as an 
aural presentation. The efficacy of this protocol on patients’ understanding and conflict in 
their treatment decisions was evaluated using a crossover RCT by comparing this to 
standard methods of providing treatment information during consultations. All 
requirements for an effective crossover design were met: testing was conducted in 
patients with a chronic disease, and carryover effects were minimised by providing a 10-
minute break before each condition, as well as employing completely different treatments 
with different levels of risks and benefits for each condition presented to the same patient.  
As predicted, the BRIMMS protocol presented either in written form or presented 
aurally greatly improved MS patients’ understanding of treatment risks and benefits 
compared to treatment information provided during standard consultations. These results 
further support the evidence that patients show poor understanding when treatment 
information is presented during standard healthcare (Reen et al., 2017), and that effective 
presentation methods, as directly tested with MS patients, have the potential to improve 
the way MS patients understand the risks and benefits of DMDs (see chapters 4-6 and 
figure 6.2). Interestingly, the written BRIMMS protocol was considerably better at 
improving MS patients’ understanding of treatment information than the BRIMMS 
protocol presented aurally. One reason for this effect may be because the BRIMMS 
protocol was designed based on the best written presentation methods from previous 
experiments, which may not have been the best aural presentation methods for providing 
treatment information. Therefore, additional studies should be conducted with MS 
patients to assess the best aural presentation methods for providing treatment information.  
Nevertheless, both BRIMMS protocols greatly improved MS patients’ 
understanding of treatment information, which can have several benefits for MS patients. 
Implementing the BRIMMS protocol in consultations could improve shared decision-
making by ensuring that patients only choose treatments with the level of risks and 
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benefits that patients would prefer. This is important considering that MS patients’ 
preferences play a large role in their decision to choose a treatment (Reen et al., 2017). 
Treatment decisions based on patient preferences can also likely improve adherence to 
treatment, as patients will have realistic expectations for the risks and benefits of 
treatments. Increased adherence to DMDs can lead to better clinical outcomes for MS 
patients, especially since DMDs need to be adhered to for long periods of time to 
effectively delay the progression of disease (Halpern et al., 2011; Steinberg et al., 2010; 
Tan et al., 2011; Winkelmann et al., 2016). 
In addition to patient understanding, the BRIMMS protocol in both written and 
aural form showed significant reductions in patients’ conflict in the treatment decisions 
made in this experiment, in comparison to treatment information presented using standard 
method of consultations. This is consistent with interventions that have been designed to 
improve decision-making for non-MS clinical patients (Montgomery et al., 2003; Murray 
et al., 2001; Protheroe et al., 2007). Therefore, the current results suggest that patients 
presented with the BRIMMS protocol were able to make treatment decisions based on 
personal preferences of treatment risks and benefits, and were thus more confident in 
their decisions. Although it is reasonable to expect that an intervention that could improve 
patients’ understanding about treatment options would also reduce conflict in their choice 
for one of those options, it should be noted that Experiments 1 to 3 found no correlations 
between patients’ understanding of treatment information and reduction in decisional 
conflict (see chapters 4 to 6). This indicates that the BRIMMS protocol may have reduced 
decisional conflict due to some additional reasons which were not necessarily related with 
improvements in understanding. Given that the BRIMMS protocol is a complex 
intervention, it was not possible to isolate the specific components to determine which 
aspect of the protocol could have reduced patients’ decisional conflict.  
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Patients’ feedback for all conditions was also recorded in the present RCT. 
Patients significantly favoured the BRIMMS protocol in both written and aural forms 
compared to information provided in standard consultations; patients reported that they 
better understood the treatment information, were better satisfied with the presentation of 
information and strongly preferred the BRIMMS protocol in comparison to standard 
consultations. In addition, patients rated the written form of the BRIMMS protocol more 
favourably than the BRIMS in aural form. 
Patients’ understanding scores on all conditions were also correlated with patient 
characteristics in this experiment. It was expected that a good intervention would be able 
to improve patients’ understanding irrespective of factors such as poor numerical 
reasoning, poor health literacy or impairments in information processing speed, verbal 
memory and visual memory. This was mostly found to be the case for the written 
BRIMMS protocol which showed the greatest improvements in understanding; 
understanding was improved irrespective of patients’ numerical reasoning skills, levels of 
anxiety and fatigue, premorbid IQ, information processing speed, verbal memory skills 
and visual memory skills. Only health literacy and depression predicted understanding of 
the BRIMMS written protocol. Whereas, patients who experienced high anxiety, were 
more depressed or had poor verbal memory, had poorer understanding on the BRIMMS 
aural protocol. For those given the standard consultations, patients with poor numerical 
reasoning, low premorbid IQ, impaired information processing speed or poor verbal 
memory were predicted to have poor understanding. Thus, the BRIMMS written protocol 
helped improve understanding despite the presence of these patient characteristics which 
predicted (and probably affected) understanding in other conditions. However, there is 
still room for improvement. The BRIMMS written protocol should be adapted so that 
understanding improves even when patients have poor health literacy and are highly 
depressed.  
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Previous interventions designed to improve MS patients’ understanding of 
treatment risks and benefits have shown moderate success; interventions show 
improvements in accuracy of treatment risks but overestimation of DMD benefits persists 
following interventions (Reen et al., 2017a). Several interventions also present treatment 
information using methods that have not been previously tested for efficacy with MS 
patients. Moreover, many interventions are designed to be implemented beyond 
consultations (Reen et al., 2017a) despite consultations with health professionals being 
the most common source of receiving information about treatments (see MS patients 
survey in Chapter 3). Additionally, only one intervention with MS patients has examined 
whether understanding could be improved for patients with symptoms that could likely 
confound patient understanding of treatment information (Basso et al., 2010). The current 
intervention thus addresses all these issues: BRIMMS written and aural protocol shows 
improvements in understanding of treatment risks and benefits combined, can be 
implemented in consultations by health professionals and shows improvements in 
understanding regardless of several patient characteristics that may confound 
understanding of treatment information.  
Despite the benefit of the BRIMMS protocol, the findings should be interpreted 
with caution due to a number of limitations. First, the experimenter was not blinded in the 
current RCT. This could have indirectly affected how the BRIMMS protocol and standard 
consultations were presented to MS patients during the experiment or how the 
comprehension questions were scored. Secondly, treatment information across all 
conditions were provided by a non-clinical experimenter. Patients may interact differently 
when treatment information is presented by health professionals in real consultations. 
Health professionals are also likely to adapt the treatment information to patients’ needs 
when providing treatment information during real consultations, or engage in questions 
and answers with patients during consultations. However, interventions that have been 
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designed with an interactive component for MS patients do not seem to affect 
understanding differently to more passive interventions (Reen et al., 2017a). Third, 
although best efforts were made to ensure that the standard consultation in the current 
experiment reflected consultations provided to MS patients within the UK, it is likely that 
current consultations in the UK vary between each session with patients and between 
health professionals. In addition, patients in the current experiment were required to 
answer comprehension questions directly after presentation of treatment risks or benefits 
which is not common practise during standard consultations. In fact, performance on 
these questions could have been affected by poor memory rather than poor understanding. 
To minimise the effects of forgetting however, patients in this experiment were given 
comprehension questions immediately after presentation of one treatment outcome. 
Finally, patients had no prior knowledge about the hypothetical treatments presented in 
the current RCT. Yet, many MS patients report searching for treatment information prior 
to discussing this with health professionals during consultations (see MS patient surveys 
in chapter 3). This may positively or negatively affect patients’ understanding of 
treatment information during real consultations.   
It is also important to acknowledge the applicability of the BRIMMS intervention 
for administration during real consultations with patients. The BRIMMS intervention in 
the current study took approximately 20 minutes to administer, but could take up to 30 
minutes for some individuals. However, time availability for patients during real 
consultations is dictated by the pre-defined slots available for patients and other external 
factors that may occur during clinic visits (e.g. previous consultations that have overrun, 
availability of staff), which could impact the time available during a consultation to 
administer the BRIMMS intervention to patients. In addition, patients are likely to talk 
about specific information needs, personal preferences associated with treatments and 
emotions about the decision-making process during a real consultation, which can further 
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influence the duration of consultations with health professionals. Moreover, patients are 
likely to have multiple consultations during the decision-making process, often making 
decisions alongside families and carers. All these factors need to be taken into account 
when considering the application of the BRIMMS intervention during consultations in 
real clinics. 
There are a number of ways that the applicability of the BRIMMS protocol in 
real clinics could be improved. First, the length of the BRIMMS protocol in the current 
study was similar to that of the standard consultation in the current experiment, indicating 
that it is possible to replace the formats used in standard consultations with the formats in 
BRIMMS without substantially increasing the length of consultations. Second, it may be 
possible to set up a dedicated consultation to provide treatment information using the 
BRIMMS protocol, prior to typical consultations with health professionals. Patients’ 
needs and preferences can then be discussed during regular consultations. Third, the 
BRIMMS protocol should be evaluated in the future with carers and families of patients 
who are likely to be involved in treatment decision-making process during consultations. 
Finally, the BRIMMS protocol should be developed and evaluated for different 
administration methods to complement the BRIMMS protocol in consultations, such as 
by basing patient leaflets and patient websites on this protocol.” 
7.4.1 Conclusion 
Combining the best presentation methods from previously conducted experiments 
into a BRIMMS protocol greatly improved patients’ understanding of treatment risks and 
benefits, and reduced conflict in their decision to take the treatment compared to 
treatment information presented using standard consultations. These improvements were 
generally greater when the BRIMMS protocol was presented in a written form compared 
to BRIMMS presented aurally. Patients also positively rated the BRIMMS protocol 
compared to standard consultation methods. From these findings, it is recommended that 
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following further evaluation, the BRIMMS protocol should be implemented in real 
consultations between health professionals and MS patients when making decisions about 
DMDs. 
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Chapter 8: General discussion 
 
MS is a chronic disease that affects over 2.3 million people around the world 
(Browne et al., 2014). Patients diagnosed with MS can present with a multitude of 
symptoms that can vary between individuals, including: physical symptoms, fatigue, 
affective disorders and cognitive impairments (Compston & Coles, 2008). As the disease 
continues to progress, the symptoms of MS can increase in severity, leading to disability 
in many patients. Although there is no cure for MS at present, extensive research in the 
last two decades have increased treatment options that can delay the progression of 
disease in the form of disease-modifying drugs (DMDs). All DMDs have different levels 
of risks and benefits, with the effects of treatments varying between patients (English & 
Aloi, 2015; Wingerchuk & Weinshenker, 2016; Winkelmann et al., 2016).  
Decisions about the most suitable DMD for MS patients should ideally be made 
within a shared decision-making context, commonly employed as part of a patient-
centred approach to healthcare (Barry & Edgman-Levitan, 2012; Charles et al., 1997, 
1999; Godolphin, 2009). A prerequisite of shared decision-making is that patients be fully 
informed about the risks and benefits of all eligible treatments, and that these are 
communicated by health professionals in a manner which is easy to understand (Barry & 
Edgman-Levitan, 2012; Charles et al., 1997). A number of recommendations have been 
made to ensure clear and comprehensible information is provided to patients making 
decisions about treatments (Bunge et al., 2010; Edwards et al., 2002; Fagerlin et al., 2011; 
Paling, 2003). These recommendations are generally based on findings from studies 
conducted with non-clinical populations and patients from numerous clinical diseases. 
However, in order to determine how understanding of the complex risk and benefit 
profiles of DMDs can be improved, it is important that the best methods of providing 
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treatment information are empirically tested with the population group most likely to 
utilise the treatment information during decision-making.  
8.1. Thesis summary 
The present thesis proposed to develop an integrated intervention to provide 
information about DMD risks and benefits to MS patients; the Benefit and Risk 
Information for Medications in Multiple Sclerosis (BRIMMS) protocol. In order to 
develop the BRIMMS protocol, it was first necessary to establish the current status of MS 
patients’ understanding of DMD risks and benefits, and the need to improve MS patients’ 
understanding within routine healthcare. Following this, reviews of existing methods of 
presenting treatment information to non-clinical and clinical populations informed the 
design of a theoretical framework about presentation methods that could improve 
understanding of MS patients. With this theoretical framework in mind, the different 
presentation methods were empirically tested with MS patients to determine the best 
methods that could improve understanding of treatment risks and benefits. Findings from 
these experiments were used to adapt the theoretical framework. The best presentation 
methods were then combined in the form of the BRIMMS protocol, which was 
subsequently compared with standard methods of receiving treatment information in 
current healthcare. The experiments employed in this thesis were therefore the first to 
provide recommendations for evidence-based practise based on a comprehensive 
assessment of methods to present treatment information.  
8.1.1 Chapter 2: Systematic reviews  
At the first stage of the thesis, a systematic review of the literature was conducted 
to explore MS patients’ current understanding and preferences for risks and benefits of 
DMDs (Reen et al., 2017). This review found that MS patients’ do not satisfactorily 
understand DMD information they receive within standard healthcare. This review also 
showed that MS patients have individual preferences for the risks and benefits of 
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treatments they are willing to take, which could affect the decision to initiate a DMD. 
Given that patients in this review generally showed a trend towards underestimating the 
risks of DMDs and overestimation of DMD benefits, it is likely that MS patients choose 
to initiate treatments with risk-benefit profiles that do not correspond with their preferred 
levels of risks and benefits. This can lead to reduced treatment adherence which can have 
a number of clinical consequences for MS patients (Halpern et al., 2011; Steinberg et al., 
2010; Tan et al., 2011). 
 A second systematic review was conducted to evaluate the interventions that 
have been designed to improve understanding of treatment risks and benefits for MS 
patients beyond standard healthcare (Reen et al., 2017a). The review found that, in 
general, understanding of DMD risks were improved following intervention but 
overestimation of DMDs persisted. However, the design and implementation of these 
interventions varied considerably between studies in this review. Interventions that were 
more comprehensive and interactive performed similarly to simple interventions. The 
methods of providing treatment risk and benefit information during the interventions had 
not always been empirically tested with MS patients. In addition, patient characteristics 
that could confound understanding of treatment information, such as cognitive 
impairments in MS, were not considered by the majority of studies in this review.  
Together, both these reviews identify a need for an intervention that could 
optimise MS patients’ understanding of DMD risks and benefits using presentation 
methods that are empirically tested with MS patients. 
8.1.2 Chapter 3: MS patient and MS nurse surveys 
The current chapter sought to explore MS patients’ experiences of receiving 
treatment information within standard healthcare in the UK. MS nurses were also 
assessed about their experiences regarding how well MS patients understand current 
DMD information and how this could be improved. A survey methodology was 
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employed. Since the surveys were expected to inform the need for subsequent 
experiments with MS patients, an exploratory analysis of surveys was deemed sufficient. 
The results from these surveys supported findings from the systematic review in chapter 
2. Approximately half of the MS patients reported poor understanding of DMD risks and 
benefits which was supported by feedback from MS nurses. MS patients and nurses also 
reported that patients commonly receive treatment information during consultations with 
health professionals, followed by online websites. In addition, both patients and nurses 
reported that current healthcare services could be improved by providing clear 
information about DMD risks and benefits so that patients could effectively compare 
treatments to make treatment decisions.  
In conjunction with the findings from the systematic review, the survey results 
identified a need to improve MS patients’ understanding of treatment risks and benefits 
primarily provided by health professionals during consultations. For this reason, 
experiments were conducted with MS patients in subsequent chapters to assess the best 
methods to present treatment information that could optimise understanding.   
8.1.3 Chapter 4: Experiment 1 
EC guidelines have recommended the use of verbal formats when presenting 
information about treatment risks and benefits to patients (EC Guidelines, 1998, 2009), 
which are employed in current clinical practise for providing DMD information to MS 
patients (see appendix 11). However, studies indicate that treatment information is often 
misunderstood when provided using verbal formats (Berry et al., 2003; Berry et al., 2002; 
Knapp et al., 2009; Knapp et al., 2004; Knapp et al., 2015). Numerical formats have also 
been recommended for presentation of the risks and benefits of treatments (Bunge et al., 
2010; Lipkus, 2007; Paling, 2003) and are used in current clinical practise for MS 
patients (see appendix 11). However, studies have not conclusively established whether 
presenting numbers in the form of frequencies or percentages can better improve 
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understanding of treatment information (Bramwell et al., 2006; Cuite et al., 2008; 
Gurmankin et al., 2004; Peters et al., 2011; Waters et al., 2006; Woolshin & Schwartz, 
2011). Moreover, the use of graphical formats have also been encouraged in order to 
facilitate understanding of treatment information (Garcia-Retamero & Galesic, 2010b; 
Garcia-Retamero & Hoffrage, 2013; Lipkus, 2007; Tait et al., 2010). Studies that have 
reviewed the effects of graphical formats such as bar charts, line graphs, pictographs and 
pie charts on understanding of treatment information, generally show that pictographs and 
bar charts are more favourable at improving understanding than other graphical formats 
(Brewer et al., 2012; Hamstra et al., 2014; Hawley et al., 2008; McCaffery et al., 2012; 
Schapira et al., 2006; Tait et al., 2012, 2010; Zikmund-Fisher, Fagerlin, Roberts, Derry, 
& Ubel, 2008). However, studies assessing verbal, numerical and graphical formats on 
understanding have generally only been conducted with non-clinical populations or with 
clinical populations other than MS. The effects of these formats on MS patients’ 
understanding had not been explored. 
Experiment 1 was therefore the first experiment to conduct a comprehensive 
assessment of how different verbal, numerical and graphical formats could facilitate MS 
patients’ understanding of hypothetical treatment risks and benefits. Patients showed poor 
understanding of treatment risks and benefits when presented in verbal formats, but 
greater understanding when information was presented numerically. Specifically, 
frequencies were understood better than percentages. In terms of graphical formats, bar 
charts and line graphs showed better understanding of treatment information in 
comparison to pictographs and pie charts. In particular, bar charts were better understood 
when presented horizontally rather than vertically. Similarly, pictographs were better 
understood when the figures showing people affected by the risks or benefiting from the 
treatment were consecutively arranged rather than presented randomly. Pie charts were 
the least understood graphical format. However, when numbers were presented alongside 
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graphical formats, all formats were well understood by MS patients. Patients’ 
understanding across all methods was not reliably related with patients’ conflict in their 
treatment decisions. However, patients with low numerical reasoning skills, low health 
literacy, poor premorbid IQ, slower information processing or poor verbal memory skills 
showed poor understanding across all formats.  
8.1.4 Chapter 5: Experiment 2 
Although Experiment 1 showed that frequencies could improve MS patients’ 
understanding of treatment information, the ratios used to present these frequencies to MS 
patients were not assessed. Frequencies can either be presented in the ratio 1-in-X, where 
the numerator is always kept constant at 1 (e.g. 1 in 20, 1 in 5), or can be presented using 
the N-in-N*X ratio where the denominator is always kept constant (e.g. 50 in 1000, 200 
in 1000). Both types of frequencies are employed within current clinical practise to 
provide DMD information to MS patients (see appendix 11). Experimental studies 
generally show that people are poor at understanding treatment information when 
frequencies were presented with the 1-in-X ratio compared to the N-in-N*X ratio (Cuite 
et al., 2008; Grimes & Snively, 1999; Pighin et al., 2011, 2013, 2015; Sirota et al., 2014; 
Witteman, Zikmund-Fisher, Waters, Gavaruzzi, & Fagerlin, 2011). However, this effect 
has not been previously observed with MS patients. The manner in which treatment risks 
and benefits are framed (i.e. positively or negatively) has also been shown to affect 
decisions (McNeil et al., 1982; Meyerowitz & Chaiken, 1987; Peters et al., 2011; 
Rothman et al., 2006; Tversky & Kahneman, 1981; Zimmermann et al., 2000). Only two 
studies assessed understanding of treatment information presented in different frames and 
found that risks and benefits framed positively were better understood (Armstrong et al., 
2002; Carling et al., 2010). Yet, both these studies were conducted with non-clinical 
populations only. 
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Experiment 2 therefore sought to determine how different frequency ratios and 
different ways of framing treatment information could affect how risks and benefits were 
understood by MS patients. Consistent with previous findings, the 1-in-X frequency ratio 
was the least understood format. In regards to framing, negatively framed treatment risks 
and benefits were better understood by MS patients. However, the size of this effect was 
very small. Similar to Experiment 1, patients’ understanding across all methods was not 
reliably related with patients’ conflict in their treatment decisions. However, patients with 
low numerical reasoning skills, poor premorbid IQ, slow information processing speed or 
poor verbal memory skills showed poor understanding of ratios and framing of 
information. 
8.1.5 Chapter 6: Experiment 3 
The risk-benefit profiles of DMDs can be established from clinical trials by 
comparing the risks and benefits of patients taking the treatment of interest to the risks 
and benefits of patients taking a placebo or an existing treatment (Braune et al., 2015; 
Fogarty et al., 2016; Miller et al., 2014). It is important that patients are able to 
understand the differences between these groups in order to make informed treatment 
decisions. There are a number of ways to communicate these differences and include: 
absolute terms, relative terms and numbers needed to treat or harm. Relative terms are 
commonly employed in current clinical practise with MS patients (see appendix 11). 
Previous studies have varied considerably in their assessment of understanding of 
differences communicated in different methods. Nevertheless, there was a trend showing 
that differences communicated using absolute terms could improve understanding of 
treatment risks and benefits compared to other methods (Bodemer et al., 2014; Covey, 
2011; Hembroff et al., 2004; Kristiansen et al., 2002; O’Donoghue et al., 2014; Perneger 
& Agoritsas, 2011; Sheridan et al., 2003). Only one study was conducted with MS 
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patients, but only evaluated one method of communicating differences from groups in a 
clinical trial (Kasper et al., 2006). 
Experiment 3 was therefore the first experiment to evaluate the effects of 
understanding treatment risks and benefits when differences were communicated in either 
absolute terms, relative terms or numbers needed to treat to MS patients. Patients showed 
greater understanding of treatment information when presented using absolute terms 
compared to all other methods. However, when baseline information (i.e. comprehensive 
information about the number of people in each group) was added, patients showed 
greater understanding of treatments when presented in all methods. Similar to previous 
experiments, patients’ understanding across all methods was not reliably related with 
patients’ conflict in their treatment decisions. However, patients with low numerical 
reasoning skills, poor premorbid IQ, slow information processing or poor verbal memory 
skills showed poor understanding of treatments when clinical trial groups were 
communicated in all methods. 
8.1.6 Chapter 7: Experiment 4 
 The main goal of this thesis was to develop the BRIMMS protocol by integrating 
the best methods of presenting treatment information to MS patients from Experiments 1 
to 3. The following methods were used: frequencies presented in the form of N-in-N*X 
ratio, horizontal bar charts with numbers presented alongside each bar and all differences 
communicated using absolute terms. All risks were framed negatively and benefits 
framed positively, due to the small effects of framing on understanding of treatment 
information in Experiment 2 and in accordance with guidelines about the best manners to 
present treatment information within interventions (Bunge et al., 2010). The BRIMMS 
protocol was compared using a randomised controlled trial with a crossover design, with 
standard methods of providing treatment information to MS patients in consultations. 
Both the BRIMMS protocol and the standard consultation was provided in a written and 
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aural form. Patients were also assessed on their decisional conflict following their 
treatment choice after each condition and were also asked to provide feedback on all 
conditions. Understanding scores for all conditions were further correlated with patient 
characteristics. 
Experiment 4 found that the BRIMMS protocol greatly increased MS patients’ 
understanding of treatment information compared to standard consultations. Specifically, 
the BRIMMS written protocol was the most effective. In fact, understanding scores for 
the BRIMMS protocol were not related to several patient characteristics, indicating that 
patients showed improvements irrespective of numerical reasoning skills, premorbid IQ 
and cognitive impairments. However, patients with high levels of depression and poor 
health literacy still showed poor understanding when presented with the BRIMMS 
protocol. Additionally, both BRIMMS protocols reduced conflict in treatment decisions 
compared to standard consultation. Patients also rated the BRIMMS written and 
BRIMMS aural protocols positively compared to standard consultations. Overall, the 
BRIMMS protocol was found to be an effective intervention to present MS patients with 
treatment information.  
8.2. Limitations and future research 
In addition to the specific limitations discussed in each chapter, there are a 
number of overreaching limitations of the whole thesis which should be taken into 
account. Future work based on the findings from this thesis will also be discussed. 
All experiments with MS patients were conducted using hypothetical treatment 
risk and benefit information. Although the levels of risks and benefits provided to patients 
were based on real DMD risk and benefit profiles, patients’ understanding of the 
hypothetical treatments may not apply to real DMD risks and benefits. In particular, 
specific risks and benefits of DMDs may be more salient for individual MS patients 
which could affect how these risks and benefits are understood in real clinical situations. 
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This may mean that the BRIMMS protocol, based on presentation methods from 
hypothetical treatment information, may not exactly mimic understanding of real DMD 
information. However, the choice to employ hypothetical treatments in the thesis was 
made due to several reasons. First, since the research was conducted by a non-clinical 
researcher, providing real treatment information to patients without support from health 
professionals was not deemed suitable. Second, the majority of studies that have been 
conducted with clinical populations about the effects of different presentation methods 
have employed hypothetical clinical scenarios (e.g., Chapman, Litton, Chamberlain, & 
Ho, 2015; O’Donoghue et al., 2014; Perneger & Agoritsas, 2011; Sheridan et al., 2003). 
However, with these limitations in mind, it is important that the BRIMMS protocol be 
validated for use with real DMD information before this can be implemented in real 
clinical situations. 
Another limitation resulting from employing hypothetical treatment information 
in the current thesis is that patients had no prior knowledge of the risk and benefit profiles 
of treatments when comprehending the information. This may be different to real 
treatment information in real clinical situations, since many patients report conducting 
independent research about treatments prior to receiving treatment information from 
health professionals (Colombo et al., 2014; Marrie, Salter, Tyry, Fox, & Cutter, 2013; 
Synnot et al., 2014; also see chapter 3). Having no prior knowledge of the risks and 
benefits of treatments in the present thesis could have increased the cognitive load for 
patients and consequently affected understanding. Despite this, patients consistently 
showed greater understanding of certain presentation methods which indicates that these 
methods were effective even with a higher cognitive load. To note, external information 
that patients search could also be inaccurate or outdated which could negatively impact 
understanding and lead to cognitive dissonance during treatment decisions. For this 
reason, the presentation methods that have been employed in the present thesis should be 
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evaluated in real clinical scenarios to ensure that understanding can improve irrespective 
of inaccurate information elsewhere. 
Patients’ conflict in their treatment decisions was assessed for a rapid decision 
about whether to initiate a hypothetical treatment across all experiments in this thesis. 
However, real treatment decisions may often be adopted after a long deliberation process 
and following discussions with relatives, other health professionals and other patients (see 
Chapter 3). This may be a reason why no relationship was observed between treatment 
understanding scores and decisional conflict in Experiments 1 to 3. Yet, patients did show 
differences in decisional conflict scores following the BRIMMS protocol and standard 
consultations, implying that decisional conflict could be affected even after prompt 
treatment decisions. Nevertheless, patients’ conflict in their treatment decisions following 
the BRIMMS protocol should be measured after patients have had time to carefully 
consider the treatments they would be willing to initiate in a real clinical situation.  
Patients’ preferences for treatment risks and benefits can greatly influence their 
choice of treatment (Currie et al., 2014; Fraenkel, 2013; Gong et al., 2015) and is another 
important aspect of shared decision-making (Charles et al., 1997, 1999). The systematic 
review conducted in this thesis also showed that MS patients’ preferences could influence 
their choice to initiate treatments with specific risk-benefit profiles (Reen et al., 2017). 
However, patients’ preferences were not measured in experiments within this thesis. 
Future work should therefore consider whether the treatment choice made following 
different presentation methods was related with patient preferences to determine whether 
an effective decision had been made. Additional outcome measures, such as adherence to 
treatment, satisfaction with treatment and patient autonomy could also be employed in 
future studies to assess whether effective treatment decisions had been made following 
different presentation methods or the BRIMMS protocol.  
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The effect of specific patient characteristics on patients’ understanding scores 
across all experiments should be interpreted with caution. All experiments in the present 
thesis were powered to detect differences in the validated DCS measure (see sections 
4.2.4, 5.2.4 and 6.2.4). Thus, factors such as fatigue, anxiety and depression may not have 
shown high correlations with patient understanding scores due to low effect sizes. 
However, the fact that patients’ numerical reasoning skills, level of premorbid IQ and 
cognitive impairments did show reliable correlations with understanding scores across all 
experiments suggests that these correlations have a larger effect. Patients with MS can 
also experience language impairments during their disease (Renauld, Mohamed-Saïd, & 
Macoir, 2017) which may have affected patients’ understanding of treatment information 
in the current thesis. However, language impairments were not assessed as this symptom 
is still poorly defined in MS and no suitable assessment measure to detect language 
impairments in MS patients has been identified (Renauld et al., 2017).  
Moreover, there was a selection bias associated with MS patients who were 
recruited in experiments 1 to 4 of the thesis. Patients that consented to take part were 
from an urban metropolitan society and results from this sample may not necessarily 
relate with patients from rural backgrounds in the UK. However, the variability in levels 
of numerical reasoning and premorbid IQ between patients indicates that there was a lot 
of diversity in the patient population (see table 8.2). Furthermore, patients were generally 
representative of the MS population in the UK (Ford et al., 2012), as the sample consisted 
of majority females with an average age of approximately 45 years (see table 8.1). 
Patients across Experiments 1 to 4 also experienced MS symptoms typical of a MS 
population (see section 1.1.2 for overview of MS symptoms). Patients were more 
commonly impaired on fatigue across all experiments, followed by cognitive impairments 
and depression (see table 8.3). Patients across Experiments 1 to 4 were also taking a range 
of first-line and later-line DMDs further increasing the representativeness of the current 
Chapter 8 
253 
sample (see section 1.2 for DMD review). The majority of patients across all experiments 
were taking interferons, followed by fingolimod and natalizumab (see table 8.1). Despite 
being a representative MS sample overall, it should be noted that the patients given the 
BRIMMS protocol (Experiment 4) showed some differences to the patients that were 
recruited in Experiments 1 to 3. For instance, MS patients in Experiment 4 did not show 
any impairments on information processing speed and had been diagnosed with MS for a 
shorter period of time. However, all other patient characteristics, DMDs taken and 
symptoms of MS for patients in Experiment 4 were similar to the previous experiments 
(see tables 8.1, 8.2 and 8.3). 
The attitudes of MS patients that consented to take part in all experiments of this 
thesis may also have differed to patients not involved in the research. For example, 
patients in the present sample may have been more autonomous and likely to be involved 
in treatment decision-making given their interest in a research study about understanding 
of treatment information. Patient autonomy was not tested in the present thesis and should 
be assessed in future experiments. Nevertheless, highly autonomous patients are more 
likely to make decisions based on treatment risk and benefit information rather than by 
passive recommendations made by health professionals, and it is therefore necessary to 
include autonomous patients in research about informed treatment decisions. 
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Table 8.1  Comparison of patient demographics in Experiments 1, 2, 3 and 4 
Patient demographics Exp 1 (n=45) Exp 2 and 3 
(n=45)  
Exp 4 (n=24) 
Age in years, mean  (SD) 42.51 (9.46) 46.76 (10.50) 42.59 (8.63) 
Gender, n (%)    
Female 34 (75.6) 36 (80.0) 21 (87.5) 
Male 11 (24.4) 9 (20.0) 3 (12.5) 
Level of education, n (%)    
High school 13 (28.9) 15 (33.3) 7 (29.2) 
College  7 (15.6) 11 (24.4) 5 (20.8) 
Bachelor’s degree 15 (33.3) 8 (17.8) 7 (29.2) 
Postgraduate 10 (22.2) 11 (24.4) 5 (20.8) 
Employment status, n (%)    
Full-time (>16 hours) 17 (37.8) 13 (28.9) 11 (45.8) 
Part-time (<16 hours) 8 (17.8) 10 (22.2) 7 (29.2) 
Self-employed 6 (13.3) 7 (15.6) 0 (0) 
Unemployed 9 (20.0) 11 (24.4) 2 (8.3) 
Medical leave 5 (11.1) 3 (6.7) 4 (16.7) 
Retired 0 (0) 1 (2.2) 0 (0) 
Time since MS diagnosis in 
years, mean (SD) 
9.80 (8.10) 10.89 (8.51) 7.88 (4.63) 
HAI disability scale, mean (SD) 1.49 (1.67) 1.64 (1.77) 1.17 (1.34) 
Current DMD, n (%)    
Interferon betas 18 (40) 15 (33.3) 8 (33.3) 
Glatiramer Acetate 4 (8.9) 4 (8.9) 1 (4.2) 
Teriflunomide 0 (0) 0 (0) 0 (0) 
Fingolimod 6 (13.3) 8 (17.8) 7 (29.2) 
Alemtuzumab 0 (0) 4 (8.9) 1 (4.2) 
Dimethyl Fumarate 9 (20) 5 (11.1) 3 (12.5) 
Natalizumab 7 (15.6) 8 (17.8) 4 (16.7) 
Mitoxantrone 1 (2.2) 1 (2.2) 0 (0) 
DMD, disease-modifying drugs; HAI = Hauser Ambulation Index; Experiments 2 and 3 have same 
patient groups 
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Table 8.2  Comparison of patients’ assessment scores of numerical reasoning, health 
literacy, premorbid IQ and MS symptoms for Experiments, 1, 2, 3 and 4 
  Mean scores (SD) 
Assessments Max 
score 
Exp 1 (n=45) Exp 2 and 3 
(n=45) 
Exp 4 (n=24) 
Numerical reasoning 25 16.20 (3.61) 16.36 (3.80) 16.63 (3.00) 
Literacy 8  7.49 (1.25) 7.42 (1.32) 7.79 (.59) 
Anxiety 21 7.51 (4.57) 6.27 (3.98) 6.88 (4.20) 
Depression 21 5.02 (4.23) 4.11 (3.69) 5.38 (4.45) 
Fatigue 63 42.64 (13.56) 44.00 (13.47) 44.71 (12.84) 
Premorbid IQ 50 37.78 (6.86) 36.69 (8.46) 35.83 (8.02) 
Info processing speed 110 57.07 (11.09) 56.62 (12.62) 63.79 (6.72) 
Verbal memory 80 48.44 (14.08) 49.07 (12.43) 49.58 (9.82) 
Visual memory 36 20.29 (6.99) 21.16 (6.46) 22.04 (6.08) 
Experiments 2 and 3 have same patient groups 
 
Table 8.3  Comparison of patients impaired on numerical reasoning, health literacy, 
premorbid IQ and MS symptoms for Experiments, 1, 2, 3 and 4 
 Frequency of patients (%) 
Assessments Exp 1 (n=45) Exp 2 and 3 (n=45) Exp 4 (n=24) 
Numerical reasoning 3 (6.7) 6 (13.3) 2 (8.3) 
Literacy 4 (8.9) 3 (6.7) 1 (4.2) 
Anxiety 14 (31.1) 5 (11.1) 5 (33.3) 
Depression 6 (13.3) 1 (2.2) 4 (16.7) 
Fatigue 21 (46.7) 22 (48.9) 13 (54.2) 
Premorbid IQ  1 (2.2) 3 (6.7) 1 (4.2) 
Info processing speed 13 (28.9) 14 (31.1) 0 (0) 
Verbal memory 15 (33.3) 15 (33.3) 7 (29.2) 
Visual memory 25 (55.6) 23 (51.1) 10 (41.7) 
Experiments 2 and 3 have same patient groups 
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With these limitations in mind, the efficacy of the BRIMMS protocol should be 
replicated in future studies. The BRIMMS protocol should be adopted and validated for 
use in a real clinical context with real DMD information and in consultations conducted 
by health professionals. This should especially be assessed in situations where patients 
are transitioning between DMDs, to examine whether the BRIMMS protocol can improve 
understanding when comparing between previously taken treatments to treatments that 
are new. Following this, a multicentre study evaluating the use of the BRIMMS protocol 
across the UK should be conducted. Along with understanding, these studies should also 
assess the best treatment decisions made by patients, by measuring patients’ preferences 
for risks and benefits and comparing this with the risks and benefits of their chosen 
treatment following the BRIMMS protocol. Patients’ decisions based on the BRIMMS 
protocol should also be followed up to evaluate whether improving understanding of 
treatment information via this protocol can increase adherence to treatment. Training 
should also be provided to MS nurses and neurologists on how to employ the BRIMMS 
protocol effectively during consultations (e.g. presenting the graphs visually if aural 
BRIMMS protocol is employed). Additionally, considering that health professionals also 
commonly direct patients to booklets and websites about DMDs following consultations 
(see chapter 3 and appendix 11), it may be possible to adapt the BRIMMS protocol for 
use in booklets and websites that patients could consult when deliberating about 
treatments beyond consultations. Future research should therefore evaluate the BRIMMS 
protocol in different formats to facilitate MS patients’ understanding at all stages of the 
decision-making process. Following its use for MS patients, the BRIMMS protocol can 
also be validated and adopted for other chronic diseases that may have similar complex 
treatment risk-benefit profiles. 
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8.3 Conclusion 
A theoretical framework was developed and tested to assess how MS patients’ 
understanding of treatment information can be affected by different presentation methods 
and symptoms of MS. The effect of patient characteristics on understanding was also 
assessed. With evidence from reviews, surveys and empirical experiments in the current 
thesis, this theoretical framework was updated and used for the development of a 
BRIMMS protocol (see figure 6.2). According to this new framework, patients with 
cognitive impairments, poor numerical reasoning and poor premorbid IQ are susceptible 
to misunderstanding treatment information. Findings from Experiments 1-3 included in 
the framework also showed that all presentation methods had an impact on MS patients’ 
understanding of treatment information. In particular, several best presentation methods 
were identified and include: bar charts, frequencies in the N-in-N*X ratios and clinical 
trial data communicated in absolute terms. The BRIMMS protocol was developed by 
integrating the best presentation methods and improved patient understanding of 
treatment information as well as reduced patients’ conflict in their treatment decisions. 
Patient understanding was not directly related to decisional conflict across all 
experiments.  
8.4 Clinical implications 
Cognitive impairments should be assessed and accommodated as part of routine 
patient engagement and management, especially when discussing the risks and benefits of 
DMDs. Numerical reasoning and premorbid IQ are other patient characteristics that 
should be taken into account during treatment decisions. Education and discussion about 
DMD risks and benefits should be supported by using the best presentation methods such 
as frequencies, bar charts and absolute terms. BRIMMS protocol effectively integrates the 
best presentation methods and showed improvements in MS patients’ understanding of 
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treatment risks and benefits. The BRIMMS protocol should therefore be validated in real 
clinical situations, before being implemented into clinical practice. 
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Appendix 5 
MS Patient survey 
                            
 
Are you currently taking a disease-modifying medication for MS?             
Yes       No                 
If you answered NO, please DO NOT complete this survey.  
If you answered YES, please continue to the next question. 
 
Please tell us the medication you are currently taking? 
Avonex                Betaferon                         Copaxone                 
Extavia                 Aubagio                             Gilenya             
Lemtrada            Rebif                               Tecfidera                  Tsyabri         
              
How long have you been taking your current medication? 
__________________________________________________________________ 
__________________________________________________________________ 
We are interested to know how well you feel you are aware of the side effects, risks and 
benefits of your current medication. 
1. How well do you feel you understand the benefits of your current medication?  Please 
tick one. 
 
Slightly              Moderately    Satisfactorily      Very well        Completely 
understood           understood          understood          understood      understood 
                                                                                           
 
Comments:____________________________________________________ 
______________________________________________________________ 
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We are interested to know how well you feel you are aware of the side effects, risks and 
benefits of your current medication. 
2. How well do you feel you understand the benefits of your current medication?  Please 
tick one. 
 
Slightly            Moderately        Satisfactorily       Very well        Completely 
Understand    understand   understand     understand       understand 
                                                                                               
 
Comments: 
_________________________________________________________________
_________________________________________________________________ 
 
3. How well do you feel you understand the side-effects of your current medication? 
Please tick one. 
 
Slightly            Moderately        Satisfactorily       Very well        Completely 
Understand    understand   understand     understand       understand 
                                                                                               
 
Comments: 
_________________________________________________________________
________________________________________________________________ 
 
4. How well do you feel you understand the significant risks of your current 
medication? 
Please tick one. 
 
Slightly              Moderately    Satisfactorily      Very well        Completely 
understood           understood          understood          understood      understood 
                                                                                           
 
Comments: 
_________________________________________________________________
_________________________________________________________________ 
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5. What source of information about risks and benefits for your current medication do 
you currently use?  
Please tick all that apply. 
 
MS Neurologist        MS Nurses                 Booklet  
Charity website (e.g. MS Trust/MS Society)                              
Patient website (e.g. Shift MS/Patients Like Me)       
App (phone or tablet)                 Video guide (DVD/YouTube)                  
Other       If other, please specify:                   
___________________________________________________________ 
6. How useful are the sources you have stated in your previous answer, in providing you 
with risk and benefit information of your current medication?  
_________________________________________________________________
_________________________________________________________________ 
 
7. What source of information about risks and benefits for your current medication, do 
you currently prefer to use or would prefer to use in the future?  
Please rate these choices from 1 to 7, where 1 is your MOST preferred source and 
7 is your LEAST preferred choice. 
 
MS Neurologist   ____________________________________________ 
MS Nurses   _______________________________________________ 
Booklet    _________________________________________________ 
Charity website (e.g. MS Trust/MS Society)    _____________________ 
Patient website (e.g. Shift MS/Patients Like Me)     ________________ 
App (phone or tablet)   ______________________________________ 
Video guide (DVD/YouTube) __________________________________ 
    
Comments: 
_________________________________________________________________
_________________________________________________________________ 
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8. How can the current way of providing risk and benefit information for your current 
medication be improved?   
_________________________________________________________________
________________________________________________________________ 
 
 
9. On average, how often do you receive information about the benefits, risks and side-
effects about your current medication: 
Every consultation        1 in 2 consultations      
1 in 5 consultations       1 in 10 consultations    
In less than 1 in 10 consultations   
Comments: 
_________________________________________________________________
_________________________________________________________________ 
 
10. What do you think the possible benefits of your current medication are for MS 
patients?  
_________________________________________________________________
________________________________________________________________ 
 
11. What do you think the possible side-effects of your current medication are for MS 
patients?  
_________________________________________________________________
_________________________________________________________________ 
 
12. What do you think the possible significant risks of your current medication are for 
MS patients? 
____________________________________________________________________
______________________________________________________________ 
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13. What benefits have you experienced from your current medication, if any?  
 
_________________________________________________________________
________________________________________________________________ 
 
 
14. What side-effects have you experienced from your current medication, if any?  
 
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
 
Thank you for completing this survey! Your answers will help us understand and improve 
the way risk and benefit information is presented to people with MS.  
 
Please return your completed survey by post using the envelope provided or hand this 
back to the researcher.  
 
You may also complete the survey online at: www.tinyurl.com/MS-DMD-survey 
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Have you had a consultation with at least one MS patient: Yes   No  
Please DO NOT complete the survey if you responded No. 
How long have you been a MS nurse?     _-
________________________________________ 
 
We are interested to know how well you feel side effects, risks and benefits of disease-
modifying drugs (DMDs) are understood by MS patients. 
15. How well do you feel benefits of DMDs are understood by MS patients? 
Please tick one. 
 
 Slightly              Moderately    Satisfactorily      Very well        Completely 
understood           understood          understood          understood      understood 
                                                                                       
 
Comments: 
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
16. How well do you feel side-effects of DMDs are understood by MS patients? 
Please tick one. 
 
 Slightly              Moderately    Satisfactorily      Very well        Completely 
understood           understood          understood          understood      understood 
                                                                                           
Comments: 
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
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17. How well do you feel significant risks of DMDs are understood by MS patients? 
Please tick one. 
 
Slightly              Moderately    Satisfactorily      Very well        Completely 
understood           understood          understood          understood      understood 
                                                                                           
 
Comments: 
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
18. What sources of information about risks and benefits of medication do patients use?  
Please tick all that apply. 
 
MS Neurologist            MS Nurses                 Booklet  
Charity website (e.g. MS Trust/MS Society)                           
Patient website (e.g. Shift MS/Patients Like Me)    
App (phone or tablet)                  Video guide (DVD/YouTube)              
Other       If other, please specify: -
__________________________________________ 
 
19. How useful are the sources you have stated in your previous answer, in providing MS 
patients with medication risk and benefit information?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
20. How can the current way of providing medication risk and benefit information be 
improved?   
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
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21. On average, do you discuss medication benefits, risks and side-effects with patients: 
Every consultation        1 in 2 consultations      
1 in 5 consultations       1 in 10 consultations    
In less than 1 in 10 consultations   
 
Comments: 
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
Thank you for completing this survey! Your answers will help us understand and improve 
the way risk and benefit information is presented to people with MS.  
 
Please return your completed survey by post using the envelope provided or you can hand 
this back to the researcher.  
 
You also may complete the survey online at: www.tinyurl.com/MS-nurse-survey 
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Participant information Sheet: 
Benefit and Risk Information for Medication in Multiple Sclerosis (BRIMMS) 
Survey 
We would like to invite you to take part in our research study. This research study is 
being conducted as part of a PhD project at Royal Holloway, University of London. 
Before you decide to take part we would like you to understand why the research is being 
done and what it would involve for you. Please take the time to read the following 
information carefully and discuss it with others if you wish. Please do not hesitate to 
contact us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part in this research study. 
What is the purpose of this study? 
 
We are conducting this study to look at how information about risks and benefits of 
medication is currently presented to people with MS. We are hoping this will help us 
identify how this information can be presented in the most effective way. 
 
Why have I been invited to take part? 
 
People who have been diagnosed with Multiple Sclerosis and are currently taking 
disease-modifying drugs (DMDs) have been invited to take part. We are surveying about 
100 patients from many different medication groups. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you decide not to, it will in no way 
affect the care you receive. If you decide to take part, you will be given this information 
sheet to keep and will be asked to sign a consent form. Even if you do agree to participate 
you may withdraw at any time without giving a reason. 
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What will I have to do? 
 
The risk and benefit profile of disease-modifying medications are complex and not 
always easy to understand and remember. We would like to find out the best way of 
providing information about the risks and benefits of disease-modifying medications to 
people with MS. 
To do this, we would like to survey people with MS about their experience of receiving 
risk and benefit information about their medication and their current level of awareness. 
We would also like  
to find out the sources that people with MS currently use for information about 
medication risks and benefits and how these could be improved. 
 
The surveys may be completed at your convenience and will take no longer than 30 
minutes of your time. Once completed, you may personally hand these to the research 
team or can post them using the envelopes provided. Your answers to all the questions 
will provide us with the best information, but you may choose to leave out any questions 
that you do not wish to answer without giving a reason. If you are uncomfortable or 
unsure of a question, you may wish to contact your MS Nurse or Doctor at any point to 
discuss this. 
 
What are the possible benefits of taking part? 
 
We cannot promise that taking part in this study will help you, but the information we get 
from this study will help improve the risk and benefit information that people with 
Multiple Sclerosis receive about medications. 
 
Will my taking part in the study be kept confidential? 
 
All information which is collected about you during the course of the research study will 
be kept strictly confidential and will only be viewed by authorised researchers in the 
research team. All data that is used beyond the research institution will be coded and 
anonymised, so you will not be identified. 
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What will happen to the results of the study? 
 
If the results of the study are published, participants will be kept anonymous and will not 
be identified in any reports or publication.  
Any direct quotations used from the study will be kept completely anonymous. 
 
Who is organising and funding the research? 
 
The research is being funded by Royal Holloway, University of London and a 
pharmaceutical company named Biogen Idec Limited. 
 
Who has reviewed the study? 
 
This research study is part of the NHS and has been looked at by an independent group of 
people called a Research Ethics Committee, to protect your interests. This study has been 
reviewed and given favourable opinion by South Central Oxford C Research Ethics 
Committee. 
 
The research has also been approved by the Ethics Committee at Royal Holloway, 
University of London.  
 
Contact details 
 
If you have any questions about the survey or would like more information about this 
research project, please contact: 
 
Miss Gurpreet Reen - Royal Holloway, University of London 
Email: gurpreet.reen.2014@live.rhul.ac.uk 
Telephone:  0787 845 1844 
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Consent form 
Benefit and Risk Information for Medication in Multiple Sclerosis (BRIMMS) 
Survey 
 
1. I confirm that I have read and understood the information sheet for the above 
study. I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason and without my medical care or legal rights 
being affected. 
 
 
3. I agree to take part in the above study.  
 
 
 
 
 
 
 Name of Participant 
 
______________________________________________________________________ 
 
 
 
Date                     Signature 
 
___________________________                      ________________________________ 
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Information sheet and consent form for offline MS nurse surveys 
 
                           
                                                 
Participant information Sheet: 
Benefit and Risk Information for Medication in Multiple Sclerosis (BRIMMS) 
MS Nurses Survey 
We would like to invite you to take part in our research study. This research study is 
being conducted as part of a PhD project at Royal Holloway, University of London. 
Before you decide to take part we would like you to understand why the research is being 
done and what it would involve for you. Please take the time to read the following 
information carefully and discuss it with others if you wish. Please do not hesitate to 
contact us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part in this research study. 
What is the purpose of this study? 
 
We are conducting this study to look at how information about risks and benefits of 
medication is presented to people with MS. At the end of the project we will have 
identified how this information can be presented in the most effective way. 
 
Why have I been invited to take part? 
 
MS Nurses, who work with patients with Multiple Sclerosis, have been invited to take 
part. We are hoping to recruit about 50 MS Nurses in the next few months. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you decide to take part you will be 
given this information sheet to keep and will be asked to sign a consent form. Even if you 
do agree to participate you may withdraw at any time without giving a reason. 
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What will I have to do? 
 
Sometimes, we don’t know how much people with MS are aware of the risks and benefits 
of their current medication and whether they would like more information about MS, 
their current medications and any side-effects and benefits they may experience from 
their current treatment. 
 
To find out, we would like to survey MS nurses regarding their experience about 
medication risks and benefits information that is provided to people with MS, and the 
different sources that patients use to obtain this information. We would also like to know 
how MS nurses think that the medication  
risk and benefit information can be improved. This will help us understand and improve 
the way risk and benefit information is presented to people with MS.  
 
The survey may be completed at your convenience and will take no longer than 30 
minutes of your time. Once completed, you may personally hand these to the research 
team or can post them using the envelopes provided. Your answers to all the questions 
will provide us with the best information, but you may choose to leave out any questions 
that you do not wish to answer without giving a reason. 
 
What are the possible benefits of taking part? 
 
We cannot promise that taking part in this study will help you, but the information we get 
from this study will help improve the risk and benefit information that people with 
Multiple Sclerosis receive about medications. 
 
Will my taking part in the study be kept confidential? 
 
All information which is collected about you during the course of the research study will 
be kept strictly confidential and will only be viewed by authorised researchers in the 
research team. All data that is used beyond the research institution will be coded and 
anonymised, so you will not be identified. 
 
What will happen to the results of the study? 
If the results of the study are published, participants will be kept anonymous and will not 
be identified in any reports or publication.  
Any direct quotations used from the study will be kept completely anonymous. 
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Who is organising and funding the research? 
 
The research is being funded by Royal Holloway, University of London and a 
pharmaceutical company named Biogen Idec Limited. 
 
Who has reviewed the study? 
 
This research study is part of the NHS and has been looked at by an independent group of 
people called a Research Ethics Committee, to protect your interests. This study has been 
reviewed and given favourable opinion by South Central Oxford C Research Ethics 
Committee.  
 
The research has also been approved by the Ethics Committee at Royal Holloway, 
University of London.  
 
Contact details 
 
If you have any questions about the survey or would like more information about this 
research project, please contact: 
 
Miss Gurpreet Reen - Royal Holloway, University of London 
Email: gurpreet.reen.2014@live.rhul.ac.uk 
Telephone:  07563 653799 
Appendices 
315 
 
Appendix 8 continued 
 
                          
 
Consent form 
Benefit and Risk Information for Medication in Multiple Sclerosis (BRIMMS) 
MS Nurses Survey 
 
1. I confirm that I have read and understood the information sheet for the above 
study. I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason and legal rights being affected.  
 
 
3. I agree to take part in the above study.  
 
 
 
 
 
Name of Participant 
 
______________________________________________________________________        
 
 
 
Date                     Signature 
 
___________________________                      __________________________________ 
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Information and consent for online MS patient surveys 
 
Survey of people with MS 
  
We would like to invite you to take part in our research study by completing this survey. 
This research study is being conducted as part of a PhD project at Royal Holloway, 
University of London.   
  
We hope to find out the best way of providing information about the risks and benefits of 
disease-modifying medications to people with MS. To do this, we would like to 
survey people with MS about their experience of receiving risk and benefit information 
about their medication and their current level of awareness.  
 
 
We would also like to find out the sources that people with MS currently use for 
information about medication risks and benefits and how these could be improved. 
 
 
By continuing onto the next screen, you are deemed to have given consent to participate 
in this research. This is an anonymous survey. Please do not enter your name or any 
personal details that could identify you.   
 
 
If you are happy to take part in this survey, please continue to the next page. 
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Information and consent for online MS nurse surveys 
  
We would like you to take part in our research study by completing this survey. This 
research study is being conducted as part of PhD project at Royal Holloway, University 
of London. 
 
We hope to find out the best way of providing information about the risks and benefits of 
disease-modifying medications to people with MS. To do this, we would like to survey 
MS Nurses regarding their experience about medication risk and benefit information that 
is provided to people with MS, and the different sources that patients use to obtain this 
information. We would also like to know how MS Nurses think the medication risk and 
benefit information for people with MS can be improved. 
 
By continuing onto the next screen, you are deemed to have given consent to participate 
in this research. This is an anonymous survey. Please do not enter your name or any 
personal details that could identify you. 
 
If you are happy to take part in this survey, please continue to the next page.  
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Example of DMD risks and benefits presented within an online and offline booklet 
produced by the charity MS Trust (with annotations) 
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Verbal 
format 
Relative risk 
reduction 
Verbal 
format 
Frequency 
1-in-X ratio 
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Appendix 12 
Example of one hypothetical disease shown to patients in Experiment 1 
 
Septhitus 
 
The following information is about a fictitious medical disease, 
Septhitus, which is a chronic medical condition (a progressive 
condition) and leads to inflammation or erosion of the lining of the 
stomach.  
 
Without any treatment, the most common symptoms of the condition are: 
 Disabling abdominal pain: Episodes of disabling pain will become frequent over 
time 
 
 High blood pressure: People will be required to take medications for this 
condition 
 
 Likely to develop Irritable Bowel Syndrome (IBS) soon after diagnosis: If 
diagnosed, people will be advised to avoid certain types of food to manage the 
condition 
 
 Inability to digest solid food: In the severe form of the disease, people will need 
to go on a liquid diet.  
 
 Development of nodules in the stomach: People with this disease go on to 
develop nodules in the abdomen which can be identified by scans. These nodules 
can cause severe complications and can be fatal. Surgery is required to remove 
nodules. 
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Example of presentation formats and comprehension questions presented with Treatment 
A (Difoxitin) in Experiment 1  
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Appendix 14 
Information sheet and consent form for Experiments 1, 2 and 3 
 
                            
                                                
Participant information Sheet: 
Benefit and Risk Information for Medication in Multiple Sclerosis (BRIMMS) 
Investigation of presentation of information 
We would like to invite you to take part in our research study. This research study is 
being conducted as part of a PhD project at Royal Holloway, University of London. 
Before you decide to take part we would like you to understand why the research is being 
done and what it would involve for you. Please take the time to read the following 
information carefully and discuss it with others if you wish. One of our team will go 
through the information sheet with you and answer any questions you have, so ask us if 
there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
What is the purpose of this study? 
 
We are conducting this study to look at how information about risks and benefits of 
medication is best presented to people with MS.  
 
Why have I been invited to take part? 
 
People who have been diagnosed with Multiple Sclerosis and are currently taking 
disease-modifying drugs (DMDs) have been invited to take part. We are hoping to recruit 
about 400 patients in total in the next 3 years. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you decide not to, it will in no way 
affect the care you receive. If you decide to take part you will be given this information 
sheet to keep and will be asked to sign a consent form. Even if you do agree to participate 
you may withdraw at any time without giving a reason. 
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What will I have to do? 
Sometimes, we don’t know how best to present risk and benefit information of 
medications to people with MS. This study will investigate which presentations best 
allow patients to understand and remember the information. 
 
During this study, you will be shown information about risks and benefits of pretend 
drugs in many different formats. You will then be asked about the information and we 
will see how well you are able to remember this information. 
 
Before the study task, you may also be required to fill in some questionnaires to find out 
some background information about you and your clinical history. You will also be 
requested to complete a few questionnaire and tasks which will inform us about your 
mood, fatigue, as well as memory and concentration. 
 
The whole session may take around 1 to 2 hours. However, breaks will be given 
throughout the study and if at any point you feel uncomfortable or tired, you may also ask 
for additional breaks. You will receive further information throughout the study but if you 
require additional help or clarification you may let us know at any time. If you feel 
uncomfortable at any point in the study, you can stop at any time and you may also wish 
to contact your MS Nurse or Doctor to discuss this.  
 
You may wish to be involved in more than one study session. If this is the case, we will 
arrange a mutually convenient time and you will be presented with this information sheet 
and consent form again at the start of each new visit. 
 
Where will the study take place? 
 
You may choose to be involved in the study at the hospital or in your own home. The 
study will be conducted by a member of the research team. 
 
What are the possible benefits of taking part? 
 
We cannot promise that taking part in this study will help you, but the information we get 
from this study will help improve the risk and benefit information that people with 
Multiple Sclerosis receive about medications. 
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Will my taking part in the study be kept confidential? 
 
All information which is collected about you during the course of the research study will 
be kept strictly confidential and will only be viewed by authorised researchers in the 
research team. All data that is used beyond the research institution will be coded and 
anonymised, so you will not be identified. 
 
What will happen to the results of the study? 
 
If the results of the study are published, participants will be kept anonymous and will not 
be identified in any reports or publication. 
Any direct quotations used from the study will be kept completely anonymous. 
 
Who is organising and funding the research? 
 
The research is being funded by Royal Holloway, University of London and a 
pharmaceutical company named Biogen Idec Limited. 
 
Who has reviewed the study? 
 
This research study is part of the NHS and has been looked at by an independent group of 
people called a Research Ethics Committee, to protect your interests. This study has been 
reviewed and given favourable opinion by South Central Oxford C Research Ethics 
Committee. 
The research has also been approved by the Ethics Committee at Royal Holloway, 
University of London. 
 
Contact details 
 
If you have any questions about this study or would like more information about this 
research project, please contact: 
 
Miss Gurpreet Reen - Royal Holloway, University of London 
Email: gurpreet.reen.2014@live.rhul.ac.uk 
Telephone: 0787 845 1844 
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Consent form 
Benefit and Risk Information for Medication in Multiple Sclerosis (BRIMMS) 
Investigation of presentation of information 
 
1. I confirm that I have read and understood the information sheet for the above study. I 
have had the opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason and without my medical care or legal rights being 
affected. 
 
 
3. I agree to take part in the above study.  
 
 
 
 
Name of Participant 
 
_______________________________________________________________________  
 
 
 
Date                     Signature 
 
___________________________                      ________________________________ 
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Appendix 15 
Example of hypothetical disease shown to patients in Experiment 2 
 
Tryken’s disease  
 
The following information is about a fake medical disease, 
Tryken’s Disease, which is a chronic medical condition (a 
progressive condition) and leads to muscle wastage. 
 
Without any treatment, the most common symptoms of the condition are: 
 Severe weight loss: Over time, weight loss can be quite severe and will be 
difficult to manage 
 
 Unusual and unexpected bruising: This could become frequent over time, and 
could develop on any parts of the body 
 
 Muscle pain: The pain would require medications to manage and could result in 
frequent time off work 
 
 Kidney failure: In the very severe form of the disease, patients could develop 
kidney failure and may require dialysis 
Appendices 
335 
 
Appendix 16  
Example of ratios and framing to present information about treatment A (Sprantil) in 
Experiment 2 
 
Appendicitis needing surgery after 1 year 
In a clinical trial, 101 out of every 1000 people on Sprantil developed appendicitis 
requiring surgery after 1 year, and 899 out of every 1000 people did NOT develop 
appendicitis requiring surgery. 
In the no-treatment group (placebo group), 12 out of every 1000 people developed 
appendicitis requiring surgery after 1 year, and 988 out of 1000 people did NOT develop 
appendicitis requiring surgery. 
 
1. If 1000 people took Sprantil for 1 year, how many people will develop 
appendicitis requiring surgery? 
 
2. Compared to the placebo group, approximately how many MORE people taking 
Sprantil will develop appendicitis after 1 year? 
 100                     300              400                  750 
 
Appendicitis needing surgery after 2 years 
In a clinical trial, 176 out of every 1000 people on Sprantil developed appendicitis 
requiring surgery after 2 years, and 824 out of every 1000 people did NOT develop 
appendicitis requiring surgery. 
In the no-treatment group (placebo group), 41 out of every 1000 people developed 
appendicitis requiring surgery after 2 years, and 959 out of 1000 people did NOT develop 
appendicitis requiring surgery. 
1. If 1000 people took Sprantil for 2 years, how many people will develop 
appendicitis requiring surgery? 
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2. Compared to the placebo group, approximately how many MORE people taking 
Sprantil will develop appendicitis after 2 years? 
 150                     250              450                  800 
 
Appendicitis needing surgery after 5 years 
In a clinical trial, 301 out of every 1000 people on Sprantil developed appendicitis 
requiring surgery after 5 years, and 699 out of every 1000 people did NOT develop 
appendicitis requiring surgery. 
In the no-treatment group (placebo group), 53 out of every 1000 people developed 
appendicitis requiring surgery after 5 years, and 947 out of 1000 people did NOT develop 
appendicitis requiring surgery 
 
1. If 1000 people took Sprantil for 5 years, how many people will develop 
appendicitis requiring surgery? 
 
2. Compared to the placebo group, approximately how many MORE people taking 
Sprantil will develop appendicitis after 5 years? 
 150                     250              400                  750 
 
Bleeding gums after 1 year 
In a clinical trial, 593 people out 1000 people on Sprantil did NOT develop bleeding 
gums after 1 year, compared to 929 out of 1000 people who did not take the treatment 
(placebo group). 
 
If 1000 people took Sprantil for 1 year, how many people will NOT develop bleeding 
gums? 
Compared to the placebo group, approximately how many FEWER people taking 
Sprantil will NOT develop bleeding gums after 1 year? 
 100                     200              350                  800 
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Bleeding gums after 2 years 
In a clinical trial, 379 people out 1000 people on Sprantil did NOT develop bleeding 
gums after 2 years, compared to 880 out of 1000 people who did not take the treatment 
(placebo group). 
 
1. If 1000 people took Sprantil for 2 years, how many people will NOT develop 
bleeding gums? 
2. Compared to the placebo group, approximately how many FEWER people 
taking Sprantil will NOT develop bleeding gums after 2 years? 
 300                     500              650                  750 
 
Bleeding gums after 5 years 
In a clinical trial, 301 people out 1000 people on Sprantil did NOT develop bleeding 
gums after 5 years, compared to 643 out of 1000 people who did not take the treatment 
(placebo group). 
 
1. If 1000 people took Sprantil for 5 years, how many people will NOT develop 
bleeding gums? 
2. Compared to the placebo group, approximately how many FEWER people 
taking Sprantil will NOT develop bleeding gums after 5 years? 
 150                     350              600                  750 
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Remain free of unexpected bruising after 1 year 
In a clinical trial, 925 people out 1000 people on Sprantil will remain free of unexpected 
bruising after 1 year, compared to 410 out of 1000 people who did not take the treatment 
(placebo group). 
1. If 1000 people took Sprantil for 1 year, how many people will remain free of 
unexpected bruising? 
2. Compared to the placebo group, approximately how many MORE people taking 
Sprantil will remain free of unexpected bruising after 1 year? 
 350                     500              700                  800 
 
Remain free of unexpected bruising after 2 years 
In a clinical trial, 870 people out 1000 people on Sprantil will remain free of unexpected 
bruising after 2 years, compared to 215 out of 1000 people who did not take the treatment 
(placebo group). 
1. If 1000 people took Sprantil for 2 years, how many people will remain free of 
unexpected bruising? 
2. Compared to the placebo group, approximately how many MORE people taking 
Sprantil will remain free of unexpected bruising after 2 years? 
 100                     450              650                  900 
 
Remain free of unexpected bruising after 5 years 
In a clinical trial, 750 people out 1000 people on Sprantil will remain free of unexpected 
bruising after 5 years, compared to 100 out of 1000 people who did not take the treatment 
(placebo group). 
1. If 1000 people took Sprantil for 5 years, how many people will remain free of 
unexpected bruising? 
2. Compared to the placebo group, approximately how many MORE people taking 
Sprantil will remain free of unexpected bruising after 5 years? 
 50                     200              350                  650 
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Remain free of kidney failure after 1 year 
In a clinical trial, around 1 out of every 1 person on Sprantil remained free of kidney 
failure after 1 year, compared to 1 out of every 2 people who did not take the treatment 
(placebo group). 
1. If 1000 people took Sprantil for 1 year, how many people will remain free of 
kidney failure? 
2. Compared to the placebo group, approximately how many MORE people taking 
Sprantil will remain free of kidney failure after 1 year? 
 250                     450              700                 800 
 
Remain free of kidney failure after 2 years 
In a clinical trial, around 1 out of every 1 person on Sprantil remained free of kidney 
failure after 2 years, compared to 1 out of every 3 people who did not take the treatment 
(placebo group). 
1. If 1000 people took Sprantil for 2 years, how many people will remain free of 
kidney failure? 
2. Compared to the placebo group, approximately how many MORE people taking 
Sprantil will remain free of kidney failure after 2 years? 
 250                     500              600                  850 
Remain free of kidney failure after 5 years 
In a clinical trial, around 1 out of every 2 people on Sprantil remained free of kidney 
failure after 5 years, compared to 1 out of every 4 people who did not take the treatment 
(placebo group). 
1. If 1000 people took Sprantil for 5 years, how many people will remain free of 
kidney failure? 
2. Compared to the placebo group, approximately how many MORE people taking 
Sprantil will remain free of kidney failure after 5 years? 
 200                     350              700                  800 
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Example of hypothetical disease shown to patients in Experiment 3 
 
Aortic Prithora 
 
The following information is about a fake medical disease, Aortic 
Prithora, which is a chronic medical condition (a progressive 
condition) and leads to complications of the heart. 
Without any treatment, the most common symptoms of the condition are: 
High cholesterol: Could lead to inflammation and dangerous blood clots over time 
Severe chest pain: Chest pain may become frequent overtime, and have a negative impact 
on daily activities 
Inactive white blood cells: This could reduce immunity overtime, increasing the 
possibility of developing a fatal infection
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Example of methods communicating differences to present information about treatment A 
(Triptyte) in Experiment 3 
 
Liver failure after 1 year 
Compared to the no-treatment group (placebo group), 61 more people out of 1000 would 
develop liver failure when taking Triptyte after 1 year. 
 
1. If 1000 people took Triptyte for 1 year, how many people will develop liver 
failure? 
2. Compared to the placebo group, approximately how many MORE people taking 
Triptyte will develop liver failure after 1 year? 
    50                     250              350                  550 
 
Liver failure after 2 years 
Compared to the no-treatment group (placebo group), 148 more people out of 1000 would 
develop liver failure when taking Triptyte after 2 years. 
 
1. If 1000 people took Triptyte for 2 years, how many people will develop liver 
failure? 
2. Compared to the placebo group, approximately how many MORE people taking 
Triptyte will develop liver failure after 2 years? 
    150                     450              650                  750 
 
Liver failure after 5 years 
Compared to the no-treatment group (placebo group), 231 more people out of 1000 would 
develop liver failure when taking Triptyte after 5 years. 
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1. If 1000 people took Triptyte for 5 years, how many people will develop liver 
failure? 
2. Compared to the placebo group, approximately how many MORE people taking 
Triptyte will develop liver failure after 5 years? 
 200                     450              650                  750 
 
Joint pain after 1 year 
In a clinical trial, 201 out of 1000 people on Triptyte developed joint pains, compared to 
95 out of 1000 people who did not take the treatment (placebo group). 
Compared to the no-treatment group (placebo group), about 9 people would need to take 
Triptyte for 1 person to develop joint pain after 1 year  
 
1. If 1000 people took Triptyte for 1 year, how many people will develop joint 
pains? 
2. Compared to the placebo group, approximately how many MORE people taking 
Triptyte will develop joint pains after 1 year? 
 100                     250              450                  600 
 
Joint pain after 2 years 
In a clinical trial, 465 out of 1000 people on Triptyte developed joint pains, compared to 
150 out of 1000 people who did not take the treatment (placebo group). 
Compared to the no-treatment group (placebo group), about 3 people would need to take 
Triptyte for 1 person to develop joint pain after 2 years  
1. If 1000 people took Triptyte for 2 years, how many people will develop joint 
pains? 
2. Compared to the placebo group, approximately how many MORE people taking 
Triptyte will develop joint pains after 2 years? 
    150                     300              500                  750 
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Joint pain after 5 years 
In a clinical trial, 588 out of 1000 people on Triptyte developed joint pains, compared to 
314 out of 1000 people who did not take the treatment (placebo group). 
Compared to the no-treatment group (placebo group), about 4 people would need to take 
Triptyte for 1 person to develop joint pain after 5 years  
 
1. If 1000 people took Triptyte for 5 years, how many people will develop joint 
pains? 
2. Compared to the placebo group, approximately how many MORE people taking 
Triptyte will develop joint pains after 5 years? 
 100                     250              800                  950 
 
Remain free of severe chest pain after 1 year 
Compared to the no-treatment group (placebo group), about 4 people would need to take 
Triptyte for 1 person to remain free of severe chest pain after 1 year  
 
1. 1000 people took Triptyte for 1 year, how many people will remain free of chest 
pains? 
2. Compared to the placebo group, approximately how many MORE people taking 
Triptyte will remain free of severe chest pain after 1 year? 
 50                     250              500                  750 
 
Remain free of severe chest pain after 2 years 
Compared to the no-treatment group (placebo group), about 3 people would need to take 
Triptyte for 1 person to remain free of severe chest pain after 2 years  
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1. If 1000 people took Triptyte for 2 years, how many people will remain free of 
chest pains? 
2. Compared to the placebo group, approximately how many MORE people taking 
Triptyte will remain free of severe chest pain after 2 years? 
 100                     300              550                  600 
 
Remain free of severe chest pain after 5 years 
Compared to the no-treatment group (placebo group), about 3 people would need to take 
Triptyte for 1 person to remain free of severe chest pain after 5 years  
 
1. If 1000 people took Triptyte for 5 years, how many people will remain free of 
chest pains? 
2. Compared to the placebo group, approximately how many more people taking 
Triptyte will remain free of severe chest pain after 5 years? 
 20                     300              600                  850 
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Table  Williams squares for all 24 sequences used in the crossover RCT design in Experiment 4 
Wiliams Square Period 1 Period 2 Period 3 Period 4 
1 A B C D 
1 B D A C 
1 C A D B 
1 D C B A 
2 A C B D 
2 B A D C 
2 C D A B 
2 D B C A 
3 A D C B 
3 B C D A 
3 C A B D 
3 D B A C 
4 A B D C 
4 B C A D 
4 C D B A 
4 D A C B 
5 A C D B 
5 B D C A 
5 C B A D 
5 D A B C 
6 A D B C 
6 B A C D 
6 C B D A 
6 D C A B 
 A = Standard consultation verbal; B= Standard consultation written; C = BRIMMS verbal; D = 
BRIMMS written; RCT = Randomised controlled trial 
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Hypothetical disease presented to patients in Experiment 4 
 
Trylan’s Disease 
 
The following information is about a fake medical disease, Trylan’s 
Disease, which is a chronic medical condition (a progressive condition) 
and can leads to complications in the pancreas and kidneys 
Without any treatment and as the disease progresses, a patient may experience the 
following symptoms: 
 
 Type 2 diabetes: With progression of the disease, people are likely to develop 
Diabetes which would require daily management with medications 
 
 Kidney stones: People may frequently experience kidney stones over time, which 
may require surgery. Regular monitoring will be required to detect kidney stones 
 
 Kidney failure: In the very severe form of the disease, people may experience 
kidney failure and require dialysis. Regular monitoring and scans during the 
condition will be used to detect kidney failure 
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BRIMMS protocol presented to patients for one hypothetical treatment in Experiment 4: 
aural condition (all information, except graphs, read aloud) and written condition (all 
information read aloud and given to patients in written form) 
 
Benefits of taking Redicin 
In a clinical trial, 1000 patients were given Redicin and 1000 patients were given a 
placebo, or a fake pill. 
This was to show the benefits of taking the medication on progression of disease. 
 
After 1 year of taking the placebo, the disease continues to progress rapidly for 550 
people out of 1000  
After 1 year of taking Redicin, the disease continues to progress rapidly for 225 people 
out of 1000 
 
So after taking Redicin for 1 year, disease progression slowed down for 325 people  
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After 2 years of taking the placebo, the disease continues to progress rapidly for 660 
people out of 1000 
After 2 years of taking Redicin, the disease continues to progress rapidly for 195 people 
out of 1000 
 
So after taking Redicin for 2 years, disease progression slowed down for 465 people  
 
 
After 5 years of taking the placebo, the disease continues to progress rapidly for 720 
people out of 1000 
After 5 years of taking Redicin, the disease continues to progress rapidly for 173 people 
out of 1000 
 
So after taking Redicin for 5 years, disease progression slowed down for 567 people  
 
Appendices 
349 
Appendix 21 continued 
 
 
 
 
 
 
 
 
 
Side-effect of taking Redicin 
A side-effect of taking Redicin is headaches 
 
After1 year of taking Redicin, 335 people out of 1000 could experience headaches 
After 2 years of taking Redicin, 408 people out of 1000 could experience headaches 
After 5 years of taking Redicin, 682 people out of 1000 could experience headaches 
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Side-effect of taking Redicin 
Another side-effect of taking Redicin is excessive sweating.  
 
After1 year of taking Redicin, 580 people out of 1000 could experience excessive 
sweating 
After 2 years of taking Redicin, 695 people out of 1000 could experience excessive 
sweating 
After 5 years of taking Redicin, 722 people out of 1000 could experience excessive 
sweating 
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Risks of taking Redicin 
A risk of taking Redicin is appendicitis 
 
After 1 year of taking Redicin, 21 people out of 1000 could develop appendicitis 
After 2 years of taking Redicin, 59 people out of 1000 could develop appendicitis  
After 5 years of taking Redicin, 78 people out of 1000 could develop appendicitis  
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Standard consultation to presented to patients for one hypothetical treatment in 
Experiment 4: Aural condition (all information read aloud) and written condition (all 
information read aloud and given to patients to in written form) 
 
Benefits of taking Redicin 
In a clinical trial, some patients were given Redicin and some were given a placebo, a 
fake pill. 
This was done to show the benefits of taking the medication on how this slows the 
progression of disease. 
 
After 1 year of taking Redicin, the progression of disease slowed down by 59% compared 
to patients taking a placebo 
After 2 years of taking Redicin, the progression of disease slowed down by 70% 
compared to patients taking a placebo 
After 5 years of taking Redicin, the progression of disease slowed down by 76% 
compared to patients taking a placebo 
 
Side-effect of taking Redicin 
A side-effect of taking Redicin is headaches 
This side-effect is very common, as it effects over 1 in 100 people after 1 year, 2 years 
and 5 years of taking Redicin 
 
Side-effect of taking Redicin 
 
Another side-effect of taking Redicin is excessive sweating 
This side-effect is very common, as it effects over 1 in 100 people after 1 year, 2 years 
and 5 years of taking Redicin 
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Risks of taking Redicin 
A risk of taking Redicin is appendicitis 
 
After 1 year of taking Redicin, more than 1 in 100 people could develop appendicitis  
After 2 years of taking Redicin, more than 1 in 100 people could develop appendicitis  
After 5 years of taking Redicin, more than 1 in 100 people could develop appendicitis  
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Information and consent form for Experiment 4 
                             
                                                
Participant information Sheet: 
Benefit and Risk Information for Medication in Multiple Sclerosis (BRIMMS) 
Randomised Controlled Trial 
We would like to invite you to take part in our research study. This research study is 
being conducted as part of a PhD project at Royal Holloway, University of London. 
Before you decide to take part we would like you to understand why the research is being 
done and what it would involve for you. Please take the time to read the following 
information carefully and discuss it with others if you wish. One of our team will go 
through the information sheet with you and answer any questions you have, so ask us if 
there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
What is the purpose of this study? 
 
We are conducting this study to compare how different ways of presenting risk and 
benefit information about drugs affect understanding and recall. This will help us identify 
how this information can be presented in the most effective way. 
 
Why have I been invited to take part? 
 
People who have been diagnosed with Multiple Sclerosis and are currently taking 
disease-modifying drugs (DMDs) have been invited to take part. We are hoping to recruit 
about 200 patients in total in the next 3 years. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you decide not to, it will in no way 
affect the care you receive. If you decide to take part, you will be given this information 
sheet to keep and will be asked to sign a consent form. Even if you do agree to participate 
you may withdraw at any time without giving a reason. 
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What will I have to do? 
 
Sometimes, we don’t know how best to present risk and benefit information of 
medications to people with MS. In this study, we will present people with different 
methods of presenting information of pretend drugs. You will then be asked about the 
data that was shown to you and we will see how well you remember this data. You will 
also be asked to complete a questionnaire that looks at your decisions based on this data. 
 
The results will then be compared to see which method of presenting information is most 
easily understood and remembered. To try to make sure the people do not all see the same 
methods of information in the same order, you will be presented different methods by 
chance (randomly) and you will have an equal chance of receiving any order. 
 
Before the study task, you may also be required to fill in some questionnaires to find out 
some background information about you, and your clinical history. You will also be 
requested to complete a few questionnaires and tasks, which will inform us about your 
mood, fatigue, as well as memory and concentration. 
 
The whole session may take around 2 to 3 hours. However, breaks will be given 
throughout the study and if at any point you feel uncomfortable or tired, you may also ask 
for additional breaks. You will receive further information throughout the study but if you 
require additional help or clarification you may let us know at any time. If you feel 
uncomfortable at any point in the study, you can stop at any time and you may also wish 
to contact your MS Nurse or Doctor to discuss this. 
 
What are the possible benefits of taking part? 
 
We cannot promise that taking part in this study will help you, but the information we get 
from this study will help improve the risk and benefit information that people with 
Multiple Sclerosis receive about medications. 
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Will my taking part in the study be kept confidential? 
 
All information which is collected about you during the course of the research study will 
be kept strictly confidential and will only be viewed by authorised researchers in the 
research team. All data that is used beyond the research institution will be coded and 
anonymised, so you will not be identified. 
 
What will happen to the results of the study? 
 
If the results of the study are published, participants will be kept anonymous and will not 
be identified in any reports or publication. 
Any direct quotations used from the study will be kept completely anonymous. 
 
Who is organising and funding the research? 
 
The research is being funded by Royal Holloway, University of London and a 
pharmaceutical company named Biogen Idec Limited. 
 
Who has reviewed the study? 
 
This research study is part of the NHS and has been looked at by an independent group of 
people called a Research Ethics Committee, to protect your interests. This study has been 
reviewed and given favourable opinion by South Central Oxford C Research Ethics 
Committee. 
The research has also been approved by the Ethics Committee at Royal Holloway, 
University of London. 
 
Contact details 
 
If you have any questions about this study or would like more information about this 
research project, please contact: 
 
Miss Gurpreet Reen - Royal Holloway, University of London 
Email: gurpreet.reen.2014@live.rhul.ac.uk 
Telephone: 0787 845 1844 
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Consent form 
Benefit and Risk Information for Medication in Multiple Sclerosis (BRIMMS) 
Randomised Controlled Trial 
 
1. I confirm that I have read and understood the information sheet for the above 
study. I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason and without my medical care or legal rights 
being affected. 
 
 
3. I agree to take part in the above study.  
 
 
 
Name of Participant 
 
______________________________________________________________________ 
 
 
 
Date                     Signature 
 
 
___________________________                      _________________________________ 
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Search terms for systematic review: primary aim and secondary aim.
Search terms for systematic review
(Multiple AND Sclerosis)
AND
(patients OR people OR persons OR patient)
AND
(risk OR beneﬁt OR side effect)
AND
(treatment OR medication OR therapy OR medicine OR medical OR therapies OR
therapeutics OR Pharmaceutical preparations)
AND
(perception OR understanding OR comprehension OR awareness OR knowledge
OR information OR communication OR preference OR decision-making)1. Introduction
Multiple sclerosis (MS) is a chronic immunological disease of the
central nervous system which progresses at different rates between in-
dividuals [1,2]. Disease-modifying drugs (DMDs) are treatments which
can delay the progression of MS, but often present complex proﬁles of
risks and beneﬁts [3]. DMDs typically provided at the earlier stages of
MS are selected for their long-term safety proﬁles and minimal moni-
toring requirements, and are generally referred to as ﬁrst-line treat-
ments [4]. The efﬁcacy of these therapies is modest [5]. More
aggressive DMDs may be considered when initial therapies are not ef-
fective. These DMDs generally offer superior efﬁcacy but also higher
probabilities of adverse effects, which can range fromﬂu-like symptoms
to fatal conditions such as leukaemia or progressive multifocal
leukoencephalopathy (PML) [3,6–9]. MS patients are thus faced with
complex risk-beneﬁt proﬁles when deciding on the best course of
treatment.
A shared decision-making approach is particularly suited for a
chronic condition such as MS, where there is great complexity and un-
certainty about suitable treatments for an individual [10,11]. This ap-
proach is deﬁned as the shared and proactive exchange of information
between health professionals and patients, whenmaking treatment de-
cisions during consultations [12–14]. Effective shared decision-making
in MS should improve patients' understanding of the risks and beneﬁts
of DMDs and allow patients to make treatment decisions in accordance
with their personal values, which will likely improve patient engage-
ment in the decision-making process [15,16].
Evidence-based information about DMDs should be effectively com-
municated during consultations based on the shared decision-making
approach, sincemanyMS patients seek autonomy during treatment de-
cisions [17,18]. Autonomous patients desire accurate information about
treatments, which includes current research ﬁndings about DMD risks
and beneﬁts [19,20]. If accurate information is not provided during con-
sultations, it is likely that autonomous patients will seek information
beyond the health care system that may be inaccurate or outdated.
The beneﬁts of providing clear and accurate treatment information to
patients is also evident beyond initial treatment decision. One such ben-
eﬁt is improvement in treatment adherence, as patients with accurate
understanding of treatment risk-beneﬁt proﬁles are less likely to dis-
continue treatment due to unrealistic optimistic expectations [21,22].
Hence, it is important to determinewhetherMSpatients sufﬁciently un-
derstand the complex risk-beneﬁt proﬁles of DMDswhen information is
provided during the standard healthcare system.
It is also important to elicit patient values and preferences in order
for shared decision-making to work effectively [16]. Patient preference
in the shared decision-making context is generally deﬁned as patient's
choice of treatment based on available treatment options [14,23]. Pref-
erence for certain risks and beneﬁts that treatments offer may be a sen-
sitive predictor of patient's preferred choice of treatment. For instance,
patients are likely to choose a treatment compatible with the level of
risks they are willing to take [24,25] and may be more likely to forgo
the beneﬁts of long-term survival for the beneﬁts of an improved qual-
ity of life [26]. In a recent review, MS patients' perception of treatment
risks was also found to greatly impact patients' treatment decisions
with their neurologists during the shared decision-making process
[27]. For this reason, it is important to identify the extent to which pa-
tient preferences for both the risks and beneﬁts that DMDs typically
offer can inﬂuence MS patients' treatment decision.
To the best of our knowledge, the present systematic review is the
ﬁrst to gather evidence on MS patients' understanding and preferencesfor risks and beneﬁts of treatments. The primary aim will evaluate MS
patients' understanding of risk and beneﬁt information for DMDs ac-
quired during their journey through standard healthcare systems, pre-
ceding any interventions or decision aids that may be provided
beyond regular consultations. The secondary aim will identify MS pa-
tients' preferences for treatment risks and beneﬁts across studies, and
assess whether these preferences can have an impact on patient's treat-
ment decisions.
2. Method
2.1. Systematic literature search
The systematic literature search was conducted in February 2016
through PubMed, Embase and Google Scholar using speciﬁc search
terms for both study aims (see Table 1). After removing duplicate en-
tries, a total of 889 records were identiﬁed (see Fig. 1).
Studies were eligible for inclusion if they were: in English, with
human adults and of any study design. Studies with patients of any
MS disease subtype were included. No date restriction was applied.
For both aims, studies were included if they had some evaluation of dis-
ease-modifying drugs and when the evaluations focused on patients
with MS.
Studies were excluded if they discussed medications for MS symp-
tom management or complementary medicines. Studies with evalua-
tion of patients' understanding of disease-modifying drugs post
educational interventionwas not included.However, baselinemeasures
prior to any educational intervention were eligible for inclusion in the
present review. Studies that assessed MS patients' understanding for
other areas in MS, including diagnosis and prognosis, were excluded.
Studies focusing only on patients' adherence to DMDs were also
excluded.
Following screening of titles and abstracts, 835 records were exclud-
ed. Full texts were subsequently accessed. Studies that were considered
relevant from screening references were also identiﬁed. Thus, data was
extracted for a total of 58 full-texts, and studies were included into the
ﬁnal review if inclusion and exclusion criteria were met (see Fig. 1).
2.2. Data extraction
Data extraction was carried out by one reviewer (GR) using data ex-
traction forms speciﬁcally designed for the current review, andwas ver-
iﬁed by another (DL). Any discrepancies were resolved by discussion.
After extraction of full texts, a total of 22 studies were included into
Fig. 1. Flow diagram for included studies: primary aim and secondary aim.
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for both the primary aim and secondary aim. Thus, 14 studies were in-
cluded into the primary aim and 9 studies were included into the sec-
ondary aim.
Baseline characteristics of MS patients were extracted from all 22
studies, which covered age, the type of MS and current DMD status.
Since very few studies exclusively assessed understanding or prefer-
ences of treatment risks and beneﬁts inMS, studies with any evaluation
of either aims were retained.
For the primary aim, any data available on understanding of treat-
ment risks or beneﬁts, or understanding of the treatment overall, was
retained. Only understanding of information about real DMDs was in-
corporated into this aim. This information sometimes existed as base-
line measures in intervention studies. Both self-report and objectiveTable 2
Quality assessment of studies investigating MS patients' understanding of DMD risks and bene
First author (year) Selection bias Study design Confounders Blinding
Mohr (1996) Moderate Moderate – Moderate
Heesen (2003) Weak Weak – Moderate
Heesen (2004) Moderate Weak – Moderate
Vlahiotis (2010) Weak Weak – Moderate
Visser (2011) Weak Moderate – Moderate
de Seze (2012) Weak Weak – Moderate
Hofmann (2012) Weak Moderate – Moderate
Kopke (2014) Strong Strong Strong Strong
Syed (2014) Weak Moderate – Moderate
Abolfazli (2014) Weak Weak – Moderate
Zimmer (2015) Moderate Moderate – Moderate
Overall quality rating: strong = no weak ratings; moderate = one weak rating; weak = two omeasures were included for review, in addition to themes from qualita-
tive studies.
For the secondary aim, patients' preferences for treatment risks only,
treatment beneﬁts only and a combined trade-off between treatment
risks and beneﬁts were considered. Preferences for treatment risks
and beneﬁts were deﬁned as patients' attitudes towards risks and ben-
eﬁts, the levels of risks and beneﬁts MS patients were willing to accept,
or MS patients' perception of their current DMD. Preferences for risks
and beneﬁts of both real DMDs and hypothetical treatment scenarios
were included in this aim, providing that hypothetical risk-beneﬁt sce-
narios were relevant to MS. Similar to the primary aim, information
from self-report and objective measures were discussed.
Relevant data was obtained from numerical information in texts, ta-
bles, graphs, and relevant statistical analysis. For qualitative studies,ﬁts: primary aim.
Data collection method Withdrawals and dropout Overall quality rating
Strong Strong Strong
Weak Weak Weak
Strong Moderate Moderate
Moderate Weak Weak
Weak Moderate Weak
Strong Weak Weak
Weak Weak Weak
Strong Strong Strong
Moderate Weak Weak
Weak Strong Weak
Moderate Strong Moderate
r more weak ratings.
Table 3
Quality assessment of qualitative studies investigating MS patients' understanding of DMD risks and beneﬁts: primary aim.
First
author
(year)
Clear
aims
Appropriate
methodology
Appropriate
design
Appropriate
recruitment
strategy
Data
collection
method
Researcher and participant
relationship considered
Ethical issues
considered
Rigorous
data
analysis
Statement
of ﬁndings
Is the
research
valuable?
Miller
(2001)
Yes Yes Yes Yes Yes No Unclear Yes Yes Yes
Miller
(2006)
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Miller
(2012)
Yes Yes Yes Yes Unclear Yes Unclear Yes Yes Yes
Quality assessed using the Critical Appraisal Skills Programme tool (CASP); all categories marked as either yes, no or can't tell/unclear.
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given as reported in each study. Due to the heterogeneity of the studies
in the present review, a narrative synthesis was conducted.
2.3. Quality assessment
All studies in this review were examined independently for quality
by two reviewers (GR and DL) using the Effective Public Health Practice
Project (EPHPP) quality assessment tool for quantitative studies [28].
This particular tool was chosen because it is often used to evaluate dif-
ferent types of quantitative studies in the health care setting [29], it
has high inter-rater reliability [29] and is considered ideal for use in sys-
tematic reviews [30]. As per the tool, theﬁnal quality ratingwas derived
from the rating of 6 measures (see Tables 2 and 4).
The Critical Appraisal Skills Programme (CASP) tool was used to ap-
praise the quality of qualitative studies in this review (see Table 3). This
tool was chosen as it has often been recommended for reviewers [31]
and was previously used in other systematic reviews [32].
3. Results
3.1. Results: primary aim
3.1.1. Patient and study characteristics
A total of 14 studies were included in the primary aim (see Tables 5
and 6). With the exception of three qualitative studies [33–35], the
studies mostly consisted of surveys and questionnaires. Data from
some studies was derived from baseline measures of randomized-con-
trolled trials [36–38]. Two quantitative studies were found to have the
strongest quality rating [36,38].
Across the 14 studies, a total 8032 patients were included with a
range of MS disease subtypes, which comprised: 27 (0.3%) patients
with clinically isolated syndrome (CIS), 2532 (31.5%) relapsing-remit-
ting MS (RRMS) patients, 349 (4.3%) primary progressive MS (PPMS)
patients and 870 (10.8%) secondary progressive MS (SPMS) patients.
Of the remaining, 251(3.1%) patients were reported as having benign
MS, with unclear or unreportedMS disease subtype for all other MS pa-
tients (49.8%). The mean age of patients was 42 (range: 34–50). The
mean value excludes MS patients in studies that only stated themedianTable 4
Quality assessment of studies investigating MS patients' preferences for treatment risks and be
First author (year) Selection bias Study design Confounders Blinding
Prosser (2002) Moderate Weak – Moderate
Kasper (2008) Strong Strong Strong Strong
Johnson (2009) Weak Weak – Moderate
Tur (2013) Moderate Moderate Moderate Weak
Abolfazli (2014) Weak Weak – Moderate
Wilson (2014) Moderate Weak – Moderate
Bruce (2015) Moderate Weak – Moderate
Fox (2015) Weak Weak – Moderate
Wilson (2015) Moderate Weak – Moderate
Overall quality rating: strong = no weak ratings; moderate = one weak rating; weak = two ovalues of age [39], the range of ages [34,35] and those studies that did
not specify age of MS patients [36,40].
Of the studieswhich recorded patient's current DMD, themajority of
patients were taking ﬁrst-line treatments, including interferons in
seven studies [34,36,38,40–43] and glatiramer acetate in four studies
[35,38,40,41]. MS patients taking aggressive medications were also re-
corded, including Natalizumab [33], Fingolimod [37] and Mitoxantrone
[40,44]. Eight studies focused primarily on MS patients taking a single
DMD [33–37,42–44].
3.1.2. Study outcomes
3.1.2.1. Understanding of overall treatment information.MS patients' un-
derstanding of overall DMD information during the routine healthcare
systemwas assessed using questionnaires and surveys by seven studies.
Self-report measures in one study indicated that 44% of MS patients
considered themselves extremely well-informed about their current
DMD [42]. Using a visual analogue scale in another study, just under
20% of patients reported being fully informed about current DMDs
[37]. Using retrospective surveys, 28% of patients reported being well-
informed about DMDs at time of diagnosis, with just over 50% patients
stating that they did not receive any information about DMDs at diagno-
sis [45]. On the other hand, between 75% to 84% ofMS patients reported
being partly or totally informed about current DMDs [39,41], and 85% of
MS patients felt they were aware about other DMD treatment options
based on one question from a 12-item questionnaire [40]. Of those pa-
tients who felt informed about DMDs, 71% of MS patients felt the infor-
mation received was of a sufﬁcient standard [45].
Objective measurements were used by two studies within the pres-
ent review to establishMS patients' understanding of overall treatment
information. Abolfazli and colleagues [43] administered a 25-item ques-
tionnaire to MS patients, nine questions of which assessed understand-
ing of the ﬁrst-line treatments in general, and three questions each
focused on understanding of the ﬁve speciﬁc DMDs that fell within
this category. Only 30% of MS patients were able to correctly answer
seven of the nine questions that assessed understanding of the drugs
generally, with the remaining two questions answered correctly by
just over 60% ofMS patients. The authors concluded that understanding
of overall information about ﬁrst-line DMDs was low for the assessedneﬁts: secondary aim.
Data collection method Withdrawals and dropout Overall quality rating
Strong Strong Moderate
Moderate Strong Strong
Strong Strong Weak
Moderate Strong Moderate
Weak Strong Weak
Moderate Moderate Moderate
Moderate Weak Weak
Moderate Weak Weak
Weak Strong Weak
r more weak ratings.
Table 5
Patient and study characteristics, and results of quantitative studies investigating MS patients' understanding of DMD risks and beneﬁts: primary aim.
First
author
(year)
Quality
rating
Study design and
methodology
Recruitment
location
Sample
size
Age (mean) Type of MS (n) DMD Real/faux
information
Self-report
or
objective
measure
Outcome measure(s) Results
Mohr
(1996)
Moderate Questionnaire:
baseline data from a
pre-post intervention
study
Outpatient
clinics
99 – Not speciﬁed Interferon beta-1b Real Objective DMD beneﬁt understanding:
survey items from BSQ
Relapse rate:
Expected b10% reduction
(‘overly pessimistic
group’) = 4% patients
Expected 10–30% reduction
(‘accurate group’) = 39%
patients
Expected N50% reduction
(‘overly optimistic
group’) = 57% patients
Disease progression:
Expected no change = 40%
patients
Expected slower
progression = 26% patients
Expected some restoration of
function = 29% patients
Expected return to normal
function = 4% patients
Heesen
(2003)
Weak Postal questionnaire:
observational study
MS patient
organisation
434 Women = 44;
men = 43
Not speciﬁed DMD not speciﬁed Real Self-report Understanding of overall DMD
information: 3 questions from
13-item questionnaire
52% of patients not informed
at time of diagnosis;
28% of patients informed
after several months of
diagnosis;
71% of patients received
sufﬁcient information
Heesen
(2004)
Weak Postal questionnaire:
observational study
MS
outpatient
clinic
169 44 RRMS (75); PPMS
(75); unclear (19)
DMD not speciﬁed Real Objective DMD risk understanding: 10
questions about DMD risks out
maximum 19
34% answers correct
Self-report DMD risk understanding: VAS
rating: perceived MS risk
knowledge
63% of perceived knowledge
Vlahiotis
(2010)
Weak Postal survey:
observational study
American
health
insurance
database
2022 – PPMS (78); RRMS
(1493); SPMS (213)
Other (29);
unknown (209)
Interferon-beta 1a IM;
interferon beta 1a SC;
interferon-beta 1b;
glatiramer acetate;
Mitoxantrone
Real Self-report DMD beneﬁt understanding:
survey questions
DMD helps MS:
Females = 79%;
males = 72%
Self-report Understanding of overall DMD
information: survey questions
Awareness of other
treatment options:
Females = 85%;
males = 80%
Visser
(2011)
Weak Postal survey:
observational study
Hospitals;
MS patient
organisation
1371 Benign MS &
RRMS = 471;
SPMS = 511;
PPMS = 521
Benign MS (251);
RRMS (525); PPMS
(120); SPMS (399);
unknown (76)
DMD not speciﬁed Real Self-report Understanding of overall DMD
information: 1 item from 72-item
questionnaire; enough treatment
information received?
‘Taking ﬁrst DMD’ group:
81% patients agree;
9% patients neutral;
10% patients disagree
‘Changed DMD’ group:
84% patients agree;
7% patients neutral;
9% patients disagree
(continued on next page)
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Table 5 (continued)
First
author
(year)
Quality
rating
Study design and
methodology
Recruitment
location
Sample
size
Age (mean) Type of MS (n) DMD Real/faux
information
Self-report
or
objective
measure
Outcome measure(s) Results
‘Stopped DMD’ group:
74% patients agree;
15% patients neutral;
11% patients disagree
de Seze
(2012)
Weak Postal questionnaire:
Observational study
Hospitals
and
community
practise
202 41 RRMS (202) Interferon-beta 1a;
interferon-beta 1b;
glatiramer acetate
Real Self-report Understanding of overall DMD
information: ‘well informed about
treatment?’
Totally agree = 35%; partly
agree = 40%; partly
disagree = 14%; totally
disagree = 5%; no
opinion = 2%
Self-report DMD beneﬁt understanding Reduced relapse frequency
with current DMD:
Totally agree = 50%; partly
agree = 40%; partly
disagree = 6%; totally
disagree = 2%; no
opinion = 3%
Delay in treatment
progression with current
DMD:
Totally agree = 36%; partly
agree = 50%; partly
disagree = 9%; totally
disagree = 2%; no
opinion = 5%
Optimistic about MS due to
DMD:
Totally agree = 28%; partly
agree = 45%; partly
disagree = 17%; totally
disagree = 7%; no
opinion = 3%
Hofmann
(2012)
Moderate Postal questionnaire:
Retrospective cohort
study
Database of
hospitals
and private
clinics
575 50 RRMS (49); PPMS
(76); SPMS (258);
other (4); unknown
(188)
Mitoxantrone Real Objective DMD risk understanding:
risk choice from 4 options about
Mitoxantrone side-effects
Leukaemia:
Accurate risk choice = 40%
patients
Underestimated risk = 58%
patients
Cardiotoxicity:
Accurate risk choice = 16%
patients
Underestimated risk = 82%
patients
Kӧpke
(2014)
Strong Telephone and postal
questionnaire:
baseline data from
double-blind RCT
MS
outpatient
clinics
192 37 CIS (27); RRMS
(133); unclear (32)
Interferon-beta; glatiramer
acetate
Real Objective DMD risk understanding: ‘good
risk knowledge’ deﬁned as
minimum 12 answers from
possible 19
IG at baseline (n-93)
35% patients with ‘good risk
knowledge’
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CG at baseline (n = 99):
23% patients with ‘good risk
knowledge’
Syed
(2014)
Weak Structured
questionnaire:
baseline data from
longitudinal study
Home
support
service
2390 42 Not speciﬁed Interferon-beta 1a Real Self-report Understanding of overall DMD
information: 3 items from survey
44% of patients felt extremely
well informed (n = 1265)
Abolfazli
(2014)
Weak Postal questionnaire:
Observational study
MS patient
organisation
425 34.3 Not speciﬁed Interferons Real Objective Understanding of overall DMD
information
Greater understanding
associated with:
High level of education
(p = 0.0010)
Delay between onset of
symptoms and deﬁnite MS
(p = 0.0190)
Increased mobility
(p = 0.220)
Younger age (p = 0.030)
Females (p = 0.001)
Ability to self-inject
(p = 0.003)
Zimmer
(2015)
Moderate Questionnaire:
baseline data from
pre-post intervention
study
MS centre in
hospital
98 411 Not speciﬁed Fingolimod Real Objective Understanding of overall DMD
information: 18-item
questionnaire
Median score = 6 out of 18
(IQR- = 4–8)
Greater understanding
associated with:
Females (p = 0.02)
Patients in a relationship
compared to singles
(p = 0.03)
Self-report Understanding of overall DMD
information: VAS (0–10);
perception of being informed
Number of patients with
following scores (n-97):
Score b 7 = 78
Score ≥ 7 = 19
Absolute numbers reported, unless speciﬁed. Abbreviations: BSQ, Betaseron questionnaire; CG, control group; CIS, clinically isolated syndrome; DMD, disease-modifying drug; IG, intervention group; MS, Multiple Sclerosis; PML, progressive mul-
tifocal leukoencephalopathy; PPMS, primary progressive multiple sclerosis; RCT, randomized controlled trial; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; VAS= visual analogue scale. 1 =median,
2 = range.
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Table 6
Patient and study characteristics, and themes from qualitative studies investigating MS patients' understanding of DMD risks and beneﬁts: primary aim.
First
author
(year)
Quality
rating
Study design
and
methodology
Recruitment
location
Sample
size
Age
(mean)
Type
of MS
(n)
DMD Real/faux
information
Self-report
or
objective
measure
Outcome
measure(s)
Results
Miller
(2001)
– Qualitative
interviews
MS centre 15 28–552 RRMS
(15)
Interferon
beta-1a
Real Self-report DMD beneﬁt
understanding:
themes from
qualitative
analysis
Overestimating beneﬁt of DMD:
“I look at Avonex as my saviour. I
probably expected a lot more from it
than I was going to get, realistically”
(pg. 242)
Miller
(2012)
– Qualitative
interviews
MS centre;
Natalizumab
infusion
centre
20 43 RRMS
(20)
Natalizumab Real Self-report DMD risk
understanding:
themes from
qualitative
analysis
Low risk perception for DMD:
“I didn't feel that it was going to a big
risk for me because I trust my doctors,
and I don't think they really pushed it if
they didn't feel conﬁdent” (pg. 41)
High risk perception for DMD:
“I′m sure anybody who goes on Tysabri
from the moment they make that
decision…worry about PML”. (pg. 42)
“I was so afraid to try Tsyabri, you
know, the warnings and the labels are
just, they're so scary.” (pg. 42)
Miller
(2006)
– Qualitative
interviews
MS clinic 20 39–642 RRMS
(20)
glatiramer
acetate
Real Self-report DMD beneﬁt
understanding:
themes from
qualitative
analysis
Beneﬁts of glatiramer acetate:
“…the importance of getting on to
these ABC drugs – Avonex, beta
interferon and Copaxone – is to start as
soon as you have symptoms” (pg. 39)
“This way (injecting glatiramer
acetate) I feel like I am doing
something progressive to help it.” (pg.
39)
“And I have researched the ingredients,
and it is so natural” (pg. 40)
Absolute numbers reported, unless speciﬁed. Abbreviations: DMD, disease-modifying drug;MS,multiple sclerosis; PML, progressivemultifocal leukoencephalopathy; RRMS, relapsing-re-
mitting multiple sclerosis. 2 = range.
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naire, whichwas presented to patients as part of a baselinemeasure be-
fore intervention [37]. MS patients in this study answered a median of
six questions correctly about overall understanding of their current
DMD from a maximum score of 18 [37]. Both studies also analysed fac-
tors which were associated with greater understanding by MS patients
for overall information about DMDs. A common signiﬁcant patient fac-
tor associated with better understanding across both studies was gen-
der, since females displayed greater understanding of overall
information about ﬁrst-line DMDs [43] and the more aggressive treat-
ment Fingolimod [37]. Greater understanding of overall DMD informa-
tion was also related to: a high level of education [43], the delay
between onset of symptoms and diagnosis of MS [43], increased mobil-
ity [43], younger age [43], ability to self-inject for some ﬁrst-line treat-
ments [43] and patients who were in a relationship as opposed to
being single [37].
In summary, majority of studies which assessedMS patients' under-
standing of overall DMD information relied heavily on patient self-re-
ports. Although the ﬁndings varied both within and across studies, it is
clear that not all patients feel sufﬁciently informed about DMDs during
the routine healthcare system. This is also supported by objective mea-
sures, albeit in only a few studies. The factors associated with good un-
derstanding of overall DMD information were also inconsistent, with
only females showing a consistent advantage across two studies.
3.1.2.2. Understanding of treatment risks.MS patients' understanding of
treatment risks was evaluated by four studies in this review.
Perceived accurate understanding of the risks of unspeciﬁed DMDs
was reported by 63% of MS patients in one study [18]. A qualitative
study interviewing MS patients taking the aggressive treatment
Natalizumab showed mixed ﬁndings for understanding of the risks as-
sociated with this treatment; patients demonstrated both high and
low perceived risks [33].Three studies used objective questionnaires to assess understanding
of DMD risks, with two of these studies administering a similar adapted
19-item questionnaire designed for newly diagnosed patients [18,38].
Approximately 30% of MS patients showed ‘good risk knowledge’ for
their DMD based on their scores from this questionnaire [38]. For the
other study employing a similar questionnaire, MS patients were only
able to answer 34% of the questions correctly on average despite per-
ceiving their risk knowledge as good [18]. Signiﬁcant correlations
were also established between greater understanding of DMD risks
and patients who had been recently diagnosed, had the RRMS disease
subtype, and were of a younger age [18]. To note, questionnaires
employed in both studies primarily measured understanding of the
risks associatedwithMS in general, with only a portion of the questions
explicitly focusing on risk understanding of DMDs. In another study
employing objective methodology for the understanding of the aggres-
sive DMDMitoxantrone, 55% of MS patients underestimated the risk of
leukaemia, and up to 82% of MS patients underestimated the risk of
cardiotoxicity; both adverse risks associated with this DMD [44].
These ﬁndings were based on baseline measures of an interventional
study [44].
In summary, although MS patients show mixed perception towards
their understanding of DMD risks, objective measures seem to indicate
that DMD risks are generally low and underestimated by MS patients
during the routine healthcare system.
3.1.2.3. Understanding of treatment beneﬁts.MS patients' understanding
of the beneﬁts associated with their treatment was evaluated by ﬁve
studies in the present review.
Over 70% of MS patients taking a range of DMDs believed their cur-
rent DMD could help their MS [40]. Likewise, a large number of MS pa-
tients totally or partially perceived their current medication to have
strong beneﬁts: 90% of MS patients perceived that their DMD could re-
duce the frequency of MS relapses, 86% of MS patients believed that
Table 7
Patient and study characteristics, and results of quantitative studies investigating MS patients' preferences for treatment risks and beneﬁts: secondary aim.
First
author
(year)
Quality
rating
Study design
and
methodology
Recruitment
location
Sample
size
Age (mean) Type of MS
(n)
DMD Real/faux
information
Self-report
or
objective
measure
Outcome measure(s) Results
Prosser
(2002)
Weak Survey:
observational
study
MS clinics 56 38 RRMS (56) Interferon-beta
1a;
interferon-beta
1b; glatiramer
acetate
Faux Objective Preferences for treatment beneﬁts:
gamble question (drug with
relapse-free days compared with dug
offering 50% chance of immediate
reduction but 50% chance of not
working)
Mean = 14.6 relapse-free days
Kasper
(2008)
Strong Questionnaire:
baseline data
from RCT
Newspapers;
websites;
national
self-help journal
297 43 CIS (45);
RRMS
(153);
PPMS (31);
SPMS (59);
unclear (9)
DMD not speciﬁed Real Self-report Preferences for treatment beneﬁts:
Likert scale
Moderately optimistic towards current
DMD:
IG group at baseline = 65% patients;
CG group at baseline = 62% patients
Johnson
(2009)
Moderate Survey:
observational
study
MS patient
organisation;
Natalizumab
clinical trial
patients
651 47 Not
speciﬁed
Natalizumab Real Objective Preferences for treatment risk-beneﬁt
proﬁles: mean annual risk acceptable
to patients
Mean annual risk for ‘slow progression
beneﬁt’ (No. of relapses in next 5 years
reduced from 4 to 1; disability
progression delay from 5 to 8 years)
0.31% of PML death or disability;
0.30% of death by liver failure;
0.35% of death by leukaemia
Mean annual risk for ‘clinically relevant
beneﬁt’ (No. of relapses in next 5 years
reduced from 4 to 1; disability
progression delay from 3 to 5 years)
0.38% of PML death or disability;
0.39% of death by liver failure;
0.48% of death by leukaemia
Mean annual risk for ‘largest tested
beneﬁt’ (No. of relapses in next 5 years
reduced from 4 to 0; disability
progression delay from 1 to 8 years)
0.74% of PML death or disability;
1.02% of death by liver failure;
1.08% of death by leukaemia
Tur
(2013)
Moderate Survey:
observational
study
MS centre;
hospital
136 Natalizumab
group = 38; other
DMD group = 39
Not
speciﬁed
Natalizumab;
ﬁrst-line DMDs
Faux Objective Preference for treatment risks: ﬁve
risk levels for ﬁve presented
therapeutic scenarios
Mean scores for level of risks accepted:
Patients taking Natalizumab
(n = 114):
Very low risk = 8.85; low risk = 8.49;
medium risk = 7.47; high risk = 4.29;
very high risk = 3.01
Patients taking any other DMD
(n = 22):
Very low risk = 7.50; low risk = 6.32;
medium risk = 4.76; high risk = 2.43;
very high risk = 1.58
Abolfazli,
2014
Weak Questionnaire:
observational
study
MS patient
organisation
425 34.3 Not
speciﬁed
Interferons Real Self-report Preference for treatment beneﬁts:
5-point Likert scale across 13
questions
Optimistic about current DMD = 20%
to 90% patients
(continued on next page)
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Table 7 (continued)
First
author
(year)
Quality
rating
Study design
and
methodology
Recruitment
location
Sample
size
Age (mean) Type of MS
(n)
DMD Real/faux
information
Self-report
or
objective
measure
Outcome measure(s) Results
Optimistic about DMD associated with:
Lack of functional problem
(p = 0.004)
No MS family history (p = 0.029)
Knowledge of interferons (p = 0.001)
Wilson
(2014)
Moderate Questionnaire:
conjoint
analysis
MS clinic 289 42 RRMS (289) Interferons;
Natalizumab;
glatiramer
acetate;
Fingolimod;
Rituximab
Faux Objective Preference for treatment risk-beneﬁt
proﬁles: estimated acceptable risk for
various DMD beneﬁts
For 1% risk of DMD severe side-effects,
patient preference for treatment
decreased by 5 times
Objective Preference for treatment risks: odds
ratio
Minor side effect:
Headache ﬂu = 0.98
Mood change = 0.91 (p b 0.001)
Severe side effect:
0.05% = 0.70 (p b 0.001)
0.10% = 0.60 (p b 0.001)
1% = 0.22 (p b 0.001)
Objective Preference for treatment beneﬁts:
odds ratio
Progression prevention:
2 years = 1
4 years = 1.36 (p b 0.001)
10 years = 2.46 (p b 0.001)
Delay in relapse:
1 year = 1
2 years = 1.20 (p b 0.001)
5 years = 1.53 (p b 0.001)
Symptom improvement:
None = 1
Mild = 1.75 (p b 0.001)
Substantial = 3.68 (p b 0.001)
Bruce,
2015
Weak Questionnaire:
probability
discounting
MS Clinics 77 Adherent = 43.26;
non-
adherent = 45.03
RRMS Not speciﬁed Faux Objective Preferences for treatment risk-beneﬁt
proﬁles: Medical Decision Making
Questionnaire
Chosen treatment beneﬁt related to
side-effect probability (p b 0.001)
interaction between side effect and
group (adherent and non-adherent)
for treatment beneﬁts chosen
(p b 0.001)
Improbable side-effects predict
treatment adherence = 83.1%
Fox,
2015
Weak Survey:
observational
study
North American
Research
Committee on
Multiple
Sclerosis
(NARCOMS)
Registry
5446 52.7 Not
speciﬁed
Not speciﬁed Faux (cure for
MS) and real
(Natalizumab)
Objective Preference for treatment risk:
standard gamble paradigm
Median risk tolerance for both
scenarios = 1:10,000
Faux DMD scenario:
No risk tolerance = 23%
Tolerate any risk = 3.6%
Faux DMD risk tolerance associated
with:
No disability = 1:100,000 versus
wheelchair-bound = 1:1000
(p b 0.0001);
116
G
.K.Reen
etal./Journalofthe
N
eurologicalSciences
375
(2017)
107–122
Male = 1:2000 versus
females = 1:50,000 (p b 0.0001);
Patients caring for dependents =
1:100,000 versus not caring for
dependents = 1: 10,000 (p b 0.0001);
Patients taking DMD = 1:50,000
versus not taking DMD = 1:50,000
(p = 0.002);
Patients taking Natalizumab = 1:1000
versus not taking
Natalizumab = 1:50,000 (p b 0.0001);
Patients who routinely use
seatbelt = 1:50,000 versus those who
do not routinely use seatbelt = 1:5000
(p = 0.0007)
Natalizumab scenario:
No risk tolerance = 15%
Tolerate any risk = 3.3%
Natalizumab scenario risk tolerance
associated with:
No disability = 1:100,000 versus
wheelchair-bound = 1:1000
(p b 0.0001);
Male = 1:2000 versus
females = 1:10,000 (p b 0.0001);
Patients caring for
dependents = 1:50,000 versus not
caring for dependents = 1: 10,000
(p = 0.004);
Patients taking Natalizumab = 1:750
versus not taking
Natalizumab = 1:10,000 (p b 0.0001);
Patients who routinely use
seatbelt = 1:10,000 versus those who
do not routinely use seatbelt = 1:1000
(p b 0.0001)
Wilson,
2015
Weak Survey:
conjoint
analysis
MS clinic 50 42.7 RRMS Glatiramer
acetate; interferon
beta;
Natalizumab;
Rituximab;
Fingolimod;
no-treatment
Faux Objective Preference for treatment risk Common adverse effects (signiﬁcance
to reference):
Increased risk of infection = reference
Injection-site reactions = −0.16
Headaches, aches, ﬂu = 0.02
Changes in mood = −0.82
(p b 0.001)
Severe adverse effects:
0% = reference
1% = −1.15 (p b 0.001)
10% = 3.06 (p b 0.001)
30% = −3.82 (p b 0.001)
Objective Preference for treatment beneﬁt:
conjoint analysis
Clinical outcomes – β coefﬁcient values
compared with baseline treatment
proﬁle:
Prevents symptom progression for
1 year = 0.12 (p b 0.001);
Prevents one relapse per year = 0.05;
Prevents MRI progression for
1 year = 0.17 (p = 0.002)
(continued on next page)
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over 70% of MS patients were generally optimistic about their condition
as a result of taking their current medication [41]. In two qualitative
studies,MS patients taking ﬁrst-line treatments described their medica-
tion as a “saviour” [34] and believed that taking the DMD felt as if they
were “doing something progressive” towards their condition [35].
Only one early study employed an objective methodology to mea-
sure understanding of DMD beneﬁts. Mohr and colleagues [36] admin-
istered a 12-item questionnaire prior to providing an intervention.
Only 39% of MS patients accurately reported the beneﬁts of taking
their ﬁrst-line DMD, and 57% of MS patients were found to optimistical-
ly and incorrectly state that MS relapses could be reduced by a half fol-
lowing uptake of their current DMD [36].
Acknowledging the difﬁculty in comparing studies with self-report
and objective measures, and those encompassing MS patients taking a
range of DMDs, the limited data in the current review indicates a gener-
al trend towards underestimation of treatment risks andoverestimation
of treatment beneﬁts by MS patients during the routine healthcare
system.
3.2. Results: secondary aim
3.2.1. Patient and study characteristics
The studies in this part of the review consistedmostly of surveys and
questionnaires (see Table 7). One study that has previously been
reviewed in the primary aim also included ﬁndings relevant to the sec-
ondary aim [43]. Only one study in this section of the reviewwas found
to have the strongest quality rating [46].
From the ﬁnal 9 studies included into the secondary aim, a total of
7427 patients were included with a range of MS disease subtypes, com-
prising of: 45 (0.6%) CIS patients, 652 (8.4%) RRMS patients, 31 (0.4%)
PPMS patients and 59 (0.8%) SPMS patients. Majority of the studies
did not clearly report or specify the MS disease subtype (89.8%). The
mean age of MS patients was 42 (range: 34–52).
Of the studies which reported the current DMDs of MS patients, ma-
jority reported patients taking ﬁrst-line treatments, which includes in-
terferons in ﬁve studies [43,47–50] and glatiramer acetate in four
studies [47–50]. Patients taking more aggressive DMDs also formed a
part of this review, speciﬁcally patients taking Natalizumab [48–51],
Fingolimod [49,50] and Rituximab [49]. Two studies focused primarily
on a single DMD [43,51].
3.2.2. Study outcomes
3.2.2.1. Preferences for treatment risks. Four studies, each employing ob-
jective methodologies, looked at MS patients' preferences for the risks
of taking a treatment.
Tur and colleagues [48] assessed the level of risks that MS patients
were willing to accept for hypothetical therapeutic scenarios. The au-
thors also assessed the relationship between accepted levels of hypo-
thetical treatment risks and current DMDs taken by MS patients. A
visual analogue scale showed that MS patients on the aggressive treat-
ment Natalizumab were willing to accept higher levels of hypothetical
treatment risks in comparison to MS patients on any other DMD [48].
Hypothetical treatment scenarios were employed by two further
studies using objective methodologies, which compared MS patients'
preferences for different levels of treatment risks [49,50]. Both studies
conﬁrmed that DMDs with signiﬁcant adverse side-effects were less
preferred than DMDs with minor side-effects. In fact, both studies re-
vealed that medications with no possibility of death or disability were
signiﬁcantly favoured to a medication with even a very low possibility
(0.05% to 1%) of death or disability [49,50]. Mood changes were the
only speciﬁc side-effect that would decrease the probability of taking a
DMD by MS patients [49,50].
Using a standard gamble question task, another study employed a
hypothetical treatment scenario which presented information about a
119G.K. Reen et al. / Journal of the Neurological Sciences 375 (2017) 107–122treatment that could cure MS, and a real treatment scenario which pre-
sented the risk proﬁle of the aggressive DMD Natalizumab [52]. MS pa-
tients showed similar preferences for risks in both the hypothetical and
real treatment risk scenarios, as adverse risks were accepted when in
the range of 1 in 10,000 [52]. For the hypothetical treatment scenario,
MS patients that were signiﬁcantly likely to prefer higher levels of ad-
verse risks were those presenting with the following characteristics:
wheelchair bound, male, not responsible for dependents, not currently
taking a DMD, taking Natalizumab and not routinely wearing a seatbelt
for car travel [52]. With the exception of MS patients whowere not tak-
ing a DMD, the same characteristics of MS patients preferred higher
levels of treatment risks in the real DMD scenario [52].
Despite the comparison of hypothetical and real treatment risk pro-
ﬁles in this section of the review, MS patients showed similar low pref-
erences for treatment risks.
3.2.2.2. Preferences for treatment beneﬁts. MS patients' preferences for
treatment beneﬁts were assessed by ﬁve studies in the present review.
Two studies used subjective measures to assess the preferences of
MS patients towards treatment beneﬁts [43,46]. MSpatientswith a pos-
itive outlook towards their current DMD ranged from 20% to 90%within
one study [43] and was approximately averaged at 60% in another [46].
Patient factors signiﬁcantly associated with a positive attitude were pa-
tientswith: lack of functional problem, noMS family history and knowl-
edge of their current DMDs [43].
Turning to objective measures, Prosser and colleagues [47] utilised a
gamble health outcomes task using hypothetical treatment scenarios to
assess preferences of MS patients for treatment beneﬁts. During this
task, patients were required to choose either a drug offering a particular
number of relapse-free days, or a drug offering a 50% chance of ending
theMS relapse immediately but with 50% chance of the drug not work-
ing at all. On average, patients chose drugs likely to lead to 14.6 MS re-
lapse-free days from the possible 29, implying a preference towards
treatments offering moderate but guaranteed beneﬁts. However, the
authors did note that approximately 30% of MS patients chose an ex-
treme number of relapse-free days, i.e. either 1 or 29 [47].
The frequency of MS relapses was also used as an outcomemeasure
to assess MS patients' preferences for treatment beneﬁts in the remain-
ing two studies and was compared alongside other beneﬁts that DMDs
typically offer [49,50]. The highest preference for MS patients in one
study was for substantial symptom improvement in MS, followed by
prevention of disease progression over 10 years, mild symptom im-
provement and a ﬁve-year delay in MS relapses [50]. Administration
in the form of an IV infusion or oral pill was also signiﬁcantly preferred
byMS patients. In fact, the ability to administer the drug orally was pre-
ferred even over a ﬁve-year delay in relapse [50]. Likewise, any form of
improvement in symptoms and the ability to take the drug orally were
also strongly preferred byMS patients in the latter study [49]. However,
unlike the previousﬁndings,MSpatients in this study showed no signif-
icant preference for delay in MS relapses or administration of drugs via
IV infusion [49]. Additionally, the ability to prevent MRI progression
over the yearswas used as an indicator only in this study andwas signif-
icantly preferred by MS patients [49].
Although all studies in this review assess MS patients' preferences
for treatment beneﬁts, chieﬂy for hypothetical treatment scenarios,
the results are not directly equivalent as the range and actual treatment
beneﬁts offered to patients differed greatly between studies. In general,
treatments offeringhigh symptom improvement, a delay in disease pro-
gression, reduction in relapses and particular administration methods
were preferred.
3.2.2.3. Preferences for treatment risk-beneﬁt proﬁles. Three studies objec-
tively measured the risk-beneﬁt trade-off by offering MS patients the
choice of beneﬁts and risks for hypothetical treatments, using the con-
joint analysismethod [49–51].Whilst all three studies used a similar ob-
jective methodology, the studies employed different treatment risk andbeneﬁt scenarios. Johnson and colleagues [51] demonstrated that for a
ﬁve-year delay of disease progression, a 0.48% risk of death by leukae-
mia was acceptable for MS patients; which increased to 1.08% for an
eight-year delay of disease progression. For a similar delay of disease
progression, the acceptable risk of death by liver failure increased by
0.53%, and acceptable risk of severe disability or death from PML in-
creased by 0.36% [51]. Wilson and colleagues [50] found that patients
were willing to accept 0.7% risk of developing PML given a delay in the
progression of disease [50]. Up to 1% adverse risks were accepted by
MS patients if substantial improvements in symptoms could be demon-
strated by the treatment [50]. Patients were willing to accept up to
0.59% of severe adverse effects if drugs could be administered orally
[50]. In fact, this level of risk acceptance was higher than for drugs
which could delay the progression of MS by four years [50] or could re-
duce the frequency ofMS relapses from four yearly to no relapseswithin
the next ﬁve years [51]. Further, a risk of up to 30% of severe adverse ef-
fects was acceptable for MS patients given 32 years of delay in progres-
sion of MS [49].
The study by Bruce and colleagues also assessed risk and beneﬁt
trade-offs of hypothetical treatment scenarios, by using a Medical Deci-
sion Making Questionnaire (MDMQ) [53]. Similar to previous studies,
the choice of whether to uptake a treatment for all patients differed sig-
niﬁcantly according to the combination of treatment risks and beneﬁts
[53]. Additionally, patients who were adherent to their current unspec-
iﬁed treatment were willing to take medications with signiﬁcantly
higher combinations of risks and beneﬁts than patients who were
assessed as non-adherent [53].
In summary, despite using similar measures to objectively assess
trade-offs of treatment risks and beneﬁts, the three studies employed
very different combinations of risks and beneﬁts, limiting any general-
ised conclusions that may be based on these ﬁndings. However, it was
clear from these studies that preferred combinations of treatment
risks and beneﬁts play a key role in the choice of treatment.
4. Discussion and conclusion
4.1. Discussion
This systematic review was carried out to explore MS patient's un-
derstanding of DMD risks and beneﬁts acquired through their standard
healthcare systems, and MS patients' preferences for these risks and
beneﬁts; factors likely to impact shared decision-making. MS patients
with different disease subtypes and those taking a range of DMDs
were assessed by 22 studies in the present review. Understanding of
DMD risks and beneﬁts were mostly addressed as part of a larger pro-
ject. MS patients' preferences for risks and beneﬁts were generally
assessed using treatments offeringhypothetical risks and beneﬁts. Stud-
ies employed both subjective and objective measures. The majority of
studies had methodologies that precluded ﬁrm conclusions.
DMDs in MS have complex risk-beneﬁt proﬁles. All DMDs offer ben-
eﬁts of varying levels, such as reduction in the frequency of MS relapses
and delay in progression of the disease. Side-effects of treatments can
range from mild symptoms to adverse effects that may lead to severe
disability or death [3]. When making decisions about DMDs based on
these complex risk-beneﬁts, a shared decision-making approach is
ideal.
For effective shared decision-making, clear and accurate DMD infor-
mation should be provided to MS patients in order to facilitate under-
standing of treatment risks and beneﬁts. Yet, it appears from the
present review thatMS patients do not sufﬁciently understand informa-
tion about DMDs following routine consultations in their standard
healthcare system. Despite evaluating their risk knowledge as high
[18], MS patients in this review showed poor objective risk understand-
ing [18,38]. There was a trend towards underestimation of treatment
risks [40,44]. This is problematic for long-term treatment adherence,
as some patients are more likely to initiate a treatment that they
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are higher than initially expected [19,22]. MS patients in this review
were generally optimistic about the beneﬁts of their current DMD [33,
34,40,46]. However, many patients overestimated the beneﬁts of their
DMD in reducing the frequency of relapses and delaying progression
of disease [36,41]. This could mean that patients' optimism towards
DMDs may not often accurately reﬂect the actual beneﬁts of the drugs.
This can further impact treatment adherence, since patients who do
not accurately understand the beneﬁts of DMDs are more likely to dis-
continue treatments overtime [22], perhaps as optimism for medica-
tions is replaced with the realisation that the medication does not
offer expected levels of beneﬁts. In fact, a signiﬁcant relationship be-
tween patients who understand information about their treatments
and their adherence to treatments is evident in several studies, includ-
ing those in the present review [21,22,38,41]. Providing accurate and
easily understandable risk and beneﬁt information to MS patients
should therefore improve treatment adherence towards their chosen
treatment.
The ability to understand overall information about DMDs provided
during the standard healthcare systemwas found to be associated with
certain patient factors, for example: age, education and functional status
[37,43]. It is also possible that symptoms of MS itself, for example de-
pression [54], anxiety [55], fatigue [56] and cognitive impairments [57,
58], may further confound understanding of information about DMDs.
However, these symptoms were not explored within the studies in
this review. Regardless, it is apparent that someMS patients require fur-
ther support to comprehend treatment information to a good standard.
This may explain what prompts many patients to independently seek
treatment data through sources beyond standard healthcare [19,41,
42]. This external treatment information may not necessarily be accu-
rate or up-to-date and could lead to further misunderstanding. Thus fu-
ture studies need to primarily focus on improving the existing methods
of providing DMD information for all MS patients, in order to improve
shared decision-making.
Effective shared decision-making also requires patients to communi-
cate their preference for a particular treatment. Preferences speciﬁcally
for risks and beneﬁts of DMDs are likely to inﬂuence MS patients' treat-
ment choice [24–26]. The secondary aim of the present review assessed
the extent to which preferences towards risks and beneﬁts that DMDs
typically offer can impact MS patients' treatment decisions. As anticipat-
ed, even very low levels of adverse risks reduced patients' preference to
take the treatment, and extremely small variations in risk had a signiﬁ-
cant impact on hypothetical treatment decisions [49,50,52]. Preference
for medications with adverse risks rarely exceeded 1%. Preferences for
risks also varied with certain patient factors, as higher risks were gener-
ally accepted by males, functionally impaired individuals, or people al-
ready taking aggressive treatments such as Natalizumab [48,52].
Similarly, certain beneﬁts that DMDs typically offer were signiﬁcantly
preferred over others and had an impact on the choice of treatment. Re-
markably, patients strongly favoured medications that could provide
symptom improvement [49,50], which implies limited understanding
for MS treatments since DMDs are not able to relieve symptoms of MS.
To note, medications presented in both studies [49,50] employed hypo-
thetical treatment scenarios and therefore it is plausible that patients
perceived symptom improvement as hypothetical despite accurate un-
derstanding of DMD beneﬁts [49,50]. It is nevertheless interesting that
patients are likely to take higher risks if DMDs can seemingly aid symp-
toms of their condition. MS patients in this review also showed a greater
preference for treatments offering large reductions in frequencies of re-
lapses, longer delay in disease progression and drugs that could be ad-
ministered orally, being prepared to accept a greater likelihood of risk
in return [49–51,53]. Overall, MS patient preferences varied according
to different combinations of particular risks and beneﬁts, and had a sig-
niﬁcant impact on their choice of treatment. Thus, it is important to elicit
patient preferences for particular risks and beneﬁts of DMDs in order to
improve shared decision-making in MS.A limitation of the present systematic review is the difﬁculty in
drawing robust conclusions or conducting ameta-analysis of the studies
as a result of the variety of outcome measures employed. A narrative
synthesis was considered to be the most appropriate format for
reviewing the studies. However, it is important to acknowledge that
such a qualitative review is subject to greater analysis bias than a quan-
titative systematic review. There were also differences in study design,
methodology and patient characteristics between studies in the review,
which limits conclusions from such ﬁndings. This reﬂects the lack of
uniformity across studies that address MS patients' understanding of
medications. The present review also does not constitute an exhaustive
search of studies or research ﬁndings; for example, the primary authors
of studies were not contacted to resolve or expand on study ﬁndings
owing to time and resource constraints. However, it seems unlikely
that supplementary results or additional outcome measures could pro-
duce less heterogeneous results.
4.2. Conclusion
The present review was the ﬁrst to our knowledge to systematically
gather evidence about patients' understanding of the risks and beneﬁts
of DMD during their standard healthcare system, and their preferences
for these risks and beneﬁts; factorswhich can likely impact shared deci-
sion-making. Despite the heterogeneous ﬁndings, it seems that current
ways of providing DMD risk and beneﬁt information are not generally
uniform or effective. MS patients tend to underestimate treatment
risks and overestimate treatment beneﬁts, with some patients ﬁnding
comprehension especially difﬁcult. MS patients prefer treatments offer-
ing extremely low levels of adverse risks, but are willing to accept
higher risks in exchange for substantial long-term improvements.
Practical implications of this review are providing extra support to
ensure all patients are effectively informed about the complex risk-ben-
eﬁt proﬁles of MS DMDs, and ensuring patients' preferences for treat-
ment risks and beneﬁts are taken into account during the shared
decision-making process.
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A B S T R A C T
Objective: The present review evaluates interventions that have been designed to improve understanding
of the complex risk-beneﬁt proﬁles of disease-modifying drugs (DMDs) in patients with Multiple
Sclerosis (MS).
Methods: A systematic search conducted using PubMed, Embase, Google Scholar and PsycINFO identiﬁed
15 studies. Interventions which provided treatment information were present across a range of study
designs. A narrative synthesis was conducted due to heterogeneity of research ﬁndings.
Results: Interventions providing treatment information ranged from comprehensive education
programmes to booklets of a few pages. MS patients favoured the interventions they received.
Understanding of overall treatment information and treatment risks speciﬁcally, generally improved
following interventions. Yet overestimation of treatment beneﬁts persisted. There was no conclusive
effect on DMD decisions. No superior intervention was identiﬁed.
Conclusion: Interventions designed to improve understanding of DMD risk and beneﬁt information are
moderately successful.
Practice implications: Additional support provided to MS patients beyond routine healthcare can generally
improve understanding of the complex risk-beneﬁt proﬁles of DMDs. Future interventions need to ensure
that patients with symptoms that may confound understanding can also beneﬁt from this additional
information.
© 2016 Elsevier Ireland Ltd. All rights reserved.
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Multiple Sclerosis (MS) is a chronic inﬂammatory disorder of
the central nervous system, which progresses at different rates
between individuals [1]. MS patients experience a range of
symptoms, including depression [2–4], anxiety [2,5], fatigue
[3,6] and cognitive impairments [5,7,8], which likely confounds
patients’ general understanding and ability to recall important
information. This could be problematic for MS patients when
deciding a course of treatment.
The treatments currently available to MS patients are disease-
modifying drugs (DMDs). Although DMDs do not target symptoms
of MS, they can potentially reduce the number of relapses and
delay progression of disease [9]. Yet the rate at which these
beneﬁts occur vary between DMDs and can even vary within
individuals treated with the same medication. In general, MS
patients are initially offered treatments with long-term safety
proﬁles and limited adverse risks, but these are only moderately
successful [10]. These treatments are also known as ﬁrst-line
DMDs. More aggressive treatments may be considered when initial
therapies are not effective. DMDs at this stage offer higher beneﬁts
but potentially adverse effects, including leukaemia, cardiotoxicity,
and progressive multifocal leukoencephalopathy (PML) [9–13]. MS
patients are therefore faced with complex risk-beneﬁt proﬁles of
DMDs when deciding on the best course of treatment.
An understanding of the risks and beneﬁts of treatments is one
of the many components required for an effective shared treatment
decision. Shared decision-making is a highly recommended
concept in patient-centered healthcare and refers to the mutual
exchange of information between patients and health professio-
nals during decision-making, such as decisions made about the
most suitable treatment course [14,15]. This approach is particu-
larly suited to chronic conditions such as MS, where the risk-
beneﬁt proﬁles of treatments are complex and need to be
effectively communicated in order to inform and engage patientsTable 1
Search terms for systematic review.
Search terms
(Multiple AND Sclerosis)
AND
(patients OR people OR persons OR patient)
AND
(risk OR beneﬁt OR side effect OR treatment OR medication OR therapy OR medicine
AND
(format OR framing OR educating OR design OR informing OR health literacy OR strate
OR learning)
AND
(perception OR understanding OR comprehension OR awareness OR knowledge OR din treatment decisions [16,17]. Thus, it is reasonable to expect that
improving MS patients’ understanding of complex risk-beneﬁt
proﬁles of DMDs can have an impact on treatment decision-
making.
To facilitate understanding, patients should ideally be pre-
sented with treatment options and treatment risk-beneﬁt proﬁles
in a clear and coherent manner [14,18]. Yet DMD information
provided to MS patients during routine healthcare is not always
clear or coherent [19–21]. This may explain why many MS patients
actively seek DMD information elsewhere [22,23]. This external
information may not be accurate or up-to-date, which could lead to
further misunderstanding of treatment information. Interventions
have been designed to provide information about the risks and
beneﬁts of DMDs that patients may seek beyond routine health-
care. Although such interventions aim to provide accurate
information about DMD risks and beneﬁts, it is also important
to consider the way this information is presented. This is because
understanding of treatment risks and beneﬁts can be inﬂuenced by
particular graphical [24–26] or numerical formats [27–29], the
framing of information [30–32] and how comparisons of risks and
beneﬁts are communicated [33–35]. Thus, an ideal intervention
will give patients unbiased and accurate treatment information
using effective presentation methods in order to optimise the
understanding of DMD risks and beneﬁts, and consequently result
in informed treatment decisions.
Köpke, Solari, Khan, Heesen and Giordono [36] recently
reviewed 10 interventions designed to aid patient understanding
of MS related information, which includes two interventions that
speciﬁcally provided information about the risks and beneﬁts of
DMDs. Although all interventions reviewed were different in many
respects, understanding of the disease generally improved post-
intervention. Despite this improvement there was no conclusive
effect on decision-making. This review, however, was limited to
randomised controlled trials only, which does not allow for a
comprehensive evaluation of all interventions that provide MS OR medical OR therapies OR therapeutics OR pharmaceutical preparations)
gy OR program OR intervention OR communicating OR information OR education
ecision-making)
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on the risks and beneﬁts of DMDs [36].
To the best of our knowledge, the present systematic review is
the ﬁrst comprehensive evaluation of interventions primarily
designed to improve understanding of risks and beneﬁts of DMDs
for MS patients. This review will also explore the effects of these
interventions on patients’ treatment decisions.
2. Methods
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) recommendations were used as guide-
lines for the presentation of this review [37]. A protocol for the
present review was not previously published or registered.
2.1. Systematic literature search
The systematic literature search was conducted in November
2016 using PubMed, Embase, Google Scholar and PsycINFO.
Uniform search terms were developed and used with all databases
(see Table 1).
2.2. Eligibility criteria
The inclusion criteria for the studies in the present review were
peer-reviewed studies in English, with human adults and with
patients of any clinical subtype of MS. No date restriction was
applied. Studies were not limited to any particular study design. No
restrictions were placed on the type of control group. Studies were
required to have interventions about either real DMD information
or information about ﬁctitious treatments which would eventuallyRecords  idenﬁed aer search 
(n = 3,457 )
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Fig. 1. PRISMA ﬂow chart for selection prosupport understanding of DMD information. Interventions were
deﬁned as any additional strategy or decision-aid which provided
treatment information beyond that given during routine health-
care. Studies with some evaluation of these interventions were
retained.
Studies were excluded if they evaluated educational interven-
tions for complementary medicines or medications for the
management of MS symptoms. Studies assessing patients’
understanding for disease diagnosis or prognosis were not eligible
for inclusion. Studies without any form of educational interven-
tion, with interventions based on other aspects of MS such as
cognition or self-management, interventions aimed primarily at
health professionals, an intervention protocol for an upcoming
study with no existing data, or interventions not exclusive to
patients with MS, were also excluded from the review.
All titles and abstracts were screened. Studies that were
considered relevant from additional reference checking were also
included. At this stage, 96 studies were considered for eligibility
and full texts were subsequently accessed (see Fig. 1).
2.3. Data extraction
Data extraction forms were created to extract relevant
information from full texts, and assess their eligibility into the
ﬁnal review. Extraction was initially carried out by one reviewer
(GR) and was veriﬁed by another (DL). Any discrepancies were
resolved by discussion. Following data extraction, 81 studies were
excluded from the ﬁnal review in line with the exclusion criteria
(see Fig. 1).
Baseline characteristics of participants were extracted from the
15 shortlisted studies, comprising (where reported) age, type ofAdd ional records  idenﬁed 
through other sources 
(n = 2)
es removed 
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Records  excluded following 
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(n = 1,32 5)
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Full-text arcles excluded, with 
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- Intervenons  on other 
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- Review (n=14)
- Non-intervenon study (n=19)
- Protocol study for  an 
intervenon (n=4)
- Intervenons  including 
paents from other condions 
(n=7)
- Not peer-revie wed (n=2)
- Other MS medicaon (n=1)
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cess of studies in systematic review.
Table 2
Quality assessment of studies evaluating interventions to improve patient understanding of DMD information in MS.
Study (ﬁrst author, year) Selection bias Study design Confounders Blinding Data collection method Withdrawals and dropout Overall quality rating
Mohr, 1996 Moderate Moderate – Moderate Strong Strong Strong
Kasper, 2006 Moderate Moderate Strong Moderate Strong Weak Moderate
Kasper, 2008 Strong Strong Strong Strong Moderate Strong Strong
Basso, 2010 Weak Strong Strong Moderate Strong Moderate Moderate
Heesen, 2010 Moderate Moderate Moderate Weak Moderate – Moderate
Kasper, 2011 Strong Strong Strong Moderate Moderate Strong Strong
Hofmann, 2012 Weak Moderate – Moderate Weak Weak Weak
Tur, 2012 Moderate Weak Strong Moderate Strong Moderate Moderate
Feicke, 2014 Moderate Strong Strong Weak Strong Strong Moderate
Köpke, 2014 Strong Strong Strong Strong Strong Strong Strong
Friedel, 2015 Moderate Moderate – Moderate Moderate Weak Moderate
Zimmer, 2015 Moderate Moderate – Moderate Moderate Strong Moderate
Colombo, 2016 Weak Weak – Weak Moderate – Weak
Kopke, 2016 Moderate Strong Strong Moderate Strong Strong Strong
Rahn, 2016 Weak Strong Strong Moderate Strong Weak Weak
Overall quality rating: Strong = no weak ratings; Moderate = one weak rating; Weak = two or more weak ratings.
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design and methodology was recorded. Information about the
interventions was further extracted, including the content, length,
presentation methods and any additional details of how the
interventions were conducted.
The impact of the interventions on either understanding of
treatment information overall or understanding of treatment risks
and beneﬁts speciﬁcally was also extracted in the present review
and incorporates data from self-report and objective measures.
Patient’s feedback on the interventions was also retained. Relevant
data for the present review was obtained from numerical
information in texts, tables and graphs, and statistical analysis.
2.4. Quality assessment
Quality of publications was independently examined by two
reviewers (GR and DL) using the Effective Public Health Practice
Project (EPHPP) quality assessment tool for quantitative studies
[38]. This particular tool was chosen because it can evaluate all
types of quantitative studies in the health care setting [39], has
high inter-rater reliability [39] and is often considered ideal for
systematic reviews [40]. As per the tool, the ﬁnal quality rating was
derived from the rating of six measures: selection bias, study
design, confounders, blinding, data collection methods, and
withdrawals or drop-outs (see Table 2).
Quality was further assessed for educational interventions
within the studies, based on their reporting of criteria for evidence-
based patient information. Eight different criteria were chosen and
adapted from Bunge and colleagues [18], depending on the extent
of evidence and relevance to both simple and complex educational
interventions (see Table 3).
3. Results
3.1. Study design and participant demographics
Fifteen studies were shortlisted in the review, and comprised
interventions which were primarily designed to improve under-
standing of DMD risk and beneﬁt information in MS patients. Four
studies in this review evaluated interventions using a randomised
controlled procedure [41–44]. A type of control group was present
in seven studies [41,42,44–48] and baseline scores prior to the
intervention were recorded by ten studies [42,43,47–53] (Table 4).
Five of the 15 studies were considered to be of a high quality
[41–43,48,49], with three studies deemed weaker in quality
[44,50,54] (see Table 2). Four of the 15 studies had interventions
that fulﬁlled or reported at least 4 of the 8 criteria for evidence-
based patient information. The most commonly reported criteria inthe interventions were the use of comprehension enhancing tools,
involvement of patients in the development process and inclusion
of numerical data (see Table 3).
A total of 2552 MS patients were included across 15 studies and
had a range of MS disease subtypes, comprising: 79(3.1%) CIS
patients, 1064 (41.7%) RRMS patients, 214 (8.4%) PPMS patients and
391 (15.3%) SPMS patients. The remaining MS patients had unclear
or unreported MS disease subtype (31.5%). The mean age of
patients was 43.1 years (range: 37–50). One study did not allow for
calculation of mean age [49] and two studies only presented
median or mode values for age [46,52]. Two studies also included
105 non-MS patients, with a mean age of 43.5 years [45,54].
Nine studies reported patients’ disease duration from initial MS
symptoms [42–44,46,47,50,53–55], with an average of 9.2 years.
Five studies reported time since MS diagnosis [41,42,48,51,52],
with an average of 5.8 years.
Only one included study reported patients’ objective cognitive
status [45]. Patients were assessed on the California Verbal
Learning Test-II (CVLT-II), Wisconsin Card Sorting Test-64 (WCST)
and the Digit Span subtest from Wechsler Adult Intelligence Scale.
MS patients were considered to be cognitively impaired if they
scored below the 5th percentile of at least one cognitive measure
[45].
A total of 1384 (54.2%) MS patients had taken disease-
modifying drugs during the course of their disease and 188
(7.4%) MS patients had not taken a DMD. The remaining studies did
not specify DMD status (980 MS patients, (38.4%)). Of studies
reporting MS patients’ current DMD, 273 patients were on the ﬁrst-
line treatment interferon-beta [42,49,51], and the remaining
patients were taking second-line treatments, with 53 patients
on Mitoxantrone [50], 173 patients on Natalizumab [46,55] and 98
patients on Fingolimod [52]. In majority of these studies, DMD
status was known by treating physicians or researchers involved
with the study [46,47,49–52,55].
3.2. Intervention characteristics
3.2.1. Intervention type
The majority of interventions contained a booklet or leaﬂet for
MS patients [41–44,46,48,50,51,53,55]. These leaﬂets ranged from
providing comprehensive information (120 pages, [41,48]; 57
pages [42]) to short summaries [46,50,53]. The booklet length was
unclear in four studies [41,44,51,55]. Four interventions which
included booklets also contained an additional intervention
component [41,42,48,51]. A short vignette of information was
read aloud in one intervention but was not handed to patients in
the form of a booklet or leaﬂet [45] (Table 5).
Table 3
Quality assessment of content and administration of evidence-based patient information: Criteria adapted from Bunge and colleagues (2010).
Study (ﬁrst
author, year)
Numerical data
(e.g. frequencies)
Graphs (e.g. bar
chart,
pictograph)
Balanced
framing
Pictures
and
drawings
Clear layout
(e.g. size of
font)
Plain language
and readability
Comprehension
enhancing tools (e.g.
mind maps)
Development process (e.g.
feedback from patients)
Mohr, 1996 X – – – – – – –
Kasper, 2006 X X – – – X – X
Kasper, 2008 X X X – X X – X
Basso, 2010 – – – – – X X –
Heesen, 2010 – – – – – – – –
Kasper, 2011 – X – X – – – –
Hofmann, 2012 X – – – X – – –
Tur, 2012 – – – – – – – X
Feicke, 2014 – – – – – – X X
Köpke, 2014 – – – – – – X X
Friedel, 2015 – – – – – – X –
Zimmer, 2015 – – – X – X X –
Colombo, 2016 X X – – X X X X
Kopke, 2016 – – – – – – X X
Rahn, 2016 X – – X – – X X
X = criteria reported; – = criteria unreported or not present.
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intervention in ﬁve studies. Four of these programmes were
conducted by health professionals [48,49,51,52] and one education
programme was conducted by a non-medical person [42].
3.2.2. Intervention content
All, bar two interventions [49,53], provided some form of
treatment risk information to patients with MS. Interventions also
included information about: treatment beneﬁts [36,41,43,45,47–
49,53,54], alternative DMDs available to patients [42,45,47,48],
efﬁcacy studies for DMDs [42,48,52–54], DMD decision-making
[41,42,48,54], administration of DMDs [51,52,54] and tailored
information about DMDs for patients’ disease subtype [41,55].
3.2.3. Intervention presentation methods
Many different methods to present information were employed
in the interventions. Methods which provided numerical informa-
tion was manipulated by some studies, for instance by presenting
or giving explanations for absolute risk numbers [41,43,50,53],
relative risk numbers [43] and conﬁdence intervals [44]. Four
studies used graphical formats in the form of either pictograms
[41,43,53] or bar graphs to convey treatment information [54]. One
study focused on whether the information was framed in a positive
or negative manner [41].
Some interventions also provided treatment information using
interactive methods, deﬁned as involving patient in the interven-
tion process, which includes: questions and answers [42,47,48,51],
discussions in person [42,47,48,51], role-playing [48], recognition
cues [45], information presented in short successions [45] and
interactive exercises presented at the end of interventions
[41,42,47,52]. Media and technology was used to present treatment
information in two studies [36,48,49,54].
Together, these strategies were designed to optimise under-
standing of the risks and beneﬁts of DMDs.
3.3. Intervention outcomes
3.3.1. Understanding of overall treatment information
Four studies looked at understanding of overall treatment
information with no particular focus on the risks or beneﬁts of
treatments. All employed an objective comprehension question-
naire to assess understanding, but maximum scores ranged from 6
to 18 (Table 6).Despite no signiﬁcant difference in the understanding of
treatment information between a non-clinical control group and
MS patients without cognitive impairment, both groups were
signiﬁcantly better than cognitively impaired MS patients [45]. The
control and MS cognitively unimpaired group showed greater
understanding following information provided in short succes-
sions or when recognition cues were provided to aid recall of
information, compared to when treatment information was
provided in an uninterrupted block [45]. A similar trend was
observed in the cognitively impaired MS group. However, this
group also showed a signiﬁcant improvement in understanding
when recognition cues were given alongside treatment informa-
tion provided in short successive steps, in comparison to
information provided in successive steps alone [45]. In two other
studies, a signiﬁcant increase in understanding of overall
treatment information was also evident following intervention
when compared to both baseline understanding [52] and a control
group receiving standard information [44]. However, there was no
signiﬁcant improvement on patients’ understanding post-inter-
vention when the control group received identical content as the
intervention in a non-interactive form [47].
To note, studies differed in the content of the intervention, as
only two of the four studies provided information about real DMDs
[47,52]. Further, only some items in the questionnaires used to
assess patients’ understanding focused speciﬁcally on treatment-
related information.
In summary, although there is a trend towards an improvement
in understanding of overall treatment information following
intervention, this cannot be established with studies employing
different interventions and comparison groups.
3.3.2. Treatment risk understanding
The understanding of treatment risks in MS patients following
intervention was assessed by ﬁve studies, using real DMD
information in four studies [42,48,50,54] and a hypothetical
treatment information in another [43].
Following a short leaﬂet about risks of taking Mitoxantrone, MS
patients showed a signiﬁcant increase in accurate risk under-
standing of Leukaemia, an adverse risk associated with the
medication [50]. This risk was initially underestimated by 58%
of MS patients [50]. Underestimation of risk persisted in 18% of MS
patients following intervention. Improved risk understanding was
not dependent on demographic factors, disease duration or the
Table 4
Study design and participant demographics.
Study
(ﬁrst
author,
year)
Quality
ratings
Methodological
design
Recruitment method Sample size Mean age in
years
Type of MS
(n)
Disease duration
and time since
diagnosis
(years)
Current DMD
status
Real/faux
risk-beneﬁt
information
Mohr,
1996
Moderate Pre-post
intervention
study
Outpatient clinics 99 – Not
speciﬁed
– Interferon
beta-1b
Real
Kasper,
2006
Pre-post
intervention
study
Outpatient clinics 169 44 RRMS (75);
PPMS (75);
Unclear (19)
Disease duration
(7.7)
DMD (103);
No DMD (66)
Real
Kasper,
2008
Strong Double-blind
RCT
Newspapers; web-sites;
National self-help journal
297 43 CIS (45);
RRMS (153);
PPMS (31);
SPMS (59);
Unclear (9)
Time since
diagnosis:
IG (8.9)
CG (8.3)
Not speciﬁed Real
Basso,
2010
Moderate Questionnaire Newspapers; Newsletter of
MS society; MS support
groups
36 MS patients
without cog
impairments
(48);
MS patients
with cog
impairment
(45);
CG (38)
RRMS (14);
Unclear
(22);
– Not speciﬁed Real 
Unrelated
to DMD
Heesen,
2010
Moderate Questionnaire MS outpatient clinics 69 40a Not
speciﬁed
Disease duration
(11)
Natalizumab Real
Kasper,
2011
Strong RCT MS outpatient clinic; Centre
of Neurology; MS society
111 43 Not
speciﬁed
Disease duration
(7.5)
Not speciﬁed Faux
Hofmann,
2012
Weak Retrospective
cohort study
Patients allocated
Mitoxantrone in last 9 years
(database of hospitals and
private clinics)
575 50 RRMS (49);
PPMS (76);
SPMS (258);
Other (4);
Unclear
(188)
Disease duration
(28.9)
Mitoxantrone
(53);
Terminated
Mitoxantrone
(522)
Real
Tur, 2012 Moderate Survey MS clinics 104 JCV
seropositive
(38);
JCV
seronegative
(37)
RRMS Disease
duration:
JCV positive
(13.72)
JCV negative
(11.73)
Natalizumab Real
Feicke,
2014
Quasi-
experimental
study design
MS clinics; private practise 64 IG (42);
CG (37)
RRMS (35);
PPMS (2);
SPMS (2);
Unclear (25)
Disease
duration:
IG (0.97)
CG (1.64)
DMD (45);
No DMD (19)
Real
Kopke,
2014
Strong Double-blind
RCT
MS outpatient clinics 192 37 CIS (27);
RRMS
(133);
Unclear (32)
Disease
duration:
IG (4.3)
CG = 4.0
Time since
diagnosis:
IG (1.4)
CG (1.2)
Not speciﬁed Real
Freidal,
2015
Moderate Prospective
longitudinal
study
MS clinics 174 40 RRMS
(125);
Unclear
(49)
Time since
diagnosis (4.84)
Interferon-
beta 1b
Previous DMD
(82);
No previous
DMD (75)
Real
Zimmer,
2015
Moderate Pre-post
intervention
study
MS Centre 98 41b Unclear Time since
diagnosis (4.64)
Fingolimod
Previous DMD
(67);
No previous
DMD (31)
Real
Colombo,
2016
Survey Press release; Website
adverts; Newsletters; E-mail
invitations; Meeting
presentations
344
MS patients
(276)
Family
reporting
about MS
patients (68)
MS patients
(43);
Family
reporting
about MS
patients (45)
MS
patients:
RRMS
(203);
PPMS (12);
SPMS (32);
Unclear (29)
Family
reporting
about MS
patients:
RRMS (26);
PPMS (3);
Disease
duration:
MS patients (9);
Family reporting
about MS
patients (9)
DMD not
speciﬁed
Real
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Table 4 (Continued)
Study
(ﬁrst
author,
year)
Quality
ratings
Methodological
design
Recruitment method Sample size Mean age in
years
Type of MS
(n)
Disease duration
and time since
diagnosis
(years)
Current DMD
status
Real/faux
risk-beneﬁt
information
SPMS (13);
Unclear (26)
Kopke,
2016
Prospective
controlled trial
Rehabilitation centres 156 IG (42);
CG (43)
CIS (5)
RRMS (105);
PPMS (13);
SPMS (14);
Unclear (19)
Time since
diagnosis:
IG (7)
CG (9)
DMD (88);
No DMD (68)
Real
Rahn,
2016
Pilot RCT MS day hospital; MS self-help
society; Other self-help
initiatives
64 IG (47);
CG (44)
CIS (2)
RRMS (42);
PPMS (2);
SPMS (13);
Unclear (5)
Disease
duration:
IG (9);
CG (10)
DMD (29);
No DMD (35)
Faux
Absolute numbers reported, unless speciﬁed. Abbreviations: CG, Control group; CIS, clinically isolated syndrome; Cog, Cognitive; DMD, Disease-modifying drug; IG,
Intervention group; MS, Multiple Sclerosis; PPMS, primary progressive multiple sclerosis; RCT, Randomised controlled trial; RRMS, relapsing-remitting multiple sclerosis;
SPMS, secondary progressive multiple sclerosis.
a Mode value.
b Median value.
G.K. Reen et al. / Patient Education and Counseling 100 (2017) 1031–1048 1037available scientiﬁc evidence at treatment initiation. However,
patients with large errors on the Medical Data Interpretation Test
(MDIT), which assessed the ability to handle probability data,
showed an underestimation of Leukaemia risk after reading the
leaﬂet [50]. Following an intervention with a 4-h education
programme combined with a 57-page leaﬂet, understanding of the
ﬁrst-line DMD risks signiﬁcantly improved for patients in the
intervention group compared to MS patients in the control group
[42]. The authors further combined the scores of risk understand-
ing with patient’s attitude towards their current DMD, which they
termed as the score of being informed. According to this measure,
patients in the intervention group were signiﬁcantly better
informed than the control group [42]. Similar results were seen
with another multi-component intervention, consisting of a 2-h
and 4-h education programme, in addition to a 120-page
information brochure [48]. In comparison to the control group
receiving standard information brochure and a rehabilitation
programme, the intervention group showed a signiﬁcant increase
in DMD risk understanding at 2 weeks and 6 months post-
intervention [48].
One study measured risk understanding using self-report
questions after trialling a DMD informational website for
interferons [54]. Over 80% of MS patients stated that they found
the presented risk information really or extremely clear and easy to
understand [54].
Using hypothetical treatment information, Kasper and col-
leagues [43] showed that the ability to recall treatment risks from
pictograms to frequencies was generally low. However the authors
noted that risks were recalled more accurately than beneﬁts [43].
Mean errors in recalling risks from pictograms which displayed
ﬁgures consecutively were signiﬁcantly lower as opposed to
pictographs with random arrangement of ﬁgures [43]. Patients
that attributed high personal risk of becoming wheelchair
dependent within two years showed a small correlation with
overestimation of risk following intervention [43].
Overall, understanding of treatment risks showed an improve-
ment of reasonable accuracy post-intervention despite the variety
of interventions employed across the reviewed studies, and studies
using a mixture of self-report and objective measures.
3.3.3. Treatment beneﬁt understanding
Understanding of treatment beneﬁts was assessed objectively
by four studies post-intervention [43,46,49,53] and with self-
report measures by one study [54].Following a 3-page information booklet, MS patients showed
signiﬁcant improvements in understanding of interferon beneﬁts
post-intervention when compared to baseline [53]. The authors
did note that around 99 of 169 patients were still not able to
understand the information after intervention [53]. Following
another educational intervention, there was a signiﬁcant reduction
in patients that were overly optimistic about the general beneﬁts of
their DMD, even though overestimation persisted in about 33% of
individuals [49]. At baseline, approximately 34% of MS patients
were unrealistically optimistic about the beneﬁts of their
medication on disease progression speciﬁcally. Yet post-interven-
tion, the number of MS patients overestimating these speciﬁc
beneﬁts about their DMD increased to about 40% [49]. Likewise, in
another study, MS patients believed that their medication will
provide a greater reduction of risk for a maximum walking distance
of 100 m following the short leaﬂet-based intervention on
Natalizumab, in comparison to physicians [46]. Even with
hypothetical treatment information, MS patients overestimated
the beneﬁts of a ﬁctitious treatment by more than 100% following
intervention [43].
Using self-report measures, over 75% reported that the
interferon beneﬁts presented in a DMD informational website
were really or extremely clear and that graphical presentations of
treatment beneﬁts were easy to understand [54].
In summary, initial overestimation of treatment beneﬁts
seemingly persists despite interventions that provide treatment
beneﬁt information beyond routine healthcare, although many
patients report their own understanding of treatment beneﬁts
following intervention as high.
3.3.4. Personal risk perception
Beyond understanding of treatment risk, two studies also
assessed personal perception for treatment risks following
interventions that provided information about real DMDs [46,50].
Following a short leaﬂet about Natalizumab, 84% of MS patients
were willing to accept a 1 in 100 or higher risk of PML, an adverse
side-effect of the medication, compared to only 51% of physicians;
showing a signiﬁcant difference [46]. The authors noted that PML
risk acceptance was not correlated with understanding of DMD
information [46]. Patient’s personal risk attribution of PML as an
adverse risk of Natalizumab was deemed signiﬁcantly lower than
the PML risk they attributed to Natalizumab generally post-
intervention [46]. However, since baseline measures were not
recorded in the study, it is difﬁcult to determine whether personal
Table 5
Outcomes of DMD informational interventions.
Study
(ﬁrst
author,
year)
Intervention type Control group Intervention content Intervention
presentation
format
Baseline
recorded
Self-
report or
objective
measure
Outcome
measure
Results
Mohr,
1996
Education session
(conducted by a MS
Nurse)
None Information about
treatment beneﬁts
Videotape Yes Objective DMD beneﬁt
understanding:
Survey items
from BSQ (follow
up: immediate)
Relapse rate:
Expected < 10%
reduction (‘overly
pessimistic group’):
Baseline = 4%
patients;
Post-
intervention = 1%
patients
Expected 10–30%
reduction (‘accurate
group’):
Baseline = 39%
patients;
Post-
intervention = 66%
patients
Expected >50%
reduction (‘overly
optimistic group’):
Baseline = 57%
patients;
Post-
intervention = 33%
patients
Disease
progression:
Expected no
change:
Baseline = 40%
patients; post-
intervention = 20%
Expected slower
progression:
Baseline = 26%
patients; post-
intervention = 41%
Expected some
restoration of
function:
Baseline = 29%
patients; post-
intervention = 37%
Expected return to
normal function:
Baseline = 4%
patients; post-
intervention = 2%
Kasper,
2006
3-page information
booklet
None Interferon DMD beneﬁts;
Clinical trial information
about interferons
Control event
rate;
Experimental
event rate;
Absolute risk
reduction;
Pictograms
Yes Objective DMD beneﬁt
understanding:
Three items
(follow up:
immediate)
Control event rate:
Pre-
intervention = 10%
Post-
intervention = 43%
Signiﬁcant
difference
(p < 0.001)
Experimental event
rate:
Pre-
intervention = 33%
Post-
intervention = 43%
Signiﬁcant
difference
(p = 0.043)
Absolute risk
reduction:
Pre-
intervention = 21%
Post-
intervention = 41%
Signiﬁcant
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Table 5 (Continued)
Study
(ﬁrst
author,
year)
Intervention type Control group Intervention content Intervention
presentation
format
Baseline
recorded
Self-
report or
objective
measure
Outcome
measure
Results
difference
(p < 0.001)
Kasper,
2008
120-page new
Information booklet;
Worksheet
80-page
booklet of
routinely
available
information
Basics of how risks are
presented;
Tailored approach to
disease subtype;
Risk-beneﬁts of DMD;
Decision-making
Probabilities;
Absolute
numbers;
Pictograms of
risks and
beneﬁts;
Positive and
negative
framing;
Interactive
exercise
Yes Self-
report
Evaluation of
intervention: VAS
(follow
up: >6 months)
IG = rated value of
information higher
than CG (p < .001)
IG = better informed
than CG (p < .001)
IG = felt more
important questions
were answered
adequately than CG
(p < .001)
DMD decisions:
VAS (follow up:
baseline, >4
week, >6
month)
Positive attitude of
current DMD:
Baseline: CG = 62%;
IG = 65%
Post-intervention:
IG more critical
towards DMD than
CG ( > 4 week;
p < 0.008)
Progress in decision:
No sig difference
between IG and CG
Basso,
2010
Treatment disclosure
vignette (5 paragraphs of
2–5 sentences each)—
read aloud to people
with MS
Treatment
disclosure
vignette (5
paragraphs of
2–5 sentences
each)—read
aloud to healthy
people
Information about
treatment; Treatment
beneﬁts and its likelihood;
Treatment risks and
likelihood; Alternative
treatments and their risks-
beneﬁts
1. Information
read aloud
uninterrupted;
2. Information
read aloud in
‘chunks’
without
recognition
cues
3. Information
read aloud in
‘chunks’ with
recognition
cues
No Objective General
understanding of
information:
comprehension
questions (max.
10 points) (follow
up: immediate)
Uninterrupted
(mean score):
CG (n = 12): 8.63
MS-unimpaired
(n = 24): 7.79
MS-cog impaired
(n = 12): 5.58
Information read
aloud in ‘chunks’
(mean score):
CG: 9.94
MS-unimpaired:
8.96
MS-cog impaired:
8.25
Information read
aloud in ‘chunks’
with recognition
cues (mean score):
CG: 9.88
MS-unimpaired:
9.38
MS-cog impaired:
9.33
CG: Chunking and
recognition cueing
better than
uninterrupted
(p < 0.001)
MS-unimpaired:
Chunking and
recognition cueing
better than
uninterrupted
(p < 0.001)
MS-cog-impaired:
Recognition cueing
better than
chunking and
uninterrupted;
chunking better
than uninterrupted
(p < 0.001)
Heesen,
2010
3-page leaﬂet 3-page leaﬂet
given to
physician’s
Information about
natalizumab-associated
PML
Unclear No Self-
report
DMD beneﬁt
understanding:
average (follow-
up: immediate)
Risk of maximum
walking distance of
100 m after
Natalizumab:
Patients = 40% to
10%
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Table 5 (Continued)
Study
(ﬁrst
author,
year)
Intervention type Control group Intervention content Intervention
presentation
format
Baseline
recorded
Self-
report or
objective
measure
Outcome
measure
Results
Physicians = 10% to
<10%
10-year risk of being
wheelchair-bound
after Natalizumab:
Patients = 40% to
10%
Physicians = 30% to
10%
Progression free
after 2 years of
Natalizumab:
Patients = 50%
Physicians = 50%
Self-
report
DMD risk
understanding:
VAS
(follow-up:
immediate)
Patient’s general
PML risk
attribution = 4.5
No signiﬁcant
difference with
physician
Self-
report
DMD risk
perception: 4 risk
options and VAS
(follow-up:
immediate)
Stop Natalizumab at
following risk levels
of PML:
2:10,000:
Patients = 17%;
Physicians = 49%
1:100:
Patients = 29%;
Physicians = 48%
>1:100:
Patients = 29%;
Physicians = 3%
Patient’s personal
PML risk
attribution = 2.7
Self-
report
DMD decisions:
VAS (0-10)
(follow-up:
immediate)
Willingness to
continue treatment
(mean VAS score):
Patients = 9.0
Physicians = 6.1
Kasper,
2011
Booklet None Risk-beneﬁt proﬁles of a
faux DMD: ‘Relevant
scenario’ (related to
medication)
Risk-beneﬁt of non-
medical problem: ‘Neutral
scenario’ (not related to
medication)
Pictograms
showing risks-
beneﬁts
without
numerical or
verbal
explanation;
Graphical
explanation of
absolute and
relative risk
reduction;
Graphical
explanation of
beneﬁt vs. no-
beneﬁt of DMD
No Objective DMD risk
understanding of
‘relevant
scenario’ (related
to medication)
(follow-up:
immediate)
Mean errors of
frequencies of side-
effects:
‘Unsorted
pictogram’
group = 15.7% (s.d.
12.4)
‘Sorted pictogram’
group = 10.8% (s.d.
9.6)
Total = 11.4%; Mean
error = +15.0
DMD beneﬁt
understanding of
‘relevant
scenario’ (related
to medication)
(follow-up:
immediate)
Mean errors of
frequencies of
beneﬁts:
‘Unsorted
pictogram’
group = 20.2% (s.d.
20.4)
‘Sorted pictogram’
group = 16.8% (s.d.
16.1)
Total = 16.5%; Mean
error = +17.7
DMD decisions:
(follow up:
immediate)
No correlation
between DMD
choice and
understanding of
treatment
information
Self-
report
Evaluation of
intervention:
Preference for
pictograms
Preference for
‘unsorted
pictograms’ = 2%
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Table 5 (Continued)
Study
(ﬁrst
author,
year)
Intervention type Control group Intervention content Intervention
presentation
format
Baseline
recorded
Self-
report or
objective
measure
Outcome
measure
Results
(follow up:
immediate)
Tur, 2012 Booklet None Risk factors of PML; Risk of
discontinuing
Natalizumab; Tailored to
individual PML risk
Unclear No Self-
report
DMD decisions:
discontinuation
of Natalizumab
treatment (follow
up: immediate)
Patients with
highest PML
risk = 60%
discontinued
treatment
Patients with
second-highest PML
risk = 24%
discontinued
treatment
Patients JCV
seronegative = 0%
discontinued
treatment
Patients JCV
seropositive for less
than 2 years = 0%
discontinued
treatment
Hofmann,
2012
5-min leaﬂet None Summary of LK and CT
risks;
General risk knowledge of
Mitox
Absolute risk
numbers;
Probability data
Yes Objective DMS risk
understanding:
Risk choice from
4 options (follow-
up: immediate)
Risk of Leukemia:
Baseline estimation
of risk:
Accurate risk at
8:1000 = 40%
Underestimation of
risk at
8:10,000 = 58%
Overestimation of
risk = 1%
Post-intervention
estimate of risk:
Accurate risk at
8:1000 = 79%
Underestimation of
risk at
8:10,000 = 18%
Overestimation of
risk = 4%
Self-
report
DMD risk
perception:
General risk
perception and
individual risk
perception using
VAS (follow-up:
immediate
Post-intervention:
Signiﬁcant increase
of risk perception
for Leukemia and
cardiotoxicity
(p<.05)
Baseline and post-
intervention:
General risk
perception higher
than individual risk
perception
(p < .001).
Self-
report
Evaluation of
intervention: VAS
rating (0-10)
(follow-up:
immediate)
Intervention
considered
important by most
patients = 1.1
median VAS rating
Intervention did not
increase
worries = 4.7
median VAS rating
Recommend
intervention to
others = 85%
Feicke,
2014
420 min training
program (conducted by
trained neurologist,
psychologists or MS
Nurse)
Brochure with
same content as
training
Seven modules including:
Risks and beneﬁts of
DMDs;
DMD options;
General info about DMDs
Discussions;
Mind maps;
rating scales;
interactive
exercises; Q&A
Yes Objective General
understanding of
information: 14
comprehension
questions (follow
up: baseline,
Mean score at
baseline:
CG = 10.70
IG = 10.77
No signiﬁcant
difference
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Table 5 (Continued)
Study
(ﬁrst
author,
year)
Intervention type Control group Intervention content Intervention
presentation
format
Baseline
recorded
Self-
report or
objective
measure
Outcome
measure
Results
immediate, > 6
month)
Mean score post-
intervention
(immediate):
CG = 11.61
IG = 12.52
No signiﬁcant
difference
Mean score post-
intervention
( > 6 months):
CG = 11.88
IG = 11.77
No signiﬁcant
difference
Kopke
2014
57-page new
educational booklet;
4-h education
programme (conducted
by a non-medical person)
5 page
information
leaﬂet;
4-h education
programme for
stress
management in
MS
Recent evidence of early
MS DMD;
DMD efﬁcacy studies;
DMD options in early MS;
Risks-beneﬁts of DMDs in
early MS;
Decision-making exercise
and discussion
PowerPoint
presentation;
Q&A;
Group
discussion;
Guided
discussion;
Interactive
exercises
Yes Objective DMD risk
understanding:
19-item
questionnaire
(follow-up:
baseline; >2
weeks)
Mean risk
knowledge at
baseline;
IG = 10.6
CG = 9.4
Mean risk
knowledge
( > 2weeks):
IG = 12.3
CG = 10.2
Signiﬁcant
difference (p < .001)
Self-
report
DMD decision-
making: PBMS
(follow-up: 2
weeks, 6 and 12
months)
IG more critical of
DMDs than CG;
IG felt less social
pressure towards
DMD uptake
DMD status
( > 6 months)
IG (n = 41):
Newly initiated
DMD = 16
Discontinued = 5
CG (n = 51)
Newly initiated
DMD = 18
Discontinued = 12
Freidal,
2015
Practical education;
telephone consultations;
home visits; (conducted
by MS Nurses); written
guide; DVD
None Injection techniques;
management of side-
effects; storage and
transportation; possible
side-effects; importance of
adherence
Q&A; private
telephone and
home
consultations
Yes Self-
report
Evaluation of
intervention: 6-
point likert scale
(1 = very good to
6 = insufﬁcient)
(follow-
up: >3 months)
Mean patient
ranking:
Satisfaction with
medication
application
(n = 114) = 1.11
Satisfaction with
injection training
(n = 111) = 1.23
Satisfaction with
telephonic care
(n = 58) = 1.43
Intervention useful?
Yes = 64
Little = 16
No = 3
Zimmer,
2015
60-minute talk for
treatment-experienced
patients; 90-minute talk
for newly diagnosed
patients; text and
picture cards; take-
home manufacturers
leaﬂet
(conducted by MS Nurse)
None Efﬁcacy and mode of
action; administration,
pauses and non-
adherence; storage;
pharmacy, costs and
insurance; side-effects and
how to understand
information leaﬂet; risks
and prevention;
monitoring over time
Interactive talk;
text cards with
pictures to
accompany
talk; ‘memory
cards’ at end
with key points
Yes Objective General
understanding of
information:
questionnaire
(follow-up:
immediate)
Median score
(maximum 18):
Pre-test = 6
Post-test = 14
Self-
report
Evaluation of
intervention: VAS
(0 = not at all
informed, to
10 = totally
informed)
(follow-up:
immediate)
Perception of being
informed:
Pre-intervention:
Score < 7 = 78; Score
> 7 = 19
Post-intervention:
Score < 7 = 0; Score
> 7 = 97
Certainty of being
able to handle all
treatment:
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Table 5 (Continued)
Study
(ﬁrst
author,
year)
Intervention type Control group Intervention content Intervention
presentation
format
Baseline
recorded
Self-
report or
objective
measure
Outcome
measure
Results
Pre-intervention:
Score < 7 = 64; Score
> 7 = 33
Post-intervention:
Score < 7 = 1; Score
> 7 = 96
Conﬁdence in being
able to handle all
treatment aspects:
Pre-intervention:
Score < 7 = 19; Score
> 7 = 78
Post-intervention:
Score < 7 = 1; Score
> 7 = 96
Colombo,
2016
Website None Interferon DMD beneﬁts;
Interferon DMD risks;
Strength of evidence;
Areas of uncertainty; Long-
term adverse effects;
Glossary; Patient stories;
Description of participant
characteristics from
clinical trials;
Questions to ask
neurologists; Practical
information about
interferons
Short and
detailed info;
Bar graphs;
frequencies;
verbal info in
tables
No Self-
report
DMD beneﬁt
understanding
(follow-up:
immediate)
Interferon beneﬁts
clear? (n = 304)
No = 6%
Somewhat = 19%
Really/
extremely = 75%
Graphic
presentation of
interferon beneﬁts
easy to understand?
(n = 304)
No = 3%
Somewhat = 18%
Really/
extremely = 79%
Self-
report
DMD risk
understanding
(follow-up:
immediate)
Interferon risks
clear? (n = 304)
No = 4%
Somewhat = 12%
Really/
extremely = 84%
Tables of interferon
risks easy to
understand?
(n = 304)
No = 3%
Somewhat = 12%
Really/
extremely = 85%
Self-
report
DMD decision-
making
(follow-up:
immediate)
Conﬁdent about
interferon decision?
(n = 286)
No = 9%
Somewhat = 29%
Really/
extremely = 62%
Self-
report
Evaluation of
intervention:
(includes non-
clinical
intervention
(n = 89))
(follow-up:
immediate)
Website easy to
navigate? (n = 418)
No = 2%
Somewhat = 5%
Really/
extremely = 93%
Information easy to
understand?
(n = 433)
No = 1%
Somewhat = 12%
Really/
extremely = 87%
Information useful?
(n = 433)
No = 2%
Somewhat = 14%
Really/
extremely = 84%
Kopke,
2016
120-page information
brochure; 2-h education
programme; 4-h
education programme
Printed
information
material;
standard
Information about
evidence of DMDs;
Decision-making with
consultants;
Powerpoint
presentations;
Discussions;
Q&A; role-play
Yes Objective DMD risk
understanding
(follow up:
Adequate risk
knowledge: (> 8
correct answers):
Baseline:
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Table 5 (Continued)
Study
(ﬁrst
author,
year)
Intervention type Control group Intervention content Intervention
presentation
format
Baseline
recorded
Self-
report or
objective
measure
Outcome
measure
Results
(programme conducted
by 2 trained MS nurses or
psychologists)
rehabilitation
programme
Risks and beneﬁts of new
oral therapies
baseline, >2
weeks, >6 months)
CG = 22.5%
IG = 20.6%
2-weeks post
intervention:
CG = 31%
IG = 54.1%
Signiﬁcant
difference from
baseline (p<.007)
6-months post
intervention:
CG = 31.2%
IG = 48.2%
Signiﬁcant
difference from 2
weeks (p = 0.058)
Mean risk
knowledge (0-19):
Baseline:
CG = 6.51
IG = 6.06
Non-signiﬁcant
difference (p > .05)
2-weeks post
intervention:
CG = 7.31
IG = 8.85
Signiﬁcant
difference (p<.004)
6-months post
intervention:
CG = 7.12
IG = 8.05
Non-signiﬁcant
difference (p > 0.05)
Improvement in risk
knowledge ( > 2
weeks
to >6 months):
CG = 0.59
IG = 2.52
Signiﬁcant
difference
(p<0.001)
Improvement in risk
knowledge
(baseline to >6
months):
CG = 0.46
IG = 2.12
Signiﬁcant
difference
(p = 0002)
Rahn,
2016
Patient information
materials
Standard
information
Explanation of conﬁdence
intervals, used to explain
DMD risks and beneﬁts
An example
story to explain
conﬁdence
intervals
(unrelated to
MS)
No Objective General
understanding of
information:
6 questions
(follow up:
immediate)
Mean correct
answers:
CG = 3.8
IG = 4.8
Signiﬁcant
difference
(p = 0.002)
Self-
report
Evaluation of
intervention:
Likert scale
(1 = not at all, to
10 = very)
(follow up:
immediate)
Understandable?
CG = 4.5
IG = 6.5
Relevant?
CG = 6.6
IG = 7.6
Improvement in
subjective
knowledge?
CG = 4.8
IG = 6.6
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Table 5 (Continued)
Study
(ﬁrst
author,
year)
Intervention type Control group Intervention content Intervention
presentation
format
Baseline
recorded
Self-
report or
objective
measure
Outcome
measure
Results
Beneﬁcial
intervention?
CG = 6.0
IG = 7.8
Absolute numbers reported, unless speciﬁed. Abbreviations: CG, Control group; CIS, clinically isolated syndrome; Cog, Cognitive; CK; Cardiotoxicity; DMD, Disease-modifying
drug; IG, Intervention group; LK, Leukemia; MDMIC, Multi-Dimensional Measure of Informed Choice; MS, Multiple Sclerosis; PBMS, Planned Behaviour in MS questionnaire;
PML, progressive multifocal leukoencephalopathy; PPMS, primary progressive multiple sclerosis; Q&A, Questions and answers; RCT, Randomised controlled trial; RRMS,
relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; VAS, visual analogue scale; UTD, Understanding Treatment Disclosure Scale.
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previously low at baseline. In another study which did record
baseline measures, MS patients showed a signiﬁcant increase from
baseline for both general and personal risk attribution of the
adverse risks associated with Mitoxantrone after reading the
informational booklet [50]. Yet similar to the previous study,
personal risk attribution of the adverse risks of the DMD was
signiﬁcantly lower than general attributed risk of adverse risks by
the MS patients [50].
In summary, two studies show that patients attribute lower
personal risks of taking their current DMD than general risks they
attribute to the DMD, despite improved understanding of their
DMD risks post-intervention.
3.3.5. Treatment decisions
Five studies recorded MS patients’ decision or their attitude for
decisions for their current DMD following intervention
[41,42,46,54,55].
Using self-report likert-scales, MS patients in the intervention
group were found to be signiﬁcantly more critical about their
current DMD compared to baseline and control group, even after
four weeks following intervention [41]. Likewise, patients were
critical towards current DMD after intervention in another study
although this attitude did not persist beyond two weeks [42]. In
another study, patients reported feeling conﬁdent in their decision
to choose interferons after receiving information about interferons
beyond routine healthcare [54].
MS patients in the intervention group did not show signiﬁcant
differences to the control group in progress of DMD decisions
during follow-up in two studies [41,42]. When compared with
physicians’ decisions however, a considerably higher number of
patients opted to continue the Natalizumab DMD post-interven-
tion [46]. Although for the same medication following another
intervention, 60% of MS patients discontinued treatment if they
had the highest risk of PML, compared to 24% patients with the
second-highest PML risk [55]. No patient discontinued the
treatment post-intervention in the lower risk groups [55].
In summary, the studies in the present review show a trend
towards a critical attitude towards their DMD post-intervention
with some discontinuation due to these attitudes, although the
impact on patients’ decisions was generally inconclusive in the
long-term.
3.3.6. Intervention feedback
MS patients in six studies provided feedback on the inter-
ventions using self-report measures. Relative to the control group,
MS patients in the intervention group felt better informed and felt
that important questions had been adequately answered even after
six months following intervention [41]. Similarly, MS patients
deemed the intervention they received as important and felt that
this did not increase worries [50]. In fact, 84% of MS patients stated
that they would recommend the intervention to other patients[50]. Majority of patients reported the intervention as useful, and
were particularly satisﬁed with speciﬁc training they received
during the intervention [51]. Likewise, there was a signiﬁcant
increase in patients perception of being informed, in addition to
the feeling of certainty and conﬁdence of being able to handle all
treatments following a DMD information intervention [52]. Over
80% of MS patients trialling an informational website reported that
the website was easy to navigate, easy to understand and was
useful [54]. Following informational materials explaining conﬁ-
dence intervals, patients in the intervention group consistently
rated the information as being understandable, relevant and
beneﬁcial [44].
Despite the diversity of the DMD interventions employed in
these six studies, self-report measures indicate that patients
generally perceive any type of interventions as favourable in
facilitating understanding of DMD information.
4. Discussion and conclusion
4.1. Discussion
The present systematic review evaluated 15 interventions
designed to improve MS patients’ ability to understand complex
risk-beneﬁt proﬁles of DMDs. Studies in the review included MS
patients with different clinical subtypes and those taking a variety
of DMDs. Studies employed a range of outcome measures and not
all studies included baseline data or control group. Some studies
had methodologies that precluded ﬁrm conclusions.
Interventions within the present review provided treatment
information using booklets, websites, vignettes and education
programmes. Half of the interventions included some form of
interactive component [41,42,45,47,48,51,52]. Yet, there was no
apparent advantage of interactive versus passive interventions on
understanding. There was also no apparent beneﬁt of longer and
multicomponent interventions in comparison to shorter and basic
interventions such as leaﬂets in the current review. From this, it
can be presumed that interventions which are easier to administer
and require fewer resources may be just as beneﬁcial to employ as
longer interventions. Moreover, less than half of the interventions
manipulated or explained the formats used to present treatment
information, such as framing, numerical formats or graphical
formats [41,43,44,50,53,54]. This is surprising considering that
presentation formats are a key criteria for an effective evidence-
based educational intervention [18] and can signiﬁcantly impact
understanding of treatment information [25,26,28,34,35]. There-
fore, the use of presentation formats should be carefully
considered when designing an educational intervention.
In general, it was difﬁcult to make comparisons between these
interventions since they were very diverse in their content and
administration. In particular, it was not possible to draw
conclusions about the most effective intervention which could
improve understanding of DMD information in MS patients.
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ventions all received favourable reviews [41,44,50–52,54], which
indicates that any form of intervention providing DMD information
beyond routine health-care are generally well-accepted by MS
patients.
In terms of the impact of interventions, four interventions
improved understanding of overall information provided during
intervention, despite using very different interventions and study
designs [44,45,47,52]. For treatment risk knowledge speciﬁcally,
MS patients initially showed an underestimation of treatment risks
during routine healthcare, but showed greater understanding of
both real and hypothetical treatment risks post-intervention. This
improvement in risk understanding seemed related to multicom-
ponent interventions [42,48], information which was easier to
understand [43,50,54] and when personal risk attribution was
perceived as low [43]. However, it was not possible to determine
the extent to which these interventions were able to improve
understanding of both adverse risks and side-effects that are less
severe but commonly associated with DMDs. Nevertheless,
interventions designed to improve understanding of treatment
risks could be very beneﬁcial for patients making treatment
decisions, since even very small changes in the risks of DMDs can
have a huge impact on treatment choice [56,57]. In fact, some
studies in the present review showed a trend towards patients
becoming critical or discontinuing treatment when risks were
better understood [41,43,46,55]. This suggests that patients are
likely to review decisions for their current DMD following new and
enhanced understanding of treatment risks. Considering this, it is
important that patients perceive information accurately about
DMD risks when making initial treatment decisions, so that the
true risks associated with their chosen treatment are in line with
patients’ preferences. Although, some studies in the review
showed that despite greater understanding of treatments risks,
MS patients seemed to underestimate their personal chance of
developing these risks [46,50]. Interventions in the future could
therefore attempt to converge personal risk attribution with
accurate understanding of treatment risks, to ensure patients are
able to apply the knowledge they gain from the intervention and
make informed treatment decisions based on personal preferences
Improvements in understanding the beneﬁts of treatments
were less pronounced. Objectively, many patients did not
understand or tended to overestimate the beneﬁts of taking their
treatment, even after receiving additional information
[43,46,49,53]. This can be problematic for selecting a course of
treatment, as patients are more likely to prematurely discontinue
treatment if DMD beneﬁts are perceived as higher than actual
beneﬁts [49,58]. Such poor adherence to DMDs can have both
direct and indirect costs for MS patients [59]. However, patients
did not signiﬁcantly change their treatment decisions following
intervention, similar to the review by Köpke and colleagues [36], it
is difﬁcult to determine the effects of accurate understanding of
treatment information on treatment adherence and shared
treatment decision-making. This afﬁrms that understanding of
treatment information is simply a precursor to effective shared
decision-making and other key factors such as patient autonomy,
patient preferences or decision regret, would also need to be
addressed in interventions to directly improve shared treatment
decision-making [15,60–62]. Such interventions or decision aids
were present in only three of the 15 included studies in the current
review [41,42,48].
Additional factors which can likely inﬂuence patient’s under-
standing of DMD information were not fully explored by
interventions in the present review. Patients’ numeracy and
literacy skills have the ability to modify understanding of the
risks and beneﬁts of treatments, with lower skills often leading to
larger number of errors [63–65]. This was only explored in onestudy within the present review, where patients unable to
interpret numerical data demonstrated the least accuracy in
understanding the treatment risk information even after inter-
vention [50]. Aspects of cognitive functions affected by MS itself
are also likely to inﬂuence patient understanding, including: verbal
and visual-spatial memory [8,66], information-processing speed
[5] and decision-making [67,68]. Yet only one interventional study
monitored cognitive impairments of MS patients in the current
review [45]. This study showed that ﬁctitious treatment under-
standing in MS patients with cognitive impairments was
considerably lower compared to MS patients who do not present
these symptoms. However, following additional cueing during
intervention, the same level of understanding and recall was
shown in cognitively impaired MS patients compared with
cognitively intact MS patients [45]. Hence, future interventions
providing treatment information to MS patients may beneﬁt from
ensuring that patients of all abilities, and those presenting
cognitive impairments due to MS, are able to beneﬁt from the
additional information given beyond routine healthcare.
A limitation of the present systematic review was the difﬁculty
in drawing robust conclusions or conducting a meta-analysis for
the efﬁcacy of interventions as a result of the different outcome
measures employed. A narrative synthesis was considered to be
the most appropriate format for reviewing the studies. It is
important to acknowledge that such a qualitative review is subject
to greater analysis bias than a quantitative systematic review.
4.2. Conclusion
The present review was an inclusive attempt to compare
different types of interventions which provide treatment informa-
tion beyond routine healthcare, while evaluating their efﬁcacy on
understanding of treatment risks and beneﬁts. Despite the
heterogeneous ﬁndings, it is conceivable to conclude that
interventions providing treatment information beyond routine
healthcare are preferred by MS patients and have the potential to
improve understanding of overall treatment information, particu-
larly treatment risks. Understanding of treatment beneﬁts do not
seem to be reliably improved by the reviewed interventions. There
was no conclusive effect of interventions on MS patients’ decisions
for DMDs. No particular intervention type emerged as reliably
efﬁcacious. Interventions that were longer and comprehensive
performed similar to shorter interventions requiring fewer
resources. There is a need for a standardised information-based
tool which can draw on the strengths of currently available
interventions and which can improve understanding of both the
risks and beneﬁts of treatments.
4.3. Practice implications
The implication from this review is that MS patients appreciate
interventions which provide information about the risks and
beneﬁts of DMDs beyond routine healthcare. Future interventions
need to ensure that effective presentation methods are employed
to optimise understanding of DMD information during decision-
making, and that MS patients of all abilities and those presenting
cognitive impairments can also beneﬁt from the additional
support.
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